|
|
| G
|
A2m
|
alpha-2-macroglobulin
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of A2M mRNA Progesterone results in decreased expression of A2M mRNA
|
CTD |
PMID:17251523 PMID:22238285 |
|
NCBI chr 4:156,570,163...156,619,870
Ensembl chr 4:156,569,860...156,619,868
|
|
| G
|
Aamp
|
angio-associated, migratory cell protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of AAMP mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 9:83,312,519...83,318,325
Ensembl chr 9:83,312,519...83,318,325
|
|
| G
|
Aard
|
alanine and arginine rich domain containing protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of AARD mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 7:85,254,322...85,259,163
Ensembl chr 7:85,253,992...85,259,163
|
|
| G
|
Abat
|
4-aminobutyrate aminotransferase
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of ABAT mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474
|
|
| G
|
Abca6
|
ATP binding cassette subfamily A member 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of ABCA6 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr10:95,642,026...95,711,535
Ensembl chr10:95,641,900...95,710,899
|
|
| G
|
Abca8
|
ATP binding cassette subfamily A member 8
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ABCA8 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:95,416,984...95,490,647
Ensembl chr10:95,416,205...95,490,452
|
|
| G
|
Abcb11
|
ATP binding cassette subfamily B member 11
|
multiple interactions decreases activity
|
ISO
|
Progesterone inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Progesterone results in decreased activity of ABCB11 protein
|
CTD |
PMID:24014644 |
|
NCBI chr 3:74,424,620...74,520,646
Ensembl chr 3:74,424,979...74,520,581
|
|
| G
|
Abcb1a
|
ATP binding cassette subfamily B member 1A
|
multiple interactions increases expression
|
ISO
|
Dactinomycin inhibits the reaction [Progesterone results in increased expression of ABCB1 mRNA]; Dactinomycin inhibits the reaction [Progesterone results in increased expression of ABCB1 protein] Progesterone results in increased expression of ABCB1 mRNA; Progesterone results in increased expression of ABCB1 protein
|
CTD |
PMID:15290871 PMID:19813763 |
|
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135
|
|
| G
|
Abcb1b
|
ATP-binding cassette, sub-family B member 1B
|
increases expression
|
EXP
|
Progesterone results in increased expression of ABCB1B mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567
|
|
| G
|
Abcb9
|
ATP binding cassette subfamily B member 9
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ABCB9 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr12:38,146,659...38,192,862
Ensembl chr12:38,159,904...38,192,860
|
|
| G
|
Abcc2
|
ATP binding cassette subfamily C member 2
|
decreases activity
|
ISO
|
Progesterone results in decreased activity of ABCC2 protein
|
CTD |
PMID:16049127 |
|
NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471
|
|
| G
|
Abcc3
|
ATP binding cassette subfamily C member 3
|
multiple interactions increases expression decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ABCC3 mRNA Progesterone results in increased expression of ABCC3 mRNA Progesterone results in decreased expression of ABCC3 mRNA
|
CTD |
PMID:17404688 PMID:21795739 PMID:22238285 |
|
NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494
|
|
| G
|
Abcc4
|
ATP binding cassette subfamily C member 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ABCC4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375
|
|
| G
|
Abcc6
|
ATP binding cassette subfamily C member 6
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ABCC6 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895
|
|
| G
|
Abcc9
|
ATP binding cassette subfamily C member 9
|
increases expression
|
ISO EXP
|
Progesterone results in increased expression of ABCC9 mRNA
|
CTD |
PMID:20726854 PMID:20864642 |
|
NCBI chr 4:177,262,848...177,386,837
Ensembl chr 4:177,262,848...177,386,348
|
|
| G
|
Abcd1
|
ATP binding cassette subfamily D member 1
|
affects expression
|
ISO
|
Progesterone affects the expression of ABCD1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr X:156,579,669...156,601,448
Ensembl chr X:156,579,785...156,601,446
|
|
| G
|
Abcd3
|
ATP binding cassette subfamily D member 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ABCD3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:212,536,791...212,590,379
Ensembl chr 2:212,536,791...212,590,504
|
|
| G
|
Abcg1
|
ATP binding cassette subfamily G member 1
|
increases expression multiple interactions decreases expression
|
ISO EXP
|
Progesterone results in increased expression of ABCG1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of ABCG1 mRNA Progesterone results in decreased expression of ABCG1 mRNA
|
CTD |
PMID:18070364 PMID:20660070 PMID:20726854 PMID:21540246 |
|
NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563
|
|
| G
|
Abcg2
|
ATP binding cassette subfamily G member 2
|
affects expression multiple interactions decreases activity
|
ISO
|
Progesterone affects the expression of ABCG2 Progesterone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]; Progesterone inhibits the reaction [Estradiol results in increased expression of ABCG2] Progesterone results in decreased activity of ABCG2 protein
|
CTD |
PMID:16849015 PMID:18086804 PMID:22581381 |
|
NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493
|
|
| G
|
Abcg5
|
ATP binding cassette subfamily G member 5
|
multiple interactions
|
ISO
|
Progesterone results in decreased activity of [ABCG5 protein binds to ABCG8 protein]
|
CTD |
PMID:17055487 |
|
NCBI chr 6:15,717,936...15,743,376
Ensembl chr 6:15,717,936...15,743,376
|
|
| G
|
Abcg8
|
ATP binding cassette subfamily G member 8
|
multiple interactions
|
ISO
|
Progesterone results in decreased activity of [ABCG5 protein binds to ABCG8 protein]
|
CTD |
PMID:17055487 |
|
NCBI chr 6:15,698,448...15,717,730
Ensembl chr 6:15,698,448...15,717,730
|
|
| G
|
Abhd11
|
abhydrolase domain containing 11
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ABHD11 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr12:27,318,739...27,322,016
Ensembl chr12:27,318,749...27,321,970
|
|
| G
|
Abhd12
|
abhydrolase domain containing 12, lysophospholipase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ABHD12 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:160,119,724...160,179,959
Ensembl chr 3:160,119,724...160,179,969
|
|
| G
|
Abhd5
|
abhydrolase domain containing 5, lysophosphatidic acid acyltransferase
|
increases expression
|
ISO
|
Progesterone results in increased expression of ABHD5 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 8:130,877,834...130,903,947
Ensembl chr 8:130,877,703...130,903,947
|
|
| G
|
Abi3bp
|
ABI family member 3 binding protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of ABI3BP mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr11:57,381,282...57,597,989
Ensembl chr11:57,381,422...57,598,120
|
|
| G
|
Ablim1
|
actin-binding LIM protein 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ABLIM1 mRNA Progesterone results in increased expression of ABLIM1 mRNA
|
CTD |
PMID:20660070 PMID:20864642 |
|
NCBI chr 1:266,088,868...266,377,169
Ensembl chr 1:266,088,870...266,377,098
|
|
| G
|
Ablim2
|
actin binding LIM protein family, member 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ABLIM2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:79,090,046...79,214,986
Ensembl chr14:79,090,923...79,214,972
|
|
| G
|
Acadl
|
acyl-CoA dehydrogenase, long chain
|
increases expression
|
EXP
|
Progesterone results in increased expression of ACADL mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 9:75,783,689...75,822,077
Ensembl chr 9:75,783,689...75,822,164
|
|
| G
|
Acan
|
aggrecan
|
increases expression
|
ISO
|
Progesterone results in increased expression of ACAN protein
|
CTD |
PMID:20673848 |
|
NCBI chr 1:142,390,951...142,453,779
Ensembl chr 1:142,390,951...142,453,779
|
|
| G
|
Acat2
|
acetyl-CoA acetyltransferase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of ACAT2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:50,100,840...50,118,886
Ensembl chr 1:50,100,817...50,135,095
|
|
| G
|
Acbd7
|
acyl-CoA binding domain containing 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of ACBD7 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:79,813,106...79,821,254
Ensembl chr17:79,813,106...79,818,448
|
|
| G
|
Ackr4
|
atypical chemokine receptor 4
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of ACKR4 mRNA Progesterone results in decreased expression of ACKR4 mRNA
|
CTD |
PMID:18070364 PMID:20864642 |
|
NCBI chr 8:113,595,325...113,599,762
Ensembl chr 8:113,595,293...113,602,372
|
|
| G
|
Acod1
|
aconitate decarboxylase 1
|
affects expression increases expression
|
ISO
|
Progesterone affects the expression of ACOD1; Progesterone affects the expression of ACOD1 mRNA Progesterone results in increased expression of ACOD1 mRNA
|
CTD |
PMID:15178747 PMID:17251523 PMID:22238285 |
|
NCBI chr15:86,286,531...86,295,803
Ensembl chr15:86,286,579...86,295,687
|
|
| G
|
Acot7
|
acyl-CoA thioesterase 7
|
affects expression
|
ISO
|
Progesterone affects the expression of ACOT7 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:167,969,284...168,062,033
Ensembl chr 5:167,968,895...168,062,033
|
|
| G
|
Acot9
|
acyl-CoA thioesterase 9
|
affects expression
|
ISO
|
Progesterone affects the expression of ACOT9 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr X:43,922,943...43,973,311
Ensembl chr X:43,914,923...43,973,205
|
|
| G
|
Acp3
|
acid phosphatase 3
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ACP3 mRNA; Progesterone inhibits the reaction [Estradiol results in increased expression of ACP3 mRNA] Progesterone results in decreased expression of ACP3 mRNA
|
CTD |
PMID:17404688 PMID:21795739 |
|
NCBI chr 8:113,784,372...113,833,033
Ensembl chr 8:113,785,032...113,833,033
|
|
| G
|
Acsl1
|
acyl-CoA synthetase long-chain family member 1
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of ACSL1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of ACSL1 mRNA Progesterone results in increased expression of ACSL1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20726854 PMID:20864642 PMID:21795739 |
|
NCBI chr16:52,487,870...52,554,110
Ensembl chr16:52,487,870...52,554,023
|
|
| G
|
Acsm3
|
acyl-CoA synthetase medium-chain family member 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ACSM3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:183,564,652...183,591,328
Ensembl chr 1:183,564,635...183,591,437
|
|
| G
|
Acta1
|
actin, alpha 1, skeletal muscle
|
increases expression
|
EXP ISO
|
Progesterone results in increased expression of ACTA1 mRNA
|
CTD |
PMID:20726854 PMID:22238285 |
|
NCBI chr19:68,781,168...68,784,194
Ensembl chr19:68,781,168...68,786,178
|
|
| G
|
Acta2
|
actin alpha 2, smooth muscle
|
increases expression decreases expression multiple interactions
|
ISO EXP
|
Progesterone results in increased expression of ACTA2 mRNA Progesterone results in decreased expression of ACTA2 mRNA Progesterone promotes the reaction [Hydrogen Peroxide results in increased expression of ACTA2 protein]
|
CTD |
PMID:16284289 PMID:18037150 PMID:20864642 PMID:21540246 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503
|
|
| G
|
Actb
|
actin, beta
|
affects expression
|
ISO
|
Progesterone affects the expression of ACTB mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242
|
|
| G
|
Actc1
|
actin, alpha, cardiac muscle 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ACTC1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:121,266,291...121,271,827
Ensembl chr 3:121,266,291...121,271,827
|
|
| G
|
Actg2
|
actin gamma 2, smooth muscle
|
affects expression increases expression
|
ISO
|
Progesterone affects the expression of ACTG2 mRNA Progesterone results in increased expression of ACTG2 mRNA
|
CTD |
PMID:17251523 PMID:20864642 |
|
NCBI chr 4:117,579,513...117,604,379
Ensembl chr 4:117,579,514...117,604,295
|
|
| G
|
Actn1
|
actinin, alpha 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ACTN1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:104,731,485...104,826,312
Ensembl chr 6:104,731,485...104,826,172
|
|
| G
|
Acvr1
|
activin A receptor type 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ACVR1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:63,387,378...63,506,980
Ensembl chr 3:63,387,381...63,477,884
|
|
| G
|
Acvr2b
|
activin A receptor type 2B
|
affects expression
|
ISO
|
Progesterone affects the expression of ACVR2B mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 8:128,016,589...128,056,193
Ensembl chr 8:128,016,526...128,048,171
|
|
| G
|
Acy1
|
aminoacylase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ACY1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 8:115,951,068...115,956,471
Ensembl chr 8:115,951,068...115,956,405
|
|
| G
|
Ada
|
adenosine deaminase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ADA mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293
|
|
| G
|
Adam12
|
ADAM metallopeptidase domain 12
|
multiple interactions affects expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ADAM12 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of ADAM12 mRNA Progesterone affects the expression of ADAM12 mRNA Progesterone results in decreased expression of ADAM12 mRNA
|
CTD |
PMID:17251523 PMID:17404688 PMID:19406945 PMID:21795739 |
|
NCBI chr 1:198,116,968...198,443,680
Ensembl chr 1:198,116,975...198,447,552
|
|
| G
|
Adam17
|
ADAM metallopeptidase domain 17
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of ADAM17 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of ADAM17 mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344
|
|
| G
|
Adam28
|
ADAM metallopeptidase domain 28
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ADAM28 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:50,184,286...50,250,605
Ensembl chr15:50,127,516...50,250,526
|
|
| G
|
Adam8
|
ADAM metallopeptidase domain 8
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ADAM8 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:204,206,206...204,218,988
Ensembl chr 1:204,206,199...204,218,485
|
|
| G
|
Adam9
|
ADAM metallopeptidase domain 9
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADAM9 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr16:73,725,186...73,804,284
Ensembl chr16:73,725,114...73,804,646
|
|
| G
|
Adamts1
|
ADAM metallopeptidase with thrombospondin type 1 motif, 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Dihydrotestosterone] results in increased expression of ADAMTS1 mRNA; [Progesterone co-treated with Dihydrotestosterone] results in increased expression of ADAMTS1 protein; [Progesterone co-treated with Estradiol] results in increased expression of ADAMTS1 mRNA; Estradiol inhibits the reaction [Progesterone results in increased expression of ADAMTS1 mRNA]; Estradiol inhibits the reaction [Progesterone results in increased expression of ADAMTS1 protein]; Mifepristone inhibits the reaction [Progesterone results in increased expression of ADAMTS1 mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of ADAMTS1 protein] Progesterone results in increased expression of ADAMTS1 mRNA; Progesterone results in increased expression of ADAMTS1 protein
|
CTD |
PMID:17018655 PMID:20226447 PMID:20864642 PMID:21795739 |
|
NCBI chr11:38,418,565...38,427,384
Ensembl chr11:38,418,101...38,427,390
|
|
| G
|
Adamts2
|
ADAM metallopeptidase with thrombospondin type 1 motif, 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADAMTS2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr10:35,422,030...35,627,483
Ensembl chr10:35,422,030...35,627,483
|
|
| G
|
Adamts20
|
ADAM metallopeptidase with thrombospondin type 1 motif, 20
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADAMTS20 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 7:127,275,538...127,407,325
Ensembl chr 7:127,275,538...127,407,296
|
|
| G
|
Adamts8
|
ADAM metallopeptidase with thrombospondin type 1 motif, 8
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of ADAMTS8 mRNA [Estradiol co-treated with Progesterone] results in increased expression of ADAMTS8 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of ADAMTS8 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of ADAMTS8 mRNA
|
CTD |
PMID:17404688 PMID:20226447 PMID:20660070 |
|
NCBI chr 8:37,607,001...37,626,597
Ensembl chr 8:37,607,001...37,626,597
|
|
| G
|
Adamts9
|
ADAM metallopeptidase with thrombospondin type 1 motif, 9
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ADAMTS9 mRNA Progesterone results in increased expression of ADAMTS9 mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr 4:126,847,726...127,019,924
Ensembl chr 4:126,847,729...127,019,876
|
|
| G
|
Adamtsl1
|
ADAMTS-like 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADAMTSL1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:105,010,471...105,965,792
Ensembl chr 5:105,010,464...105,964,394
|
|
| G
|
Adap2
|
ArfGAP with dual PH domains 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ADAP2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:65,635,891...65,665,019
Ensembl chr10:65,622,434...65,664,022
|
|
| G
|
Adcy1
|
adenylate cyclase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADCY1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr14:86,125,119...86,234,459
Ensembl chr14:86,124,850...86,261,075
|
|
| G
|
Adcy2
|
adenylate cyclase 2
|
multiple interactions
|
EXP
|
[Genistein co-treated with estradiol-17-benzoate co-treated with Progesterone] results in increased expression of ADCY2 protein
|
CTD |
PMID:26529183 |
|
NCBI chr 1:36,204,054...36,650,645
Ensembl chr 1:36,204,054...36,650,645
|
|
| G
|
Adcy5
|
adenylate cyclase 5
|
increases expression
|
EXP
|
Progesterone results in increased expression of ADCY5 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr11:78,976,861...79,123,343
Ensembl chr11:78,976,861...79,123,343
|
|
| G
|
Adcyap1
|
adenylate cyclase activating polypeptide 1
|
increases abundance
|
ISO
|
ADCYAP1 protein results in increased abundance of Progesterone
|
CTD |
PMID:19926922 |
|
NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383
|
|
| G
|
Adcyap1r1
|
ADCYAP receptor type I
|
multiple interactions
|
ISO
|
ADCYAP1R1 protein promotes the reaction [LHB protein results in increased abundance of Progesterone]
|
CTD |
PMID:19926922 |
|
NCBI chr 4:85,924,171...85,972,973
Ensembl chr 4:85,924,100...85,972,973
|
|
| G
|
Adgrd1
|
adhesion G protein-coupled receptor D1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ADGRD1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr12:33,124,981...33,239,778
Ensembl chr12:33,125,915...33,272,509
|
|
| G
|
Adgrg6
|
adhesion G protein-coupled receptor G6
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADGRG6 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:10,633,004...10,774,685
Ensembl chr 1:10,631,829...10,774,023
|
|
| G
|
Adgrl2
|
adhesion G protein-coupled receptor L2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ADGRL2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:240,356,176...240,987,246
Ensembl chr 2:240,356,177...240,855,933
|
|
| G
|
Adh1c
|
alcohol dehydrogenase 1C (class I), gamma polypeptide
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADH1C mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 2:229,470,703...229,482,291
Ensembl chr 2:229,470,703...229,482,291
|
|
| G
|
Adh5
|
alcohol dehydrogenase 5 (class III), chi polypeptide
|
multiple interactions
|
ISO
|
[Progesterone results in increased activity of PGR protein] which results in increased expression of ADH5 mRNA
|
CTD |
PMID:15845616 |
|
NCBI chr 2:229,648,557...229,660,964
Ensembl chr 2:229,648,501...229,665,232
|
|
| G
|
Adi1
|
acireductone dioxygenase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ADI1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:51,035,267...51,042,229
Ensembl chr 6:51,034,931...51,042,855
|
|
| G
|
Adipoq
|
adiponectin, C1Q and collagen domain containing
|
affects expression multiple interactions increases abundance
|
ISO
|
Progesterone affects the expression of ADIPOQ mRNA ADIPOQ protein promotes the reaction [IGF1 protein results in increased abundance of Progesterone] ADIPOQ protein results in increased abundance of Progesterone
|
CTD |
PMID:17251523 PMID:19081562 PMID:27181934 |
|
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:91,226,180...91,240,169
|
|
| G
|
Adipor1
|
adiponectin receptor 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADIPOR1 mRNA
|
CTD |
PMID:29603059 |
|
NCBI chr13:48,411,438...48,431,251
Ensembl chr13:48,411,826...48,431,255
|
|
| G
|
Adipor2
|
adiponectin receptor 2
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of ADIPOR2 mRNA Progesterone results in increased expression of ADIPOR2 mRNA
|
CTD |
PMID:17404688 PMID:29603059 |
|
NCBI chr 4:154,195,440...154,261,141
Ensembl chr 4:154,172,567...154,231,666
|
|
| G
|
Adm
|
adrenomedullin
|
multiple interactions affects abundance
|
ISO EXP
|
ADM protein modified form inhibits the reaction [ADM protein inhibits the reaction [CGA protein results in increased secretion of Progesterone]] ADM protein affects the abundance of Progesterone
|
CTD |
PMID:18401014 PMID:21824440 |
|
NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371
|
|
| G
|
Adora2b
|
adenosine A2B receptor
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ADORA2B mRNA Progesterone results in increased expression of ADORA2B mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr10:47,439,712...47,456,092
Ensembl chr10:47,439,701...47,456,091
|
|
| G
|
Adra2a
|
adrenoceptor alpha 2A
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADRA2A mRNA
|
CTD |
PMID:15713686 |
|
NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871
|
|
| G
|
Adra2c
|
adrenoceptor alpha 2C
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADRA2C mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr14:79,695,514...79,697,476
Ensembl chr14:79,694,995...79,706,656
|
|
| G
|
Adrb2
|
adrenoceptor beta 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of ADRB2 mRNA
|
CTD |
PMID:15985637 PMID:20726854 |
|
NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803
|
|
| G
|
Adrb3
|
adrenoceptor beta 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of ADRB3 mRNA
|
CTD |
PMID:15713686 |
|
NCBI chr16:71,544,603...71,547,410
Ensembl chr16:71,542,567...71,547,420
|
|
| G
|
Afap1l2
|
actin filament associated protein 1-like 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of AFAP1L2 mRNA
|
CTD |
PMID:20864642 PMID:21795739 |
|
NCBI chr 1:265,969,368...266,065,951
Ensembl chr 1:265,969,368...266,065,943
|
|
| G
|
Afp
|
alpha-fetoprotein
|
multiple interactions increases response to substance
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of AFP protein AFP protein results in increased susceptibility to Progesterone
|
CTD |
PMID:18497072 PMID:22720075 |
|
NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649
|
|
| G
|
Agap3
|
ArfGAP with GTPase domain, ankyrin repeat and PH domain 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of AGAP3 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 4:11,567,191...11,617,610
Ensembl chr 4:11,567,191...11,617,285
|
|
| G
|
Agpat4
|
1-acylglycerol-3-phosphate O-acyltransferase 4
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of AGPAT4 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:51,075,081...51,181,548
Ensembl chr 1:51,075,081...51,180,976
|
|
| G
|
Agrn
|
agrin
|
increases expression
|
EXP
|
Progesterone results in increased expression of AGRN protein
|
CTD |
PMID:16777347 |
|
NCBI chr 5:172,031,528...172,064,429
Ensembl chr 5:172,031,528...172,064,539
|
|
| G
|
Agt
|
angiotensinogen
|
multiple interactions decreases expression decreases secretion
|
ISO
|
Progesterone inhibits the reaction [AGT protein results in increased abundance of Inositol Phosphates] Progesterone results in decreased expression of AGT mRNA AGT protein results in decreased secretion of Progesterone
|
CTD |
PMID:1337236 PMID:22095930 PMID:28235592 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944
|
|
| G
|
Ahr
|
aryl hydrocarbon receptor
|
affects binding affects expression multiple interactions decreases expression
|
ISO EXP
|
Progesterone binds to AHR protein Progesterone affects the expression of AHR mRNA; Progesterone affects the expression of AHR protein [Progesterone co-treated with Estradiol] affects the expression of AHR mRNA; [Progesterone co-treated with Estradiol] affects the expression of AHR protein Progesterone results in decreased expression of AHR mRNA
|
CTD |
PMID:10478797 PMID:24777823 PMID:32668270 |
|
NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901
|
|
| G
|
Ahrr
|
aryl-hydrocarbon receptor repressor
|
affects expression multiple interactions
|
EXP
|
Progesterone affects the expression of AHRR mRNA [Progesterone co-treated with Estradiol] affects the expression of AHRR mRNA
|
CTD |
PMID:24777823 |
|
NCBI chr 1:30,822,219...30,917,251
Ensembl chr 1:30,810,866...30,952,866
|
|
| G
|
Aicda
|
activation-induced cytidine deaminase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of AICDA mRNA; Progesterone results in decreased expression of AICDA protein
|
CTD |
PMID:19139166 PMID:19553525 |
|
NCBI chr 4:157,446,120...157,455,958
Ensembl chr 4:157,444,697...157,456,356
|
|
| G
|
Aif1
|
allograft inflammatory factor 1
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of AIF1 protein
|
CTD |
PMID:21277368 |
|
NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339
|
|
| G
|
Ajap1
|
adherens junctions associated protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of AJAP1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:169,190,477...169,302,938
Ensembl chr 5:169,190,477...169,304,515
|
|
| G
|
Ak1
|
adenylate kinase 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of AK1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 3:36,310,113...36,320,760
Ensembl chr 3:36,310,197...36,320,757
|
|
| G
|
Akap1
|
A-kinase anchoring protein 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of AKAP1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:74,118,232...74,151,366
Ensembl chr10:74,119,124...74,138,190
|
|
| G
|
Akap12
|
A-kinase anchoring protein 12
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of AKAP12 mRNA Progesterone results in increased expression of AKAP12 mRNA; Progesterone results in increased expression of AKAP12 protein
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr 1:43,135,515...43,225,245
Ensembl chr 1:43,199,008...43,225,557
|
|
| G
|
Akap13
|
A-kinase anchoring protein 13
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of AKAP13 mRNA Progesterone results in increased expression of AKAP13 mRNA
|
CTD |
PMID:20660070 PMID:20864642 |
|
NCBI chr 1:138,722,445...139,029,401
Ensembl chr 1:138,724,150...139,029,401
|
|
| G
|
Akap5
|
A-kinase anchoring protein 5
|
increases expression
|
EXP
|
Progesterone results in increased expression of AKAP5 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 6:100,787,169...100,796,712
Ensembl chr 6:100,790,148...100,796,620
|
|
| G
|
Akap8
|
A-kinase anchoring protein 8
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of AKAP8 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 7:11,966,769...11,983,056
Ensembl chr 7:11,966,772...11,982,900
|
|
| G
|
Akap9
|
A-kinase anchoring protein 9
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of AKAP9 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 4:31,011,475...31,147,338
Ensembl chr 4:31,011,475...31,147,338
|
|
| G
|
Akr1b10
|
aldo-keto reductase family 1 member B10
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of AKR1B10 mRNA Progesterone results in decreased expression of AKR1B10 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 4:64,005,632...64,027,860
Ensembl chr 4:64,007,420...64,020,847
|
|
| G
|
Akr1c1
|
aldo-keto reductase family 1, member C1
|
affects reduction increases reduction multiple interactions decreases expression
|
ISO
|
AKR1C1 protein affects the reduction of Progesterone AKR1C1 protein results in increased reduction of Progesterone AKR1C1 protein affects the metabolism of and results in decreased activity of Progesterone Progesterone results in decreased expression of AKR1C1 mRNA
|
CTD |
PMID:11995921 PMID:12604236 PMID:16338060 PMID:16962702 PMID:22245609 PMID:23183084 More...
|
|
NCBI chr17:70,720,397...70,747,285
Ensembl chr17:70,720,398...70,747,247
|
|
| G
|
Akr1c2
|
aldo-keto reductase family 1, member C2
|
increases reduction
|
ISO
|
AKR1C2 protein results in increased reduction of Progesterone
|
CTD |
PMID:11158055 PMID:22245609 PMID:25463305 |
|
NCBI chr17:70,669,684...70,717,935
Ensembl chr17:70,669,710...70,685,686
|
|
| G
|
Akr1c3
|
aldo-keto reductase family 1, member C3
|
multiple interactions increases metabolic processing decreases expression increases expression increases reduction affects abundance affects metabolic processing
|
ISO EXP
|
[AKR1C3 protein results in increased metabolism of Progesterone] which results in increased chemical synthesis of 20-alpha-Dihydroprogesterone; [AKR1C3 protein results in increased reduction of Progesterone] which results in increased chemical synthesis of 20-alpha-Dihydroprogesterone Progesterone results in decreased expression of AKR1C3 mRNA Progesterone results in increased expression of AKR1C3 mRNA AKR1C18 protein affects the abundance of Progesterone AKR1C18 protein affects the metabolism of Progesterone AKR1C18 protein results in increased metabolism of Progesterone
|
CTD |
PMID:8172618 PMID:15261307 PMID:15471942 PMID:17122075 PMID:19010312 PMID:20036328 PMID:23183084 PMID:25463305 More...
|
|
NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438
|
|
| G
|
Akr1d1
|
aldo-keto reductase family 1, member D1
|
increases reduction multiple interactions
|
ISO
|
AKR1D1 protein results in increased reduction of Progesterone [AKR1D1 protein alternative form results in increased reduction of Progesterone] which results in increased chemical synthesis of 5-alpha-Dihydroprogesterone AKR1D1 protein alternative form results in increased reduction of Progesterone; AKR1D1 protein results in increased reduction of Progesterone
|
CTD |
PMID:18624455 PMID:30928400 |
|
NCBI chr 4:67,121,288...67,154,543
Ensembl chr 4:67,120,024...67,154,540
|
|
| G
|
Akt1
|
AKT serine/threonine kinase 1
|
multiple interactions increases phosphorylation
|
ISO EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Progesterone results in increased phosphorylation of AKT1 protein] Progesterone inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein] [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased phosphorylation of AKT1 protein; Mifepristone inhibits the reaction [Progesterone results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [Progesterone results in increased phosphorylation of AKT1 protein]
|
CTD |
PMID:15358673 PMID:15845746 PMID:22465879 PMID:28324061 |
|
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610
|
|
| G
|
Alad
|
aminolevulinate dehydratase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ALAD mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:80,977,562...80,987,901
Ensembl chr 5:80,977,562...80,988,041
|
|
| G
|
Alas1
|
5'-aminolevulinate synthase 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of ALAS1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 8:115,755,238...115,768,642
Ensembl chr 8:115,755,238...115,768,642
|
|
| G
|
Alas2
|
5'-aminolevulinate synthase 2
|
affects expression
|
ISO
|
Progesterone affects the expression of ALAS2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr X:22,890,650...22,914,046
Ensembl chr X:22,890,689...22,914,043
|
|
| G
|
Alb
|
albumin
|
multiple interactions
|
ISO
|
[[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the expression of ALB protein; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the expression of ALB protein
|
CTD |
PMID:20621171 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865
|
|
| G
|
Alcam
|
activated leukocyte cell adhesion molecule
|
increases expression
|
ISO
|
Progesterone results in increased expression of ALCAM mRNA
|
CTD |
PMID:18497975 PMID:21795739 |
|
NCBI chr11:61,804,932...62,005,250
Ensembl chr11:61,805,049...62,006,876
|
|
| G
|
Aldh1a1
|
aldehyde dehydrogenase 1 family, member A1
|
affects expression multiple interactions decreases expression
|
ISO
|
Progesterone affects the expression of ALDH1A1 mRNA [Progesterone results in increased activity of PGR protein] which results in increased expression of ALDH1A1 mRNA Progesterone results in decreased expression of ALDH1A1 mRNA
|
CTD |
PMID:15845616 PMID:17251523 PMID:22238285 |
|
NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500
|
|
| G
|
Aldh1a2
|
aldehyde dehydrogenase 1 family, member A2
|
affects expression
|
ISO
|
Progesterone affects the expression of ALDH1A2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883
|
|
| G
|
Aldh1a3
|
aldehyde dehydrogenase 1 family, member A3
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ALDH1A3 mRNA Progesterone results in decreased expression of ALDH1A3 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777
|
|
| G
|
Aldh1l1
|
aldehyde dehydrogenase 1 family, member L1
|
increases expression
|
EXP
|
Progesterone results in increased expression of ALDH1L1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:124,617,182...124,663,674
Ensembl chr 4:124,617,217...124,664,704
|
|
| G
|
Aldh3a1
|
aldehyde dehydrogenase 3 family, member A1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ALDH3A1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151
|
|
| G
|
Aldh3b2
|
aldehyde dehydrogenase 3 family, member B2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ALDH3B2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:210,679,749...210,694,187
Ensembl chr 1:210,675,302...210,694,155
|
|
| G
|
Aldh3b3
|
aldehyde dehydrogenase 3 family, member B3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ALDH3B2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:210,617,090...210,629,886
Ensembl chr 1:210,622,639...210,629,879
|
|
| G
|
Aldh6a1
|
aldehyde dehydrogenase 6 family, member A1
|
increases expression
|
EXP
|
Progesterone results in increased expression of ALDH6A1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 6:109,809,092...109,829,725
Ensembl chr 6:109,809,122...109,829,743
|
|
| G
|
Aldoc
|
aldolase, fructose-bisphosphate C
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ALDOC mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:63,715,544...63,719,133
Ensembl chr10:63,715,489...63,719,133
|
|
| G
|
Alg2
|
ALG2, alpha-1,3/1,6-mannosyltransferase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ALG2 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 5:66,564,328...66,568,887
Ensembl chr 5:66,564,330...66,568,887
|
|
| G
|
Alox15
|
arachidonate 15-lipoxygenase
|
affects expression increases expression
|
ISO EXP
|
Progesterone affects the expression of ALOX15 mRNA Progesterone results in increased expression of ALOX15 mRNA
|
CTD |
PMID:17251523 PMID:21770760 |
|
NCBI chr10:55,559,060...55,567,535
Ensembl chr10:55,559,061...55,567,723
|
|
| G
|
Alox15b
|
arachidonate 15-lipoxygenase, type B
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ALOX15B mRNA Progesterone results in increased expression of ALOX15B mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr10:54,391,331...54,400,648
Ensembl chr10:54,391,302...54,400,648
|
|
| G
|
Alpg
|
alkaline phosphatase, germ cell
|
multiple interactions affects expression
|
ISO
|
perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of ALPPL2 mRNA]; Progesterone inhibits the reaction [perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of ALPPL2 mRNA]]
|
CTD |
PMID:31896193 |
|
NCBI chr 9:95,187,995...95,205,127
Ensembl chr 9:95,198,334...95,205,742
|
|
| G
|
Alpl
|
alkaline phosphatase, biomineralization associated
|
multiple interactions increases activity increases expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ALPL mRNA; [Progesterone co-treated with Estradiol] results in increased expression of ALPL mRNA; fenvalerate inhibits the reaction [Progesterone results in increased activity of ALPL protein]; Permethrin inhibits the reaction [Progesterone results in increased activity of ALPL protein] Progesterone results in increased expression of ALPL mRNA Progesterone results in decreased expression of ALPL mRNA
|
CTD |
PMID:16326432 PMID:17404688 PMID:20660070 PMID:21540246 |
|
NCBI chr 5:155,234,770...155,289,785
Ensembl chr 5:155,234,775...155,254,167
|
|
| G
|
Alpp
|
alkaline phosphatase, placental
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of ALPP mRNA Progesterone results in increased expression of ALPP mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 9:95,213,763...95,216,509
Ensembl chr 9:95,213,374...95,219,451
|
|
| G
|
Amigo2
|
adhesion molecule with Ig like domain 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of AMIGO2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:130,270,639...130,273,735
Ensembl chr 7:130,270,554...130,282,218
|
|
| G
|
Amigo3
|
adhesion molecule with Ig like domain 3
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of AMIGO3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 8:117,620,499...117,622,025
Ensembl chr 8:117,616,629...117,626,577
|
|
| G
|
Ammecr1
|
AMMECR nuclear protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of AMMECR1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr X:111,262,792...111,368,099
Ensembl chr X:111,262,792...111,368,099
|
|
| G
|
Ampd3
|
adenosine monophosphate deaminase 3
|
affects expression
|
ISO
|
Progesterone affects the expression of AMPD3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:174,319,526...174,364,605
Ensembl chr 1:174,294,867...174,364,608
|
|
| G
|
Amph
|
amphiphysin
|
increases expression
|
ISO
|
Progesterone results in increased expression of AMPH mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:50,435,018...50,678,583
Ensembl chr17:50,435,018...50,678,501
|
|
| G
|
Amy2a5
|
amylase 2a5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of AMY2A5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:203,949,578...203,958,111
|
|
| G
|
Andpro
|
androgen regulated protein
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CST4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:157,171,739...157,178,262
Ensembl chr 3:157,171,740...157,178,104
|
|
| G
|
Ang
|
angiogenin
|
increases expression affects expression
|
ISO
|
Progesterone results in increased expression of ANG mRNA Progesterone affects the expression of ANG mRNA
|
CTD |
PMID:17251523 PMID:21795739 |
|
NCBI chr15:26,786,233...26,796,883
Ensembl chr15:26,786,065...26,801,106
|
|
| G
|
Angpt1
|
angiopoietin 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ANGPT1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:75,415,959...75,668,696
Ensembl chr 7:75,418,218...75,668,696
|
|
| G
|
Angpt2
|
angiopoietin 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ANGPT2 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of ANGPT2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr16:77,790,760...77,841,241
Ensembl chr16:77,790,563...77,841,239
|
|
| G
|
Angpt4
|
angiopoietin 4
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estrogens] results in increased expression of ANGPT4 mRNA Progesterone results in increased expression of ANGPT4 mRNA
|
CTD |
PMID:22821867 |
|
NCBI chr 3:160,880,539...160,913,923
Ensembl chr 3:160,880,728...160,913,921
|
|
| G
|
Angptl1
|
angiopoietin-like 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estrogens] results in increased expression of ANGPTL1 mRNA Progesterone results in increased expression of ANGPTL1 mRNA
|
CTD |
PMID:22350948 |
|
NCBI chr13:71,463,913...71,531,810
Ensembl chr13:71,511,727...71,531,818
|
|
| G
|
Angptl2
|
angiopoietin-like 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ANGPTL2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 3:36,914,876...36,944,715
Ensembl chr 3:36,914,745...36,945,876
|
|
| G
|
Angptl3
|
angiopoietin-like 3
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of ANGPTL3 mRNA [Progesterone co-treated with Estrogens] results in decreased expression of ANGPTL3 mRNA
|
CTD |
PMID:22350948 |
|
NCBI chr 5:118,818,494...118,825,531
Ensembl chr 5:118,818,499...118,826,444
|
|
| G
|
Angptl4
|
angiopoietin-like 4
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of ANGPTL4 mRNA Progesterone inhibits the reaction [Estrogens results in decreased expression of ANGPTL4 mRNA]
|
CTD |
PMID:21795739 PMID:22350948 |
|
NCBI chr 7:15,252,450...15,259,971
Ensembl chr 7:15,252,473...15,258,681
|
|
| G
|
Angptl6
|
angiopoietin-like 6
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estrogens] results in increased expression of ANGPTL6 mRNA Progesterone results in increased expression of ANGPTL6 mRNA
|
CTD |
PMID:22350948 |
|
NCBI chr 8:27,689,804...27,696,172
Ensembl chr 8:27,689,806...27,696,111
|
|
| G
|
Angptl7
|
angiopoietin like 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of ANGPTL7 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:164,215,223...164,220,408
Ensembl chr 5:164,215,223...164,220,584
|
|
| G
|
Ank3
|
ankyrin 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ANK3 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr20:18,601,307...19,224,790
Ensembl chr20:18,601,826...19,084,879
|
|
| G
|
Ankh
|
ANKH inorganic pyrophosphate transport regulator
|
affects expression
|
ISO
|
Progesterone affects the expression of ANK mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:79,883,544...80,011,699
|
|
| G
|
Ankrd22
|
ankyrin repeat domain 22
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ANKRD22 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:241,052,235...241,083,737
Ensembl chr 1:241,052,237...241,105,559
|
|
| G
|
Ankrd35
|
ankyrin repeat domain 35
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ANKRD35 mRNA Progesterone results in decreased expression of ANKRD35 mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr 2:186,895,896...186,915,903
Ensembl chr 2:186,895,945...186,915,902
|
|
| G
|
Ankrd50
|
ankyrin repeat domain containing 50
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ANKRD50 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:123,394,311...123,428,788
Ensembl chr 2:123,396,606...123,427,340
|
|
| G
|
Ankrd55
|
ankyrin repeat domain 55
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of ANKRD55 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 2:45,617,011...45,717,086
Ensembl chr 2:45,617,177...45,717,057
|
|
| G
|
Anln
|
anillin, actin binding protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ANLN mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 8:29,134,222...29,197,513
Ensembl chr 8:29,134,222...29,197,513
|
|
| G
|
Ano9
|
anoctamin 9
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ANO9 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:205,638,571...205,659,780
Ensembl chr 1:205,638,572...205,659,489
|
|
| G
|
Antxr1
|
ANTXR cell adhesion molecule 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ANTXR1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of ANTXR1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 4:121,148,102...121,335,549
Ensembl chr 4:121,148,103...121,336,892
|
|
| G
|
Antxr2
|
ANTXR cell adhesion molecule 2
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ANTXR2 mRNA Progesterone results in increased expression of ANTXR2 mRNA
|
CTD |
PMID:20660070 PMID:20864642 PMID:22238285 |
|
NCBI chr14:11,845,774...11,986,166
Ensembl chr14:11,845,700...11,986,168
|
|
| G
|
Anxa3
|
annexin A3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ANXA3 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr14:13,031,675...13,085,678
Ensembl chr14:13,023,762...13,085,849
|
|
| G
|
Aoc3
|
amine oxidase, copper containing 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of AOC3 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr10:86,773,018...86,780,961
|
|
| G
|
Aox1
|
aldehyde oxidase 1
|
increases expression
|
ISO EXP
|
Progesterone results in increased expression of AOX1 mRNA
|
CTD |
PMID:20726854 PMID:21540246 PMID:21795739 |
|
NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980
|
|
| G
|
Ap3m2
|
adaptor related protein complex 3 subunit mu 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of AP3M2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr16:75,908,459...75,937,915
Ensembl chr16:75,920,084...75,937,923
|
|
| G
|
Ap5m1
|
adaptor related protein complex 5 subunit mu 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of AP5M1 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr15:24,835,122...24,864,854
Ensembl chr15:24,835,100...24,862,606
|
|
| G
|
Apcdd1
|
APC down-regulated 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of APCDD1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr18:58,655,696...58,686,359
Ensembl chr18:58,655,919...58,686,356
|
|
| G
|
Apex1
|
apurinic/apyrimidinic endodeoxyribonuclease 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of APEX1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr15:26,618,146...26,620,330
Ensembl chr15:26,618,224...26,620,329
|
|
| G
|
Apoc4
|
apolipoprotein C4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of APOC4 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:88,463,713...88,467,909
Ensembl chr 1:88,463,713...88,468,044
|
|
| G
|
Apod
|
apolipoprotein D
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of APOD mRNA Progesterone results in increased expression of APOD mRNA
|
CTD |
PMID:17404688 PMID:20864642 PMID:21795739 |
|
NCBI chr11:82,936,216...82,957,264
Ensembl chr11:82,936,038...82,957,263
|
|
| G
|
Apom
|
apolipoprotein M
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of APOM mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr20:3,695,618...3,698,218
Ensembl chr20:3,692,737...3,698,218
|
|
| G
|
App
|
amyloid beta precursor protein
|
decreases metabolic processing multiple interactions
|
ISO
|
APP gene mutant form results in decreased metabolism of Progesterone metabolite Progesterone inhibits the reaction [APP gene mutant form results in decreased metabolism of Progesterone metabolite]
|
CTD |
PMID:17988898 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971
|
|
| G
|
Aqp1
|
aquaporin 1
|
affects localization multiple interactions increases expression
|
EXP
|
Progesterone affects the localization of AQP1 protein [Estradiol co-treated with Progesterone] results in decreased expression of AQP1 mRNA; [Estradiol co-treated with Progesterone] results in increased expression of AQP1 protein; [Progesterone co-treated with Estrogens] affects the localization of AQP1 protein; Quercetin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of AQP1 mRNA]; Quercetin promotes the reaction [[Estradiol co-treated with Progesterone] results in increased expression of AQP1 protein] Progesterone results in increased expression of AQP1 mRNA
|
CTD |
PMID:16452730 PMID:20726854 PMID:28341573 |
|
NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504
|
|
| G
|
Aqp2
|
aquaporin 2
|
increases expression multiple interactions
|
ISO EXP
|
Progesterone results in increased expression of AQP2 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of AQP2 mRNA; [Estradiol co-treated with Progesterone] results in decreased expression of AQP2 protein; Quercetin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of AQP2 mRNA]; Quercetin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of AQP2 protein]
|
CTD |
PMID:18692832 PMID:28341573 |
|
NCBI chr 7:132,590,286...132,595,321
Ensembl chr 7:132,590,225...132,595,319
|
|
| G
|
Aqp3
|
aquaporin 3 (Gill blood group)
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of AQP3 mRNA Progesterone results in decreased expression of AQP3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:61,035,166...61,040,685
|
|
| G
|
Aqp5
|
aquaporin 5
|
affects localization multiple interactions decreases expression
|
EXP ISO
|
Progesterone affects the localization of AQP5 protein [Estradiol co-treated with Progesterone] results in increased expression of AQP5 mRNA; [Estradiol co-treated with Progesterone] results in increased expression of AQP5 protein; [Progesterone co-treated with Estrogens] affects the localization of AQP5 protein; Progesterone inhibits the reaction [Estradiol results in decreased expression of AQP5 mRNA]; Progesterone promotes the reaction [Estradiol results in decreased expression of AQP5 protein]; Quercetin affects the reaction [[Estradiol co-treated with Progesterone] results in increased expression of AQP5 mRNA] Progesterone results in decreased expression of AQP5 mRNA
|
CTD |
PMID:16452730 PMID:22238285 PMID:28341573 |
|
NCBI chr 7:132,601,528...132,605,060
Ensembl chr 7:132,601,059...132,605,062
|
|
| G
|
Aqp7
|
aquaporin 7
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of AQP7 mRNA; [Estradiol co-treated with Progesterone] results in increased expression of AQP7 protein; Quercetin inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of AQP7 mRNA]; Quercetin inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of AQP7 protein]
|
CTD |
PMID:28341573 |
|
NCBI chr 5:60,968,495...60,982,618
Ensembl chr 5:60,967,558...60,982,618
|
|
| G
|
Ar
|
androgen receptor
|
multiple interactions affects binding increases activity affects activity decreases expression
|
EXP ISO
|
Progesterone analog binds to and results in decreased activity of AR protein Progesterone binds to AR protein Progesterone binds to and results in decreased activity of AR protein; Progesterone binds to and results in increased activity of AR protein; Progesterone inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; Progesterone inhibits the reaction [Metribolone results in increased activity of AR protein] Progesterone results in increased activity of AR protein Progesterone affects the activity of AR protein Progesterone results in decreased expression of AR mRNA
|
CTD |
PMID:9073609 PMID:12676605 PMID:14565775 PMID:15084347 PMID:17804755 PMID:18324785 PMID:19833195 PMID:20359488 PMID:20438827 PMID:21543282 PMID:26867867 PMID:28803809 PMID:33728745 More...
|
|
NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467
|
|
| G
|
Araf
|
A-Raf proto-oncogene, serine/threonine kinase
|
affects expression
|
ISO
|
Progesterone affects the expression of ARAF mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr X:3,780,932...3,845,919
Ensembl chr X:3,780,932...3,792,611
|
|
| G
|
Arap3
|
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ARAP3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr18:30,058,739...30,085,415
Ensembl chr18:30,058,275...30,084,865
|
|
| G
|
Arc
|
activity-regulated cytoskeleton-associated protein
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of ARC mRNA
|
CTD |
PMID:16376865 |
|
NCBI chr 7:108,444,959...108,448,413
Ensembl chr 7:108,444,692...108,451,220
|
|
| G
|
Areg
|
amphiregulin
|
multiple interactions increases expression increases abundance affects expression
|
ISO EXP
|
[Progesterone affects the activity of PGR protein alternative form] which affects the expression of AREG mRNA Progesterone results in increased expression of AREG mRNA AREG protein results in increased abundance of Progesterone [Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of AREG mRNA; [Estradiol co-treated with Progesterone] results in increased expression of AREG mRNA; Estradiol promotes the reaction [Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of AREG protein]]; NRG1 protein promotes the reaction [AREG protein results in increased abundance of Progesterone]; Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of AREG protein]; Progesterone promotes the reaction [Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of AREG protein]] Progesterone affects the expression of AREG [Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in increased expression of AREG mRNA; [Methylnitrosourea co-treated with Progesterone] results in increased expression of AREG mRNA; [Progesterone co-treated with Estrogens] results in increased expression of AREG protein; Estrogens promotes the reaction [Progesterone results in increased expression of AREG mRNA]
|
CTD |
PMID:15178747 PMID:15866122 PMID:16794005 PMID:18070364 PMID:18556351 PMID:18591650 PMID:20732338 PMID:21047912 PMID:21258428 PMID:22414604 PMID:32186404 More...
|
|
NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641
|
|
| G
|
Arfgap2
|
ARF GTPase activating protein 2
|
affects expression
|
ISO
|
Progesterone affects the expression of ARFGAP2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:97,692,105...97,704,246
Ensembl chr 3:97,692,110...97,704,247
|
|
| G
|
Arg1
|
arginase 1
|
affects expression multiple interactions
|
ISO
|
Progesterone affects the expression of ARG1 mRNA Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with IL4 protein] results in increased expression of ARG1 mRNA]; Progesterone inhibits the reaction [IL4 protein results in increased expression of ARG1 mRNA]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of ARG1 mRNA]
|
CTD |
PMID:17251523 PMID:21977998 |
|
NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713
|
|
| G
|
Arg2
|
arginase 2
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ARG2 mRNA Progesterone results in decreased expression of ARG2 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 6:103,669,001...103,694,375
Ensembl chr 6:103,668,988...103,694,375
|
|
| G
|
Arhgap18
|
Rho GTPase activating protein 18
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ARHGAP18 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 1:20,222,948...20,456,827
Ensembl chr 1:20,222,954...20,456,670
|
|
| G
|
Arhgap28
|
Rho GTPase activating protein 28
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ARHGAP28 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:115,277,849...115,444,789
Ensembl chr 9:115,279,734...115,445,008
|
|
| G
|
Arhgdia
|
Rho GDP dissociation inhibitor alpha
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ARHGDIA mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:106,352,858...106,356,347
Ensembl chr10:106,353,491...106,356,347
|
|
| G
|
Arhgef17
|
Rho guanine nucleotide exchange factor 17
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ARHGEF17 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:164,642,690...164,702,241
Ensembl chr 1:164,642,690...164,702,241
|
|
| G
|
Arhgef3
|
Rho guanine nucleotide exchange factor 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of ARHGEF3 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr16:2,308,311...2,588,634
Ensembl chr16:2,308,400...2,588,819
|
|
| G
|
Arl4a
|
ARF like GTPase 4A
|
increases expression
|
ISO
|
Progesterone results in increased expression of ARL4A mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:62,809,287...62,811,297
Ensembl chr 6:62,804,548...62,820,760
|
|
| G
|
Arl4c
|
ARF like GTPase 4C
|
affects expression decreases expression multiple interactions
|
ISO
|
Progesterone affects the expression of ARL4C mRNA Progesterone results in decreased expression of ARL4C mRNA [Estradiol co-treated with Progesterone] results in decreased expression of ARL4C mRNA
|
CTD |
PMID:17251523 PMID:20660070 PMID:20864642 |
|
NCBI chr 9:96,748,075...96,751,510
Ensembl chr 9:96,745,069...96,752,772
|
|
| G
|
Armc9
|
armadillo repeat containing 9
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ARMC9 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 9:94,250,492...94,376,589
Ensembl chr 9:94,250,859...94,376,589
|
|
| G
|
Arnt
|
aryl hydrocarbon receptor nuclear translocator
|
affects expression multiple interactions
|
EXP
|
Progesterone affects the expression of ARNT mRNA [Progesterone co-treated with Estradiol] affects the expression of ARNT mRNA
|
CTD |
PMID:24777823 |
|
NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546
|
|
| G
|
Arnt2
|
aryl hydrocarbon receptor nuclear translocator 2
|
affects expression
|
EXP
|
Progesterone affects the expression of ARNT2 mRNA
|
CTD |
PMID:24777823 |
|
NCBI chr 1:147,645,354...147,801,986
Ensembl chr 1:147,599,058...147,801,997
|
|
| G
|
Arpc4
|
actin related protein 2/3 complex, subunit 4
|
affects expression
|
ISO
|
Progesterone affects the expression of ARPC4 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:148,077,799...148,088,427
Ensembl chr 4:148,077,240...148,088,428
|
|
| G
|
Arpin
|
actin-related protein 2/3 complex inhibitor
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ARPIN mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 1:143,273,590...143,282,426
Ensembl chr 1:143,273,590...143,282,532
|
|
| G
|
Art3
|
ADP-ribosyltransferase 3
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of ART3 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of ART3 mRNA Progesterone results in increased expression of ART3 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20726854 |
|
NCBI chr14:15,921,540...16,003,764
Ensembl chr14:15,921,395...15,949,806
|
|
| G
|
Asap2
|
ArfGAP with SH3 domain, ankyrin repeat and PH domain 2
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ASAP2 mRNA Progesterone results in increased expression of ASAP2 mRNA
|
CTD |
PMID:18037150 PMID:20660070 |
|
NCBI chr 6:46,386,605...46,549,669
Ensembl chr 6:46,386,605...46,549,669
|
|
| G
|
Asb2
|
ankyrin repeat and SOCS box-containing 2
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with TGFB1 protein] results in increased expression of ASB2 mRNA Progesterone results in increased expression of ASB2 mRNA
|
CTD |
PMID:21768398 |
|
NCBI chr 6:128,239,550...128,275,833
Ensembl chr 6:128,239,552...128,266,321
|
|
| G
|
Asgr1
|
asialoglycoprotein receptor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ASGR1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr10:55,274,299...55,278,323
Ensembl chr10:55,274,706...55,278,322
|
|
| G
|
Asns
|
asparagine synthetase (glutamine-hydrolyzing)
|
increases expression
|
ISO
|
Progesterone results in increased expression of ASNS mRNA
|
CTD |
PMID:18037150 PMID:21795739 |
|
NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050
|
|
| G
|
Asph
|
aspartate-beta-hydroxylase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ASPH mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:27,398,933...27,611,519
Ensembl chr 5:27,398,949...27,611,215
|
|
| G
|
Asphd2
|
aspartate beta-hydroxylase domain containing 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ASPHD2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr12:49,908,539...49,919,060
Ensembl chr12:49,908,241...49,925,254
|
|
| G
|
Aspm
|
assembly factor for spindle microtubules
|
increases expression
|
ISO
|
Progesterone results in increased expression of ASPM mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr13:53,625,584...53,674,489
Ensembl chr13:53,625,584...53,674,489
|
|
| G
|
Aspn
|
asporin
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ASPN mRNA Progesterone results in increased expression of ASPN mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr17:15,286,338...15,310,567
Ensembl chr17:15,287,065...15,310,632
|
|
| G
|
Asrgl1
|
asparaginase and isoaspartyl peptidase 1
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of ASRGL1 mRNA Progesterone results in decreased expression of ASRGL1 mRNA
|
CTD |
PMID:17404688 PMID:21540246 |
|
NCBI chr 1:215,436,180...215,456,188
Ensembl chr 1:215,435,218...215,456,198
|
|
| G
|
Atad2
|
ATPase family, AAA domain containing 2
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ATAD2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of ATAD2 mRNA Progesterone results in increased expression of ATAD2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 7:91,523,626...91,566,238
Ensembl chr 7:91,523,626...91,566,238
|
|
| G
|
Atf3
|
activating transcription factor 3
|
multiple interactions increases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of ATF3 mRNA]
|
CTD |
PMID:15674352 |
|
NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750
|
|
| G
|
Atf4
|
activating transcription factor 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of ATF4 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739
|
|
| G
|
Atg13
|
autophagy related 13
|
affects expression
|
ISO
|
Progesterone affects the expression of ATG13 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:98,102,831...98,136,741
Ensembl chr 3:98,101,552...98,136,743
|
|
| G
|
Atg2b
|
autophagy related 2B
|
increases expression
|
ISO
|
Progesterone results in increased expression of ATG2B mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 6:130,286,979...130,357,109
Ensembl chr 6:130,286,986...130,357,109
|
|
| G
|
Atp10a
|
ATPase phospholipid transporting 10A (putative)
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ATP10A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:118,692,456...118,866,117
Ensembl chr 1:118,692,478...118,866,114
|
|
| G
|
Atp10b
|
ATPase phospholipid transporting 10B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ATP10B mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:27,996,729...28,252,801
Ensembl chr10:27,910,295...28,251,450
|
|
| G
|
Atp1a1
|
ATPase Na+/K+ transporting subunit alpha 1
|
increases expression increases activity
|
ISO EXP
|
Progesterone results in increased expression of ATP1A1 mRNA Progesterone results in increased activity of ATP1A1 protein
|
CTD |
PMID:18037150 PMID:20726854 PMID:22759964 |
|
NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:191,709,311...191,737,425
|
|
| G
|
Atp1b1
|
ATPase Na+/K+ transporting subunit beta 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ATP1B1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr13:79,319,708...79,340,226
Ensembl chr13:79,319,706...79,340,549
|
|
| G
|
Atp2a1
|
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1
|
multiple interactions decreases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in decreased expression of ATP2A1 mRNA]
|
CTD |
PMID:27264040 |
|
NCBI chr 1:190,457,198...190,475,410
Ensembl chr 1:190,457,198...190,475,423
|
|
| G
|
Atp2a2
|
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of ATP2A2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr12:39,733,519...39,782,942
Ensembl chr12:39,733,458...39,782,934
|
|
| G
|
Atp2b4
|
ATPase plasma membrane Ca2+ transporting 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ATP2B4 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr13:47,708,157...47,807,389
Ensembl chr13:47,711,121...47,758,876
|
|
| G
|
Atp2c2
|
ATPase secretory pathway Ca2+ transporting 2
|
multiple interactions increases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in increased expression of ATP2C2 mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr19:64,662,729...64,719,998
Ensembl chr19:64,662,715...64,719,996
|
|
| G
|
Atp5f1b
|
ATP synthase F1 subunit beta
|
increases phosphorylation
|
EXP
|
Progesterone results in increased phosphorylation of ATP5F1B protein
|
CTD |
PMID:17303654 |
|
NCBI chr 7:1,100,058...1,106,461
Ensembl chr 7:1,099,860...1,106,462
|
|
| G
|
Atp6v1a
|
ATPase H+ transporting V1 subunit A
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of ATP6V1A mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr11:70,066,800...70,120,603
Ensembl chr11:70,035,134...70,120,603
|
|
| G
|
Atp7b
|
ATPase copper transporting beta
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ATP7B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr16:76,654,725...76,726,092
Ensembl chr16:76,653,660...76,728,801
|
|
| G
|
Atp8a1
|
ATPase phospholipid transporting 8A1
|
affects expression
|
ISO
|
Progesterone affects the expression of ATP8A1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr14:40,668,932...40,911,465
Ensembl chr14:40,731,846...40,911,463
|
|
| G
|
Atp8a2
|
ATPase phospholipid transporting 8A2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ATP8A2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:37,993,507...38,526,408
Ensembl chr15:38,002,305...38,526,212
|
|
| G
|
Atp8b1
|
ATPase phospholipid transporting 8B1
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ATP8B1 mRNA Progesterone results in decreased expression of ATP8B1 mRNA
|
CTD |
PMID:20660070 PMID:20864642 |
|
NCBI chr18:60,286,605...60,427,862
Ensembl chr18:60,288,464...60,427,027
|
|
| G
|
Aurka
|
aurora kinase A
|
increases expression multiple interactions decreases expression
|
ISO EXP
|
Progesterone results in increased expression of AURKA mRNA [Estrogens co-treated with Progesterone] inhibits the reaction [Methylnitrosourea results in increased expression of AURKA mRNA] Progesterone results in decreased expression of AURKA mRNA
|
CTD |
PMID:12124350 PMID:16888808 PMID:21795739 |
|
NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771
|
|
| G
|
Aurkb
|
aurora kinase B
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of AURKB mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285
|
|
| G
|
Avp
|
arginine vasopressin
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of AVP protein
|
CTD |
PMID:16454802 |
|
NCBI chr 3:138,246,544...138,248,522
Ensembl chr 3:138,246,554...138,248,522
|
|
| G
|
Avpi1
|
arginine vasopressin-induced 1
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of AVPI1 mRNA Progesterone results in increased expression of AVPI1 mRNA
|
CTD |
PMID:20660070 PMID:20726854 |
|
NCBI chr 1:250,879,530...250,885,448
Ensembl chr 1:250,879,530...250,885,704
|
|
| G
|
Avpr1a
|
arginine vasopressin receptor 1A
|
increases expression
|
ISO
|
Progesterone results in increased expression of AVPR1A mRNA
|
CTD |
PMID:20864642 PMID:22238285 |
|
NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:59,999,738...60,003,837
|
|
| G
|
Axin1
|
axin 1
|
affects expression increases expression
|
ISO EXP
|
Progesterone affects the expression of AXIN1 mRNA Progesterone results in increased expression of AXIN1 mRNA
|
CTD |
PMID:17170212 PMID:17251523 |
|
NCBI chr10:15,667,894...15,720,092
Ensembl chr10:15,667,958...15,720,092
|
|
| G
|
Axin2
|
axin 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of AXIN2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:94,393,379...94,426,579
Ensembl chr10:94,395,909...94,426,575
|
|
| G
|
B3gnt5
|
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of B3GNT5 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr11:94,645,480...94,657,584
Ensembl chr11:94,645,480...94,660,514
|
|
| G
|
B4galt2
|
beta-1,4-galactosyltransferase 2
|
decreases expression affects expression
|
ISO
|
Progesterone results in decreased expression of B4GALT2 mRNA Progesterone affects the expression of B4GALT2 mRNA
|
CTD |
PMID:17251523 PMID:18037150 |
|
NCBI chr 5:136,697,981...136,707,783
Ensembl chr 5:136,697,981...136,710,422
|
|
| G
|
B4galt6
|
beta-1,4-galactosyltransferase 6
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of B4GALT6 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr18:12,233,350...12,290,204
Ensembl chr18:12,233,351...12,290,204
|
|
| G
|
Baalc
|
BAALC binder of MAP3K1 and KLF4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of BAALC mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:71,803,640...71,877,608
Ensembl chr 7:71,774,898...71,879,261
|
|
| G
|
Bach1
|
BTB domain and CNC homolog 1
|
affects expression
|
ISO
|
Progesterone affects the expression of BACH1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr11:40,425,721...40,461,118
Ensembl chr11:40,425,664...40,461,277
|
|
| G
|
Bad
|
BCL2-associated agonist of cell death
|
decreases expression multiple interactions
|
EXP
|
Progesterone results in decreased expression of BAD mRNA [Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in decreased expression of BAD mRNA
|
CTD |
PMID:15941375 PMID:20732338 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:213,562,187...213,572,034
|
|
| G
|
Bag1
|
BAG cochaperone 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of BAG1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:60,864,476...60,877,059
Ensembl chr 5:60,864,476...60,878,161
|
|
| G
|
Bag3
|
BAG cochaperone 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of BAG3 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:192,533,460...192,557,281
Ensembl chr 1:192,475,828...192,557,280
|
|
| G
|
Bag4
|
BAG cochaperone 4
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of BAG4 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr16:72,991,407...73,008,620
Ensembl chr16:72,991,362...73,013,273
|
|
| G
|
Bag5
|
BAG cochaperone 5
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of BAG5 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:136,589,623...136,593,278
Ensembl chr 6:136,584,741...136,598,492
|
|
| G
|
Baiap2
|
BAR/IMD domain containing adaptor protein 2
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of BAIAP2 mRNA Progesterone results in increased expression of BAIAP2 mRNA
|
CTD |
PMID:20660070 PMID:20726854 |
|
NCBI chr10:105,721,371...105,788,549
Ensembl chr10:105,721,417...105,788,549
|
|
| G
|
Batf3
|
basic leucine zipper ATF-like transcription factor 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of BATF3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr13:105,220,782...105,232,365
Ensembl chr13:105,220,390...105,232,369
|
|
| G
|
Bax
|
BCL2 associated X, apoptosis regulator
|
decreases expression multiple interactions increases expression
|
EXP ISO
|
Progesterone results in decreased expression of BAX mRNA [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in decreased expression of BAX protein; [Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in decreased expression of BAX mRNA; [Methylnitrosourea co-treated with Progesterone] results in decreased expression of BAX mRNA CALB1 protein inhibits the reaction [Progesterone results in increased expression of BAX protein]; S100G protein inhibits the reaction [Progesterone results in increased expression of BAX protein]
|
CTD |
PMID:15941375 PMID:20732338 PMID:21882229 PMID:22465879 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429
|
|
| G
|
Baz1a
|
bromodomain adjacent to zinc finger domain, 1A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of BAZ1A mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:78,124,872...78,247,672
Ensembl chr 6:78,124,872...78,247,648
|
|
| G
|
Bbs10
|
Bardet-Biedl syndrome 10
|
increases expression
|
ISO
|
Progesterone results in increased expression of BBS10 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 7:48,637,324...48,640,395
Ensembl chr 7:48,637,356...48,640,391
|
|
| G
|
Bbs7
|
Bardet-Biedl syndrome 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of BBS7 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 2:121,362,884...121,402,473
Ensembl chr 2:121,362,885...121,402,473
|
|
| G
|
Bcar3
|
BCAR3 adaptor protein, NSP family member
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of BCAR3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:213,209,907...213,323,305
Ensembl chr 2:213,209,893...213,323,302
|
|
| G
|
Bcat1
|
branched chain amino acid transaminase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of BCAT1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:179,695,662...179,777,973
Ensembl chr 4:179,695,662...179,777,288
|
|
| G
|
Bcat2
|
branched chain amino acid transaminase 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of BCAT2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:105,175,157...105,196,474
Ensembl chr 1:105,176,977...105,196,463
|
|
| G
|
Bcl11a
|
BCL11 transcription factor A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of BCL11A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:102,230,147...102,325,289
Ensembl chr14:102,231,113...102,325,623
|
|
| G
|
Bcl2
|
BCL2, apoptosis regulator
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of BCL2 mRNA; Progesterone results in increased expression of BCL2 protein [Progesterone co-treated with Estrogens, Conjugated (USP)] results in increased expression of BCL2 protein [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of BCL2 protein; [Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in increased expression of BCL2 mRNA; [Methylnitrosourea co-treated with Progesterone] results in increased expression of BCL2 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of BCL2 mRNA
|
CTD |
PMID:15779298 PMID:15941375 PMID:18829022 PMID:20732338 PMID:22465879 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900
|
|
| G
|
Bcl2l1
|
Bcl2-like 1
|
multiple interactions affects response to substance increases expression
|
EXP
|
BCL2L1 mRNA affects the reaction [Progesterone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Progesterone results in increased expression of BCL2L1 protein] BCL2L1 mRNA affects the susceptibility to Progesterone Progesterone results in increased expression of BCL2L1 mRNA; Progesterone results in increased expression of BCL2L1 protein
|
CTD |
PMID:15941375 PMID:20726854 PMID:26915917 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907 Ensembl chr 1:161,745,540...161,764,907
|
|
| G
|
Bcl3
|
BCL3, transcription coactivator
|
affects expression
|
ISO
|
Progesterone affects the expression of BCL3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:88,599,321...88,613,555
Ensembl chr 1:88,599,321...88,614,368
|
|
| G
|
Bcl6
|
BCL6, transcription repressor
|
increases expression
|
ISO
|
Progesterone results in increased expression of BCL6 mRNA
|
CTD |
PMID:33728745 |
|
NCBI chr11:90,358,753...90,382,049
Ensembl chr11:90,358,753...90,382,047
|
|
| G
|
Bdh1
|
3-hydroxybutyrate dehydrogenase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of BDH1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636
|
|
| G
|
Bdh2
|
3-hydroxybutyrate dehydrogenase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of BDH2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:226,376,346...226,397,010
Ensembl chr 2:226,376,356...226,397,006
|
|
| G
|
Bdkrb1
|
bradykinin receptor B1
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of BDKRB1 mRNA Progesterone results in decreased expression of BDKRB1 mRNA
|
CTD |
PMID:17404688 PMID:20864642 PMID:21795739 |
|
NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973
|
|
| G
|
Bdnf
|
brain-derived neurotrophic factor
|
decreases expression affects localization multiple interactions increases expression
|
ISO EXP
|
Progesterone results in decreased expression of BDNF mRNA Progesterone affects the localization of BDNF protein Progesterone inhibits the reaction [VPS54 gene mutant form results in decreased expression of BDNF mRNA] Progesterone inhibits the reaction [Estradiol results in increased expression of BDNF protein] Progesterone results in increased expression of BDNF mRNA; Progesterone results in increased expression of BDNF protein
|
CTD |
PMID:15570173 PMID:17052708 PMID:17549730 PMID:18070364 PMID:23157231 |
|
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:116,619,633...116,670,657
|
|
| G
|
Bend6
|
BEN domain containing 6
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of BEND6 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:43,576,982...43,631,437
Ensembl chr 9:43,576,982...43,631,194
|
|
| G
|
Bet1
|
Bet1 golgi vesicular membrane trafficking protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of BET1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 4:33,070,892...33,081,162
Ensembl chr 4:33,070,891...33,081,164
|
|
| G
|
Bhlhe40
|
basic helix-loop-helix family, member e40
|
increases expression
|
ISO
|
Progesterone results in increased expression of BHLHE40 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783
|
|
| G
|
Bhlhe41
|
basic helix-loop-helix family, member e41
|
multiple interactions decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of BHLHE41 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of BHLHE41 mRNA Progesterone results in decreased expression of BHLHE41 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20726854 |
|
NCBI chr 4:180,565,003...180,569,415
Ensembl chr 4:180,565,003...180,569,355
|
|
| G
|
Bicd1
|
BICD cargo adaptor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of BICD1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:184,208,891...184,362,840
Ensembl chr 4:184,210,363...184,357,391
|
|
| G
|
Bid
|
BH3 interacting domain death agonist
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of BID mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275
|
|
| G
|
Bin1
|
bridging integrator 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of BIN1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr18:24,282,840...24,341,461
Ensembl chr18:24,283,801...24,341,458
|
|
| G
|
Birc2
|
baculoviral IAP repeat-containing 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of BIRC2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911
|
|
| G
|
Birc3
|
baculoviral IAP repeat-containing 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of BIRC3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:13,285,703...13,298,590
|
|
| G
|
Birc5
|
baculoviral IAP repeat-containing 5
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of BIRC5 mRNA Progesterone results in increased expression of BIRC5 mRNA
|
CTD |
PMID:21549006 PMID:21795739 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155
|
|
| G
|
Blm
|
BLM RecQ like helicase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of BLM mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 1:143,819,072...143,905,300
Ensembl chr 1:143,819,090...143,905,210
|
|
| G
|
Blnk
|
B-cell linker
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of BLNK mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:249,703,064...249,770,533
Ensembl chr 1:249,703,072...249,770,533
|
|
| G
|
Bmal1
|
basic helix-loop-helix ARNT like 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of BMAL1 mRNA
|
CTD |
PMID:20096720 |
|
NCBI chr 1:176,766,222...176,864,741
Ensembl chr 1:176,829,305...176,864,739
|
|
| G
|
Bmerb1
|
bMERB domain containing 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of BMERB1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:2,286,999...2,453,890
Ensembl chr10:2,287,000...2,453,728
|
|
| G
|
Bmf
|
Bcl2 modifying factor
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of BMF mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 3:125,953,466...125,974,087
Ensembl chr 3:125,953,466...125,974,258
|
|
| G
|
Bmp15
|
bone morphogenetic protein 15
|
multiple interactions
|
EXP
|
[BMP15 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; IGF1 protein inhibits the reaction [BMP15 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]
|
CTD |
PMID:22067323 |
|
NCBI chr X:18,840,943...18,846,006
Ensembl chr X:18,840,829...18,847,438
|
|
| G
|
Bmp2
|
bone morphogenetic protein 2
|
multiple interactions decreases expression decreases abundance
|
ISO EXP
|
[Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of BMP2 mRNA; NCOA2 protein affects the reaction [Progesterone results in decreased expression of BMP2 mRNA]; PGR protein affects the reaction [Progesterone results in decreased expression of BMP2 mRNA] 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of BMP2 mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of BMP2 mRNA; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of BMP2 mRNA]; NOG protein inhibits the reaction [BMP2 protein results in decreased abundance of Progesterone] [BMP2 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; IGF1 protein inhibits the reaction [BMP2 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]
|
CTD |
PMID:17556502 PMID:20639315 PMID:20660070 PMID:22067323 PMID:23313114 PMID:32186404 More...
|
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:141,264,646...141,274,760
|
|
| G
|
Bmp4
|
bone morphogenetic protein 4
|
multiple interactions
|
EXP
|
[BMP4 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; GH1 protein inhibits the reaction [BMP4 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP4 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]
|
CTD |
PMID:22067323 |
|
NCBI chr15:22,098,191...22,113,145
Ensembl chr15:22,098,470...22,105,172
|
|
| G
|
Bmp5
|
bone morphogenetic protein 5
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of BMP5 mRNA]; PGR protein affects the reaction [Progesterone results in decreased expression of BMP5 mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr 8:85,397,629...85,520,374
Ensembl chr 8:85,396,925...85,520,189
|
|
| G
|
Bmp6
|
bone morphogenetic protein 6
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of BMP6 mRNA; BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]; FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]] Progesterone results in increased expression of BMP6 mRNA [BMP6 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; GH1 protein inhibits the reaction [BMP6 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP6 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]
|
CTD |
PMID:18936084 PMID:20660070 PMID:20726854 PMID:22067323 |
|
NCBI chr17:26,523,704...26,785,558
Ensembl chr17:26,523,704...26,675,261
|
|
| G
|
Bmp7
|
bone morphogenetic protein 7
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of BMP7 mRNA; BMP7 protein inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA]; BMP7 protein inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of IGFBP1 protein] Progesterone results in increased expression of BMP7 mRNA Progesterone results in decreased expression of BMP7 mRNA [BMP7 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; GH1 protein inhibits the reaction [BMP7 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP7 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]
|
CTD |
PMID:20085912 PMID:20726854 PMID:22067323 |
|
NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137
|
|
| G
|
Bnipl
|
BCL2 interacting protein like
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of BNIPL mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:185,507,591...185,519,415
Ensembl chr 2:185,507,593...185,517,582
|
|
| G
|
Bpgm
|
bisphosphoglycerate mutase
|
affects expression multiple interactions
|
ISO
|
Progesterone affects the expression of BPGM mRNA [Estradiol co-treated with Progesterone] results in decreased expression of BPGM mRNA
|
CTD |
PMID:17251523 PMID:20660070 |
|
NCBI chr 4:64,106,809...64,135,749
Ensembl chr 4:64,106,804...64,135,627
|
|
| G
|
Brd7
|
bromodomain containing 7
|
affects expression
|
ISO
|
Progesterone affects the expression of BRD7 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr19:34,882,238...34,910,944
Ensembl chr19:34,882,304...34,910,944
|
|
| G
|
Brix1
|
biogenesis of ribosomes BRX1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of BRIX1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:61,177,769...61,188,647
Ensembl chr 2:61,177,771...61,188,647
|
|
| G
|
Btbd3
|
BTB domain containing 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of BTBD3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:146,044,053...146,074,189
Ensembl chr 3:146,044,096...146,074,635
|
|
| G
|
Btd
|
biotinidase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of BTD mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr16:6,869,448...6,900,711
Ensembl chr16:6,869,291...6,901,410
|
|
| G
|
Btg2
|
BTG anti-proliferation factor 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of BTG2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690
|
|
| G
|
Btnl9
|
butyrophilin-like 9
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of BTNL9 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:33,967,098...33,990,304
Ensembl chr10:33,970,675...33,990,354
|
|
| G
|
Btrc
|
beta-transducin repeat containing E3 ubiquitin protein ligase
|
increases expression
|
EXP
|
Progesterone results in increased expression of BTRC mRNA
|
CTD |
PMID:17170212 |
|
NCBI chr 1:254,159,085...254,324,819
Ensembl chr 1:254,159,124...254,328,357
|
|
| G
|
Bub1b
|
BUB1 mitotic checkpoint serine/threonine kinase B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of BUB1B mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796
|
|
| G
|
Bzw2
|
basic leucine zipper and W2 domains 2
|
affects expression
|
ISO
|
Progesterone affects the expression of BZW2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 6:58,555,362...58,615,921
Ensembl chr 6:58,554,961...58,615,912
|
|
| G
|
C1qbp
|
complement C1q binding protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of C1QBP mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr10:56,198,534...56,203,185
Ensembl chr10:56,198,540...56,203,235
|
|
| G
|
C1qtnf7
|
C1q and TNF related 7
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of C1QTNF7 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:71,680,415...71,792,931
Ensembl chr14:71,680,479...71,792,865
|
|
| G
|
C2
|
complement C2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of C2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr20:3,944,722...3,975,006
Ensembl chr20:3,955,776...3,981,740
|
|
| G
|
C2cd4a
|
C2 calcium-dependent domain containing 4A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of C2CD4A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:77,348,161...77,359,996
Ensembl chr 8:77,348,310...77,359,958
|
|
| G
|
C2cd4b
|
C2 calcium-dependent domain containing 4B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of C2CD4B mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 8:77,254,327...77,277,620
Ensembl chr 8:77,238,551...77,279,879
|
|
| G
|
C3
|
complement C3
|
multiple interactions decreases activity
|
EXP ISO
|
Progesterone inhibits the reaction [Estradiol affects the expression of C3 mRNA]; Progesterone inhibits the reaction [Ethinyl Estradiol results in increased expression of C3 mRNA] Progesterone inhibits the reaction [C3 protein results in increased phosphorylation of PRKCA protein]; Progesterone inhibits the reaction [C3 protein results in increased phosphorylation of PRKCZ protein] Progesterone results in decreased activity of C3 protein
|
CTD |
PMID:11566438 PMID:18615583 PMID:24777823 |
|
NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339
|
|
| G
|
C5ar2
|
complement C5a receptor 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of C5AR2 mRNA; Progesterone results in decreased expression of C5AR2 protein
|
CTD |
PMID:18615583 |
|
NCBI chr 1:86,058,557...86,073,583
Ensembl chr 1:86,057,256...86,061,372
|
|
| G
|
Ca12
|
carbonic anhydrase 12
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CA12 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:76,169,723...76,225,465
Ensembl chr 8:76,169,815...76,225,465
|
|
| G
|
Ca3
|
carbonic anhydrase 3
|
affects expression
|
ISO
|
Progesterone affects the expression of CAR3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524
|
|
| G
|
Cacna1c
|
calcium voltage-gated channel subunit alpha1 C
|
increases expression
|
EXP
|
Progesterone results in increased expression of CACNA1C mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:153,431,169...154,051,932
Ensembl chr 4:153,436,427...154,051,762
|
|
| G
|
Cacna1d
|
calcium voltage-gated channel subunit alpha1 D
|
increases expression
|
ISO
|
Progesterone results in increased expression of CACNA1D mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr16:5,233,682...5,527,549
Ensembl chr16:5,233,690...5,674,692
|
|
| G
|
Cacna1g
|
calcium voltage-gated channel subunit alpha1 G
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of CACNA1G mRNA Progesterone results in increased expression of CACNA1G mRNA
|
CTD |
PMID:17404688 PMID:20726854 |
|
NCBI chr10:79,851,886...79,919,926
Ensembl chr10:79,851,896...79,919,634
|
|
| G
|
Cacna2d1
|
calcium voltage-gated channel auxiliary subunit alpha2delta 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CACNA2D1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:19,902,324...20,330,287
Ensembl chr 4:19,905,764...20,330,147
|
|
| G
|
Cadm1
|
cell adhesion molecule 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CADM1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:56,744,374...57,075,264
Ensembl chr 8:56,744,372...57,080,192
|
|
| G
|
Cadps2
|
calcium dependent secretion activator 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of CADPS2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 4:52,746,054...53,275,252
Ensembl chr 4:52,746,065...53,275,004
|
|
| G
|
Calb1
|
calbindin 1
|
multiple interactions decreases expression increases expression
|
ISO
|
CALB1 protein inhibits the reaction [Progesterone results in increased expression of BAX protein]; CALB1 protein inhibits the reaction [Progesterone results in increased expression of CASP3 protein]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of CALB1 mRNA] Progesterone results in increased expression of CALB1 mRNA
|
CTD |
PMID:17556502 PMID:21882229 PMID:22238285 |
|
NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160
|
|
| G
|
Calca
|
calcitonin-related polypeptide alpha
|
increases activity increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased activity of CALCA protein Progesterone results in increased expression of CALCA mRNA [Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of CALCA mRNA
|
CTD |
PMID:9887042 PMID:21770760 PMID:32186404 |
|
NCBI chr 1:178,312,636...178,317,588
Ensembl chr 1:178,312,638...178,317,529
|
|
| G
|
Calcrl
|
calcitonin receptor like receptor
|
increases expression
|
EXP
|
Progesterone results in increased expression of CALCRL mRNA
|
CTD |
PMID:15469997 |
|
NCBI chr 3:89,835,071...89,932,616
Ensembl chr 3:89,835,077...89,887,350
|
|
| G
|
Calhm6
|
calcium homeostasis modulator family member 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of CALHM6 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr20:26,638,721...26,640,466
Ensembl chr20:26,638,722...26,640,408
|
|
| G
|
Calm1
|
calmodulin 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of CALM1 mRNA
|
CTD |
PMID:16376865 |
|
NCBI chr 6:125,217,191...125,227,855
Ensembl chr 6:125,217,246...125,225,381
|
|
| G
|
Calm2
|
calmodulin 2
|
multiple interactions decreases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in decreased expression of CALM2 mRNA]
|
CTD |
PMID:27264040 PMID:31566189 |
|
NCBI chr 6:12,845,170...12,857,830
Ensembl chr15:64,519,554...64,520,657 Ensembl chr 6:64,519,554...64,520,657
|
|
| G
|
Caln1
|
calneuron 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CALN1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr12:31,447,964...31,939,847
|
|
| G
|
Calr
|
calreticulin
|
increases expression decreases expression
|
EXP ISO
|
Progesterone results in increased expression of CALR mRNA Progesterone results in decreased expression of CALR protein
|
CTD |
PMID:16376865 PMID:19460863 |
|
NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236
|
|
| G
|
Caly
|
calcyon neuron-specific vesicular protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CALY mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:204,292,317...204,303,506
Ensembl chr 1:204,292,318...204,303,196
|
|
| G
|
Camk1d
|
calcium/calmodulin-dependent protein kinase ID
|
increases expression
|
ISO
|
Progesterone results in increased expression of CAMK1D mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:77,491,191...77,892,018
Ensembl chr17:77,491,220...77,892,012
|
|
| G
|
Camk2b
|
calcium/calmodulin-dependent protein kinase II beta
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CAMK2B mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr14:85,059,166...85,148,121
Ensembl chr14:85,059,191...85,148,485
|
|
| G
|
Camk2d
|
calcium/calmodulin-dependent protein kinase II delta
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CAMK2D mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:217,698,324...217,961,898
Ensembl chr 2:217,698,551...217,960,276
|
|
| G
|
Camk2n1
|
calcium/calmodulin-dependent protein kinase II inhibitor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CAMK2N1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:155,958,116...155,959,897
Ensembl chr 5:155,957,878...155,961,058
|
|
| G
|
Camp
|
cathelicidin antimicrobial peptide
|
increases expression
|
ISO
|
Progesterone results in increased expression of CAMP mRNA; Progesterone results in increased expression of CAMP protein
|
CTD |
PMID:17701593 |
|
NCBI chr 8:118,720,184...118,721,998
Ensembl chr 8:118,720,184...118,721,998
|
|
| G
|
Cap2
|
cyclase associated actin cytoskeleton regulatory protein 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of CAP2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr17:18,260,462...18,409,681
Ensembl chr17:18,261,646...18,409,563
|
|
| G
|
Capn6
|
calpain 6
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of CAPN6 mRNA [Estradiol co-treated with Progesterone] results in increased expression of CAPN6 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of CAPN6 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr X:112,177,467...112,202,178
Ensembl chr X:112,177,467...112,202,178
|
|
| G
|
Capn9
|
calpain 9
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CAPN9 mRNA Progesterone results in decreased expression of CAPN9 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr19:69,446,847...69,483,810
Ensembl chr19:69,446,847...69,483,810
|
|
| G
|
Car2
|
carbonic anhydrase 2
|
multiple interactions decreases expression increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CA2 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of CA2 mRNA Progesterone results in decreased expression of CA2 mRNA Progesterone results in increased expression of CA2 mRNA Progesterone results in decreased expression of CAR2 mRNA
|
CTD |
PMID:17404688 PMID:18037150 PMID:18497975 PMID:20660070 PMID:22238285 |
|
NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:88,462,872...88,478,064
|
|
| G
|
Casp3
|
caspase 3
|
multiple interactions increases activity increases expression
|
ISO EXP
|
[CCN2 gene mutant form results in increased abundance of Progesterone] which results in increased expression of CASP3 mRNA; CALB1 protein inhibits the reaction [Progesterone results in increased expression of CASP3 protein]; S100G protein inhibits the reaction [Progesterone results in increased expression of CASP3 protein] [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in decreased activity of CASP3 protein; [Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in decreased expression of CASP3 mRNA; [Methylnitrosourea co-treated with Progesterone] results in decreased expression of CASP3 mRNA; BCL2L1 mRNA affects the reaction [Progesterone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Progesterone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]]; Progesterone inhibits the reaction [Dicumarol promotes the reaction [Doxorubicin results in increased activity of CASP3 protein]]; Progesterone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; Progesterone inhibits the reaction [Isoproterenol results in increased activity of CASP3 protein]; Progesterone inhibits the reaction [Palmitates results in increased activity of CASP3 protein] Progesterone results in increased activity of CASP3 protein
|
CTD |
PMID:20726854 PMID:20732338 PMID:21868453 PMID:21882229 PMID:21933904 PMID:21947872 PMID:22465879 PMID:26915917 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732
|
|
| G
|
Casp4
|
caspase 4
|
increases expression
|
EXP
|
Progesterone results in increased expression of CASP4 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727
|
|
| G
|
Casp8
|
caspase 8
|
increases expression multiple interactions
|
ISO EXP
|
Progesterone results in increased expression of CASP8 mRNA [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in decreased activity of CASP8 protein; [Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in decreased expression of CASP8 mRNA Progesterone inhibits the reaction [Cisplatin results in increased activity of CASP8 protein]
|
CTD |
PMID:20732338 PMID:21549006 PMID:21770760 PMID:22465879 PMID:23482746 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699
|
|
| G
|
Casp9
|
caspase 9
|
multiple interactions
|
EXP ISO
|
[Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in decreased expression of CASP9 mRNA Progesterone inhibits the reaction [Cisplatin results in increased activity of CASP9 protein]
|
CTD |
PMID:20732338 PMID:23482746 |
|
Ensembl chr 5:159,391,188...159,409,648
|
|
| G
|
Catsperb
|
cation channel sperm associated auxiliary subunit beta
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CATSPERB mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 6:126,148,156...126,526,814
Ensembl chr 6:126,147,645...126,472,079
|
|
| G
|
Cav1
|
caveolin 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of CAV1 mRNA Mifepristone inhibits the reaction [Progesterone results in increased expression of CAV1 mRNA]
|
CTD |
PMID:15674352 |
|
NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740
|
|
| G
|
Cav3
|
caveolin 3
|
multiple interactions
|
ISO
|
CAV3 mutant form inhibits the reaction [Progesterone results in decreased expression of GNAI3 protein]; CAV3 mutant form inhibits the reaction [Progesterone results in increased expression of GNAS protein]
|
CTD |
PMID:19221014 |
|
NCBI chr 4:147,137,993...147,153,967
Ensembl chr 4:147,137,797...147,153,967
|
|
| G
|
Cbfa2t3
|
CBFA2/RUNX1 partner transcriptional co-repressor 3
|
affects expression
|
ISO
|
Progesterone affects the expression of CBFA2T3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr19:67,584,319...67,658,533
Ensembl chr19:67,589,258...67,658,136
|
|
| G
|
Cblc
|
Cbl proto-oncogene C
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CBLC mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 1:88,567,930...88,584,709
Ensembl chr 1:88,567,932...88,584,709
|
|
| G
|
Cblif
|
cobalamin binding intrinsic factor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CBLIF mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 1:218,030,756...218,045,004
Ensembl chr 1:218,030,731...218,045,117
|
|
| G
|
Cbr3
|
carbonyl reductase 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CBR3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:46,478,295...46,486,555
Ensembl chr11:46,478,274...46,486,558
|
|
| G
|
Cbs
|
cystathionine beta synthase
|
increases expression
|
ISO
|
Progesterone results in increased expression of CBS mRNA
|
CTD |
PMID:21795739 PMID:22238285 |
|
NCBI chr20:9,709,394...9,733,925
Ensembl chr20:9,709,395...9,734,066
|
|
| G
|
Ccdc3
|
coiled-coil domain containing 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CCDC3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:77,941,148...78,044,820
Ensembl chr17:77,944,977...78,044,470
|
|
| G
|
Ccdc68
|
coiled-coil domain containing 68
|
increases expression
|
ISO
|
Progesterone results in increased expression of CCDC68 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr18:65,817,232...65,859,529
Ensembl chr18:65,786,926...65,859,526
|
|
| G
|
Ccdc71l
|
coiled-coil domain containing 71-like
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CCDC71L mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 6:54,687,474...54,691,566
Ensembl chr 6:54,617,540...55,014,344
|
|
| G
|
Cck
|
cholecystokinin
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CCK mRNA Progesterone results in decreased expression of CCK mRNA
|
CTD |
PMID:19693291 PMID:22238285 |
|
NCBI chr 8:130,031,012...130,037,702
Ensembl chr 8:130,031,013...130,037,686
|
|
| G
|
Ccl2
|
C-C motif chemokine ligand 2
|
multiple interactions decreases expression affects expression
|
ISO EXP
|
Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of CCL2 protein] [Estradiol co-treated with Progesterone] results in decreased expression of CCL2 mRNA; [Estradiol co-treated with Progesterone] results in decreased expression of CCL2 protein Progesterone results in decreased expression of CCL2 mRNA Progesterone affects the expression of CCL2 mRNA Progesterone results in decreased expression of CCL2 mRNA; Progesterone results in decreased expression of CCL2 protein
|
CTD |
PMID:17251523 PMID:20726854 PMID:21277368 PMID:21549006 PMID:22014880 |
|
NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875
|
|
| G
|
Ccl3
|
C-C motif chemokine ligand 3
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of CCL3 mRNA
|
CTD |
PMID:21277368 |
|
NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439
|
|
| G
|
Ccl5
|
C-C motif chemokine ligand 5
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of CCL5 mRNA; TGFB1 protein promotes the reaction [Progesterone results in increased expression of CCL5 mRNA] [Estradiol co-treated with Progesterone] results in decreased expression of CCL5 mRNA; [Estradiol co-treated with Progesterone] results in decreased expression of CCL5 protein
|
CTD |
PMID:17404688 PMID:21277368 PMID:21768398 |
|
NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884
|
|
| G
|
Ccn2
|
cellular communication network factor 2
|
affects expression multiple interactions increases abundance increases expression
|
ISO
|
Progesterone affects the expression of CCN2 mRNA [CCN2 gene mutant form results in increased abundance of Progesterone] which results in increased expression of CASP3 mRNA Progesterone results in increased expression of CCN2 mRNA
|
CTD |
PMID:17251523 PMID:21868453 PMID:22238285 |
|
NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976
|
|
| G
|
Ccn3
|
cellular communication network factor 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CCN3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:87,983,788...87,990,810
Ensembl chr 7:87,982,216...87,994,581
|
|
| G
|
Ccn5
|
cellular communication network factor 5
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of CCN5 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of CCN5 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of CCN5 mRNA
|
CTD |
PMID:17404688 PMID:18692832 PMID:20660070 |
|
NCBI chr 3:172,910,670...172,922,064
Ensembl chr 3:172,910,681...172,922,062
|
|
| G
|
Ccna1
|
cyclin A1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CCNA1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of CCNA1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 2:141,383,352...141,428,205
Ensembl chr 2:141,382,468...141,393,300
|
|
| G
|
Ccna2
|
cyclin A2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CCNA2 mRNA; Lithium Chloride inhibits the reaction [Progesterone inhibits the reaction [Estradiol results in increased expression of CCNA2 protein]]; Progesterone inhibits the reaction [Estradiol results in increased expression of CCNA2 protein]
|
CTD |
PMID:15845746 PMID:19693291 |
|
NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701
|
|
| G
|
Ccnb1
|
cyclin B1
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of CCNB1 mRNA Progesterone results in increased expression of CCNB1 mRNA
|
CTD |
PMID:18037150 PMID:18070364 PMID:19000923 PMID:20726854 |
|
NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225
|
|
| G
|
Ccnb2
|
cyclin B2
|
increases expression decreases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of CCNB2 mRNA Progesterone results in decreased expression of CCNB2 mRNA [Estradiol co-treated with Progesterone] results in increased expression of CCNB2 mRNA
|
CTD |
PMID:18070364 PMID:19693291 PMID:21795739 |
|
NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682
|
|
| G
|
Ccnd1
|
cyclin D1
|
increases expression multiple interactions decreases expression
|
ISO EXP
|
Progesterone results in increased expression of CCND1 mRNA [Estradiol co-treated with Progesterone] results in increased expression of CCND1 mRNA; Lithium Chloride inhibits the reaction [Progesterone inhibits the reaction [Estradiol affects the localization of CCND1 protein]]; Progesterone inhibits the reaction [Estradiol affects the localization of CCND1 protein] Progesterone results in decreased expression of CCND1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of CCND1 mRNA [Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in increased expression of CCND1 mRNA; [Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in increased expression of CCND1 protein; [Methylnitrosourea co-treated with Progesterone] results in increased expression of CCND1 mRNA; [Methylnitrosourea co-treated with Progesterone] results in increased expression of CCND1 protein
|
CTD |
PMID:15845746 PMID:16888808 PMID:16966611 PMID:17170212 PMID:18070364 PMID:18556351 PMID:19847363 PMID:20660070 PMID:20732338 PMID:20864642 More...
|
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810
|
|
| G
|
Ccnd3
|
cyclin D3
|
increases expression
|
EXP
|
Progesterone results in increased expression of CCND3 mRNA
|
CTD |
PMID:17170212 |
|
NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033
|
|
| G
|
Ccne1
|
cyclin E1
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of CCNE1 mRNA Progesterone results in increased expression of CCNE1 mRNA
|
CTD |
PMID:16966611 PMID:19847363 |
|
NCBI chr 1:99,918,672...99,927,986
Ensembl chr 1:99,918,674...99,927,822
|
|
| G
|
Ccng1
|
cyclin G1
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of CCNG1 mRNA; PGR gene mutant form inhibits the reaction [Progesterone results in increased expression of CCNG1 mRNA]
|
CTD |
PMID:15661853 PMID:20726854 |
|
NCBI chr10:25,678,503...25,684,876
Ensembl chr10:25,677,885...25,683,766
|
|
| G
|
Ccni
|
cyclin I
|
affects expression
|
ISO
|
Progesterone affects the expression of CCNI mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr14:15,164,047...15,186,885
Ensembl chr14:15,164,095...15,186,885
|
|
| G
|
Ccr1
|
C-C motif chemokine receptor 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of CCR1 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 8:132,433,711...132,439,266
Ensembl chr 8:132,431,592...132,439,374
|
|
| G
|
Cd14
|
CD14 molecule
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CD14 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr18:28,609,558...28,611,409
Ensembl chr18:28,608,883...28,611,292
|
|
| G
|
Cd164
|
CD164 molecule
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CD164 mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr20:46,606,439...46,618,015
Ensembl chr20:46,606,107...46,638,649
|
|
| G
|
Cd180
|
CD180 molecule
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CD180 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 2:35,589,889...35,602,837
Ensembl chr 2:35,589,451...35,603,982
|
|
| G
|
Cd200
|
Cd200 molecule
|
increases expression decreases expression
|
ISO EXP
|
Progesterone results in increased expression of CD200 mRNA Progesterone results in decreased expression of CD200 mRNA
|
CTD |
PMID:20726854 PMID:22238285 |
|
NCBI chr11:68,916,200...68,943,570
Ensembl chr11:68,916,224...68,943,569
|
|
| G
|
Cd226
|
CD226 molecule
|
increases expression
|
ISO
|
Progesterone results in increased expression of CD226 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr18:84,723,330...84,819,836
Ensembl chr18:84,725,242...84,819,835
|
|
| G
|
Cd24
|
CD24 molecule
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CD24 mRNA Progesterone results in decreased expression of CD24 mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785
|
|
| G
|
Cd247
|
Cd247 molecule
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CD247 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr13:80,576,264...80,651,422
Ensembl chr13:80,576,202...80,655,248
|
|
| G
|
Cd302
|
CD302 molecule
|
increases expression
|
ISO
|
Progesterone results in increased expression of CD302 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 3:65,131,017...65,164,737
Ensembl chr 3:65,113,102...65,164,737
|
|
| G
|
Cd36
|
CD36 molecule
|
increases expression
|
EXP
|
Progesterone results in increased expression of CD36 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:18,209,088...18,302,142
|
|
| G
|
Cd38
|
CD38 molecule
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with TGFB1 protein] results in increased expression of CD38 mRNA Progesterone results in increased expression of CD38 mRNA
|
CTD |
PMID:21768398 PMID:21770760 |
|
NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505
|
|
| G
|
Cd3e
|
CD3 epsilon subunit of T-cell receptor complex
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of CD3E mRNA; [Estradiol co-treated with Progesterone] results in decreased expression of CD3E protein
|
CTD |
PMID:21277368 |
|
NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:54,200,617...54,211,876
|
|
| G
|
Cd44
|
CD44 molecule
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of CD44 mRNA Progesterone results in decreased expression of CD44 mRNA Progesterone results in increased expression of CD44 mRNA
|
CTD |
PMID:18692832 PMID:20226447 PMID:20726854 PMID:21770760 PMID:22238285 |
|
NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424
|
|
| G
|
Cd52
|
CD52 molecule
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CD52 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 5:151,603,537...151,605,096
Ensembl chr 5:151,603,524...151,605,086
|
|
| G
|
Cd68
|
Cd68 molecule
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of CD68 mRNA
|
CTD |
PMID:21277368 |
|
NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540
|
|
| G
|
Cd7
|
Cd7 molecule
|
affects expression
|
ISO
|
Progesterone affects the expression of CD7 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:106,802,373...106,805,269
Ensembl chr10:106,802,383...106,805,294
|
|
| G
|
Cd80
|
Cd80 molecule
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CD80 protein
|
CTD |
PMID:21856019 |
|
NCBI chr11:75,760,073...75,798,978
Ensembl chr11:75,760,147...75,797,540
|
|
| G
|
Cd83
|
CD83 molecule
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of CD83 mRNA Progesterone results in increased expression of CD83 mRNA
|
CTD |
PMID:18037150 PMID:22238285 |
|
NCBI chr17:21,093,281...21,113,223
Ensembl chr17:21,093,281...21,113,047
|
|
| G
|
Cd86
|
CD86 molecule
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CD86 protein
|
CTD |
PMID:21856019 |
|
NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361
|
|
| G
|
Cd8b
|
CD8 subunit beta
|
affects expression
|
ISO
|
Progesterone affects the expression of CD8B1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:104,870,911...104,886,838
Ensembl chr 4:104,870,893...104,886,868
|
|
| G
|
Cd96
|
CD96 molecule
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CD96 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr11:68,164,926...68,239,266
Ensembl chr11:68,164,872...68,241,937
|
|
| G
|
Cda
|
cytidine deaminase
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] affects the expression of CDA mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 5:155,839,929...155,866,541
Ensembl chr 5:155,839,929...155,866,541
|
|
| G
|
Cdc14b
|
cell division cycle 14B
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CDC14B mRNA; [Progesterone co-treated with Estradiol] results in increased expression of CDC14B mRNA Progesterone results in increased expression of CDC14B mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr17:850,272...938,972
Ensembl chr17:850,390...971,164
|
|
| G
|
Cdc20
|
cell division cycle 20
|
increases expression decreases expression
|
ISO EXP
|
Progesterone results in increased expression of CDC20 mRNA Progesterone results in decreased expression of CDC20 mRNA
|
CTD |
PMID:18070364 PMID:19693291 PMID:20726854 |
|
NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799
|
|
| G
|
Cdc25b
|
cell division cycle 25B
|
increases expression
|
ISO
|
Progesterone results in increased expression of CDC25B mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 3:138,860,148...138,870,287
Ensembl chr 3:138,860,130...138,870,492
|
|
| G
|
Cdc42ep3
|
CDC42 effector protein 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of CDC42EP3 mRNA
|
CTD |
PMID:17404688 PMID:21795739 PMID:22238285 |
|
NCBI chr 6:21,463,081...21,483,553
Ensembl chr 6:21,461,762...21,508,540
|
|
| G
|
Cdc6
|
cell division cycle 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of CDC6 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:84,360,361...84,374,239
Ensembl chr10:84,360,381...84,374,241
|
|
| G
|
Cdca3
|
cell division cycle associated 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CDCA3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 4:159,321,203...159,325,072
Ensembl chr 4:159,321,014...159,325,068
|
|
| G
|
Cdca7
|
cell division cycle associated 7
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CDCA7 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:77,730,315...77,740,950
Ensembl chr 3:77,729,970...77,740,947
|
|
| G
|
Cdh16
|
cadherin 16
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CDH16 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr19:367,202...377,710
Ensembl chr19:367,274...388,934
|
|
| G
|
Cdh2
|
cadherin 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CDH2 mRNA
|
CTD |
PMID:17556502 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288
|
|
| G
|
Cdh4
|
cadherin 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CDH4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:186,902,763...187,381,020
Ensembl chr 3:186,902,751...187,381,020
|
|
| G
|
Cdh5
|
cadherin 5
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CDH5 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr19:821,875...860,931
Ensembl chr19:822,464...860,822
|
|
| G
|
Cdh6
|
cadherin 6
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CDH6 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 2:63,801,630...63,952,309
Ensembl chr 2:63,806,135...63,952,287
|
|
| G
|
Cdk1
|
cyclin-dependent kinase 1
|
increases expression decreases expression
|
ISO EXP
|
Progesterone results in increased expression of CDK1 mRNA Progesterone results in decreased expression of CDK1 mRNA
|
CTD |
PMID:18070364 PMID:20726854 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455
|
|
| G
|
Cdk19
|
cyclin-dependent kinase 19
|
increases expression
|
ISO
|
Progesterone results in increased expression of CDK19 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr20:45,324,911...45,465,121
Ensembl chr20:45,324,862...45,465,121
|
|
| G
|
Cdk2
|
cyclin dependent kinase 2
|
multiple interactions decreases activity increases expression
|
ISO
|
Progesterone promotes the reaction [CDK2 protein binds to CDKN1A protein]; Progesterone promotes the reaction [CDK2 protein binds to CDKN1B protein] Progesterone results in decreased activity of CDK2 protein Progesterone results in increased expression of CDK2 mRNA
|
CTD |
PMID:18850315 PMID:19847363 |
|
NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878
|
|
| G
|
Cdk4
|
cyclin-dependent kinase 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of CDK4 mRNA
|
CTD |
PMID:19847363 |
|
NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163
|
|
| G
|
Cdk5rap2
|
CDK5 regulatory subunit associated protein 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CDK5RAP2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:88,807,402...88,976,005
Ensembl chr 5:88,807,402...88,976,069
|
|
| G
|
Cdk8
|
cyclin-dependent kinase 8
|
increases expression
|
ISO
|
Progesterone results in increased expression of CDK8 mRNA
|
CTD |
PMID:16888808 |
|
NCBI chr12:13,851,024...13,919,017
Ensembl chr12:13,851,024...13,917,992
|
|
| G
|
Cdk9
|
cyclin-dependent kinase 9
|
increases expression
|
ISO
|
Progesterone results in increased expression of CDK9 mRNA
|
CTD |
PMID:16888808 |
|
NCBI chr 3:36,394,168...36,399,016
Ensembl chr 3:36,394,169...36,399,528
|
|
| G
|
Cdkl1
|
cyclin dependent kinase like 1
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of CDKL1 mRNA NCOA2 protein affects the reaction [Progesterone results in decreased expression of CDKL1 mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr 6:93,960,157...94,005,207
Ensembl chr 6:93,959,911...94,006,115
|
|
| G
|
Cdkl2
|
cyclin dependent kinase like 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CDKL2 mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr14:16,312,154...16,347,524
Ensembl chr14:16,312,932...16,347,523
|
|
| G
|
Cdkn1a
|
cyclin-dependent kinase inhibitor 1A
|
multiple interactions increases expression
|
ISO
|
Progesterone promotes the reaction [CDK2 protein binds to CDKN1A protein]; TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1A mRNA]; TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1A protein] Progesterone results in increased expression of CDKN1A mRNA; Progesterone results in increased expression of CDKN1A protein
|
CTD |
PMID:18045962 PMID:18850315 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969
|
|
| G
|
Cdkn1b
|
cyclin-dependent kinase inhibitor 1B
|
multiple interactions affects localization increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CDKN1B mRNA; [Progesterone co-treated with Estradiol] results in increased expression of and results in increased stability of CDKN1B protein; FZR1 mutant form inhibits the reaction [Progesterone affects the localization of CDKN1B protein]; Progesterone promotes the reaction [CDK2 protein binds to CDKN1B protein]; TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1B mRNA]; TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1B protein] Progesterone results in increased expression of CDKN1B mRNA; Progesterone results in increased expression of CDKN1B protein
|
CTD |
PMID:18850315 PMID:22064387 PMID:23029392 |
|
NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498
|
|
| G
|
Cdkn1c
|
cyclin-dependent kinase inhibitor 1C
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of CDKN1C mRNA Progesterone results in increased expression of CDKN1C mRNA
|
CTD |
PMID:20726854 PMID:22064387 |
|
NCBI chr 1:208,084,801...208,087,680
Ensembl chr 1:208,084,787...208,087,498
|
|
| G
|
Cdkn2aip
|
CDKN2A interacting protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of CDKN2AIP mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr16:51,266,613...51,274,051
Ensembl chr16:51,268,896...51,274,049
|
|
| G
|
Cdkn2b
|
cyclin-dependent kinase inhibitor 2B
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CDKN2B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:109,123,308...109,134,906
Ensembl chr 5:109,114,322...109,134,855
|
|
| G
|
Cdkn2c
|
cyclin-dependent kinase inhibitor 2C
|
increases expression
|
ISO
|
Progesterone results in increased expression of CDKN2C mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 5:129,639,736...129,645,564
Ensembl chr 5:129,639,736...129,644,891
|
|
| G
|
Cdkn3
|
cyclin-dependent kinase inhibitor 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CDKN3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr15:22,502,299...22,513,725
Ensembl chr15:22,502,382...22,513,722
|
|
| G
|
Cdo1
|
cysteine dioxygenase type 1
|
affects expression increases expression
|
ISO EXP
|
Progesterone affects the expression of CDO1 mRNA Progesterone results in increased expression of CDO1 mRNA
|
CTD |
PMID:17251523 PMID:20726854 |
|
NCBI chr18:41,619,076...41,633,719
Ensembl chr18:41,619,070...41,633,891
|
|
| G
|
Cdt1
|
chromatin licensing and DNA replication factor 1
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of CDT1 protein]
|
CTD |
PMID:16966611 |
|
NCBI chr19:67,529,249...67,534,195
Ensembl chr19:67,529,201...67,534,194
|
|
| G
|
Ceacam1
|
CEA cell adhesion molecule 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CEACAM1 mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:90,171,401...90,187,798
|
|
| G
|
Ceacam6
|
CEA cell adhesion molecule 6
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CEACAM6 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:89,544,415...89,562,552
Ensembl chr 1:89,544,400...89,562,552
|
|
| G
|
Cebpb
|
CCAAT/enhancer binding protein beta
|
increases response to substance increases expression decreases expression
|
ISO EXP
|
CEBPB protein results in increased susceptibility to Progesterone Progesterone results in increased expression of CEBPB mRNA Progesterone results in decreased expression of CEBPB mRNA
|
CTD |
PMID:20726854 PMID:21549006 PMID:23097472 |
|
NCBI chr 3:176,817,005...176,818,436
Ensembl chr 3:176,816,859...176,838,072
|
|
| G
|
Cebpd
|
CCAAT/enhancer binding protein delta
|
affects expression multiple interactions increases expression
|
ISO EXP
|
Progesterone affects the expression of CEBPD mRNA [Estradiol co-treated with Progesterone] results in increased expression of CEBPD mRNA Progesterone results in increased expression of CEBPD mRNA
|
CTD |
PMID:17251523 PMID:18037150 PMID:20660070 PMID:20726854 PMID:21795739 |
|
NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824
|
|
| G
|
Cebpg
|
CCAAT/enhancer binding protein gamma
|
increases expression
|
ISO
|
Progesterone results in increased expression of CEBPG mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:96,820,981...96,829,736
Ensembl chr 1:96,810,214...96,830,283
|
|
| G
|
Cemip
|
cell migration inducing hyaluronidase 1
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of CEMIP mRNA]
|
CTD |
PMID:21795739 |
|
NCBI chr 1:147,316,052...147,471,552
Ensembl chr 1:147,316,052...147,471,768
|
|
| G
|
Cenpa
|
centromere protein A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CENPA mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 6:31,420,062...31,431,703
|
|
| G
|
Cenpf
|
centromere protein F
|
increases expression
|
ISO
|
Progesterone results in increased expression of CENPF mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886
|
|
| G
|
Cenpn
|
centromere protein N
|
increases expression
|
ISO
|
Progesterone results in increased expression of CENPN mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr19:61,880,101...61,902,850
Ensembl chr19:61,877,148...61,902,918
|
|
| G
|
Cenpq
|
centromere protein Q
|
increases expression
|
ISO
|
Progesterone results in increased expression of CENPQ mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 9:27,454,339...27,469,371
Ensembl chr 9:27,454,252...27,469,366
|
|
| G
|
Cenpu
|
centromere protein U
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of CENPU mRNA Progesterone results in decreased expression of CENPU mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr16:52,448,446...52,471,662
Ensembl chr16:52,425,096...52,471,662
|
|
| G
|
Cenpv
|
centromere protein V
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CENPV mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:47,713,778...47,746,800
Ensembl chr10:47,713,778...47,727,679
|
|
| G
|
Cep131
|
centrosomal protein 131
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CEP131 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr10:105,844,433...105,868,811
Ensembl chr10:105,844,433...105,868,797
|
|
| G
|
Cep15
|
centrosomal protein 15
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CEP15 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr15:15,247,627...15,265,560
Ensembl chr15:15,247,932...15,265,475
|
|
| G
|
Cep162
|
centrosomal protein 162
|
increases expression
|
ISO
|
Progesterone results in increased expression of CEP162 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 8:97,029,677...97,088,243
Ensembl chr 8:97,029,677...97,088,207
|
|
| G
|
Cep55
|
centrosomal protein 55
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of CEP55 mRNA Progesterone results in decreased expression of CEP55 mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr 1:245,245,272...245,260,835
Ensembl chr 1:245,245,306...245,260,890
|
|
| G
|
Cep57
|
centrosomal protein 57
|
increases expression
|
ISO
|
Progesterone results in increased expression of CEP57 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 8:18,951,179...18,971,205
Ensembl chr 8:18,932,808...18,970,890
|
|
| G
|
Cep76
|
centrosomal protein 76
|
increases expression
|
ISO
|
Progesterone results in increased expression of CEP76 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr18:63,444,389...63,478,358
Ensembl chr18:63,443,746...63,478,358
|
|
| G
|
Cerk
|
ceramide kinase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CERK mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:119,105,674...119,149,885
Ensembl chr 7:119,105,674...119,148,570
|
|
| G
|
Cers3
|
ceramide synthase 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CERS3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:129,728,136...129,833,182
Ensembl chr 1:129,677,781...129,833,181
|
|
| G
|
Cers6
|
ceramide synthase 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of CERS6 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 3:74,038,520...74,287,544
Ensembl chr 3:74,038,851...74,287,544
|
|
| G
|
Ces4a
|
carboxylesterase 4A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CES4A mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr19:49,921,643...49,942,838
Ensembl chr19:49,921,608...49,939,461
|
|
| G
|
Cfb
|
complement factor B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CFB mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr20:3,975,271...3,981,138
Ensembl chr20:3,955,776...3,981,740
|
|
| G
|
Cfd
|
complement factor D
|
affects expression
|
ISO
|
Progesterone affects the expression of CFD mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:10,463,773...10,465,496
Ensembl chr 7:10,463,775...10,465,572
|
|
| G
|
Cfh
|
complement factor H
|
increases expression decreases expression
|
ISO EXP
|
Progesterone results in increased expression of CFH mRNA Progesterone results in decreased expression of CFH mRNA
|
CTD |
PMID:20726854 PMID:20864642 PMID:21795739 |
|
NCBI chr13:54,063,079...54,164,523
Ensembl chr13:54,062,531...54,164,532
|
|
| G
|
Cfhr1
|
complement factor H-related 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CFHR1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr13:53,946,298...53,961,282
Ensembl chr13:53,919,927...53,961,303
|
|
| G
|
Cfi
|
complement factor I
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CFI mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:221,062,206...221,104,790
Ensembl chr 2:221,062,212...221,104,786
|
|
| G
|
Cfl1
|
cofilin 1
|
multiple interactions
|
ISO
|
CFL1 protein affects the reaction [CGA protein results in increased secretion of Progesterone]
|
CTD |
PMID:20610540 |
|
NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:212,226,121...212,231,353
|
|
| G
|
Cflar
|
CASP8 and FADD-like apoptosis regulator
|
increases expression
|
EXP
|
Progesterone results in increased expression of CFLAR mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434
|
|
| G
|
Cftr
|
CF transmembrane conductance regulator
|
multiple interactions decreases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of CFTR mRNA Progesterone results in decreased expression of CFTR mRNA; Progesterone results in decreased expression of CFTR protein [Genistein co-treated with estradiol-17-benzoate co-treated with Progesterone] results in increased expression of CFTR mRNA; [Genistein co-treated with estradiol-17-benzoate co-treated with Progesterone] results in increased expression of CFTR protein
|
CTD |
PMID:15471937 PMID:17404688 PMID:26529183 |
|
NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643
|
|
| G
|
Cga
|
glycoprotein hormones, alpha polypeptide
|
multiple interactions increases abundance increases secretion
|
EXP ISO
|
[[3,4',5-trimethoxystilbene co-treated with CGA protein] results in decreased expression of CYP17A1 protein] which results in increased secretion of Progesterone; [[resveratrol analog co-treated with CGA protein] results in decreased expression of CYP17A1 protein] which results in increased secretion of Progesterone; [[resveratrol co-treated with CGA protein] results in decreased expression of CYP17A1 protein] which results in increased secretion of Progesterone; ADM protein inhibits the reaction [CGA protein results in increased secretion of Progesterone]; bifenthrin analog inhibits the reaction [CGA protein results in increased abundance of Progesterone] lead acetate inhibits the reaction [CGA protein results in increased abundance of Progesterone]; mono-(2-ethylhexyl)phthalate inhibits the reaction [CGA protein results in increased abundance of Progesterone] [3,4',5-trimethoxystilbene co-treated with CGA protein] results in increased secretion of Progesterone; [CGA protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; [CGA protein co-treated with FSHB protein] results in increased abundance of Progesterone; [CGA protein co-treated with FSHB protein] results in increased secretion of Progesterone; [Resveratrol analog co-treated with CGA protein] results in increased secretion of Progesterone; [Resveratrol co-treated with CGA protein] results in increased secretion of Progesterone; [T0901317 co-treated with fatostatin] promotes the reaction [CGA protein results in increased secretion of Progesterone]; ADM protein modified form inhibits the reaction [ADM protein inhibits the reaction [CGA protein results in increased secretion of Progesterone]]; butylbenzyl phthalate inhibits the reaction [CGA protein results in increased secretion of Progesterone]; CFL1 protein affects the reaction [CGA protein results in increased secretion of Progesterone]; DDT inhibits the reaction [CGA protein results in increased secretion of Progesterone]; decabromobiphenyl ether inhibits the reaction [CGA protein results in increased secretion of Progesterone]; Dibutyl Phthalate inhibits the reaction [CGA protein results in increased secretion of Progesterone]; Diethylhexyl Phthalate inhibits the reaction [CGA protein results in increased secretion of Progesterone]; fatostatin promotes the reaction [CGA protein results in increased secretion of Progesterone]; T0901317 inhibits the reaction [[CGA protein co-treated with FSHB protein] results in increased abundance of Progesterone]
|
CTD |
PMID:11213355 PMID:12647776 PMID:18401014 PMID:19228890 PMID:19603415 PMID:20610540 PMID:20926582 PMID:21458522 PMID:21871944 PMID:23071612 PMID:25016925 PMID:27181934 PMID:29366778 PMID:31132478 PMID:33638691 PMID:34768887 More...
|
|
NCBI chr 5:54,283,109...54,295,464
Ensembl chr 5:54,235,019...54,295,464
|
|
| G
|
Ch25h
|
cholesterol 25-hydroxylase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CH25H mRNA
|
CTD |
PMID:21795739 PMID:22238285 |
|
NCBI chr 1:241,428,048...241,429,366
Ensembl chr 1:241,331,619...241,431,190
|
|
| G
|
Chac1
|
ChaC glutathione-specific gamma-glutamylcyclotransferase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CHAC1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:126,796,131...126,799,352
Ensembl chr 3:126,796,024...126,799,361
|
|
| G
|
Chaf1a
|
chromatin assembly factor 1 subunit A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CHAF1A mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr 9:961,225...987,825
Ensembl chr 9:961,084...987,868
|
|
| G
|
Chaf1b
|
chromatin assembly factor 1 subunit B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CHAF1B mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr11:46,670,560...46,690,739
Ensembl chr11:46,670,630...46,690,733
|
|
| G
|
Chat
|
choline O-acetyltransferase
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [VPS54 gene mutant form results in decreased activity of CHAT protein]; Progesterone inhibits the reaction [VPS54 gene mutant form results in decreased expression of CHAT protein]; Progesterone inhibits the reaction [VPS54 mutant form results in decreased expression of CHAT protein]
|
CTD |
PMID:17052708 PMID:19693665 |
|
NCBI chr16:7,663,665...7,723,416
Ensembl chr16:7,663,665...7,723,416
|
|
| G
|
Chchd10
|
coiled-coil-helix-coiled-coil-helix domain containing 10
|
affects expression
|
ISO
|
Progesterone affects the expression of CHCHD10 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr20:12,725,274...12,730,295
Ensembl chr20:12,725,277...12,745,677
|
|
| G
|
Chek1
|
checkpoint kinase 1
|
decreases expression increases phosphorylation multiple interactions
|
EXP ISO
|
Progesterone results in decreased expression of CHEK1 mRNA Progesterone results in increased phosphorylation of CHEK1 protein Mifepristone inhibits the reaction [Progesterone results in increased phosphorylation of CHEK1 protein]
|
CTD |
PMID:20726854 PMID:22403396 |
|
NCBI chr 8:44,609,417...44,629,867
Ensembl chr 8:44,609,417...44,629,359
|
|
| G
|
Chga
|
chromogranin A
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CHGA mRNA Progesterone results in decreased expression of CHGA mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 6:127,460,895...127,472,238
Ensembl chr 6:127,460,854...127,472,237
|
|
| G
|
Chi3l1
|
chitinase 3 like 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CHI3L1 mRNA Progesterone results in increased expression of CHI3L1 mRNA
|
CTD |
PMID:18497975 PMID:20660070 |
|
NCBI chr13:48,193,839...48,201,822
Ensembl chr13:48,193,800...48,201,825
|
|
| G
|
Chn1
|
chimerin 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CHN1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:78,917,329...79,084,040
Ensembl chr 3:78,917,329...79,084,197
|
|
| G
|
Chn2
|
chimerin 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CHN2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:84,478,989...84,738,068
Ensembl chr 4:84,704,862...84,738,068
|
|
| G
|
Chordc1
|
cysteine and histidine rich domain containing 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CHORDC1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 8:23,650,721...23,674,786
Ensembl chr 8:23,650,865...23,677,696
|
|
| G
|
Chpt1
|
choline phosphotransferase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CHPT1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 7:24,753,880...24,802,529
Ensembl chr 7:24,750,343...24,802,521
|
|
| G
|
Chrdl1
|
chordin-like 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CHRDL1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr X:111,685,864...111,789,684
Ensembl chr X:111,685,866...111,789,661
|
|
| G
|
Chrdl2
|
chordin-like 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of CHRDL2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:163,755,316...163,782,758
Ensembl chr 1:163,755,316...163,782,757
|
|
| G
|
Chrm1
|
cholinergic receptor, muscarinic 1
|
multiple interactions
|
EXP
|
Progesterone inhibits the reaction [Acetylcholine binds to CHRM1 protein]; Progesterone inhibits the reaction [Quinuclidinyl Benzilate binds to CHRM1 protein]
|
CTD |
PMID:15900516 |
|
NCBI chr 1:214,996,180...215,012,136
Ensembl chr 1:214,995,872...215,020,602
|
|
| G
|
Chrm3
|
cholinergic receptor, muscarinic 3
|
multiple interactions
|
EXP
|
Progesterone inhibits the reaction [Acetylcholine binds to CHRM3 protein]; Progesterone inhibits the reaction [Quinuclidinyl Benzilate binds to CHRM3 protein]
|
CTD |
PMID:15900516 |
|
NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304
|
|
| G
|
Chrna4
|
cholinergic receptor nicotinic alpha 4 subunit
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Acetylcholine] results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
|
CTD |
PMID:11517245 |
|
NCBI chr 3:188,506,802...188,535,558
Ensembl chr 3:188,501,209...188,535,105
|
|
| G
|
Chrna5
|
cholinergic receptor nicotinic alpha 5 subunit
|
increases expression
|
ISO
|
Progesterone results in increased expression of CHRNA5 protein Progesterone results in increased expression of CHRNA5 mRNA
|
CTD |
PMID:19220484 |
|
NCBI chr 8:64,265,879...64,294,233
Ensembl chr 8:64,265,879...64,294,233
|
|
| G
|
Chrnb2
|
cholinergic receptor nicotinic beta 2 subunit
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Acetylcholine] results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]
|
CTD |
PMID:11517245 |
|
NCBI chr 2:177,479,091...177,487,306
Ensembl chr 2:177,479,091...177,491,326
|
|
| G
|
Chrne
|
cholinergic receptor nicotinic epsilon subunit
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CHRNE mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:55,829,835...55,838,853
Ensembl chr10:55,829,836...55,834,154
|
|
| G
|
Chst11
|
carbohydrate sulfotransferase 11
|
increases expression
|
ISO
|
Progesterone results in increased expression of CHST11 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 7:22,412,121...22,630,577
Ensembl chr 7:22,415,686...22,630,441
|
|
| G
|
Chst15
|
carbohydrate sulfotransferase 15
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CHST15 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:196,458,978...196,540,088
Ensembl chr 1:196,460,425...196,491,444
|
|
| G
|
Chst4
|
carbohydrate sulfotransferase 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CHST4 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr19:54,900,914...54,911,735
Ensembl chr19:54,882,719...54,916,648
|
|
| G
|
Chst7
|
carbohydrate sulfotransferase 7
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CHST7 mRNA Progesterone results in increased expression of CHST7 mRNA
|
CTD |
PMID:17404688 PMID:20864642 |
|
NCBI chr X:4,949,810...4,986,372
Ensembl chr X:4,938,757...4,986,907
|
|
| G
|
Chst9
|
carbohydrate sulfotransferase 9
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CHST9 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr18:6,850,874...7,125,222
Ensembl chr18:6,851,831...7,125,161
|
|
| G
|
Chsy3
|
chondroitin sulfate synthase 3
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CHSY3 mRNA Progesterone results in increased expression of CHSY3 mRNA
|
CTD |
PMID:20660070 PMID:20864642 |
|
NCBI chr18:54,842,260...55,096,008
Ensembl chr18:54,842,180...55,095,981
|
|
| G
|
Cidec
|
cell death-inducing DFFA-like effector c
|
affects expression
|
ISO
|
Progesterone affects the expression of CIDEC mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:148,124,924...148,137,806
Ensembl chr 4:148,124,925...148,137,806
|
|
| G
|
Cilp
|
cartilage intermediate layer protein
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CILP mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:74,671,696...74,687,420
Ensembl chr 8:74,671,534...74,687,409
|
|
| G
|
Cish
|
cytokine inducible SH2-containing protein
|
multiple interactions
|
EXP
|
Progesterone inhibits the reaction [Estrogens results in increased expression of CISH mRNA]; Progesterone inhibits the reaction [PRL protein results in increased expression of CISH mRNA]
|
CTD |
PMID:18325991 |
|
NCBI chr 8:116,850,969...116,855,917
Ensembl chr 8:116,850,773...116,855,986
|
|
| G
|
Cited1
|
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CITED1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr X:71,390,328...71,395,023
Ensembl chr X:71,390,331...71,393,649
|
|
| G
|
Cited2
|
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CITED2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of CITED2 mRNA [Progesterone results in increased activity of PGR protein] which results in increased expression of CITED2 mRNA
|
CTD |
PMID:15845616 PMID:17404688 PMID:20660070 |
|
NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782
|
|
| G
|
Cited4
|
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of CITED4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:139,532,165...139,533,056
Ensembl chr 5:139,531,584...139,533,361
|
|
| G
|
Ckap2
|
cytoskeleton associated protein 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CKAP2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr16:76,542,114...76,567,297
Ensembl chr16:76,542,104...76,567,352
|
|
| G
|
Ckb
|
creatine kinase B
|
multiple interactions increases expression affects expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CKB mRNA; [Progesterone co-treated with Estradiol] results in increased expression of CKB mRNA Progesterone results in increased expression of CKB mRNA Progesterone affects the expression of CKB mRNA
|
CTD |
PMID:17251523 PMID:17404688 PMID:20660070 |
|
NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478
|
|
| G
|
Ckm
|
creatine kinase, M-type
|
increases expression
|
EXP
|
Progesterone results in increased expression of CKM mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:88,189,382...88,199,717
Ensembl chr 1:88,189,485...88,199,719
|
|
| G
|
Cks1b
|
CDC28 protein kinase regulatory subunit 1B
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CKS1B protein [Estradiol co-treated with Progesterone] results in increased expression of CKS1B mRNA
|
CTD |
PMID:18556351 PMID:23029392 |
|
NCBI chr 2:177,130,751...177,135,333
Ensembl chr 2:177,130,777...177,135,365
|
|
| G
|
Clca1
|
chloride channel accessory 1
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of CLCA1 mRNA Progesterone results in decreased expression of CLCA1 mRNA
|
CTD |
PMID:17251523 PMID:22238285 |
|
NCBI chr 2:236,599,022...236,624,714
Ensembl chr 2:236,599,022...236,624,714
|
|
| G
|
Clca4
|
chloride channel accessory 4
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CLCA4 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 2:236,543,975...236,565,096
Ensembl chr 2:236,544,201...236,563,435
|
|
| G
|
Clcn4
|
chloride voltage-gated channel 4
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CLCN4 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr X:27,290,769...27,356,967
Ensembl chr X:27,290,868...27,356,939
|
|
| G
|
Cldn1
|
claudin 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CLDN1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:87,926,376...87,941,533
Ensembl chr11:87,926,337...87,941,529
|
|
| G
|
Cldn23
|
claudin 23
|
multiple interactions increases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in increased expression of CLDN23 mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr16:63,117,045...63,118,769
Ensembl chr16:63,116,781...63,118,957
|
|
| G
|
Cldn3
|
claudin 3
|
affects expression
|
ISO
|
Progesterone affects the expression of CLDN3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr12:27,345,075...27,346,547
Ensembl chr12:27,345,076...27,348,841
|
|
| G
|
Cldn4
|
claudin 4
|
decreases expression affects expression
|
ISO
|
Progesterone results in decreased expression of CLDN4 mRNA Progesterone affects the expression of CLDN4 mRNA
|
CTD |
PMID:17251523 PMID:18037150 |
|
NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958
|
|
| G
|
Cldn5
|
claudin 5
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of CLDN5 mRNA [Estradiol co-treated with Progesterone] results in increased expression of CLDN5 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr11:95,717,172...95,718,598
Ensembl chr11:95,717,176...95,719,322
|
|
| G
|
Cldn6
|
claudin 6
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CLDN6 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:13,213,837...13,218,578
Ensembl chr10:13,213,956...13,218,581
|
|
| G
|
Cldn8
|
claudin 8
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CLDN8 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:41,362,081...41,364,330
|
|
| G
|
Cldnd1
|
claudin domain containing 1
|
affects expression
|
ISO
|
Progesterone affects the expression of CLDND1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr11:55,352,321...55,358,779
Ensembl chr11:55,352,321...55,358,907
|
|
| G
|
Clec3b
|
C-type lectin domain family 3, member B
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CLEC3B mRNA Progesterone results in increased expression of CLEC3B mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr 8:131,687,575...131,693,292
|
|
| G
|
Clec4d
|
C-type lectin domain family 4, member D
|
affects expression
|
ISO
|
Progesterone affects the expression of CLEC4D mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:158,275,287...158,286,978
Ensembl chr 4:158,275,341...158,287,055
|
|
| G
|
Clgn
|
calmegin
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CLGN mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr19:41,601,568...41,633,207
Ensembl chr19:41,601,568...41,633,325
|
|
| G
|
Clic2
|
chloride intracellular channel 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CLIC2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr20:154,630...169,655
Ensembl chr20:154,255...169,648
|
|
| G
|
Clic3
|
chloride intracellular channel 3
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CLIC3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 3:28,670,176...28,672,166
Ensembl chr 3:28,670,229...28,675,723
|
|
| G
|
Clic4
|
chloride intracellular channel 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CLIC4 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 5:152,737,371...152,797,118
Ensembl chr 5:152,737,371...152,797,118
|
|
| G
|
Clic6
|
chloride intracellular channel 6
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CLIC6 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr11:45,223,715...45,266,261
Ensembl chr11:45,223,669...45,267,344
|
|
| G
|
Clmn
|
calmin
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of CLMN mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr 6:129,470,613...129,572,079
Ensembl chr 6:129,478,149...129,572,027
|
|
| G
|
Clstn2
|
calsyntenin 2
|
increases expression
|
EXP ISO
|
Progesterone results in increased expression of CLSTN2 mRNA
|
CTD |
PMID:20726854 PMID:22238285 |
|
NCBI chr 8:106,899,894...107,516,402
Ensembl chr 8:106,899,894...107,040,053
|
|
| G
|
Clu
|
clusterin
|
increases expression
|
EXP
|
Progesterone results in increased expression of CLU mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860
|
|
| G
|
Cmbl
|
carboxymethylenebutenolidase homolog
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CMBL mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:84,280,128...84,301,878
Ensembl chr 2:84,242,512...84,301,880
|
|
| G
|
Cmklr1
|
chemerin chemokine-like receptor 1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of CMKLR1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr12:48,634,929...48,687,833
Ensembl chr12:48,634,003...48,691,458
|
|
| G
|
Cmpk2
|
cytidine/uridine monophosphate kinase 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CMPK2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:48,802,150...48,813,652
Ensembl chr 6:48,802,321...48,813,652
|
|
| G
|
Cmtm3
|
CKLF-like MARVEL transmembrane domain containing 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CMTM3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr19:629,000...637,152
Ensembl chr19:628,895...636,225
|
|
| G
|
Cndp2
|
carnosine dipeptidase 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CNDP2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr18:80,314,799...80,331,900
Ensembl chr18:80,314,801...80,331,900
|
|
| G
|
Cnga1
|
cyclic nucleotide gated channel subunit alpha 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CNGA1 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr14:35,920,948...35,959,065
Ensembl chr14:35,926,854...35,959,056
|
|
| G
|
Cnih3
|
cornichon family AMPA receptor auxiliary protein 3
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CNIH3 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of CNIH3 mRNA Progesterone results in decreased expression of CNIH3 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr13:95,548,440...95,739,500
Ensembl chr13:95,598,998...95,772,064
|
|
| G
|
Cnn1
|
calponin 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CNN1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 8:28,908,437...28,917,099
Ensembl chr 8:28,908,330...28,919,482
|
|
| G
|
Cnot7
|
CCR4-NOT transcription complex, subunit 7
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CNOT7 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr16:58,478,882...58,498,046
Ensembl chr16:58,478,900...58,498,046
|
|
| G
|
Cnp
|
2',3'-cyclic nucleotide 3' phosphodiesterase
|
increases expression
|
EXP
|
Progesterone results in increased expression of CNP mRNA
|
CTD |
PMID:19853640 |
|
NCBI chr10:86,011,504...86,018,063
Ensembl chr10:86,011,495...86,018,063
|
|
| G
|
Cnr1
|
cannabinoid receptor 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CNR1 mRNA Progesterone results in increased expression of CNR1 mRNA
|
CTD |
PMID:17404688 PMID:20864642 |
|
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252
|
|
| G
|
Cntn1
|
contactin 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CNTN1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:125,142,638...125,440,397
Ensembl chr 7:125,142,696...125,440,391
|
|
| G
|
Cntn3
|
contactin 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of CNTN3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 4:136,397,575...136,770,765
Ensembl chr 4:136,398,572...136,770,717
|
|
| G
|
Cntnap2
|
contactin associated protein 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CNTNAP2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:75,109,358...77,366,258
Ensembl chr 4:75,109,858...77,366,258
|
|
| G
|
Cntnap3
|
contactin associated protein family member 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CNTNAP3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:273,137...461,233
Ensembl chr17:273,137...461,233
|
|
| G
|
Coch
|
cochlin
|
increases expression
|
ISO
|
Progesterone results in increased expression of COCH mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:74,766,485...74,780,504
Ensembl chr 6:74,766,419...74,780,502
|
|
| G
|
Col11a1
|
collagen type XI alpha 1 chain
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of COL11A1 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of COL11A1 mRNA
|
CTD |
PMID:18070364 PMID:20226447 |
|
NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264
|
|
| G
|
Col12a1
|
collagen type XII alpha 1 chain
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of COL12A1 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr 8:89,427,834...89,545,886
Ensembl chr 8:89,427,834...89,545,711
|
|
| G
|
Col13a1
|
collagen type XIII alpha 1 chain
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of COL13A1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr20:30,326,744...30,466,800
Ensembl chr20:30,326,744...30,466,800
|
|
| G
|
Col14a1
|
collagen type XIV alpha 1 chain
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of COL14A1 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938
|
|
| G
|
Col15a1
|
collagen type XV alpha 1 chain
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of COL15A1 mRNA Progesterone results in increased expression of COL15A1 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr 5:66,297,546...66,403,172
Ensembl chr 5:66,297,461...66,403,170
|
|
| G
|
Col16a1
|
collagen type XVI alpha 1 chain
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of COL16A1 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of COL16A1 mRNA
|
CTD |
PMID:18070364 PMID:20226447 |
|
NCBI chr 5:147,672,559...147,727,007
Ensembl chr 5:147,672,601...147,727,011
|
|
| G
|
Col1a1
|
collagen type I alpha 1 chain
|
decreases expression affects expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of COL1A1 mRNA Progesterone affects the expression of COL1A1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of COL1A1 mRNA
|
CTD |
PMID:17251523 PMID:18070364 PMID:19693291 |
|
NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460
|
|
| G
|
Col1a2
|
collagen type I alpha 2 chain
|
multiple interactions decreases expression increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of COL1A2 mRNA Progesterone results in decreased expression of COL1A2 mRNA Progesterone results in increased expression of COL1A2 mRNA
|
CTD |
PMID:18070364 PMID:18692832 PMID:20660070 PMID:21540246 |
|
NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995
|
|
| G
|
Col23a1
|
collagen type XXIII alpha 1 chain
|
increases expression
|
ISO
|
Progesterone results in increased expression of COL23A1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:36,050,327...36,337,279
Ensembl chr10:36,050,259...36,337,897
|
|
| G
|
Col3a1
|
collagen type III alpha 1 chain
|
affects expression
|
ISO
|
Progesterone affects the expression of COL3A1 protein
|
CTD |
PMID:20864640 |
|
NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232
|
|
| G
|
Col4a1
|
collagen type IV alpha 1 chain
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of COL4A1 mRNA Progesterone results in increased expression of COL4A1 mRNA
|
CTD |
PMID:18070364 PMID:20864642 |
|
NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482
|
|
| G
|
Col5a2
|
collagen type V alpha 2 chain
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of COL5A2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 9:54,940,768...55,090,151
Ensembl chr 9:54,940,764...55,090,150
|
|
| G
|
Col6a1
|
collagen type VI alpha 1 chain
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of COL6A1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr20:11,905,690...11,924,111
Ensembl chr20:11,905,457...11,924,107
|
|
| G
|
Col6a3
|
collagen type VI alpha 3 chain
|
affects expression
|
ISO
|
Progesterone affects the expression of COL6A3 protein
|
CTD |
PMID:20864640 |
|
NCBI chr 9:98,809,171...98,887,060
Ensembl chr 9:98,809,171...98,886,990
|
|
| G
|
Col7a1
|
collagen type VII alpha 1 chain
|
affects expression
|
ISO
|
Progesterone affects the expression of COL7A1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 8:118,483,364...118,515,736
Ensembl chr 8:118,483,364...118,517,439
|
|
| G
|
Col8a1
|
collagen type VIII alpha 1 chain
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of COL8A1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr11:56,245,998...56,378,586
Ensembl chr11:56,369,868...56,376,229
|
|
| G
|
Col8a2
|
collagen type VIII alpha 2 chain
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of COL8A2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 5:143,870,754...143,897,372
Ensembl chr 5:143,870,742...143,897,884
|
|
| G
|
Colec12
|
collectin sub-family member 12
|
increases expression
|
ISO
|
Progesterone results in increased expression of COLEC12 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr18:1,005,787...1,193,455
Ensembl chr18:1,005,741...1,195,297
|
|
| G
|
Comt
|
catechol-O-methyltransferase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of COMT protein
|
CTD |
PMID:17138778 |
|
NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533
|
|
| G
|
Cops7a
|
COP9 signalosome subunit 7A
|
affects expression
|
ISO
|
Progesterone affects the expression of COPS7A mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:159,452,878...159,478,878
Ensembl chr 4:159,452,897...159,460,315
|
|
| G
|
Corin
|
corin, serine peptidase
|
increases expression
|
ISO
|
Progesterone results in increased expression of CORIN mRNA
|
CTD |
PMID:20864642 PMID:21795739 |
|
NCBI chr14:36,034,613...36,264,671
Ensembl chr14:36,034,993...36,264,649
|
|
| G
|
Coro6
|
coronin 6
|
increases expression
|
EXP
|
Progesterone results in increased expression of CORO6 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:62,808,172...62,817,788
Ensembl chr10:62,809,689...62,817,787
|
|
| G
|
Cotl1
|
coactosin-like F-actin binding protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of COTL1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr19:64,780,309...64,814,629
Ensembl chr19:64,780,322...64,814,840
|
|
| G
|
Cox4i1
|
cytochrome c oxidase subunit 4i1
|
increases abundance
|
ISO
|
COX4I1 protein results in increased abundance of Progesterone
|
CTD |
PMID:21558439 |
|
NCBI chr19:65,630,383...65,636,623
Ensembl chr19:65,630,432...65,636,624
|
|
| G
|
Cox6a2
|
cytochrome c oxidase subunit 6A2
|
increases expression
|
EXP
|
Progesterone results in increased expression of COX6A2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:192,218,970...192,221,188
Ensembl chr 1:192,218,970...192,219,716
|
|
| G
|
Cox6b1
|
cytochrome c oxidase subunit 6B1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of COX6B1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 1:95,002,513...95,011,516
Ensembl chr 1:95,001,707...95,011,431 Ensembl chr 5:95,001,707...95,011,431
|
|
| G
|
Cox7a1
|
cytochrome c oxidase subunit 7A1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of COX7A1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:94,549,663...94,572,330
Ensembl chr 1:94,569,216...94,570,889
|
|
| G
|
Cox8b
|
cytochrome c oxidase, subunit VIIIb
|
increases expression
|
EXP
|
Progesterone results in increased expression of COX8H mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:205,406,813...205,408,273
Ensembl chr 1:205,406,813...205,408,311
|
|
| G
|
Cp
|
ceruloplasmin
|
affects expression multiple interactions increases expression
|
ISO EXP
|
Progesterone affects the expression of CP mRNA Mifepristone inhibits the reaction [Progesterone affects the expression of CP mRNA] Progesterone results in increased expression of CP mRNA
|
CTD |
PMID:17251523 PMID:20726854 PMID:22414680 |
|
NCBI chr 2:104,368,336...104,427,119
Ensembl chr 2:104,368,456...104,427,087
|
|
| G
|
Cpeb2
|
cytoplasmic polyadenylation element binding protein 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CPEB2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:71,999,958...72,056,012
Ensembl chr14:72,002,072...72,052,263
|
|
| G
|
Cped1
|
cadherin-like and PC-esterase domain containing 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of CPED1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:51,482,497...51,755,440
Ensembl chr 4:51,482,545...51,755,442
|
|
| G
|
Cpm
|
carboxypeptidase M
|
decreases expression multiple interactions increases expression
|
ISO
|
Progesterone results in decreased expression of CPM mRNA [Estradiol co-treated with Progesterone] results in decreased expression of CPM mRNA Progesterone results in increased expression of CPM mRNA
|
CTD |
PMID:17404688 PMID:18070364 PMID:20660070 PMID:20864642 |
|
NCBI chr 7:55,111,599...55,172,114
Ensembl chr 7:55,111,599...55,172,114
|
|
| G
|
Cpq
|
carboxypeptidase Q
|
affects response to substance
|
ISO
|
CPQ gene SNP affects the susceptibility to Progesterone
|
CTD |
PMID:25622337 |
|
NCBI chr 7:66,148,973...66,719,189
Ensembl chr 7:66,149,377...66,716,137
|
|
| G
|
Cpt1b
|
carnitine palmitoyltransferase 1B
|
increases expression
|
EXP
|
Progesterone results in increased expression of CPT1B mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 7:122,370,974...122,380,473
Ensembl chr 7:122,370,444...122,380,036
|
|
| G
|
Cpxm1
|
carboxypeptidase X (M14 family), member 1
|
affects expression
|
ISO
|
Progesterone affects the expression of CPXM1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:138,041,645...138,048,443
Ensembl chr 3:138,041,645...138,048,857
|
|
| G
|
Cpz
|
carboxypeptidase Z
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of CPZ mRNA Progesterone results in increased expression of CPZ mRNA
|
CTD |
PMID:17404688 PMID:20726854 |
|
NCBI chr14:79,448,242...79,471,557
Ensembl chr14:79,448,139...79,471,556
|
|
| G
|
Crabp1
|
cellular retinoic acid binding protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CRABP1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 8:64,047,431...64,055,469
Ensembl chr 8:64,047,060...64,055,470
|
|
| G
|
Crabp2
|
cellular retinoic acid binding protein 2
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CRABP2 mRNA Progesterone results in decreased expression of CRABP2 mRNA
|
CTD |
PMID:17404688 PMID:22238285 |
|
NCBI chr 2:175,714,862...175,719,208
Ensembl chr 2:175,707,312...175,728,385
|
|
| G
|
Creb1
|
cAMP responsive element binding protein 1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of CREB1 mRNA
|
CTD |
PMID:21371490 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339
|
|
| G
|
Creb5
|
cAMP responsive element binding protein 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CREB5 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 4:83,723,587...84,124,786
Ensembl chr 4:83,723,194...84,120,793
|
|
| G
|
Creg1
|
cellular repressor of E1A-stimulated genes 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CREG1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr13:80,552,779...80,565,272
Ensembl chr13:80,549,933...80,565,272
|
|
| G
|
Creld2
|
cysteine-rich with EGF-like domains 2
|
affects expression
|
ISO
|
Progesterone affects the expression of CRELD2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:121,788,754...121,796,230
Ensembl chr 7:121,788,745...121,796,228
|
|
| G
|
Crh
|
corticotropin releasing hormone
|
multiple interactions decreases abundance increases secretion
|
ISO EXP
|
CRH protein inhibits the reaction [Go 6976 results in increased abundance of Progesterone]; Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP]; Progesterone promotes the reaction [CRHR1 protein binds to and results in increased activity of CRH protein] CRH protein results in decreased abundance of Progesterone CRH protein results in increased secretion of Progesterone
|
CTD |
PMID:17170093 PMID:20702571 PMID:23133512 |
|
NCBI chr 2:104,059,184...104,061,048
Ensembl chr 2:104,058,770...104,061,386
|
|
| G
|
Crhr1
|
corticotropin releasing hormone receptor 1
|
multiple interactions increases expression
|
ISO
|
Progesterone promotes the reaction [[CRHR1 protein binds to and results in increased activity of CRH protein] which results in increased abundance of Cyclic AMP]; Progesterone promotes the reaction [CRHR1 protein binds to and results in increased activity of CRH protein] Progesterone results in increased expression of CRHR1 mRNA
|
CTD |
PMID:20702571 |
|
NCBI chr10:89,540,192...89,583,466
Ensembl chr10:89,540,192...89,583,466
|
|
| G
|
Crip1
|
cysteine rich protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CRIP1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 6:138,047,801...138,055,672
Ensembl chr 6:138,047,801...138,055,672
|
|
| G
|
Crispld2
|
cysteine-rich secretory protein LCCL domain containing 2
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of CRISPLD2 mRNA Progesterone results in increased expression of CRISPLD2 mRNA
|
CTD |
PMID:17404688 PMID:20726854 PMID:20864642 PMID:21795739 |
|
NCBI chr19:64,961,764...65,020,099
Ensembl chr19:64,961,771...65,020,349
|
|
| G
|
Crlf1
|
cytokine receptor-like factor 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CRLF1 mRNA Progesterone results in increased expression of CRLF1 mRNA
|
CTD |
PMID:17404688 PMID:19693291 |
|
NCBI chr16:18,958,695...18,970,026
Ensembl chr16:18,957,956...18,969,970
|
|
| G
|
Crtam
|
cytotoxic and regulatory T cell molecule
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CRTAM mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:50,237,210...50,274,472
Ensembl chr 8:50,237,210...50,274,472
|
|
| G
|
Cryab
|
crystallin, alpha B
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of CRYAB mRNA Progesterone results in increased expression of CRYAB mRNA
|
CTD |
PMID:17404688 PMID:20726854 |
|
NCBI chr 8:59,989,885...59,995,532
Ensembl chr 8:59,989,814...59,995,528
|
|
| G
|
Crybg2
|
crystallin beta-gamma domain containing 2
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of CRYBG2 mRNA Progesterone results in decreased expression of CRYBG2 mRNA
|
CTD |
PMID:17404688 PMID:21540246 |
|
NCBI chr 5:151,570,154...151,602,164
Ensembl chr 5:151,570,540...151,602,163
|
|
| G
|
Crybg3
|
crystallin beta-gamma domain containing 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of CRYBG3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr11:54,218,399...54,330,962
Ensembl chr11:54,208,444...54,330,960
|
|
| G
|
Csf2ra
|
colony stimulating factor 2 receptor subunit alpha
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CSF2RA mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr14:113,219...118,808
Ensembl chr14:113,225...118,117
|
|
| G
|
Csf3
|
colony stimulating factor 3
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CSF3 mRNA Progesterone results in increased expression of CSF3 mRNA
|
CTD |
PMID:17404688 PMID:21549006 |
|
NCBI chr10:84,157,485...84,159,860
Ensembl chr10:84,157,211...84,159,860
|
|
| G
|
Csk
|
C-terminal Src kinase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CSK mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:66,925,651...66,930,274
|
|
| G
|
Csmd2
|
CUB and Sushi multiple domains 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CSMD2 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 5:145,626,823...146,196,815
Ensembl chr 5:145,626,845...146,196,812
|
|
| G
|
Cspg5
|
chondroitin sulfate proteoglycan 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CSPG5 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 8:119,098,932...119,113,191
Ensembl chr 8:119,098,925...119,143,907
|
|
| G
|
Csrnp2
|
cysteine and serine rich nuclear protein 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of CSRNP2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 7:133,473,027...133,488,868
Ensembl chr 7:133,473,027...133,488,868
|
|
| G
|
Csrp2
|
cysteine and glycine-rich protein 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CSRP2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 7:48,235,415...48,254,049
Ensembl chr 7:48,235,383...48,266,238
|
|
| G
|
Csrp3
|
cysteine and glycine rich protein 3
|
increases expression
|
EXP
|
Progesterone results in increased expression of CSRP3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:107,664,338...107,682,916
Ensembl chr 1:107,664,338...107,682,916
|
|
| G
|
Cst8
|
cystatin 8
|
affects response to substance
|
ISO
|
CST8 protein affects the susceptibility to Progesterone
|
CTD |
PMID:20811015 |
|
NCBI chr 3:156,697,776...156,704,413
Ensembl chr 3:156,697,767...156,724,636
|
|
| G
|
Csta
|
cystatin A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CSTA mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr11:78,125,813...78,136,818
Ensembl chr11:78,125,800...78,136,822
|
|
| G
|
Ctbp1
|
C-terminal binding protein 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CTBP1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr14:81,679,956...81,707,331
Ensembl chr14:81,679,765...81,707,554
|
|
| G
|
Ctdspl
|
CTD small phosphatase like
|
increases expression
|
ISO
|
Progesterone results in increased expression of CTDSPL mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 8:127,520,478...127,644,999
Ensembl chr 8:127,520,499...127,644,999
|
|
| G
|
Cth
|
cystathionine gamma-lyase
|
increases expression
|
ISO
|
Progesterone results in increased expression of CTH mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:249,634,731...249,661,066
Ensembl chr 2:249,634,731...249,661,066
|
|
| G
|
Ctnna2
|
catenin alpha 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CTNNA2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:110,852,265...112,001,351
Ensembl chr 4:110,852,265...112,001,365
|
|
| G
|
Ctnnb1
|
catenin beta 1
|
increases expression increases response to substance decreases abundance
|
EXP ISO
|
Progesterone results in increased expression of CTNNB1 protein CTNNB1 protein results in increased susceptibility to Progesterone CTNNB1 protein results in decreased abundance of Progesterone
|
CTD |
PMID:17170212 PMID:20610534 PMID:22958837 |
|
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662
|
|
| G
|
Ctnnd2
|
catenin delta 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CTNND2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:82,879,469...83,727,409
Ensembl chr 2:82,879,469...83,727,409
|
|
| G
|
Ctsd
|
cathepsin D
|
increases expression
|
ISO
|
Progesterone results in increased expression of CTSD mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821
|
|
| G
|
Ctse
|
cathepsin E
|
affects expression increases expression
|
ISO
|
Progesterone affects the expression of CTSE mRNA Progesterone results in increased expression of CTSE mRNA
|
CTD |
PMID:17251523 PMID:17404688 |
|
NCBI chr13:45,644,168...45,666,722
Ensembl chr13:45,644,147...45,666,722
|
|
| G
|
Ctsh
|
cathepsin H
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CTSH mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:99,488,756...99,507,639
Ensembl chr 8:99,488,874...99,509,181
|
|
| G
|
Ctsk
|
cathepsin K
|
increases expression
|
EXP
|
Progesterone results in increased expression of CTSK mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:185,747,165...185,765,582
|
|
| G
|
Ctsw
|
cathepsin W
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of CTSW mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:212,201,904...212,208,028
Ensembl chr 1:212,201,904...212,205,292
|
|
| G
|
Cux2
|
cut-like homeobox 2
|
multiple interactions decreases expression increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CUX2 mRNA Progesterone results in decreased expression of CUX2 mRNA Progesterone results in increased expression of CUX2 mRNA
|
CTD |
PMID:17404688 PMID:18070364 |
|
NCBI chr12:40,168,402...40,368,303
Ensembl chr12:40,149,292...40,366,528
|
|
| G
|
Cwh43
|
cell wall biogenesis 43 C-terminal homolog
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of CWH43 mRNA Progesterone results in increased expression of CWH43 mRNA
|
CTD |
PMID:21540246 PMID:22238285 |
|
NCBI chr14:35,108,328...35,154,578
Ensembl chr14:35,108,338...35,154,863
|
|
| G
|
Cx3cl1
|
C-X3-C motif chemokine ligand 1
|
multiple interactions decreases expression
|
ISO
|
CX3CL1 protein promotes the reaction [CGB3 protein results in increased abundance of Progesterone] Progesterone results in decreased expression of CX3CL1 mRNA
|
CTD |
PMID:18292196 PMID:22238285 |
|
NCBI chr19:10,233,326...10,244,856
Ensembl chr19:10,233,329...10,242,999
|
|
| G
|
Cxcl1
|
C-X-C motif chemokine ligand 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CXCL1 mRNA; Progesterone results in decreased expression of CXCL1 protein
|
CTD |
PMID:22615136 |
|
NCBI chr14:17,477,542...17,479,321
Ensembl chr14:17,477,549...17,479,811
|
|
| G
|
Cxcl10
|
C-X-C motif chemokine ligand 10
|
multiple interactions increases expression decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CXCL10 mRNA Progesterone results in increased expression of CXCL10 mRNA Progesterone results in decreased expression of CXCL10 mRNA; Progesterone results in decreased expression of CXCL10 protein
|
CTD |
PMID:15557169 PMID:17404688 PMID:21549006 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261
|
|
| G
|
Cxcl11
|
C-X-C motif chemokine ligand 11
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CXCL11 mRNA Progesterone results in increased expression of CXCL11 mRNA
|
CTD |
PMID:15557169 PMID:17404688 |
|
NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,973,720...15,976,567
|
|
| G
|
Cxcl12
|
C-X-C motif chemokine ligand 12
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of CXCL12 mRNA Progesterone results in decreased expression of CXCL12 mRNA Progesterone results in increased expression of CXCL12 mRNA [Estradiol co-treated with Progesterone] results in increased expression of CXCL12 mRNA
|
CTD |
PMID:18556351 PMID:20660070 PMID:20726854 PMID:21795739 PMID:22238285 |
|
NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627
|
|
| G
|
Cxcl14
|
C-X-C motif chemokine ligand 14
|
affects expression multiple interactions increases expression
|
ISO
|
Progesterone affects the expression of CXCL14 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of CXCL14 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of CXCL14 mRNA; Progesterone promotes the reaction [PGR protein results in increased expression of CXCL14 mRNA] Progesterone results in increased expression of CXCL14 mRNA
|
CTD |
PMID:17251523 PMID:17404688 PMID:19903701 PMID:20660070 |
|
NCBI chr17:8,323,150...8,331,176
Ensembl chr17:8,323,143...8,331,172
|
|
| G
|
Cxcl17
|
C-X-C motif chemokine ligand 17
|
increases expression
|
ISO
|
Progesterone results in increased expression of CXCL17 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:90,112,561...90,124,648
Ensembl chr 1:90,112,771...90,124,535
|
|
| G
|
Cxcl2
|
C-X-C motif chemokine ligand 2
|
decreases expression increases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of CXCL2 mRNA; Progesterone results in decreased expression of CXCL2 protein Progesterone results in increased expression of CXCL2 mRNA [Progesterone co-treated with 1-Naphthylisothiocyanate] results in increased expression of CXCL2 mRNA; [Progesterone co-treated with Dicloxacillin] results in increased expression of CXCL2 mRNA; [Progesterone co-treated with Halothane] results in increased expression of CXCL2 mRNA; [Progesterone co-treated with Halothane] results in increased expression of CXCL2 protein; gadolinium chloride inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of CXCL2 mRNA]; Mifepristone inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of CXCL2 mRNA]]; Progesterone promotes the reaction [Halothane results in increased expression of CXCL2 mRNA]; Progesterone promotes the reaction [Thioacetamide results in increased expression of CXCL2 mRNA]; U 0126 inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of CXCL2 mRNA]
|
CTD |
PMID:21501669 PMID:21795739 PMID:22157104 PMID:22615136 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,465,242...17,467,255
|
|
| G
|
Cxcl3
|
C-X-C motif chemokine ligand 3
|
decreases expression affects expression multiple interactions increases expression
|
ISO
|
Progesterone results in decreased expression of CXCL1 mRNA; Progesterone results in decreased expression of CXCL1 protein Progesterone affects the expression of CXCL1 mRNA gadolinium chloride inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of CXCL1 mRNA]]; gadolinium chloride inhibits the reaction [Progesterone results in increased expression of CXCL1 mRNA]; Mifepristone inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of CXCL1 mRNA]]; Mifepristone inhibits the reaction [Progesterone results in increased expression of CXCL1 mRNA]; Progesterone promotes the reaction [1-Naphthylisothiocyanate results in increased expression of CXCL1 mRNA]; Progesterone promotes the reaction [Dicloxacillin results in increased expression of CXCL1 mRNA]; Progesterone promotes the reaction [Halothane results in increased expression of CXCL1 mRNA]; Progesterone promotes the reaction [Thioacetamide results in increased expression of CXCL1 mRNA]; U 0126 inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of CXCL1 mRNA]]; U 0126 inhibits the reaction [Progesterone results in increased expression of CXCL1 mRNA] Progesterone results in increased expression of CXCL1 mRNA; Progesterone results in increased expression of CXCL1 protein
|
CTD |
PMID:17251523 PMID:21501669 PMID:22157104 PMID:22615136 |
|
NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624
|
|
| G
|
Cxcl9
|
C-X-C motif chemokine ligand 9
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CXCL9 mRNA Progesterone results in increased expression of CXCL9 mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr14:16,007,166...16,012,077
Ensembl chr14:16,007,204...16,014,299
|
|
| G
|
Cxcr4
|
C-X-C motif chemokine receptor 4
|
decreases expression multiple interactions
|
EXP ISO
|
Progesterone results in decreased expression of CXCR4 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of CXCR4 mRNA
|
CTD |
PMID:20660070 PMID:20726854 |
|
NCBI chr13:42,630,383...42,634,288
Ensembl chr13:42,630,104...42,634,459
|
|
| G
|
Cxxc5
|
CXXC finger protein 5
|
affects expression
|
ISO
|
Progesterone affects the expression of CXXC5 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr18:27,701,650...27,732,633
Ensembl chr18:27,701,188...27,732,635
|
|
| G
|
Cyb5a
|
cytochrome b5 type A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CYB5A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr18:80,487,923...80,520,544
Ensembl chr18:14,453,966...14,455,094 Ensembl chr18:14,453,966...14,455,094
|
|
| G
|
Cyb5b
|
cytochrome b5 type B
|
increases expression
|
ISO
|
Progesterone results in increased expression of CYB5B mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr19:51,972,611...52,006,477
Ensembl chr19:51,972,547...52,026,980
|
|
| G
|
Cyba
|
cytochrome b-245 alpha chain
|
increases expression
|
ISO
|
Progesterone results in increased expression of CYBA mRNA
|
CTD |
PMID:16195479 |
|
NCBI chr19:67,396,143...67,404,214
Ensembl chr19:67,396,143...67,404,214
|
|
| G
|
Cycs
|
cytochrome c, somatic
|
multiple interactions
|
EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of CYCS mRNA
|
CTD |
PMID:18829022 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816 Ensembl chr18:80,982,668...80,984,816
|
|
| G
|
Cyfip2
|
cytoplasmic FMR1 interacting protein 2
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CYFIP2 mRNA Progesterone results in decreased expression of CYFIP2 mRNA
|
CTD |
PMID:20660070 PMID:20864642 |
|
NCBI chr10:31,122,653...31,242,440
Ensembl chr10:31,122,653...31,242,440
|
|
| G
|
Cyp11a1
|
cytochrome P450, family 11, subfamily a, polypeptide 1
|
affects abundance affects chemical synthesis multiple interactions increases chemical synthesis
|
ISO EXP
|
CYP11A1 protein affects the abundance of Progesterone CYP11A1 protein affects the chemical synthesis of Progesterone [2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane results in decreased activity of CYP11A1 protein] which results in decreased chemical synthesis of Progesterone; [bisphenol A affects the expression of CYP11A1 mRNA] which affects the abundance of Progesterone; [Diethylstilbestrol results in decreased expression of CYP11A1 protein] which results in decreased abundance of Progesterone; [FSHB protein results in increased expression of CYP11A1 mRNA] which results in increased abundance of Progesterone; GH1 protein promotes the reaction [[FSHB protein results in increased expression of CYP11A1 mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of CYP11A1 mRNA] which results in increased abundance of Progesterone]; manganese chloride inhibits the reaction [CYP11A1 protein results in increased chemical synthesis of Progesterone] CYP11A1 mRNA affects the abundance of Progesterone
|
CTD |
PMID:10964264 PMID:11502818 PMID:12699903 PMID:15819722 PMID:18191889 PMID:21664964 PMID:22067323 PMID:23873838 More...
|
|
NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196
|
|
| G
|
Cyp17a1
|
cytochrome P450, family 17, subfamily a, polypeptide 1
|
multiple interactions affects metabolic processing increases hydroxylation
|
ISO EXP
|
[[abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; [abiraterone results in decreased activity of CYP17A1 protein] which results in decreased hydroxylation of Progesterone; [CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 16-hydroxyprogesterone; [CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone; CYP17A1 protein binds to and affects the metabolism of Progesterone; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Venlafaxine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Venlafaxine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone] CYP17A1 protein affects the metabolism of Progesterone [[3,4',5-trimethoxystilbene co-treated with CGA protein] results in decreased expression of CYP17A1 protein] which results in increased secretion of Progesterone; [[resveratrol analog co-treated with CGA protein] results in decreased expression of CYP17A1 protein] which results in increased secretion of Progesterone; [[resveratrol co-treated with CGA protein] results in decreased expression of CYP17A1 protein] which results in increased secretion of Progesterone
|
CTD |
PMID:14522586 PMID:15261307 PMID:15562394 PMID:16030167 PMID:16054388 PMID:17194026 PMID:19603415 PMID:29100959 More...
|
|
NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974
|
|
| G
|
Cyp19a1
|
cytochrome P450, family 19, subfamily a, polypeptide 1
|
increases activity decreases expression multiple interactions
|
ISO EXP
|
Progesterone results in increased activity of CYP19A1 protein Progesterone results in decreased expression of CYP19A1 mRNA [FSHB protein results in increased expression of CYP19A1 mRNA] which results in increased abundance of Progesterone; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of CYP19A1 mRNA] which results in increased abundance of Progesterone]
|
CTD |
PMID:15862960 PMID:22067323 PMID:22130322 |
|
NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917
|
|
| G
|
Cyp1a1
|
cytochrome P450, family 1, subfamily a, polypeptide 1
|
increases hydroxylation multiple interactions decreases expression decreases activity
|
ISO EXP
|
CYP1A1 protein results in increased hydroxylation of Progesterone [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; [Estradiol co-treated with Progesterone] affects the expression of CYP1A1 mRNA; Progesterone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] Progesterone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Progesterone results in decreased expression of CYP1A1 mRNA Progesterone results in decreased activity of CYP1A1 protein
|
CTD |
PMID:8674863 PMID:10975606 PMID:11281733 PMID:24777823 PMID:32668270 PMID:34181028 More...
|
|
NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012
|
|
| G
|
Cyp1b1
|
cytochrome P450, family 1, subfamily b, polypeptide 1
|
decreases expression multiple interactions increases expression decreases activity
|
ISO EXP
|
Progesterone results in decreased expression of CYP1B1 mRNA [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Progesterone inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; Progesterone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] Progesterone results in decreased expression of CYP1B1 protein [Estradiol co-treated with Progesterone] results in increased expression of CYP1B1 mRNA; Progesterone promotes the reaction [laquinimod metabolite results in increased expression of CYP1B1 mRNA] Progesterone results in increased expression of CYP1B1 mRNA Progesterone results in decreased activity of CYP1B1 protein
|
CTD |
PMID:8674863 PMID:18037150 PMID:20660070 PMID:20726854 PMID:32668270 PMID:33814510 More...
|
|
NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142
|
|
| G
|
Cyp24a1
|
cytochrome P450, family 24, subfamily a, polypeptide 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of CYP24A1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:179,694,647...179,709,083
Ensembl chr 3:179,694,647...179,709,083
|
|
| G
|
Cyp26a1
|
cytochrome P450, family 26, subfamily a, polypeptide 1
|
multiple interactions increases expression affects expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CYP26A1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of CYP26A1 mRNA Progesterone results in increased expression of CYP26A1 mRNA [Progesterone results in increased activity of PGR protein] which results in increased expression of CYP26A1 mRNA Progesterone affects the expression of CYP26A1 mRNA
|
CTD |
PMID:15845616 PMID:17251523 PMID:17404688 PMID:20660070 |
|
NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657
|
|
| G
|
Cyp27a1
|
cytochrome P450, family 27, subfamily a, polypeptide 1
|
multiple interactions increases expression
|
ISO
|
CYP27A1 protein affects the metabolism of and affects the abundance of Progesterone Progesterone results in increased expression of CYP27A1 mRNA
|
CTD |
PMID:19671838 PMID:22238285 |
|
NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215
|
|
| G
|
Cyp27b1
|
cytochrome P450, family 27, subfamily b, polypeptide 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CYP27B1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 7:64,756,626...64,761,570
Ensembl chr 7:64,756,626...64,761,570
|
|
| G
|
Cyp2b3
|
cytochrome P450, family 2, subfamily b, polypeptide 3
|
multiple interactions increases expression decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; [Progesterone co-treated with Estradiol] inhibits the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]; Progesterone inhibits the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA] Progesterone results in increased expression of CYP2B6 mRNA Progesterone results in decreased expression of CYP2B10 mRNA Progesterone results in increased expression of CYP2B10 mRNA
|
CTD |
PMID:7771797 PMID:11075820 PMID:21768169 PMID:22837389 |
|
NCBI chr 1:90,780,468...90,859,852
|
|
| G
|
Cyp2c11
|
cytochrome P450, subfamily 2, polypeptide 11
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of CYP2C18 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:246,175,216...246,211,445
Ensembl chr 1:246,174,711...246,211,853
|
|
| G
|
Cyp2c6
|
cytochrome P450, family 2, subfamily C, polypeptide 6
|
increases hydroxylation
|
ISO
|
CYP2C19 protein results in increased hydroxylation of Progesterone
|
CTD |
PMID:18957504 |
|
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798
|
|
| G
|
Cyp2c79
|
cytochrome P450, family 2, subfamily c, polypeptide 79
|
increases expression
|
ISO
|
Progesterone results in increased expression of CYP2C8 mRNA
|
CTD |
PMID:22837389 |
|
|
|
| G
|
Cyp2e1
|
cytochrome P450, family 2, subfamily e, polypeptide 1
|
affects expression multiple interactions
|
ISO EXP
|
Progesterone affects the expression of CYP2E1 mRNA Progesterone promotes the reaction [Benzene results in decreased activity of CYP2E1 protein]
|
CTD |
PMID:17251523 PMID:18407866 |
|
NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495
|
|
| G
|
Cyp2g1
|
cytochrome P450, family 2, subfamily g, polypeptide 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of CYP2G1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 1:91,273,309...91,284,499
Ensembl chr 1:91,272,680...91,284,498
|
|
| G
|
Cyp3a2
|
cytochrome P450, family 3, subfamily a, polypeptide 2
|
increases expression multiple interactions increases hydroxylation
|
ISO
|
Progesterone results in increased expression of CYP3A4 mRNA Progesterone promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] CYP3A4 protein results in increased hydroxylation of Progesterone
|
CTD |
PMID:18957504 PMID:19299527 PMID:22837389 |
|
NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857
|
|
| G
|
Cyp3a23-3a1
|
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of CYP3A23-3A1 mRNA
|
CTD |
PMID:10707959 |
|
NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813
|
|
| G
|
Cyp3a9
|
cytochrome P450, family 3, subfamily a, polypeptide 9
|
increases expression
|
ISO
|
Progesterone results in increased expression of CYP3A5 mRNA
|
CTD |
PMID:22837389 |
|
NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154
|
|
| G
|
Cyp46a1
|
cytochrome P450, family 46, subfamily a, polypeptide 1
|
increases hydroxylation
|
ISO
|
CYP46A1 protein results in increased hydroxylation of Progesterone
|
CTD |
PMID:14640697 |
|
NCBI chr 6:133,011,948...133,039,167
Ensembl chr 6:133,011,989...133,041,971
|
|
| G
|
Cyp4b1
|
cytochrome P450, family 4, subfamily b, polypeptide 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of CYP4B1 mRNA Progesterone results in increased expression of CYP4B1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 5:134,375,807...134,413,635
Ensembl chr 5:134,375,807...134,393,116
|
|
| G
|
Cyp51
|
cytochrome P450, family 51
|
increases expression
|
ISO
|
Progesterone results in increased expression of CYP51A1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 4:30,991,693...31,010,147
Ensembl chr 4:30,991,613...31,010,450
|
|
| G
|
Dab1
|
DAB adaptor protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of DAB1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:123,621,510...124,742,585
Ensembl chr 5:124,369,415...124,742,584
|
|
| G
|
Dach1
|
dachshund family transcription factor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of DACH1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:80,936,063...81,317,746
Ensembl chr15:80,936,063...81,317,627
|
|
| G
|
Dact1
|
dishevelled-binding antagonist of beta-catenin 1
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of DACT1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of DACT1 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of DACT1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 6:95,526,645...95,538,625
Ensembl chr 6:95,526,690...95,551,053
|
|
| G
|
Dap3
|
death associated protein 3
|
affects expression
|
ISO
|
Progesterone affects the expression of DAP3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:176,617,151...176,645,293
Ensembl chr 2:176,617,155...176,644,270
|
|
| G
|
Dbi
|
diazepam binding inhibitor
|
affects expression
|
ISO
|
Progesterone affects the expression of DBI mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450
|
|
| G
|
Dbn1
|
drebrin 1
|
multiple interactions decreases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of DBN1 mRNA Progesterone results in decreased expression of DBN1 mRNA
|
CTD |
PMID:17404688 PMID:20726854 |
|
NCBI chr17:9,155,729...9,170,121
Ensembl chr17:9,155,787...9,170,122
|
|
| G
|
Dbndd2
|
dysbindin domain containing 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of DBNDD2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:173,634,551...173,639,999
|
|
| G
|
Dbnl
|
drebrin-like
|
affects expression
|
ISO
|
Progesterone affects the expression of DBNL mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr14:84,880,085...84,895,122
Ensembl chr14:84,880,142...84,897,133
|
|
| G
|
Dbp
|
D-box binding PAR bZIP transcription factor
|
affects expression decreases expression
|
ISO EXP
|
Progesterone affects the expression of DBP mRNA Progesterone results in decreased expression of DBP mRNA
|
CTD |
PMID:17251523 PMID:20726854 |
|
NCBI chr 1:105,312,256...105,317,205
Ensembl chr 1:105,312,108...105,317,205
|
|
| G
|
Dcaf12
|
DDB1 and CUL4 associated factor 12
|
affects expression
|
ISO
|
Progesterone affects the expression of DCAF12 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:61,256,353...61,278,155
Ensembl chr 5:61,256,353...61,278,119
|
|
| G
|
Dcbld2
|
discoidin, CUB and LCCL domain containing 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DCBLD2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr11:55,594,691...55,649,113
Ensembl chr11:55,594,691...55,649,085
|
|
| G
|
Dchs1
|
dachsous cadherin-related 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of DCHS1 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of DCHS1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 1:169,516,758...169,550,789
Ensembl chr 1:169,516,762...169,536,639
|
|
| G
|
Dclk1
|
doublecortin-like kinase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of DCLK1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 2:141,567,215...141,861,088
Ensembl chr 2:141,571,983...141,861,090
|
|
| G
|
Dcxr
|
dicarbonyl and L-xylulose reductase
|
increases expression
|
EXP
|
Progesterone results in increased expression of DCXR mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:106,504,730...106,506,619
|
|
| G
|
Ddah1
|
dimethylarginine dimethylaminohydrolase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of DDAH1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:237,327,812...237,460,624
Ensembl chr 2:237,327,766...237,460,626
|
|
| G
|
Ddah2
|
DDAH family member 2, ADMA-independent
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of DDAH2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr20:3,766,115...3,769,161
Ensembl chr20:3,766,120...3,769,183
|
|
| G
|
Ddit3
|
DNA-damage inducible transcript 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of DDIT3 mRNA; Progesterone results in increased expression of DDIT3 protein
|
CTD |
PMID:18037150 PMID:21525004 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509
|
|
| G
|
Ddit4
|
DNA-damage-inducible transcript 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of DDIT4 mRNA
|
CTD |
PMID:18037150 PMID:21795739 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037
|
|
| G
|
Ddt
|
D-dopachrome tautomerase
|
increases expression
|
EXP
|
Progesterone results in increased expression of DDT mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr20:12,883,025...12,886,121
|
|
| G
|
Ddx21
|
DExD-box helicase 21
|
affects expression
|
ISO
|
Progesterone affects the expression of DDX21 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr20:31,077,044...31,097,238
Ensembl chr20:31,077,045...31,097,238
|
|
| G
|
Ddx39a
|
DExD-box helicase 39A
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of DDX39A mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr19:41,323,465...41,331,413
Ensembl chr19:41,322,836...41,332,306
|
|
| G
|
Ddx43
|
DEAD-box helicase 43
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DDX43 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 8:88,135,255...88,172,872
Ensembl chr 8:88,135,882...88,164,749
|
|
| G
|
Ddx6
|
DEAD-box helicase 6
|
affects expression
|
ISO
|
Progesterone affects the expression of DDX6 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 8:53,827,661...53,864,538
Ensembl chr 8:53,827,835...53,860,977
|
|
| G
|
Defb1
|
defensin beta 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of DEFB1 mRNA [Progesterone co-treated with bazedoxifene] results in increased expression of DEFB1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of DEFB1 mRNA; [Progesterone co-treated with Lasofoxifene] results in increased expression of DEFB1 mRNA; [Progesterone co-treated with Raloxifene Hydrochloride] results in increased expression of DEFB1 mRNA
|
CTD |
PMID:18367319 PMID:20660070 |
|
NCBI chr16:77,001,326...77,016,068
Ensembl chr16:77,001,326...77,016,068
|
|
| G
|
Defb5
|
defensin beta 5
|
multiple interactions increases expression
|
ISO
|
Lipopolysaccharides inhibits the reaction [Progesterone results in increased expression of DEFB4A mRNA]
|
CTD |
PMID:19819163 |
|
NCBI chr16:77,315,424...77,317,828
Ensembl chr16:77,315,424...77,317,828
|
|
| G
|
Dek
|
DEK proto-oncogene
|
increases expression
|
ISO
|
Progesterone results in increased expression of DEK protein
|
CTD |
PMID:23071688 |
|
NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,787,139...17,810,122
|
|
| G
|
Dennd1c
|
DENN domain containing 1C
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DENND1C mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 9:1,991,035...2,003,330
Ensembl chr 9:1,991,039...2,003,151
|
|
| G
|
Dennd2a
|
DENN domain containing 2A
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of DENND2A mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 4:69,199,814...69,299,128
Ensembl chr 4:69,199,814...69,298,984
|
|
| G
|
Dennd2d
|
DENN domain containing 2D
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DENND2D mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:196,661,465...196,680,505
Ensembl chr 2:196,661,345...196,682,397
|
|
| G
|
Depdc1
|
DEP domain containing 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DEPDC1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:251,343,250...251,376,709
Ensembl chr 2:251,343,281...251,376,709
|
|
| G
|
Depdc1b
|
DEP domain containing 1B
|
increases expression
|
ISO
|
Progesterone results in increased expression of DEPDC1B mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 2:41,605,686...41,697,207
Ensembl chr 2:41,624,922...41,697,202
|
|
| G
|
Depp1
|
DEPP autophagy regulator 1
|
multiple interactions increases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of DEPP1 mRNA]
|
CTD |
PMID:16123073 PMID:18070364 PMID:20864642 |
|
NCBI chr 4:151,583,105...151,585,455
Ensembl chr 4:151,581,502...151,586,233
|
|
| G
|
Deptor
|
DEP domain containing MTOR-interacting protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DEPTOR mRNA
|
CTD |
PMID:23541542 |
|
NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041
|
|
| G
|
Des
|
desmin
|
decreases expression multiple interactions increases expression
|
ISO EXP
|
Progesterone results in decreased expression of DES mRNA [Estradiol co-treated with Progesterone] results in increased expression of DES mRNA Progesterone results in increased expression of DES mRNA [Progesterone co-treated with Estradiol] results in decreased expression of DES mRNA
|
CTD |
PMID:18070364 PMID:18692832 PMID:19089455 PMID:20726854 |
|
NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347
|
|
| G
|
Dgkb
|
diacylglycerol kinase, beta
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DGKB mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 6:60,368,101...61,124,420
Ensembl chr 6:60,368,519...61,124,420
|
|
| G
|
Dgkd
|
diacylglycerol kinase, delta
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DGKD mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 9:95,964,507...96,055,160
Ensembl chr 9:95,964,148...96,055,160
|
|
| G
|
Dhcr7
|
7-dehydrocholesterol reductase
|
increases expression
|
ISO
|
Progesterone results in increased expression of DHCR7 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:208,444,434...208,460,408
Ensembl chr 1:208,444,434...208,461,382
|
|
| G
|
Dhrs3
|
dehydrogenase/reductase 3
|
multiple interactions increases expression
|
ISO
|
7-propyl spirolactone inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; [Estradiol co-treated with Progesterone] results in decreased expression of DHRS3 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein; Aldosterone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of DHRS3 protein]; Mifepristone promotes the reaction [Progesterone affects the expression of DHRS3 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA] Progesterone results in increased expression of DHRS3 mRNA
|
CTD |
PMID:20660070 PMID:21540246 PMID:22414680 PMID:23275455 |
|
NCBI chr 5:162,031,853...162,065,655
Ensembl chr 5:162,031,386...162,065,653
|
|
| G
|
Dhx15
|
DEAH-box helicase 15
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DHX15 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr14:62,999,886...63,037,829
Ensembl chr14:62,999,877...63,037,828
|
|
| G
|
Diaph1
|
diaphanous-related formin 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DIAPH1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr18:29,920,889...30,020,280
Ensembl chr18:29,920,889...30,020,280
|
|
| G
|
Diaph2
|
diaphanous-related formin 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of DIAPH2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr X:96,700,535...97,528,080
Ensembl chr X:96,700,726...97,528,080
|
|
| G
|
Diaph3
|
diaphanous-related formin 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DIAPH3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr15:68,951,992...69,421,623
Ensembl chr15:68,951,989...69,421,552
|
|
| G
|
Dicer1
|
dicer 1 ribonuclease III
|
increases expression
|
ISO
|
Progesterone results in increased expression of DICER1 mRNA
|
CTD |
PMID:20852728 |
|
NCBI chr 6:129,392,298...129,457,252
Ensembl chr 6:129,396,014...129,457,252
|
|
| G
|
Dio2
|
iodothyronine deiodinase 2
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of DIO2 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of DIO2 mRNA Progesterone results in decreased expression of DIO2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594
|
|
| G
|
Dkk1
|
dickkopf WNT signaling pathway inhibitor 1
|
multiple interactions affects response to substance increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of DKK1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of DKK1 mRNA; Mifepristone inhibits the reaction [Progesterone results in increased expression of DKK1 mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of DKK1 protein] DKK1 protein affects the susceptibility to Progesterone Progesterone results in increased expression of DKK1 mRNA; Progesterone results in increased expression of DKK1 protein
|
CTD |
PMID:16449346 PMID:17404688 PMID:20660070 PMID:20864642 PMID:21546446 PMID:21795739 More...
|
|
NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650
|
|
| G
|
Dkk3
|
dickkopf WNT signaling pathway inhibitor 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DKK3 mRNA
|
CTD |
PMID:21273126 |
|
NCBI chr 1:175,672,834...175,715,867
Ensembl chr 1:175,672,834...175,715,186
|
|
| G
|
Dlc1
|
DLC1 Rho GTPase activating protein
|
multiple interactions increases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of DLC1 mRNA]
|
CTD |
PMID:15674352 |
|
NCBI chr16:61,954,177...62,374,819
Ensembl chr16:61,995,001...62,374,819
|
|
| G
|
Dld
|
dihydrolipoamide dehydrogenase
|
increases abundance
|
EXP
|
DLD protein results in increased abundance of Progesterone
|
CTD |
PMID:25981801 |
|
NCBI chr 6:53,631,686...53,655,059
Ensembl chr 6:53,619,631...53,652,354
|
|
| G
|
Dleu7
|
deleted in lymphocytic leukemia, 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of DLEU7 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr15:40,655,563...40,671,759
Ensembl chr15:40,655,563...40,671,759
|
|
| G
|
Dlg5
|
discs large MAGUK scaffold protein 5
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of DLG5 mRNA Progesterone results in increased expression of DLG5 mRNA
|
CTD |
PMID:18497975 PMID:20660070 |
|
NCBI chr15:125,287...237,334
Ensembl chr15:125,290...237,332
|
|
| G
|
Dlgap1
|
DLG associated protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DLGAP1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 9:117,304,144...118,173,463
Ensembl chr 9:117,614,061...118,173,463
|
|
| G
|
Dlgap5
|
DLG associated protein 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DLGAP5 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr15:23,113,678...23,144,281
Ensembl chr15:23,113,678...23,144,176
|
|
| G
|
Dlx2
|
distal-less homeobox 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DLX2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:76,777,912...76,781,255
Ensembl chr 3:76,777,912...76,781,255
|
|
| G
|
Dlx4
|
distal-less homeobox 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of DLX4 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:80,581,878...80,587,272
Ensembl chr10:80,582,303...80,587,294
|
|
| G
|
Dlx5
|
distal-less homeobox 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DLX5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:35,965,579...35,969,973
Ensembl chr 4:35,965,579...35,969,845
|
|
| G
|
Dmac2l
|
distal membrane arm assembly component 2 like
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of DMAC2L mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 6:93,941,605...93,959,932
Ensembl chr 6:93,941,690...93,960,662
|
|
| G
|
Dmbt1
|
deleted in malignant brain tumors 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of DMBT1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:195,047,702...195,126,704
Ensembl chr 1:195,047,713...195,126,704
|
|
| G
|
Dmd
|
dystrophin
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of DMD mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr X:51,070,098...53,437,845
Ensembl chr X:51,070,273...53,437,835
|
|
| G
|
Dmp1
|
dentin matrix acidic phosphoprotein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of DMP1 mRNA
|
CTD |
PMID:19000923 |
|
NCBI chr14:5,833,111...5,867,154
Ensembl chr14:5,833,111...5,843,993
|
|
| G
|
Dmpk
|
DM1 protein kinase
|
affects expression
|
ISO
|
Progesterone affects the expression of DMPK mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:87,858,294...87,868,624
Ensembl chr 1:87,858,316...87,868,910
|
|
| G
|
Dnaaf2
|
dynein, axonemal, assembly factor 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of DNAAF2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 6:93,397,157...93,406,323
Ensembl chr 6:93,397,164...93,406,323
|
|
| G
|
Dnajb1
|
DnaJ heat shock protein family (Hsp40) member B1
|
increases expression
|
ISO
|
Progesterone results in increased expression of DNAJB1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416
|
|
| G
|
Dnajb11
|
DnaJ heat shock protein family (Hsp40) member B11
|
affects expression
|
ISO
|
Progesterone affects the expression of DNAJB11 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr11:91,656,334...91,672,800
Ensembl chr11:91,656,335...91,672,800
|
|
| G
|
Dnajb9
|
DnaJ heat shock protein family (Hsp40) member B9
|
increases expression
|
ISO
|
Progesterone results in increased expression of DNAJB9 mRNA
|
CTD |
PMID:18037150 PMID:18070364 |
|
NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344
|
|
| G
|
Dnajc15
|
DnaJ heat shock protein family (Hsp40) member C15
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of DNAJC15 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:59,594,314...59,658,862
Ensembl chr15:59,594,314...59,658,987
|
|
| G
|
Dnajc8
|
DnaJ heat shock protein family (Hsp40) member C8
|
affects expression
|
ISO
|
Progesterone affects the expression of DNAJC8 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:150,029,064...150,047,115
Ensembl chr 5:150,026,286...150,047,117
|
|
| G
|
Dnajc9
|
DnaJ heat shock protein family (Hsp40) member C9
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of DNAJC9 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:3,970,843...4,003,009
Ensembl chr15:3,970,114...3,977,304
|
|
| G
|
Dner
|
delta/notch-like EGF repeat containing
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of DNER mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:93,035,108...93,350,568
Ensembl chr 9:93,035,108...93,350,568
|
|
| G
|
Dnm3
|
dynamin 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DNM3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:76,892,381...77,371,346
Ensembl chr13:76,892,171...77,371,350
|
|
| G
|
Dnmbp
|
dynamin binding protein
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of DNMBP mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 1:252,685,406...252,778,642
Ensembl chr 1:252,685,406...252,778,688
|
|
| G
|
Dnttip1
|
deoxynucleotidyltransferase, terminal, interacting protein 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of DNTTIP1 mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 3:173,901,070...173,924,742
Ensembl chr 3:173,900,945...173,925,098
|
|
| G
|
Doc2b
|
double C2 domain beta
|
increases expression
|
ISO
|
Progesterone results in increased expression of DOC2B mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:61,126,295...61,151,533
Ensembl chr10:61,126,295...61,151,533
|
|
| G
|
Dock4
|
dedicator of cytokinesis 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DOCK4 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 6:63,240,050...63,629,772
Ensembl chr 6:63,240,136...63,629,772
|
|
| G
|
Dpep1
|
dipeptidase 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of DPEP1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr19:68,118,270...68,143,781
Ensembl chr19:68,118,453...68,143,775
|
|
| G
|
Dpp4
|
dipeptidylpeptidase 4
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of DPP4 mRNA Progesterone results in increased expression of DPP4 mRNA
|
CTD |
PMID:17404688 PMID:21540246 PMID:21795739 |
|
NCBI chr 3:67,370,794...67,452,422
Ensembl chr 3:67,370,804...67,452,422
|
|
| G
|
Dpp6
|
dipeptidyl peptidase like 6
|
increases expression
|
EXP
|
Progesterone results in increased expression of DPP6 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:8,323,220...9,242,694
Ensembl chr 4:8,324,843...9,242,209
|
|
| G
|
Dpp7
|
dipeptidylpeptidase 7
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of DPP7 mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 3:28,563,240...28,567,492
Ensembl chr 3:28,563,240...28,567,492
|
|
| G
|
Dpt
|
dermatopontin
|
increases expression
|
ISO
|
Progesterone results in increased expression of DPT mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr13:79,656,341...79,684,759
Ensembl chr13:79,655,985...79,684,758
|
|
| G
|
Drd4
|
dopamine receptor D4
|
increases expression
|
ISO
|
Progesterone results in increased expression of DRD4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:205,826,049...205,830,458
|
|
| G
|
Dsp
|
desmoplakin
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of DSP mRNA]
|
CTD |
PMID:17556502 PMID:22238285 |
|
NCBI chr17:26,829,153...26,877,419
Ensembl chr17:26,829,153...26,877,121
|
|
| G
|
Dst
|
dystonin
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DST mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 9:43,631,716...44,025,535
Ensembl chr 9:43,631,517...44,025,533
|
|
| G
|
Dtl
|
denticleless E3 ubiquitin protein ligase homolog
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DTL mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:105,646,908...105,685,921
Ensembl chr13:105,646,908...105,686,174
|
|
| G
|
Duox1
|
dual oxidase 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DUOX1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 3:129,714,125...129,749,186
Ensembl chr 3:129,714,149...129,749,187
|
|
| G
|
Dus1l
|
dihydrouridine synthase 1-like
|
increases expression
|
EXP
|
Progesterone results in increased expression of DUS1L mRNA
|
CTD |
PMID:16376865 |
|
NCBI chr10:106,553,841...106,560,977
Ensembl chr10:106,553,238...106,561,285
|
|
| G
|
Dus3l
|
dihydrouridine synthase 3-like
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of DUS3L mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 9:1,680,619...1,685,784
Ensembl chr 9:1,675,819...1,686,367
|
|
| G
|
Dusp1
|
dual specificity phosphatase 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of DUSP1 mRNA Progesterone results in increased expression of DUSP1 mRNA
|
CTD |
PMID:17404688 PMID:21795739 |
|
NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644
|
|
| G
|
Dusp22
|
dual specificity phosphatase 22
|
increases expression
|
ISO
|
Progesterone results in increased expression of DUSP22 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr17:33,989,637...34,040,021
Ensembl chr17:33,989,637...34,039,895
|
|
| G
|
Dusp26
|
dual specificity phosphatase 26
|
increases expression
|
ISO
|
Progesterone results in increased expression of DUSP26 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr16:67,744,830...67,752,673
Ensembl chr16:67,744,842...67,752,101
|
|
| G
|
Dusp5
|
dual specificity phosphatase 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of DUSP5 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:262,543,774...262,557,201
Ensembl chr 1:262,543,738...262,562,417
|
|
| G
|
Dusp6
|
dual specificity phosphatase 6
|
increases expression multiple interactions decreases expression
|
ISO
|
Progesterone results in increased expression of DUSP6 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of DUSP6 mRNA Progesterone results in decreased expression of DUSP6 mRNA
|
CTD |
PMID:18037150 PMID:20660070 PMID:20864642 |
|
NCBI chr 7:35,979,502...35,983,834
Ensembl chr 7:35,977,921...35,983,833
|
|
| G
|
Dxo
|
decapping exoribonuclease
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of DXO mRNA Progesterone results in increased expression of DXO mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr20:3,997,953...4,000,115
Ensembl chr20:3,997,955...4,000,037
|
|
| G
|
Dynlrb1
|
dynein light chain roadblock-type 1
|
affects expression
|
ISO
|
Progesterone affects the expression of DYNLRB1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:164,197,892...164,224,409
Ensembl chr 3:164,202,953...164,224,409
|
|
| G
|
Dyrk2
|
dual specificity tyrosine phosphorylation regulated kinase 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of DYRK2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 7:56,235,276...56,265,741
Ensembl chr 7:56,235,276...56,265,942
|
|
| G
|
E2f1
|
E2F transcription factor 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of E2F1 mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr 3:163,524,739...163,535,563
Ensembl chr 3:163,524,739...163,535,563
|
|
| G
|
E2f8
|
E2F transcription factor 8
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of E2F8 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 1:107,701,985...107,720,538
Ensembl chr 1:107,701,985...107,720,009
|
|
| G
|
Eaf2
|
ELL associated factor 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of EAF2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:77,465,585...77,509,993
Ensembl chr11:77,406,020...77,509,993
|
|
| G
|
Ebi3
|
Epstein-Barr virus induced 3
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of EBI3 mRNA TGFB1 protein promotes the reaction [Progesterone results in increased expression of EBI3 mRNA]
|
CTD |
PMID:21768398 |
|
NCBI chr 9:861,441...874,731
Ensembl chr 9:870,792...874,973
|
|
| G
|
Ebp
|
EBP, cholestenol delta-isomerase
|
increases expression
|
ISO
|
Progesterone results in increased expression of EBP mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr X:16,971,372...16,977,782
Ensembl chr X:16,971,405...16,977,781
|
|
| G
|
Ece2
|
endothelin-converting enzyme 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ECE2 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr11:93,767,559...93,782,896
Ensembl chr11:93,767,559...93,793,292
|
|
| G
|
Ech1
|
enoyl-CoA hydratase 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of ECH1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:93,241,076...93,248,314
Ensembl chr 1:93,241,734...93,248,440
|
|
| G
|
Echdc2
|
enoyl CoA hydratase domain containing 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ECHDC2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 5:128,144,241...128,163,611
Ensembl chr 5:128,144,425...128,163,610
|
|
| G
|
Echs1
|
enoyl-CoA hydratase, short chain 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of ECHS1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:204,324,679...204,333,506
Ensembl chr 1:204,324,682...204,333,506
|
|
| G
|
Ecm1
|
extracellular matrix protein 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ECM1 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr 2:185,976,439...185,981,656
Ensembl chr 2:185,976,440...185,981,606
|
|
| G
|
Edn1
|
endothelin 1
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
Progesterone inhibits the reaction [Estradiol results in increased expression of EDN1 mRNA]; Progesterone inhibits the reaction [Estradiol results in increased secretion of EDN1 protein] Progesterone results in decreased expression of EDN1 mRNA Progesterone results in increased expression of EDN1 mRNA
|
CTD |
PMID:20726854 PMID:21795739 PMID:22238285 |
|
NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687
|
|
| G
|
Edn3
|
endothelin 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of EDN3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:183,980,458...184,004,958
Ensembl chr 3:183,980,668...184,005,329
|
|
| G
|
Ednra
|
endothelin receptor type A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of EDNRA mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284
|
|
| G
|
Ednrb
|
endothelin receptor type B
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of EDNRB mRNA Progesterone results in increased expression of EDNRB mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765
|
|
| G
|
Eef2k
|
eukaryotic elongation factor-2 kinase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of EEF2K mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:184,824,420...184,888,048
Ensembl chr 1:184,824,420...184,888,048
|
|
| G
|
Efemp1
|
EGF containing fibulin extracellular matrix protein 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of EFEMP1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:106,811,769...106,890,961
Ensembl chr14:106,802,304...106,892,808
|
|
| G
|
Efhd1
|
EF-hand domain family, member D1
|
increases expression
|
ISO
|
Progesterone results in increased expression of EFHD1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 9:95,386,155...95,432,800
Ensembl chr 9:95,386,169...95,432,798
|
|
| G
|
Efna1
|
ephrin A1
|
increases expression
|
ISO
|
Progesterone results in increased expression of EFNA1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726
|
|
| G
|
Efnb2
|
ephrin B2
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of EFNB2 mRNA Progesterone results in decreased expression of EFNB2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr16:87,485,215...87,529,224
Ensembl chr16:87,485,198...87,529,208
|
|
| G
|
Efs
|
embryonal Fyn-associated substrate
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of EFS mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr15:32,362,401...32,374,490
Ensembl chr15:32,361,843...32,371,743
|
|
| G
|
Egf
|
epidermal growth factor
|
multiple interactions increases expression
|
ISO EXP
|
Mifepristone inhibits the reaction [Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]]; Mifepristone inhibits the reaction [Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]]; Progesterone promotes the reaction [EGF protein affects the localization of FOS protein]; Progesterone promotes the reaction [EGF protein results in increased expression of FOS mRNA]; Progesterone promotes the reaction [EGF protein results in increased expression of FOS protein]; Progesterone promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]]; U 0126 inhibits the reaction [Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]] Progesterone results in increased expression of EGF mRNA
|
CTD |
PMID:16175315 PMID:18591650 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297
|
|
| G
|
Egfl6
|
EGF-like-domain, multiple 6
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of EGFL6 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr X:31,515,752...31,573,699
Ensembl chr X:31,515,767...31,574,632
|
|
| G
|
Egfr
|
epidermal growth factor receptor
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of EGFR mRNA; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; Progesterone promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein] Progesterone results in increased expression of EGFR protein Estradiol promotes the reaction [Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]]; Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]; Progesterone promotes the reaction [Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of EGFR protein]] Progesterone results in increased expression of EGFR mRNA [Estrogens co-treated with Progesterone] results in increased expression of EGFR mRNA; [Estrogens co-treated with Progesterone] results in increased expression of EGFR protein
|
CTD |
PMID:16175315 PMID:18591650 PMID:18692832 PMID:21258428 PMID:21520325 PMID:22414604 More...
|
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358
|
|
| G
|
Egln3
|
egl-9 family hypoxia-inducible factor 3
|
increases expression
|
EXP
|
Progesterone results in increased expression of EGLN3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 6:77,385,549...77,411,015
Ensembl chr 6:77,385,549...77,411,015
|
|
| G
|
Egr1
|
early growth response 1
|
multiple interactions affects expression increases expression decreases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of EGR1 mRNA Progesterone affects the expression of EGR1 mRNA Progesterone results in increased expression of EGR1 mRNA Progesterone results in decreased expression of EGR1 mRNA Mifepristone inhibits the reaction [Progesterone inhibits the reaction [bisphenol A results in increased expression of EGR1 mRNA]]; Mifepristone inhibits the reaction [Progesterone inhibits the reaction [Estradiol results in increased expression of EGR1 mRNA]]; Progesterone inhibits the reaction [bisphenol A results in increased expression of EGR1 mRNA]; Progesterone inhibits the reaction [Estradiol results in increased expression of EGR1 mRNA]
|
CTD |
PMID:17404688 PMID:20726854 PMID:21795739 PMID:23461915 PMID:25461906 |
|
NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843
|
|
| G
|
Egr2
|
early growth response 2
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of EGR2 mRNA; Progesterone results in increased expression of EGR2 protein [Estradiol co-treated with Progesterone] results in decreased expression of EGR2 mRNA
|
CTD |
PMID:17478888 PMID:20660070 |
|
NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748
|
|
| G
|
Egr3
|
early growth response 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of EGR3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:51,560,482...51,565,778
Ensembl chr15:51,560,344...51,565,712
|
|
| G
|
Ehbp1
|
EH domain binding protein 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of EHBP1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:100,294,585...100,581,764
Ensembl chr14:100,294,585...100,546,579
|
|
| G
|
Ehd1
|
EH-domain containing 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of EHD1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:213,009,113...213,031,488
Ensembl chr 1:213,008,049...213,031,485
|
|
| G
|
Ehd2
|
EH-domain containing 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of EHD2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:85,767,757...85,786,974
Ensembl chr 1:85,768,667...85,786,943
|
|
| G
|
Ehf
|
ets homologous factor
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of EHF mRNA Progesterone results in decreased expression of EHF mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 3:110,094,770...110,134,991
Ensembl chr 3:110,096,756...110,134,928
|
|
| G
|
Eif1
|
eukaryotic translation initiation factor 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of EIF1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr10:85,747,064...85,749,447
Ensembl chr 5:25,895,968...25,896,654 Ensembl chr10:25,895,968...25,896,654
|
|
| G
|
Eif2s3
|
eukaryotic translation initiation factor 2 subunit gamma
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of EIF2S3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr X:62,910,292...62,933,936
Ensembl chr X:62,910,293...62,934,489
|
|
| G
|
Eif4ebp1
|
eukaryotic translation initiation factor 4E binding protein 1
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased phosphorylation of EIF4EBP1 protein
|
CTD |
PMID:22465879 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874
|
|
| G
|
Eif4ebp2
|
eukaryotic translation initiation factor 4E binding protein 2
|
affects expression
|
ISO
|
Progesterone affects the expression of EIF4EBP2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr20:29,922,260...29,942,922
Ensembl chr20:29,922,260...29,942,922
|
|
| G
|
Eif4g3
|
eukaryotic translation initiation factor 4 gamma, 3
|
affects expression
|
ISO
|
Progesterone affects the expression of EIF4G3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:155,481,378...155,702,194
Ensembl chr 5:155,481,378...155,702,194
|
|
| G
|
Eif5
|
eukaryotic translation initiation factor 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of EIF5 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:136,410,333...136,418,827
Ensembl chr 6:136,407,440...136,418,821
|
|
| G
|
Elf3
|
E74 like ETS transcription factor 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of ELF3 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr13:49,242,265...49,247,102
Ensembl chr13:49,242,267...49,247,380
|
|
| G
|
Ell3
|
elongation factor for RNA polymerase II 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ELL3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:128,866,755...128,870,896
Ensembl chr 3:128,864,777...128,870,852
|
|
| G
|
Eloa
|
elongin A
|
increases expression
|
EXP
|
Progesterone results in increased expression of ELOA mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 5:153,513,246...153,530,819
Ensembl chr 5:153,515,066...153,530,916
|
|
| G
|
Elovl1
|
ELOVL fatty acid elongase 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ELOVL1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:137,246,781...137,251,351
Ensembl chr 5:137,246,849...137,251,352
|
|
| G
|
Elovl6
|
ELOVL fatty acid elongase 6
|
increases expression
|
ISO EXP
|
Progesterone results in increased expression of ELOVL6 mRNA Progesterone results in increased expression of ELOVL6 protein
|
CTD |
PMID:18070364 PMID:23180365 |
|
NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:220,738,064...220,845,549
|
|
| G
|
Elovl7
|
ELOVL fatty acid elongase 7
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ELOVL7 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:41,522,695...41,592,021
Ensembl chr 2:41,522,738...41,592,020
|
|
| G
|
Emb
|
embigin
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of EMB mRNA NCOA2 protein affects the reaction [Progesterone results in decreased expression of EMB mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr 2:50,803,468...50,858,001
Ensembl chr 2:50,801,973...50,862,920
|
|
| G
|
Emp2
|
epithelial membrane protein 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of EMP2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr10:5,866,869...5,901,533
Ensembl chr10:5,866,922...5,901,532
|
|
| G
|
Enc1
|
ectodermal-neural cortex 1
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ENC1 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of ENC1 mRNA Progesterone results in decreased expression of ENC1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721
|
|
| G
|
Eng
|
endoglin
|
multiple interactions increases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of ENG mRNA]
|
CTD |
PMID:20431248 |
|
NCBI chr 3:36,332,190...36,370,324
Ensembl chr 3:36,326,202...36,370,933
|
|
| G
|
Enpep
|
glutamyl aminopeptidase
|
increases expression
|
ISO
|
Progesterone results in increased expression of ENPEP mRNA
|
CTD |
PMID:17404688 PMID:20864642 PMID:21540246 |
|
NCBI chr 2:220,456,258...220,526,218
Ensembl chr 2:220,456,278...220,526,218
|
|
| G
|
Enpp1
|
ectonucleotide pyrophosphatase/phosphodiesterase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of ENPP1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 1:22,518,051...22,583,044
Ensembl chr 1:22,518,069...22,583,044
|
|
| G
|
Enpp2
|
ectonucleotide pyrophosphatase/phosphodiesterase 2
|
affects expression
|
ISO
|
Progesterone affects the expression of ENPP2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:88,092,140...88,214,758
Ensembl chr 7:88,092,140...88,214,957
|
|
| G
|
Enpp3
|
ectonucleotide pyrophosphatase/phosphodiesterase 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of ENPP3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:22,382,717...22,454,324
Ensembl chr 1:22,382,964...22,454,314
|
|
| G
|
Enpp4
|
ectonucleotide pyrophosphatase/phosphodiesterase 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ENPP4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:24,386,351...24,396,248
Ensembl chr 9:24,360,272...24,396,152
|
|
| G
|
Entpd8
|
ectonucleoside triphosphate diphosphohydrolase 8
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ENTPD8 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:28,283,392...28,295,686
Ensembl chr 3:28,285,777...28,293,686
|
|
| G
|
Entrep1
|
endosomal transmembrane epsin interactor 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of ENTREP1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:231,018,987...231,073,474
Ensembl chr 1:231,018,987...231,102,708
|
|
| G
|
Epb41l4a
|
erythrocyte membrane protein band 4.1 like 4A
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of EPB41L4A mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr18:25,680,169...25,890,998
Ensembl chr18:25,680,171...25,888,498
|
|
| G
|
Epb41l4b
|
erythrocyte membrane protein band 4.1 like 4B
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of EPB41L4B mRNA Progesterone results in decreased expression of EPB41L4B mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 5:76,486,886...76,647,752
Ensembl chr 5:76,486,902...76,647,752
|
|
| G
|
Epb41l5
|
erythrocyte membrane protein band 4.1 like 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of EPB41L5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr13:33,221,705...33,321,400
Ensembl chr13:33,223,589...33,321,133
|
|
| G
|
Epha3
|
Eph receptor A3
|
increases expression
|
ISO
|
Progesterone results in increased expression of EPHA3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr11:14,585,041...14,920,721
Ensembl chr11:14,586,727...14,920,425
|
|
| G
|
Epha6
|
Eph receptor A6
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of EPHA6 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr11:53,226,784...54,178,120
Ensembl chr11:53,226,954...54,166,987
|
|
| G
|
Epha7
|
Eph receptor A7
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of EPHA7 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:47,771,776...47,925,189
Ensembl chr 5:47,771,865...47,925,058
|
|
| G
|
Epha8
|
Eph receptor A8
|
increases expression
|
ISO
|
Progesterone results in increased expression of EPHA8 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:154,449,566...154,476,966
Ensembl chr 5:154,449,566...154,476,966
|
|
| G
|
Erbb4
|
erb-b2 receptor tyrosine kinase 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ERBB4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 9:76,973,386...78,045,633
Ensembl chr 9:76,973,227...78,045,772
|
|
| G
|
Erbin
|
erbb2 interacting protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of ERBIN mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:36,660,399...36,762,584
Ensembl chr 2:36,660,399...36,762,153
|
|
| G
|
Erc2
|
ELKS/RAB6-interacting/CAST family member 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of ERC2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr16:2,819,399...3,680,258
Ensembl chr16:2,819,512...3,680,258
|
|
| G
|
Erp27
|
endoplasmic reticulum protein 27
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ERP27 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:171,535,845...171,552,848
Ensembl chr 4:171,535,847...171,553,072
|
|
| G
|
Errfi1
|
ERBB receptor feedback inhibitor 1
|
affects expression increases expression
|
ISO
|
Progesterone affects the expression of ERRFI1 mRNA Progesterone results in increased expression of ERRFI1 mRNA
|
CTD |
PMID:17251523 PMID:20864642 PMID:21795739 |
|
NCBI chr 5:166,606,841...166,620,124
Ensembl chr 5:166,606,834...166,620,432
|
|
| G
|
Esr1
|
estrogen receptor 1
|
decreases expression multiple interactions decreases activity increases activity
|
ISO EXP
|
Progesterone results in decreased expression of ESR1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of ESR1 mRNA; [Estradiol co-treated with Progesterone] results in decreased expression of ESR1 mRNA alternative form; [Estradiol co-treated with Progesterone] results in increased expression of ESR1 mRNA; bisphenol A inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of ESR1 protein]; Diethylstilbestrol inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of ESR1 protein]; Progesterone inhibits the reaction [Estradiol results in increased expression of ESR1 mRNA] ESR1 protein affects the reaction [Progesterone results in increased expression of GREB1 mRNA]; ESR1 protein affects the reaction [Progesterone results in increased expression of SGK1 mRNA]; Fulvestrant inhibits the reaction [Progesterone results in increased activity of ESR1 protein] Progesterone results in decreased expression of ESR1 mRNA; Progesterone results in decreased expression of ESR1 mRNA alternative form; Progesterone results in decreased expression of ESR1 protein ESR1 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased expression of IHH mRNA]; ESR1 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased expression of LIF mRNA]; Progesterone inhibits the reaction [ESR1 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]] Progesterone results in decreased activity of ESR1 protein
|
CTD |
PMID:16002535 PMID:17974624 PMID:18037150 PMID:18653720 PMID:19094096 PMID:21277368 PMID:22562034 PMID:25012808 PMID:25210133 PMID:33405908 More...
|
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354
|
|
| G
|
Esr2
|
estrogen receptor 2
|
increases expression multiple interactions affects binding decreases expression
|
ISO EXP
|
Progesterone metabolite results in increased expression of ESR2 mRNA ESR2 affects the reaction [[Estradiol co-treated with Progesterone] results in increased expression of OXT mRNA]; Progesterone inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]] Progesterone binds to ESR2 protein [Estradiol co-treated with Progesterone] results in decreased expression of ESR2 mRNA; Progesterone inhibits the reaction [Estradiol results in increased expression of ESR2 mRNA] Progesterone results in decreased expression of ESR2 mRNA
|
CTD |
PMID:12834440 PMID:17683929 PMID:17974624 PMID:19094096 PMID:19913605 PMID:21277368 More...
|
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709
|
|
| G
|
Esrra
|
estrogen related receptor, alpha
|
increases expression
|
ISO
|
Progesterone results in increased expression of ESRRA mRNA
|
CTD |
PMID:15968320 |
|
NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811
|
|
| G
|
Etl4
|
enhancer trap locus 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of KIAA1217 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr17:87,749,486...88,213,158
Ensembl chr17:87,403,819...88,213,158
|
|
| G
|
Etv1
|
ETS variant transcription factor 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of ETV1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of ETV1 mRNA
|
CTD |
PMID:18070364 PMID:20660070 |
|
NCBI chr 6:61,316,836...61,408,985
Ensembl chr 6:61,317,429...61,408,959
|
|
| G
|
Etv5
|
ETS variant transcription factor 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ETV5 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr11:92,113,171...92,170,758
Ensembl chr11:92,113,224...92,170,767
|
|
| G
|
Evi2a
|
ecotropic viral integration site 2A
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of EVI2A mRNA [Estradiol co-treated with Progesterone] results in decreased expression of EVI2A mRNA
|
CTD |
PMID:18070364 PMID:20660070 |
|
NCBI chr10:64,983,727...64,987,627
Ensembl chr10:64,983,705...64,999,516
|
|
| G
|
Exo1
|
exonuclease 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of EXO1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr13:90,341,947...90,366,861
Ensembl chr13:90,342,018...90,366,861
|
|
| G
|
Ezh2
|
enhancer of zeste 2 polycomb repressive complex 2 subunit
|
increases expression
|
ISO
|
Progesterone results in increased expression of EZH2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 4:77,624,223...77,698,598
Ensembl chr 4:77,624,223...77,687,183
|
|
| G
|
F10
|
coagulation factor X
|
increases expression
|
ISO
|
Progesterone results in increased expression of F10 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr16:83,170,973...83,190,280
Ensembl chr16:83,170,977...83,190,280
|
|
| G
|
F13a1
|
coagulation factor XIII A1 chain
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of F13A1 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of F13A1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr17:28,021,197...28,197,960
Ensembl chr17:28,020,845...28,197,948
|
|
| G
|
F2
|
coagulation factor II, thrombin
|
multiple interactions
|
ISO
|
[Hirudins binds to and results in decreased activity of F2 protein] promotes the reaction [CGB3 protein results in increased chemical synthesis of Progesterone] [Hirudins binds to and results in decreased activity of F2 protein] which results in increased chemical synthesis of Progesterone
|
CTD |
PMID:22207716 |
|
NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246
|
|
| G
|
F2r
|
coagulation factor II (thrombin) receptor
|
affects expression multiple interactions increases expression
|
ISO EXP
|
Progesterone affects the expression of F2R mRNA [C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [CGB3 protein results in increased chemical synthesis of Progesterone]; [N3-cyclopropyl-7-((4-(1-methylethyl)phenyl)methyl)-7H-pyrrolo(3, 2-f)quinazoline-1,3-diamine binds to and results in decreased activity of F2R protein] promotes the reaction [CGB3 protein results in increased chemical synthesis of Progesterone] [N3-cyclopropyl-7-((4-(1-methylethyl)phenyl)methyl)-7H-pyrrolo(3, 2-f)quinazoline-1,3-diamine binds to and results in decreased activity of F2R protein] which results in increased chemical synthesis of Progesterone Progesterone results in increased expression of F2R mRNA
|
CTD |
PMID:11733402 PMID:17251523 PMID:21770760 PMID:22207716 |
|
NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:28,604,066...28,620,579
|
|
| G
|
F2rl1
|
F2R like trypsin receptor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of F2RL1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954
|
|
| G
|
F2rl2
|
coagulation factor II (thrombin) receptor-like 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of F2RL2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 2:28,706,766...28,711,808
Ensembl chr 2:28,706,501...28,712,473
|
|
| G
|
F2rl3
|
F2R like thrombin or trypsin receptor 3
|
multiple interactions
|
ISO
|
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [CGB3 protein results in increased chemical synthesis of Progesterone]
|
CTD |
PMID:22207716 |
|
NCBI chr16:17,151,516...17,153,509
Ensembl chr16:17,151,516...17,153,823
|
|
| G
|
F3
|
coagulation factor III, tissue factor
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of F3 mRNA; Mifepristone inhibits the reaction [Progesterone results in increased expression of F3 protein] Progesterone results in increased expression of F3 mRNA; Progesterone results in increased expression of F3 protein
|
CTD |
PMID:15562024 PMID:20660070 PMID:20726854 PMID:21795739 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369
|
|
| G
|
Faah
|
fatty acid amide hydrolase
|
increases expression increases activity
|
ISO
|
Progesterone results in increased expression of FAAH mRNA; Progesterone results in increased expression of FAAH protein Progesterone results in increased activity of FAAH protein
|
CTD |
PMID:16154199 |
|
NCBI chr 5:134,716,545...134,735,396
Ensembl chr 5:134,716,545...134,735,396
|
|
| G
|
Fabp3
|
fatty acid binding protein 3
|
increases expression
|
EXP
|
Progesterone results in increased expression of FABP3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 5:147,936,027...147,942,870
Ensembl chr 5:147,936,119...147,942,881
|
|
| G
|
Fabp4
|
fatty acid binding protein 4
|
increases expression
|
ISO EXP
|
Progesterone results in increased expression of FABP4 mRNA
|
CTD |
PMID:15713686 PMID:21770760 |
|
NCBI chr 2:93,488,251...93,492,961
Ensembl chr 2:93,488,271...93,492,972
|
|
| G
|
Fabp5
|
fatty acid binding protein 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FABP5 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:93,672,458...93,676,127
|
|
| G
|
Fadd
|
Fas associated via death domain
|
increases expression
|
ISO
|
Progesterone results in increased expression of FADD mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr 1:209,169,245...209,175,423
Ensembl chr 1:209,169,318...209,174,976
|
|
| G
|
Fads1
|
fatty acid desaturase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of FADS1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:216,252,602...216,267,615
|
|
| G
|
Fads2
|
fatty acid desaturase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of FADS2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066
|
|
| G
|
Fads3
|
fatty acid desaturase 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of FADS3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 1:216,110,547...216,127,431
Ensembl chr 1:216,110,201...216,141,758
|
|
| G
|
Faim
|
Fas apoptotic inhibitory molecule
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of FAIM mRNA Progesterone results in increased expression of FAIM mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 8:108,423,259...108,445,365
Ensembl chr 8:108,423,221...108,440,151
|
|
| G
|
Fam107a
|
family with sequence similarity 107, member A
|
increases expression
|
ISO
|
Progesterone results in increased expression of FAM107A mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr15:19,038,726...19,060,644
Ensembl chr15:19,038,616...19,065,219
|
|
| G
|
Fam110c
|
family with sequence similarity 110, member C
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FAM110C mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 6:53,366,013...53,372,270
Ensembl chr 6:53,352,870...53,401,117
|
|
| G
|
Fam171b
|
family with sequence similarity 171, member B
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of FAM171B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:89,337,566...89,392,973
Ensembl chr 3:89,337,661...89,392,971
|
|
| G
|
Fam181b
|
family with sequence similarity 181, member B
|
increases expression
|
ISO
|
Progesterone results in increased expression of FAM181B mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 1:156,578,821...156,580,318
Ensembl chr 1:156,491,094...156,595,845
|
|
| G
|
Fam43a
|
family with sequence similarity 43, member A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FAM43A mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr11:83,633,165...83,636,313
Ensembl chr11:83,633,154...83,695,297
|
|
| G
|
Fam83g
|
family with sequence similarity 83, member G
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FAM83G mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:46,862,983...46,887,499
Ensembl chr10:46,862,369...46,886,277
|
|
| G
|
Fanci
|
FA complementation group I
|
increases expression
|
ISO
|
Progesterone results in increased expression of FANCI mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:142,736,636...142,792,999
Ensembl chr 1:142,736,653...142,792,999
|
|
| G
|
Fat2
|
FAT atypical cadherin 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FAT2 mRNA
|
CTD |
PMID:18037150 PMID:22238285 |
|
NCBI chr10:39,864,765...39,957,027
Ensembl chr10:39,864,766...39,956,902
|
|
| G
|
Faxdc2
|
fatty acid hydroxylase domain containing 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of FAXDC2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:42,747,323...42,772,156
Ensembl chr10:42,747,524...42,781,458
|
|
| G
|
Fbln1
|
fibulin 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of FBLN1 mRNA
|
CTD |
PMID:15774544 |
|
NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965
|
|
| G
|
Fbln2
|
fibulin 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of FBLN2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 4:125,261,464...125,321,030
Ensembl chr 4:125,261,607...125,321,029
|
|
| G
|
Fbln5
|
fibulin 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of FBLN5 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 6:126,664,100...126,742,847
Ensembl chr 6:126,664,100...126,746,296
|
|
| G
|
Fbn2
|
fibrillin 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of FBN2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr18:53,696,197...53,901,992
Ensembl chr18:53,697,708...53,902,191
|
|
| G
|
Fbxl7
|
F-box and leucine-rich repeat protein 7
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of FBXL7 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:78,870,236...79,239,697
Ensembl chr 2:78,871,287...79,239,697
|
|
| G
|
Fbxo11
|
F-box protein 11
|
increases expression
|
ISO
|
Progesterone results in increased expression of FBXO11 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:12,240,348...12,316,223
Ensembl chr 6:12,239,801...12,316,221
|
|
| G
|
Fbxo32
|
F-box protein 32
|
multiple interactions
|
ISO
|
[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA]
|
CTD |
PMID:23275455 |
|
NCBI chr 7:91,620,925...91,654,491
Ensembl chr 7:91,620,925...91,654,491
|
|
| G
|
Fcgr3a
|
Fc gamma receptor 3A
|
increases expression
|
ISO
|
Progesterone results in increased expression of FCGR3A mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr13:85,782,636...85,792,656
Ensembl chr13:85,782,490...85,792,651
|
|
| G
|
Fcsk
|
fucose kinase
|
affects response to substance
|
ISO
|
FCSK gene SNP affects the susceptibility to Progesterone
|
CTD |
PMID:25622337 |
|
NCBI chr19:55,743,746...55,783,873
Ensembl chr19:55,739,842...55,800,496
|
|
| G
|
Fdft1
|
farnesyl diphosphate farnesyl transferase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of FDFT1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr15:41,588,114...41,616,168
Ensembl chr15:41,588,117...41,616,168
|
|
| G
|
Fdps
|
farnesyl diphosphate synthase
|
increases expression affects expression
|
ISO
|
Progesterone results in increased expression of FDPS mRNA Progesterone affects the expression of FDPS mRNA
|
CTD |
PMID:17251523 PMID:18070364 |
|
NCBI chr 2:176,795,192...176,804,816
Ensembl chr 2:176,795,192...176,807,136
|
|
| G
|
Fen1
|
flap structure-specific endonuclease 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FEN1 mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr 1:216,270,016...216,274,873
Ensembl chr 1:216,269,163...216,275,016
|
|
| G
|
Fermt1
|
FERM domain containing kindlin 1
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of FERMT1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of FERMT1 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of FERMT1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 3:140,624,434...140,666,419
Ensembl chr 3:140,624,434...140,666,419
|
|
| G
|
Fermt2
|
FERM domain containing kindlin 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of FERMT2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr15:21,162,603...21,257,995
Ensembl chr15:21,162,605...21,258,115
|
|
| G
|
Fga
|
fibrinogen alpha chain
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of FGA mRNA
|
CTD |
PMID:17404688 PMID:18692832 |
|
NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577
|
|
| G
|
Fgb
|
fibrinogen beta chain
|
increases expression
|
ISO
|
Progesterone results in increased expression of FGB mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434
|
|
| G
|
Fgd4
|
FYVE, RhoGEF and PH domain containing 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of FGD4 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr11:97,904,182...98,055,190
Ensembl chr11:97,904,182...98,055,190
|
|
| G
|
Fgf13
|
fibroblast growth factor 13
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of FGF13 mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr X:142,312,381...142,838,581
Ensembl chr X:142,312,391...142,423,536
|
|
| G
|
Fgf18
|
fibroblast growth factor 18
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of FGF18 mRNA Progesterone results in decreased expression of FGF18 mRNA
|
CTD |
PMID:17404688 PMID:18037150 |
|
NCBI chr10:18,210,240...18,241,929
Ensembl chr10:18,210,512...18,240,933
|
|
| G
|
Fgf2
|
fibroblast growth factor 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of FGF2 mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493
|
|
| G
|
Fgf4
|
fibroblast growth factor 4
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of FGF4 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 1:209,453,229...209,457,085
Ensembl chr 1:209,453,229...209,457,085
|
|
| G
|
Fgf9
|
fibroblast growth factor 9
|
multiple interactions decreases expression
|
ISO
|
[FGF9 protein co-treated with FSHB protein] affects the abundance of Progesterone; [Progesterone co-treated with Estradiol] results in decreased expression of FGF9 mRNA; FGF9 protein inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased abundance of Progesterone]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]]; FGF9 protein inhibits the reaction [IGF1 protein results in increased abundance of Progesterone]; FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] Progesterone results in decreased expression of FGF9 mRNA
|
CTD |
PMID:17404688 PMID:22238285 PMID:22798350 |
|
NCBI chr15:36,325,552...36,369,995
Ensembl chr15:36,325,599...36,367,926
|
|
| G
|
Fgfbp1
|
fibroblast growth factor binding protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FGFBP1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr14:71,316,171...71,319,965
Ensembl chr14:71,317,065...71,320,309
|
|
| G
|
Fgfr2
|
fibroblast growth factor receptor 2
|
affects expression multiple interactions
|
ISO
|
Progesterone affects the expression of FGFR2 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of FGFR2 mRNA
|
CTD |
PMID:17251523 PMID:20660070 |
|
NCBI chr 1:194,175,703...194,280,914
Ensembl chr 1:194,175,705...194,280,914
|
|
| G
|
Fgl1
|
fibrinogen-like 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of FGL1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr16:57,824,127...57,854,413
Ensembl chr16:57,824,200...57,854,429
|
|
| G
|
Fgl2
|
fibrinogen-like 2
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of FGL2 mRNA Progesterone results in increased expression of FGL2 mRNA
|
CTD |
PMID:17404688 PMID:22238285 |
|
NCBI chr 4:14,602,762...14,608,405
Ensembl chr 4:14,602,771...14,608,405
|
|
| G
|
Fh
|
fumarate hydratase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FH mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr13:90,056,565...90,082,450
Ensembl chr13:90,056,570...90,089,627
|
|
| G
|
Fhl2
|
four and a half LIM domains 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of FHL2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:52,881,091...52,954,540
Ensembl chr 9:52,880,998...52,923,326
|
|
| G
|
Fhod3
|
formin homology 2 domain containing 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FHOD3 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr18:16,267,830...16,700,508
Ensembl chr18:16,267,977...16,700,508
|
|
| G
|
Fibin
|
fin bud initiation factor homolog
|
increases expression
|
ISO
|
Progesterone results in increased expression of FIBIN mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:117,396,973...117,399,244
Ensembl chr 3:117,391,724...117,399,479
|
|
| G
|
Filip1l
|
filamin A interacting protein 1-like
|
increases expression
|
ISO
|
Progesterone results in increased expression of FILIP1L mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr11:56,403,467...56,646,422
Ensembl chr11:56,410,582...56,646,402
|
|
| G
|
Fjx1
|
four-jointed box kinase 1
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of FJX1 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of FJX1 mRNA Progesterone results in decreased expression of FJX1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20864642 |
|
NCBI chr 3:109,229,223...109,231,324
Ensembl chr 3:109,227,170...109,232,479
|
|
| G
|
Fkbp11
|
FKBP prolyl isomerase 11
|
affects expression
|
ISO
|
Progesterone affects the expression of FKBP11 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:131,750,828...131,757,784
Ensembl chr 7:131,750,672...131,770,123
|
|
| G
|
Fkbp5
|
FKBP prolyl isomerase 5
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of FKBP5 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of FKBP5 mRNA; Arsenic inhibits the reaction [Progesterone results in increased expression of FKBP5 mRNA]
|
CTD |
PMID:17404688 PMID:18037150 PMID:19693291 PMID:20660070 PMID:20864642 PMID:21795739 PMID:33047385 More...
|
|
NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,458,940...6,543,118
|
|
| G
|
Flrt2
|
fibronectin leucine rich transmembrane protein 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of FLRT2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 6:120,507,998...120,603,133
Ensembl chr 6:120,507,689...120,609,004
|
|
| G
|
Flt1
|
Fms related receptor tyrosine kinase 1
|
affects expression
|
ISO
|
Progesterone affects the expression of FLT1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr12:12,333,050...12,504,750
Ensembl chr12:12,333,430...12,504,750
|
|
| G
|
Fmn1
|
formin 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FMN1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:120,555,445...120,939,978
Ensembl chr 3:120,555,431...120,933,124
|
|
| G
|
Fmo3
|
flavin containing dimethylaniline monoxygenase 3
|
increases expression
|
EXP
|
Progesterone results in increased expression of FMO3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr13:77,838,899...77,868,869
Ensembl chr13:77,842,602...77,861,256
|
|
| G
|
Fn1
|
fibronectin 1
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of FN1 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of FN1 mRNA
|
CTD |
PMID:18070364 PMID:20226447 |
|
NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137
|
|
| G
|
Fndc1
|
fibronectin type III domain containing 1
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of FNDC1 mRNA Progesterone results in decreased expression of FNDC1 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 1:49,686,856...49,769,263
Ensembl chr 1:49,686,856...49,769,263
|
|
| G
|
Fndc3a
|
fibronectin type III domain containing 3a
|
increases expression
|
ISO
|
Progesterone results in increased expression of FNDC3A mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr15:54,099,510...54,276,963
Ensembl chr15:54,099,510...54,276,407
|
|
| G
|
Folr1
|
folate receptor alpha
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of FOLR1 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of FOLR1 mRNA
|
CTD |
PMID:18692832 PMID:20660070 |
|
NCBI chr 1:165,631,462...165,650,430
Ensembl chr 1:165,631,462...165,642,669
|
|
| G
|
Fos
|
Fos proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of FOS mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of FOS mRNA; Progesterone promotes the reaction [EGF protein affects the localization of FOS protein]; Progesterone promotes the reaction [EGF protein results in increased expression of FOS mRNA]; Progesterone promotes the reaction [EGF protein results in increased expression of FOS protein] Progesterone results in decreased expression of FOS mRNA Progesterone results in increased expression of FOS mRNA [estradiol 3-benzoate co-treated with Progesterone] results in increased abundance of FOS protein; [Estradiol co-treated with Progesterone] results in increased expression of FOS mRNA [Estrogens co-treated with Progesterone] results in increased expression of FOS protein
|
CTD |
PMID:16175315 PMID:16376865 PMID:18556351 PMID:18692832 PMID:19847363 PMID:20660070 PMID:21258428 PMID:22577852 More...
|
|
NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598
|
|
| G
|
Fosb
|
FosB proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of FOSB mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477
|
|
| G
|
Fosl1
|
FOS like 1, AP-1 transcription factor subunit
|
increases expression
|
ISO
|
Progesterone results in increased expression of FOSL1 mRNA
|
CTD |
PMID:19000923 |
|
NCBI chr 1:212,183,885...212,192,391
Ensembl chr 1:212,183,833...212,192,391
|
|
| G
|
Foxa2
|
forkhead box A2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FOXA2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:155,923,305...155,927,508
Ensembl chr 3:155,923,307...155,928,757
|
|
| G
|
Foxo1
|
forkhead box O1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone promotes the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]] Progesterone results in increased expression of FOXO1 mRNA; Progesterone results in increased expression of FOXO1A mRNA
|
CTD |
PMID:20864642 PMID:21768169 PMID:21795739 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419
|
|
| G
|
Foxp3
|
forkhead box P3
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of FOXP3 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of FOXP3 mRNA [Progesterone co-treated with Estradiol] inhibits the reaction [Vaccines, Virus-Like Particle results in decreased expression of FOXP3 protein]; Progesterone inhibits the reaction [Vaccines, Virus-Like Particle results in decreased expression of FOXP3 protein]
|
CTD |
PMID:19693291 PMID:20130130 |
|
NCBI chr X:17,580,380...17,601,181
Ensembl chr X:17,580,380...17,595,894
|
|
| G
|
Fpr1
|
formyl peptide receptor 1
|
affects expression
|
ISO
|
Progesterone affects the expression of FPR1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:67,417,991...67,429,813
Ensembl chr 1:67,421,313...67,422,520
|
|
| G
|
Frmd3
|
FERM domain containing 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of FRMD3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:92,810,989...93,077,326
Ensembl chr 5:92,810,736...93,077,325
|
|
| G
|
Frmd4a
|
FERM domain containing 4A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FRMD4A mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr17:78,577,062...79,167,924
Ensembl chr17:78,579,277...79,167,663
|
|
| G
|
Frmd6
|
FERM domain containing 6
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of FRMD6 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:95,081,958...95,155,561
Ensembl chr 6:95,081,985...95,155,560
|
|
| G
|
Fry
|
FRY microtubule binding protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FRY mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr12:9,530,360...9,773,391
Ensembl chr12:9,530,360...9,897,603
|
|
| G
|
Frzb
|
frizzled-related protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of FRZB mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 3:85,739,162...85,772,168
Ensembl chr 3:85,739,165...85,772,096
|
|
| G
|
Fscn1
|
fascin actin-bundling protein 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of FSCN1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr12:16,710,601...16,723,734
Ensembl chr12:16,710,601...16,723,734
|
|
| G
|
Fshb
|
follicle stimulating hormone subunit beta
|
multiple interactions increases expression increases secretion decreases expression increases chemical synthesis increases abundance
|
ISO EXP
|
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [TGFB1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]]; [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] promotes the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride results in decreased activity of SMAD3 protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [CGA protein co-treated with FSHB protein] results in increased abundance of Progesterone; [CGA protein co-treated with FSHB protein] results in increased secretion of Progesterone; [FGF9 protein co-treated with FSHB protein] affects the abundance of Progesterone; [FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Progesterone; [IGF1 protein co-treated with FSHB protein] results in increased abundance of Progesterone; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; Carbaryl inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; FGF9 protein inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased abundance of Progesterone]; finrozole inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; Fulvestrant inhibits the reaction [TGFB1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]]; GDF9 protein inhibits the reaction [INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]]; INHA mutant form inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; INHA mutant form inhibits the reaction [GDF9 protein inhibits the reaction [INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]]]; INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; Lipopolysaccharides inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[FSHB protein co-treated with Testosterone] results in increased chemical synthesis of Progesterone]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; PHB1 protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; T-2 Toxin inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; T0901317 inhibits the reaction [[CGA protein co-treated with FSHB protein] results in increased abundance of Progesterone]; TGFB1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]; Trichlorfon inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; U 0126 inhibits the reaction [Lipopolysaccharides inhibits the reaction [FSHB protein results in increased abundance of Progesterone]] Progesterone results in increased expression of FSHB mRNA 2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[FSHB protein co-treated with TGFB1 protein] results in increased abundance of Progesterone]; [BMP15 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [BMP2 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [BMP4 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [BMP6 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [BMP7 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased abundance of Progesterone]; [FSHB protein co-treated with TGFB1 protein] results in increased abundance of Progesterone; [FSHB protein results in increased expression of CYP11A1 mRNA] which results in increased abundance of Progesterone; [FSHB protein results in increased expression of CYP19A1 mRNA] which results in increased abundance of Progesterone; [FSHB protein results in increased expression of HSD3B2 mRNA] which results in increased abundance of Progesterone; [FSHB protein results in increased expression of STAR mRNA] which results in increased abundance of Progesterone; [Triclosan co-treated with FSHB protein] results in increased secretion of Progesterone; AG 538 inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide promotes the reaction [FSHB protein results in increased abundance of Progesterone]; Dihydrotestosterone inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; GH1 protein inhibits the reaction [BMP4 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; GH1 protein inhibits the reaction [BMP6 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; GH1 protein inhibits the reaction [BMP7 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; GH1 protein promotes the reaction [[FSHB protein results in increased expression of CYP11A1 mRNA] which results in increased abundance of Progesterone]; GH1 protein promotes the reaction [[FSHB protein results in increased expression of HSD3B2 mRNA] which results in increased abundance of Progesterone]; GH1 protein promotes the reaction [[FSHB protein results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]; GH1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]; IGF1 protein inhibits the reaction [BMP15 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP2 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP4 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP6 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP7 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of CYP11A1 mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of CYP19A1 mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of HSD3B2 mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]; INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; Metformin inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; Methoxychlor metabolite inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; NOG protein promotes the reaction [GH1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]]; Octreotide inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; pasireotide inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; pyrazolanthrone inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; RARRES2 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; tyrphostin AG 1024 inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; U 0126 inhibits the reaction [FSHB protein results in increased abundance of Progesterone] Progesterone results in decreased expression of FSHB protein NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]
|
CTD |
PMID:15781295 PMID:15967414 PMID:16413094 PMID:16574160 PMID:16675544 PMID:16737795 PMID:16760380 PMID:17099214 PMID:17329077 PMID:17954979 PMID:18325989 PMID:18511507 PMID:18535249 PMID:19081562 PMID:19228890 PMID:19336472 PMID:19729004 PMID:20660033 PMID:20926582 PMID:21520325 PMID:21826657 PMID:22067323 PMID:22798350 PMID:22948218 PMID:23137853 PMID:23254195 PMID:30447264 PMID:30951242 More...
|
|
NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072
|
|
| G
|
Fst
|
follistatin
|
multiple interactions increases expression
|
ISO
|
FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]] Progesterone results in increased expression of FST mRNA; Progesterone results in increased expression of FST mRNA alternative form [Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of FST mRNA
|
CTD |
PMID:18936084 PMID:22238285 PMID:22285243 PMID:32186404 |
|
NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:47,856,345...47,863,491
|
|
| G
|
Fxyd3
|
FXYD domain-containing ion transport regulator 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of FXYD3 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 1:95,432,918...95,440,129
Ensembl chr 1:95,432,919...95,439,702
|
|
| G
|
Fxyd4
|
FXYD domain-containing ion transport regulator 4
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of FXYD4 mRNA Progesterone results in increased expression of FXYD4 mRNA
|
CTD |
PMID:21540246 PMID:22238285 |
|
NCBI chr 4:152,782,181...152,786,118
Ensembl chr 4:152,782,181...152,786,039
|
|
| G
|
Fxyd5
|
FXYD domain-containing ion transport regulator 5
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of FXYD5 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:95,395,327...95,404,722
Ensembl chr 1:95,395,146...95,405,364
|
|
| G
|
Fxyd6
|
FXYD domain-containing ion transport regulator 6
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of FXYD6 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 8:54,575,578...54,602,715
Ensembl chr 8:54,575,591...54,602,715
|
|
| G
|
Fzd10
|
frizzled class receptor 10
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of FZD10 mRNA Progesterone results in decreased expression of FZD10 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr12:33,734,364...33,737,559
Ensembl chr12:33,734,364...33,741,646
|
|
| G
|
Fzd5
|
frizzled class receptor 5
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of FZD5 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:73,606,860...73,618,612
|
|
| G
|
Fzd7
|
frizzled class receptor 7
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of FZD7 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585
|
|
| G
|
Fzr1
|
fizzy and cell division cycle 20 related 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of FZR1 protein; FZR1 mutant form inhibits the reaction [Progesterone affects the localization of CDKN1B protein]
|
CTD |
PMID:23029392 |
|
NCBI chr 7:8,982,765...8,994,689
Ensembl chr 7:8,989,769...8,995,199
|
|
| G
|
G0s2
|
G0/G1switch 2
|
increases expression multiple interactions affects expression
|
ISO
|
Progesterone results in increased expression of G0S2 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of G0S2 mRNA; perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of G0S2 mRNA]; Progesterone inhibits the reaction [perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of G0S2 mRNA]]
|
CTD |
PMID:20660070 PMID:21795739 PMID:31896193 |
|
NCBI chr13:107,335,036...107,335,948
Ensembl chr13:107,335,036...107,336,293
|
|
| G
|
G6pc1
|
glucose-6-phosphatase catalytic subunit 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]; [Progesterone co-treated with Estradiol] inhibits the reaction [Phenobarbital results in decreased expression of G6PC1 mRNA]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [Phenobarbital results in decreased expression of G6PC1 mRNA]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]; Progesterone inhibits the reaction [Phenobarbital results in decreased expression of G6PC1 mRNA]; Progesterone promotes the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [FOXO1 protein binds to G6PC1 promoter]]] 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [[Progesterone co-treated with Estradiol] results in increased expression of G6PC1 mRNA]; [Progesterone co-treated with Estradiol] results in increased expression of G6PC1 mRNA
|
CTD |
PMID:21768169 |
|
NCBI chr10:86,807,659...86,819,023
Ensembl chr10:86,757,899...86,818,033
|
|
| G
|
Gabbr1
|
gamma-aminobutyric acid type B receptor subunit 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GABBR1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr20:1,469,779...1,499,352
Ensembl chr20:1,469,779...1,498,607
|
|
| G
|
Gabpa
|
GA binding protein transcription factor subunit alpha
|
multiple interactions
|
EXP
|
[Progesterone co-treated with Norepinephrine] results in increased expression of GABPA mRNA
|
CTD |
PMID:16954335 |
|
NCBI chr11:37,375,040...37,404,060
Ensembl chr11:37,375,084...37,404,059
|
|
| G
|
Gabra2
|
gamma-aminobutyric acid type A receptor subunit alpha 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of GABRA2 mRNA
|
CTD |
PMID:16000229 |
|
NCBI chr14:37,451,218...37,587,458
Ensembl chr14:37,450,683...37,587,457
|
|
| G
|
Gabra4
|
gamma-aminobutyric acid type A receptor subunit alpha 4
|
affects expression affects response to substance multiple interactions
|
EXP
|
Progesterone affects the expression of GABRA4 protein GABRA4 protein affects the susceptibility to Progesterone [Progesterone co-treated with estradiol 3-benzoate] results in decreased expression of GABRA4 mRNA
|
CTD |
PMID:12522171 PMID:15834956 PMID:19394921 |
|
NCBI chr14:36,944,747...37,021,652
Ensembl chr14:36,944,388...37,021,648
|
|
| G
|
Gabra5
|
gamma-aminobutyric acid type A receptor subunit alpha 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GABRA5 mRNA
|
CTD |
PMID:16000229 |
|
NCBI chr 1:117,404,446...117,517,424
Ensembl chr 1:117,404,494...117,516,635
|
|
| G
|
Gabrb1
|
gamma-aminobutyric acid type A receptor subunit beta1
|
affects expression
|
EXP
|
Progesterone affects the expression of GABRB1 protein
|
CTD |
PMID:15834956 |
|
NCBI chr14:36,434,339...36,917,920
Ensembl chr14:36,434,352...36,902,893
|
|
| G
|
Gabrd
|
gamma-aminobutyric acid type A receptor subunit delta
|
affects expression multiple interactions decreases expression
|
EXP
|
Progesterone affects the expression of GABRD mRNA; Progesterone affects the expression of GABRD protein; Progesterone metabolite affects the expression of GABRD mRNA Finasteride inhibits the reaction [Progesterone affects the expression of GABRD mRNA]; Finasteride inhibits the reaction [Progesterone affects the expression of GABRD protein] Progesterone results in decreased expression of GABRD protein
|
CTD |
PMID:15834956 PMID:16879715 PMID:16914187 |
|
NCBI chr 5:171,240,813...171,252,709
Ensembl chr 5:171,240,789...171,253,094
|
|
| G
|
Gabre
|
gamma-aminobutyric acid type A receptor subunit epsilon
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GABRE mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr X:155,102,078...155,120,821
Ensembl chr X:155,102,083...155,120,735
|
|
| G
|
Gabrg3
|
gamma-aminobutyric acid type A receptor subunit gamma 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of GABRG3 mRNA
|
CTD |
PMID:16000229 |
|
NCBI chr 1:116,763,332...117,386,770
Ensembl chr 1:116,763,129...117,382,536
|
|
| G
|
Gabrp
|
gamma-aminobutyric acid type A receptor subunit pi
|
multiple interactions affects localization increases expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GABRP mRNA; HOXA10 protein affects the reaction [Progesterone affects the localization of GABRP protein]; HOXA10 protein affects the reaction [Progesterone results in increased expression of GABRP mRNA] Progesterone results in decreased expression of GABRP mRNA
|
CTD |
PMID:20103740 PMID:20660070 PMID:22238285 |
|
NCBI chr10:18,647,243...18,673,806
Ensembl chr10:18,647,243...18,673,727
|
|
| G
|
Gadd45a
|
growth arrest and DNA-damage-inducible, alpha
|
increases expression multiple interactions
|
ISO EXP
|
Progesterone results in increased expression of GADD45A mRNA [Estradiol co-treated with Progesterone] results in decreased expression of GADD45A mRNA
|
CTD |
PMID:18037150 PMID:20660070 PMID:20726854 |
|
NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807
|
|
| G
|
Gadd45g
|
growth arrest and DNA-damage-inducible, gamma
|
affects expression
|
ISO
|
Progesterone affects the expression of GADD45G mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr17:13,528,606...13,530,351
Ensembl chr17:13,528,610...13,530,369
|
|
| G
|
Gal
|
galanin and GMAP prepropeptide
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of GAL mRNA; [Estrogens co-treated with Progesterone] results in increased expression of GAL mRNA; Dizocilpine Maleate inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of GAL mRNA]; Pentobarbital inhibits the reaction [[Estrogens co-treated with Progesterone] results in increased expression of GAL mRNA]; Phenoxybenzamine inhibits the reaction [[Estrogens co-treated with Progesterone] results in increased expression of GAL mRNA]
|
CTD |
PMID:7512492 PMID:8730651 |
|
NCBI chr 1:210,079,709...210,084,572
Ensembl chr 1:210,079,702...210,084,229
|
|
| G
|
Galk2
|
galactokinase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of GALK2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 3:133,563,524...133,696,423
Ensembl chr 3:133,563,538...133,696,528
|
|
| G
|
Galm
|
galactose mutarotase
|
affects expression
|
ISO
|
Progesterone affects the expression of GALM mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 6:20,589,775...20,641,516
Ensembl chr 6:20,589,776...20,644,417
|
|
| G
|
Galnt10
|
polypeptide N-acetylgalactosaminyltransferase 10
|
affects response to substance
|
ISO
|
GALNT10 gene SNP affects the susceptibility to Progesterone
|
CTD |
PMID:25622337 |
|
NCBI chr10:42,321,691...42,468,087
Ensembl chr10:42,322,161...42,468,087
|
|
| G
|
Gap43
|
growth associated protein 43
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of GAP43 mRNA Progesterone inhibits the reaction [VPS54 mutant form results in increased expression of GAP43 mRNA]
|
CTD |
PMID:17404688 PMID:19693665 |
|
NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797
|
|
| G
|
Gapdh
|
glyceraldehyde-3-phosphate dehydrogenase
|
increases expression
|
EXP
|
Progesterone results in increased expression of GAPDH mRNA
|
CTD |
PMID:16376865 |
|
NCBI chr 4:159,648,592...159,653,436
Ensembl chr 4:159,648,592...159,653,377
|
|
| G
|
Gar1
|
GAR1 ribonucleoprotein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GAR1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:221,049,471...221,056,749
Ensembl chr 2:221,049,473...221,056,749
|
|
| G
|
Gars1
|
glycyl-tRNA synthetase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of GARS1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:85,493,753...85,542,876
|
|
| G
|
Gas1
|
growth arrest-specific 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of GAS1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr17:4,487,716...4,490,701
Ensembl chr17:4,484,283...4,497,657
|
|
| G
|
Gas2l3
|
growth arrest-specific 2 like 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GAS2L3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 7:25,690,929...25,726,806
Ensembl chr 7:25,693,660...25,716,942
|
|
| G
|
Gas6
|
growth arrest specific 6
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of GAS6 mRNA Progesterone results in increased expression of GAS6 mRNA
|
CTD |
PMID:20660070 PMID:20726854 PMID:22238285 |
|
NCBI chr16:82,747,676...82,778,090
Ensembl chr16:82,747,345...82,778,088
|
|
| G
|
Gask1b
|
golgi associated kinase 1B
|
increases expression
|
ISO
|
Progesterone results in increased expression of GASK1B mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:167,345,738...167,410,606
Ensembl chr 2:167,345,809...167,410,603
|
|
| G
|
Gast
|
gastrin
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of GAST mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:85,765,216...85,767,881
Ensembl chr10:85,765,216...85,767,880
|
|
| G
|
Gata2
|
GATA binding protein 2
|
multiple interactions
|
ISO
|
[Progesterone results in increased activity of PGR protein] which results in increased expression of GATA2 mRNA
|
CTD |
PMID:15845616 |
|
NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:122,211,829...122,225,055
|
|
| G
|
Gata4
|
GATA binding protein 4
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of GATA4 mRNA Mifepristone inhibits the reaction [Progesterone results in decreased expression of GATA4 mRNA]
|
CTD |
PMID:27264040 PMID:31566189 |
|
NCBI chr15:41,635,572...41,707,252
Ensembl chr15:41,635,572...41,681,609
|
|
| G
|
Gata6
|
GATA binding protein 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of GATA6 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr18:2,460,909...2,492,322
Ensembl chr18:2,458,253...2,492,322
|
|
| G
|
Gatm
|
glycine amidinotransferase
|
decreases expression
|
EXP ISO
|
Progesterone results in decreased expression of GATM mRNA
|
CTD |
PMID:20726854 PMID:22238285 |
|
NCBI chr 3:130,112,508...130,137,664
Ensembl chr 3:130,112,509...130,129,355
|
|
| G
|
Gbp2
|
guanylate binding protein 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GBP2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:234,005,727...234,021,812
Ensembl chr 2:234,008,590...234,021,810
|
|
| G
|
Gbp4
|
guanylate binding protein 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GBP4 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 2:233,978,163...233,992,124
Ensembl chr 2:233,978,486...233,992,120
|
|
| G
|
Gclc
|
glutamate-cysteine ligase, catalytic subunit
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GCLC mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893
|
|
| G
|
Gcnt1
|
glucosaminyl (N-acetyl) transferase 1
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of GCNT1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of GCNT1 mRNA
|
CTD |
PMID:20660070 PMID:20726854 PMID:20864642 PMID:21795739 |
|
NCBI chr 1:224,145,104...224,182,496
Ensembl chr 1:224,141,108...224,185,741
|
|
| G
|
Gcsam
|
germinal center-associated, signaling and motility
|
affects expression
|
ISO
|
Progesterone affects the expression of GCSAM mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr11:68,658,350...68,669,598
Ensembl chr11:68,660,438...68,669,584
|
|
| G
|
Gda
|
guanine deaminase
|
increases expression
|
EXP
|
Progesterone results in increased expression of GDA mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:228,333,401...228,408,901
Ensembl chr 1:228,333,364...228,409,348
|
|
| G
|
Gdf15
|
growth differentiation factor 15
|
increases expression multiple interactions decreases expression
|
ISO EXP
|
Progesterone results in increased expression of GDF15 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of GDF15 mRNA Progesterone results in decreased expression of GDF15 mRNA
|
CTD |
PMID:18037150 PMID:20660070 PMID:20726854 PMID:22238285 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022
|
|
| G
|
Gdf5
|
growth differentiation factor 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of GDF5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:164,914,401...164,918,593
Ensembl chr 3:164,914,401...164,918,593
|
|
| G
|
Gdf9
|
growth differentiation factor 9
|
multiple interactions
|
ISO
|
GDF9 protein inhibits the reaction [INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]]; GDF9 protein inhibits the reaction [INHBA protein results in decreased secretion of Progesterone]; INHA mutant form inhibits the reaction [GDF9 protein inhibits the reaction [INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]]]
|
CTD |
PMID:20660033 |
|
NCBI chr10:38,090,021...38,100,801
Ensembl chr10:38,089,878...38,100,797
|
|
| G
|
Gdnf
|
glial cell derived neurotrophic factor
|
increases expression
|
ISO
|
Progesterone results in increased expression of GDNF mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:58,621,327...58,647,240
|
|
| G
|
Gdpd2
|
glycerophosphodiester phosphodiesterase domain containing 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of GDPD2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr X:69,866,395...69,875,419
Ensembl chr X:69,866,799...69,875,414
|
|
| G
|
Gem
|
GTP binding protein overexpressed in skeletal muscle
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GEM mRNA Progesterone results in increased expression of GEM mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 5:30,011,641...30,022,554
Ensembl chr 5:30,011,592...30,022,542
|
|
| G
|
Gemin6
|
gem (nuclear organelle) associated protein 6
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GEMIN6 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:20,538,325...20,542,867
Ensembl chr 6:20,538,325...20,542,852
|
|
| G
|
Gfap
|
glial fibrillary acidic protein
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] promotes the reaction [Cuprizone results in increased expression of GFAP mRNA] Finasteride inhibits the reaction [Progesterone results in increased expression of GFAP mRNA] Progesterone results in decreased expression of GFAP protein
|
CTD |
PMID:19031445 PMID:19360904 PMID:21770760 PMID:23157231 |
|
NCBI chr10:88,352,987...88,361,661
Ensembl chr10:88,352,986...88,361,685
|
|
| G
|
Gfi1
|
growth factor independent 1 transcriptional repressor
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of GFI1 mRNA TGFB1 protein promotes the reaction [Progesterone results in increased expression of GFI1 mRNA]
|
CTD |
PMID:21768398 |
|
NCBI chr14:2,185,489...2,204,191
Ensembl chr14:2,187,286...2,196,730
|
|
| G
|
Gfpt2
|
glutamine-fructose-6-phosphate transaminase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of GFPT2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr10:34,616,146...34,662,420
Ensembl chr10:34,615,370...34,662,419
|
|
| G
|
Gfra2
|
GDNF family receptor alpha 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of GFRA2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr15:52,351,499...52,443,369
Ensembl chr15:52,351,514...52,477,782
|
|
| G
|
Gga1
|
golgi associated, gamma adaptin ear containing, ARF binding protein 1
|
affects expression
|
ISO
|
Progesterone affects the expression of GGA1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:112,316,530...112,332,249
Ensembl chr 7:112,315,449...112,332,249
|
|
| G
|
Ggt5
|
gamma-glutamyltransferase 5
|
increases expression affects expression
|
ISO
|
Progesterone results in increased expression of GGT5 mRNA Progesterone affects the expression of GGT5 mRNA
|
CTD |
PMID:17251523 PMID:21540246 |
|
NCBI chr20:13,042,694...13,070,960
Ensembl chr20:13,042,696...13,070,892
|
|
| G
|
Ggt6
|
gamma-glutamyl transferase 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of GGT6 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:57,550,447...57,553,461
Ensembl chr10:57,550,492...57,553,460
|
|
| G
|
Ggta1
|
glycoprotein alpha-galactosyltransferase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of GGTA1 mRNA; Mifepristone inhibits the reaction [Progesterone affects the expression of GGTA1 mRNA]
|
CTD |
PMID:20660070 PMID:22414680 |
|
NCBI chr 3:39,130,466...39,208,652
Ensembl chr 3:39,130,467...39,206,870
|
|
| G
|
Gh1
|
growth hormone 1
|
multiple interactions increases secretion
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased secretion of GH1 protein Progesterone results in increased secretion of GH1 protein GH1 protein inhibits the reaction [BMP4 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; GH1 protein inhibits the reaction [BMP6 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; GH1 protein inhibits the reaction [BMP7 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; GH1 protein promotes the reaction [[FSHB protein results in increased expression of CYP11A1 mRNA] which results in increased abundance of Progesterone]; GH1 protein promotes the reaction [[FSHB protein results in increased expression of HSD3B2 mRNA] which results in increased abundance of Progesterone]; GH1 protein promotes the reaction [[FSHB protein results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]; GH1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]; NOG protein promotes the reaction [GH1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]]
|
CTD |
PMID:15772906 PMID:22067323 |
|
NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859
|
|
| G
|
Ghr
|
growth hormone receptor
|
increases expression
|
EXP
|
Progesterone results in increased expression of GHR mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:54,269,066...54,532,595
Ensembl chr 2:54,270,206...54,532,331
|
|
| G
|
Gipc2
|
GIPC PDZ domain containing family, member 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GIPC2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:243,690,742...243,770,199
Ensembl chr 2:243,690,748...243,770,199
|
|
| G
|
Gja1
|
gap junction protein, alpha 1
|
increases expression decreases expression
|
EXP ISO
|
Progesterone results in increased expression of GJA1 mRNA Progesterone results in decreased expression of GJA1 protein
|
CTD |
PMID:20726854 PMID:21558462 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689
|
|
| G
|
Gja4
|
gap junction protein, alpha 4
|
multiple interactions decreases expression increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GJA4 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of GJA4 mRNA Progesterone results in decreased expression of GJA4 mRNA Progesterone results in increased expression of GJA4 mRNA
|
CTD |
PMID:17404688 PMID:18692832 PMID:20660070 |
|
NCBI chr 5:144,917,791...144,920,324
Ensembl chr 5:144,914,147...144,921,216
|
|
| G
|
Gja5
|
gap junction protein, alpha 5
|
increases expression
|
EXP
|
Progesterone results in increased expression of GJA5 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:187,291,227...187,310,770
Ensembl chr 2:187,234,674...187,318,512
|
|
| G
|
Gjb2
|
gap junction protein, beta 2
|
affects expression multiple interactions decreases expression
|
ISO
|
Progesterone affects the expression of GJB2 mRNA [Estradiol co-treated with Progesterone] results in increased expression of GJB2 mRNA Progesterone results in decreased expression of GJB2 protein Progesterone results in decreased expression of GJB2 mRNA
|
CTD |
PMID:17251523 PMID:20660070 PMID:21558462 PMID:22238285 |
|
NCBI chr15:35,375,977...35,393,817
Ensembl chr15:35,375,692...35,393,877
|
|
| G
|
Gjb3
|
gap junction protein, beta 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GJB3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:144,933,692...144,939,435
Ensembl chr 5:144,933,696...144,940,280
|
|
| G
|
Gjb6
|
gap junction protein, beta 6
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of GJB6 mRNA Progesterone results in decreased expression of GJB6 mRNA
|
CTD |
PMID:17251523 PMID:22238285 |
|
NCBI chr15:35,400,147...35,410,649
Ensembl chr15:35,398,770...35,410,849
|
|
| G
|
Gk
|
glycerol kinase
|
increases expression
|
ISO
|
Progesterone results in increased expression of GK mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr X:54,106,708...54,189,940
Ensembl chr X:54,112,214...54,196,701
|
|
| G
|
Glb1l2
|
galactosidase, beta 1-like 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of GLB1L2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 8:33,391,201...33,442,587
Ensembl chr 8:33,390,678...33,442,695
|
|
| G
|
Gldc
|
glycine decarboxylase
|
increases expression
|
ISO
|
Progesterone results in increased expression of GLDC mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:237,296,753...237,375,620
Ensembl chr 1:237,296,753...237,375,604
|
|
| G
|
Gli1
|
GLI family zinc finger 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of GLI1 mRNA
|
CTD |
PMID:22958837 |
|
NCBI chr 7:65,042,237...65,054,888
Ensembl chr 7:65,042,237...65,054,540
|
|
| G
|
Gli2
|
GLI family zinc finger 2
|
affects expression
|
ISO
|
Progesterone affects the expression of GLI2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr13:32,499,678...32,716,418
Ensembl chr13:32,499,678...32,716,418
|
|
| G
|
Glipr1
|
GLI pathogenesis-related 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GLIPR1 mRNA Progesterone results in increased expression of GLIPR1 mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr 7:49,373,579...49,399,190
Ensembl chr 7:49,373,581...49,384,640
|
|
| G
|
Glis2
|
GLIS family zinc finger 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GLIS2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr10:11,457,594...11,484,948
Ensembl chr10:11,457,792...11,477,995
|
|
| G
|
Glt1d1
|
glycosyltransferase 1 domain containing 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of GLT1D1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr12:34,611,942...34,685,591
Ensembl chr12:34,612,643...34,685,468
|
|
| G
|
Gltp
|
glycolipid transfer protein
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of GLTP mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr12:47,567,797...47,587,949
Ensembl chr12:47,567,770...47,587,946
|
|
| G
|
Glul
|
glutamate-ammonia ligase
|
increases expression
|
EXP
|
Progesterone results in increased expression of GLUL mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr13:68,519,500...68,585,554
Ensembl chr13:68,576,067...68,585,520
|
|
| G
|
Glyat
|
glycine-N-acyltransferase
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of GLYAT mRNA Progesterone results in increased expression of GLYAT mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:219,128,798...219,149,615
Ensembl chr 1:219,128,811...219,150,774
|
|
| G
|
Gmnn
|
geminin, DNA replication inhibitor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GMNN mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr17:40,729,760...40,738,077
Ensembl chr17:40,729,824...40,738,068
|
|
| G
|
Gmpr
|
guanosine monophosphate reductase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GMPR mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr17:19,357,992...19,395,807
Ensembl chr17:19,357,992...19,431,655
|
|
| G
|
Gna11
|
G protein subunit alpha 11
|
affects expression
|
ISO
|
Progesterone affects the expression of GNA11 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:8,814,285...8,828,628
Ensembl chr 7:8,814,327...8,830,558
|
|
| G
|
Gnai3
|
G protein subunit alpha i3
|
multiple interactions decreases expression
|
ISO
|
CAV3 mutant form inhibits the reaction [Progesterone results in decreased expression of GNAI3 protein]; Cholesterol inhibits the reaction [Progesterone results in decreased expression of GNAI3 protein]
|
CTD |
PMID:19221014 |
|
NCBI chr 2:198,430,920...198,468,874
|
|
| G
|
Gnao1
|
G protein subunit alpha o1
|
increases expression
|
EXP
|
Progesterone results in increased expression of GNAO1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr19:11,040,788...11,198,437
Ensembl chr19:11,040,788...11,198,437
|
|
| G
|
Gnas
|
GNAS complex locus
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of GNAS protein CAV3 mutant form inhibits the reaction [Progesterone results in increased expression of GNAS protein]; Cholesterol inhibits the reaction [Progesterone results in increased expression of GNAS protein]
|
CTD |
PMID:15469997 PMID:19221014 |
|
NCBI chr 3:183,489,648...183,554,570
Ensembl chr 3:183,503,243...183,554,536
|
|
| G
|
Gng11
|
G protein subunit gamma 11
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of GNG11 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:32,977,681...32,983,121
Ensembl chr 4:32,977,664...32,984,438
|
|
| G
|
Gng12
|
G protein subunit gamma 12
|
affects expression
|
ISO
|
Progesterone affects the expression of GNG12 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:97,340,830...97,464,422
Ensembl chr 4:97,340,472...97,464,476
|
|
| G
|
Gng2
|
G protein subunit gamma 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GNG2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:4,365,222...4,466,060
Ensembl chr15:4,365,135...4,466,059
|
|
| G
|
Gng4
|
G protein subunit gamma 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GNG4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:93,432,791...93,481,709
Ensembl chr17:93,433,195...93,481,709
|
|
| G
|
Gnl2
|
G protein nucleolar 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GNL2 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 5:142,577,798...142,603,185
Ensembl chr 5:142,577,731...142,603,178
|
|
| G
|
Gnrh1
|
gonadotropin releasing hormone 1
|
multiple interactions decreases abundance
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased secretion of GNRH1 protein; Tamoxifen inhibits the reaction [[Progesterone co-treated with Estradiol] results in increased secretion of GNRH1 protein] GNRH1 protein results in decreased abundance of Progesterone
|
CTD |
PMID:10566683 PMID:19261682 |
|
NCBI chr15:46,147,878...46,152,086
Ensembl chr15:46,148,301...46,148,977 Ensembl chr15:46,148,301...46,148,977
|
|
| G
|
Gnrhr
|
gonadotropin releasing hormone receptor
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] inhibits the reaction [Triptorelin Pamoate affects the expression of GNRHR mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of GNRHR mRNA; Progesterone promotes the reaction [Triptorelin Pamoate affects the expression of GNRHR mRNA]
|
CTD |
PMID:17185802 |
|
NCBI chr14:22,211,666...22,229,654
|
|
| G
|
Got1
|
glutamic-oxaloacetic transaminase 1
|
increases expression multiple interactions
|
ISO EXP
|
Progesterone results in increased expression of GOT1 mRNA [Estradiol co-treated with Progesterone] results in increased expression of GOT1 mRNA
|
CTD |
PMID:18037150 PMID:20660070 PMID:20726854 |
|
NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871
|
|
| G
|
Gp1bb
|
glycoprotein Ib platelet subunit beta
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of GP1BB mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr11:95,882,561...95,883,738
|
|
| G
|
Gpaa1
|
glycosylphosphatidylinositol anchor attachment 1
|
affects expression
|
ISO
|
Progesterone affects the expression of GPAA1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:109,932,556...109,936,139
Ensembl chr 7:109,932,544...109,936,138
|
|
| G
|
Gpd1
|
glycerol-3-phosphate dehydrogenase 1
|
affects expression
|
ISO
|
Progesterone affects the expression of GPD1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:132,721,915...132,730,368
|
|
| G
|
Gpd1l
|
glycerol-3-phosphate dehydrogenase 1 like
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of GPD1L mRNA; [Progesterone co-treated with Estradiol] results in increased expression of GPD1L mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 8:123,469,282...123,498,948
Ensembl chr 8:123,466,667...123,498,908
|
|
| G
|
Gpd2
|
glycerol-3-phosphate dehydrogenase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of GPD2 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 3:62,209,432...62,346,590
Ensembl chr 3:62,210,814...62,346,593
|
|
| G
|
Gpr149
|
G protein-coupled receptor 149
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of GPR149 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:149,059,333...149,130,798
Ensembl chr 2:149,059,336...149,130,785
|
|
| G
|
Gpr155
|
G protein-coupled receptor 155
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GPR155 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:78,623,931...78,677,803
Ensembl chr 3:78,607,976...78,677,803
|
|
| G
|
Gpr17
|
G protein-coupled receptor 17
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of GPR17 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of GPR17 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr18:23,850,460...23,857,381
Ensembl chr18:23,850,107...23,857,702
|
|
| G
|
Gprc5a
|
G protein-coupled receptor, class C, group 5, member A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GPRC5A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:169,634,896...169,653,627
Ensembl chr 4:169,634,748...169,653,625
|
|
| G
|
Gprc5b
|
G protein-coupled receptor, class C, group 5, member B
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GPRC5B mRNA Progesterone results in increased expression of GPRC5B mRNA
|
CTD |
PMID:20660070 PMID:20864642 |
|
NCBI chr 1:182,748,247...182,772,711
Ensembl chr 1:182,748,247...182,772,757
|
|
| G
|
Gprc5c
|
G protein-coupled receptor, class C, group 5, member C
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GPRC5C mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr10:100,385,682...100,407,953
Ensembl chr10:100,383,631...100,426,962
|
|
| G
|
Gpt
|
glutamic--pyruvic transaminase
|
multiple interactions
|
EXP
|
[Progesterone co-treated with Estradiol] results in decreased activity of GPT protein
|
CTD |
PMID:15820610 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160
|
|
| G
|
Gpx2
|
glutathione peroxidase 2
|
multiple interactions decreases expression affects expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of GPX2 mRNA Progesterone results in decreased expression of GPX2 mRNA Progesterone affects the expression of GPX2 mRNA
|
CTD |
PMID:17251523 PMID:17404688 |
|
NCBI chr 6:101,226,745...101,230,033
Ensembl chr 6:101,226,745...101,230,862
|
|
| G
|
Gpx3
|
glutathione peroxidase 3
|
affects expression increases expression multiple interactions
|
ISO EXP
|
Progesterone affects the expression of GPX3 mRNA Progesterone results in increased expression of GPX3 mRNA [Estradiol co-treated with Progesterone] results in increased expression of GPX3 mRNA
|
CTD |
PMID:17251523 PMID:18556351 PMID:19693291 PMID:20726854 PMID:20864642 |
|
NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405
|
|
| G
|
Grb10
|
growth factor receptor bound protein 10
|
increases expression
|
ISO
|
Progesterone results in increased expression of GRB10 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr14:90,708,653...90,816,399
Ensembl chr14:90,708,653...90,816,387
|
|
| G
|
Grb2
|
growth factor receptor bound protein 2
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of GRB2 mRNA; [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of GRB2 protein
|
CTD |
PMID:22465879 |
|
NCBI chr10:101,380,354...101,448,138
Ensembl chr10:101,380,356...101,448,138
|
|
| G
|
Greb1
|
growth regulating estrogen receptor binding 1
|
multiple interactions increases expression decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of GREB1 mRNA; ESR1 protein affects the reaction [Progesterone results in increased expression of GREB1 mRNA]; Fulvestrant inhibits the reaction [Progesterone results in increased expression of GREB1 mRNA] Progesterone results in decreased expression of GREB1 mRNA
|
CTD |
PMID:17404688 PMID:20864642 PMID:22238285 PMID:33405908 |
|
NCBI chr 6:45,169,289...45,321,973
Ensembl chr 6:45,169,289...45,291,126
|
|
| G
|
Grem1
|
gremlin 1, DAN family BMP antagonist
|
multiple interactions decreases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of GREM1 mRNA Progesterone results in decreased expression of GREM1 mRNA
|
CTD |
PMID:17404688 PMID:20726854 PMID:20864642 |
|
NCBI chr 3:120,966,639...120,978,319
Ensembl chr 3:120,966,623...120,979,089
|
|
| G
|
Grhl1
|
grainyhead-like transcription factor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of GRHL1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:46,935,947...46,986,126
Ensembl chr 6:46,935,967...46,980,264
|
|
| G
|
Grhl3
|
grainyhead-like transcription factor 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GRHL3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:153,057,760...153,089,890
Ensembl chr 5:153,057,760...153,089,890
|
|
| G
|
Gria1
|
glutamate ionotropic receptor AMPA type subunit 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of GRIA1 mRNA [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]
|
CTD |
PMID:21795739 PMID:23275455 |
|
NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,711,080...42,030,309
|
|
| G
|
Grp
|
gastrin releasing peptide
|
increases expression
|
ISO
|
Progesterone results in increased expression of GRP mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr18:61,658,655...61,672,037
Ensembl chr18:61,658,250...61,672,037
|
|
| G
|
Grpel1
|
GrpE-like 1, mitochondrial
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GRPEL1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr14:78,517,049...78,522,868
Ensembl chr14:78,517,052...78,522,861
|
|
| G
|
Grwd1
|
glutamate-rich WD repeat containing 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GRWD1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:105,437,708...105,443,410
Ensembl chr 1:105,437,709...105,443,825
|
|
| G
|
Gsdme
|
gasdermin E
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GSDME mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:80,590,344...80,651,943
Ensembl chr 4:80,588,614...80,641,525
|
|
| G
|
Gsk3b
|
glycogen synthase kinase 3 beta
|
multiple interactions increases phosphorylation decreases phosphorylation decreases expression
|
ISO EXP
|
Mifepristone inhibits the reaction [Progesterone results in increased phosphorylation of GSK3B protein] Progesterone inhibits the reaction [Estradiol results in increased phosphorylation of GSK3B protein] Estradiol inhibits the reaction [Progesterone results in decreased expression of GSK3B mRNA] Progesterone results in decreased phosphorylation of GSK3B protein Progesterone results in decreased expression of GSK3B mRNA; Progesterone results in decreased expression of GSK3B protein
|
CTD |
PMID:15845746 PMID:16882987 PMID:17170212 PMID:17443805 |
|
NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249
|
|
| G
|
Gsn
|
gelsolin
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of GSN mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:38,982,671...39,035,850
|
|
| G
|
Gsta1
|
glutathione S-transferase alpha 1
|
increases chemical synthesis increases expression
|
ISO EXP
|
GSTA1 protein results in increased chemical synthesis of Progesterone Progesterone results in increased expression of GSTA1 mRNA
|
CTD |
PMID:20726854 PMID:23650189 |
|
NCBI chr 9:31,199,887...31,216,606
Ensembl chr 9:31,199,888...31,211,528
|
|
| G
|
Gsta2
|
glutathione S-transferase alpha 2
|
multiple interactions increases expression
|
EXP
|
[Progesterone co-treated with Estradiol] affects the expression of GSTA2 mRNA Progesterone results in increased expression of GSTA2 mRNA
|
CTD |
PMID:11502894 PMID:24777823 |
|
NCBI chr 8:88,064,829...88,077,168
Ensembl chr 8:88,064,616...88,077,092
|
|
| G
|
Gstk1
|
glutathione S-transferase kappa 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of GSTK1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:72,085,532...72,089,934
Ensembl chr 4:72,085,531...72,089,927
|
|
| G
|
Gstm2
|
glutathione S-transferase mu 2
|
affects expression
|
ISO
|
Progesterone affects the expression of GSTM2 mRNA; Progesterone affects the expression of GSTM5 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:198,312,179...198,316,962
|
|
| G
|
Gsto1
|
glutathione S-transferase omega 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of GSTO1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:256,662,377...256,672,515
Ensembl chr 1:256,662,531...256,676,167
|
|
| G
|
Gstt1
|
glutathione S-transferase theta 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of GSTT1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr20:12,856,068...12,873,020
Ensembl chr20:12,856,083...12,873,019
|
|
| G
|
Gstt2
|
glutathione S-transferase theta 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of GSTT2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr20:12,819,053...12,822,724
Ensembl chr20:12,818,540...12,822,718
|
|
| G
|
Gsx1
|
GS homeobox 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of GSX1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr12:12,994,588...12,996,874
Ensembl chr12:12,994,588...12,996,874
|
|
| G
|
Gtf2ird1
|
GTF2I repeat domain containing 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of GTF2IRD1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr12:27,890,594...27,997,506
Ensembl chr12:27,890,675...27,997,494
|
|
| G
|
Gtse1
|
G-2 and S-phase expressed 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of GTSE1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 7:118,829,793...118,846,662
Ensembl chr 7:118,829,903...118,846,661
|
|
| G
|
Guca2b
|
guanylate cyclase activator 2B
|
affects expression
|
ISO
|
Progesterone affects the expression of GUCA2B mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:138,532,160...138,534,210
Ensembl chr 5:138,532,178...138,534,235
|
|
| G
|
Gucy1a1
|
guanylate cyclase 1 soluble subunit alpha 1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of GUCY1A1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:169,716,684...169,780,360
Ensembl chr 2:169,716,709...169,779,737
|
|
| G
|
Gyg1
|
glycogenin 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of GYG1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:104,540,927...104,583,038
Ensembl chr 2:104,540,533...104,582,818
|
|
| G
|
Gzmb
|
granzyme B
|
affects expression increases expression
|
ISO EXP
|
Progesterone affects the expression of GZMB mRNA Progesterone results in increased expression of GZMB mRNA
|
CTD |
PMID:17251523 PMID:21770760 |
|
NCBI chr15:34,459,007...34,462,469
Ensembl chr15:34,459,007...34,462,469
|
|
| G
|
H19
|
H19 imprinted maternally expressed transcript
|
affects expression
|
ISO
|
Progesterone affects the expression of H19 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:207,160,175...207,162,851
|
|
| G
|
H1f2
|
H1.2 linker histone, cluster member
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of H1F2 mRNA [Progesterone co-treated with Estradiol] results in increased expression of H1-2 mRNA
|
CTD |
PMID:17404688 PMID:22238285 |
|
NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,779,051...41,822,317
|
|
| G
|
H1f5
|
H1.5 linker histone, cluster member
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of H1F5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:47,421,875...47,422,905
Ensembl chr17:47,421,843...47,477,387
|
|
| G
|
H2ac18
|
H2A clustered histone 18
|
increases expression
|
ISO
|
Progesterone results in increased expression of H2AC18 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:186,497,271...186,497,865
|
|
| G
|
H2az1
|
H2A.Z variant histone 1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of H2AZ1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:229,026,464...229,031,411
Ensembl chr 2:229,028,843...229,031,411
|
|
| G
|
H2az2
|
H2A.Z variant histone 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of H2AZ2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr14:85,507,228...85,526,166
Ensembl chr14:85,507,228...85,526,207 Ensembl chr16:85,507,228...85,526,207
|
|
| G
|
H2bc14
|
H2B clustered histone 14
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of H2BC5 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr17:47,488,627...47,489,008
|
|
| G
|
H2bc4
|
H2B clustered histone 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of H2BC4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:47,388,085...47,392,349
Ensembl chr17:47,404,375...47,419,020
|
|
| G
|
H2bc9
|
H2B clustered histone 9
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of H2BC9 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr17:47,166,372...47,174,369
|
|
| G
|
Habp2
|
hyaluronan binding protein 2
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of HABP2 mRNA Progesterone results in increased expression of HABP2 mRNA
|
CTD |
PMID:17404688 PMID:21540246 |
|
NCBI chr 1:265,321,084...265,355,375
Ensembl chr 1:265,303,172...265,355,374
|
|
| G
|
Hacd1
|
3-hydroxyacyl-CoA dehydratase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of HACD1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:81,992,284...82,014,676
Ensembl chr17:81,992,292...82,014,592
|
|
| G
|
Hacd4
|
3-hydroxyacyl-CoA dehydratase 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of HACD4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:107,935,514...107,961,271
Ensembl chr 5:107,934,937...107,962,836
|
|
| G
|
Hadh
|
hydroxyacyl-CoA dehydrogenase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of HADH mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:222,462,049...222,504,446
Ensembl chr 2:222,462,049...222,504,446
|
|
| G
|
Hand2
|
heart and neural crest derivatives expressed 2
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of HAND2 mRNA Progesterone results in increased expression of HAND2 mRNA [Estradiol co-treated with Progesterone] results in increased expression of HAND2 protein; [Progesterone co-treated with S-Adenosylmethionine] results in increased methylation of HAND2 promoter; S-Adenosylmethionine inhibits the reaction [Progesterone results in increased expression of HAND2 mRNA]
|
CTD |
PMID:17404688 PMID:18070364 PMID:20864642 PMID:25210133 PMID:30892605 |
|
NCBI chr16:37,928,145...37,931,488
Ensembl chr16:37,928,145...37,931,488
|
|
| G
|
Hapln1
|
hyaluronan and proteoglycan link protein 1
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of HAPLN1 mRNA Progesterone results in increased expression of HAPLN1 mRNA
|
CTD |
PMID:21540246 PMID:21795739 |
|
NCBI chr 2:22,366,967...22,431,709
Ensembl chr 2:22,366,967...22,429,098
|
|
| G
|
Has1
|
hyaluronan synthase 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of HAS1 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr 1:67,366,460...67,378,686
Ensembl chr 1:67,366,460...67,378,444
|
|
| G
|
Has3
|
hyaluronan synthase 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of HAS3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr19:51,668,276...51,691,042
|
|
| G
|
Hba-a1
|
hemoglobin alpha, adult chain 1
|
affects expression
|
ISO
|
Progesterone affects the expression of HBA-A1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:15,841,724...15,842,580
Ensembl chr10:15,841,763...15,842,603
|
|
| G
|
Hba-a2
|
hemoglobin alpha, adult chain 2
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of HBA1 mRNA Progesterone results in increased expression of HBA1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:15,828,291...15,829,138
Ensembl chr10:15,828,377...15,829,141
|
|
| G
|
Hba-a3
|
hemoglobin alpha, adult chain 3
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of HBA2 mRNA Progesterone results in increased expression of HBA2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:15,816,099...15,816,943
Ensembl chr10:15,816,096...15,817,167
|
|
| G
|
Hbb
|
hemoglobin subunit beta
|
multiple interactions increases expression affects expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of HBB mRNA Progesterone results in increased expression of HBB mRNA Progesterone affects the expression of HBB-B1 mRNA
|
CTD |
PMID:17251523 PMID:17404688 PMID:18070364 |
|
NCBI chr 1:167,662,310...167,663,721
Ensembl chr 1:167,630,245...167,663,873
|
|
| G
|
Hbb-b1
|
hemoglobin, beta adult major chain
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of HBD mRNA Progesterone results in increased expression of HBD mRNA
|
CTD |
PMID:17404688 PMID:18070364 |
|
NCBI chr 1:167,636,064...167,643,577
|
|
| G
|
Hbb-b2
|
hemoglobin, beta adult minor chain
|
affects expression
|
ISO
|
Progesterone affects the expression of HBB-B2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:167,655,583...167,656,963
|
|
| G
|
Hbg1
|
hemoglobin subunit gamma 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of HBG1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:167,683,760...167,685,315
Ensembl chr 1:167,683,760...167,706,139
|
|
| G
|
Hbp1
|
HMG-box transcription factor 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of HBP1 mRNA [Estradiol co-treated with Progesterone] results in increased expression of HBP1 mRNA
|
CTD |
PMID:18070364 PMID:18556351 |
|
NCBI chr 6:54,257,118...54,283,373
Ensembl chr 6:54,256,864...54,283,366
|
|
| G
|
Hbs1l
|
HBS1-like translational GTPase
|
increases expression
|
ISO
|
Progesterone results in increased expression of HBS1L mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:17,912,139...17,989,651
Ensembl chr 1:17,912,070...17,989,646
|
|
| G
|
Hcls1
|
hematopoietic cell specific Lyn substrate 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of HCLS1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr11:77,322,873...77,346,333
Ensembl chr11:77,322,873...77,346,387
|
|
| G
|
Hcrt
|
hypocretin neuropeptide precursor
|
decreases secretion
|
EXP
|
HCRT protein results in decreased secretion of Progesterone
|
CTD |
PMID:22749989 |
|
NCBI chr10:86,190,289...86,191,524
Ensembl chr10:86,189,775...86,191,524
|
|
| G
|
Hdac1
|
histone deacetylase 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of HDAC1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:147,138,328...147,165,387
Ensembl chr 5:147,138,156...147,165,387
|
|
| G
|
Hdc
|
histidine decarboxylase
|
affects expression
|
ISO
|
Progesterone affects the expression of HDC; Progesterone affects the expression of HDC mRNA
|
CTD |
PMID:16794005 PMID:17251523 |
|
NCBI chr 3:134,300,628...134,318,704
Ensembl chr 3:134,300,632...134,318,711
|
|
| G
|
Heg1
|
heart development protein with EGF-like domains 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of HEG1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:80,512,096...80,600,150
Ensembl chr11:80,512,096...80,600,092
|
|
| G
|
Hells
|
helicase, lymphoid specific
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of HELLS mRNA
|
CTD |
PMID:16966611 PMID:21795739 PMID:22238285 |
|
NCBI chr 1:246,113,580...246,159,230
Ensembl chr 1:246,114,096...246,159,228
|
|
| G
|
Heph
|
hephaestin
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of HEPH mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr X:65,160,628...65,412,457
Ensembl chr X:65,305,773...65,412,453
|
|
| G
|
Herpud1
|
homocysteine inducible ER protein with ubiquitin like domain 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of HERPUD1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr19:10,604,360...10,624,168
Ensembl chr19:10,604,362...10,624,081
|
|
| G
|
Hes1
|
hes family bHLH transcription factor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of HES1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061
|
|
| G
|
Hes5
|
hes family bHLH transcription factor 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of HES5 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:170,803,940...170,806,021
|
|
| G
|
Hgd
|
homogentisate 1, 2-dioxygenase
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of HGD mRNA Progesterone results in decreased expression of HGD mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr11:76,592,202...76,643,776
Ensembl chr11:76,592,204...76,643,767
|
|
| G
|
Hgf
|
hepatocyte growth factor
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of HGF mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of HGF mRNA Progesterone results in increased expression of HGF mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:22238285 |
|
NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851
|
|
| G
|
Hibadh
|
3-hydroxyisobutyrate dehydrogenase
|
increases expression
|
EXP
|
Progesterone results in increased expression of HIBADH mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:82,979,759...83,077,819
Ensembl chr 4:82,979,765...83,111,242
|
|
| G
|
Hibch
|
3-hydroxyisobutyryl-CoA hydrolase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of HIBCH mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:56,082,091...56,161,886
|
|
| G
|
Hic1
|
HIC ZBTB transcriptional repressor 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with TGFB1 protein] results in increased expression of HIC1 mRNA Progesterone results in increased expression of HIC1 mRNA
|
CTD |
PMID:21768398 |
|
NCBI chr10:60,512,855...60,517,812
Ensembl chr10:60,500,565...60,523,448
|
|
| G
|
Hif1a
|
hypoxia inducible factor 1 subunit alpha
|
increases expression
|
ISO
|
Progesterone results in increased expression of HIF1A
|
CTD |
PMID:15845616 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323
|
|
| G
|
Hip1r
|
huntingtin interacting protein 1 related
|
affects expression
|
ISO
|
Progesterone affects the expression of HIP1R mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr12:38,251,085...38,279,756
Ensembl chr12:38,251,086...38,279,654
|
|
| G
|
Hipk2
|
homeodomain interacting protein kinase 2
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of HIPK2 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of HIPK2 mRNA
|
CTD |
PMID:18070364 PMID:20660070 |
|
NCBI chr 4:68,399,358...68,586,404
Ensembl chr 4:68,369,099...68,586,108
|
|
| G
|
Hjurp
|
Holliday junction recognition protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of HJURP mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 9:96,301,183...96,315,587
Ensembl chr 9:96,302,530...96,315,657
|
|
| G
|
Hmcn1
|
hemicentin 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of HMCN1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:65,165,532...65,634,681
Ensembl chr13:65,165,532...65,634,519
|
|
| G
|
Hmga1
|
high mobility group AT-hook 1
|
multiple interactions decreases expression
|
ISO
|
4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of HMGA1 mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of HMGA1 mRNA; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of HMGA1 mRNA]; pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of HMGA1 mRNA] Progesterone results in decreased expression of HMGA1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:22238285 |
|
NCBI chr20:5,612,902...5,620,596
Ensembl chr20:5,613,471...5,620,593
|
|
| G
|
Hmga2
|
high mobility group AT-hook 2
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of HMGA2 mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr 7:57,762,710...57,884,555
Ensembl chr 7:57,765,675...57,880,341
|
|
| G
|
Hmgb1
|
high mobility group box 1
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of CCL2 protein]; Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of CXCL8 protein]; Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of IL6 protein]; Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]
|
CTD |
PMID:22014880 |
|
NCBI chr12:11,009,236...11,015,941
Ensembl chr16:39,039,050...39,041,327 Ensembl chr12:39,039,050...39,041,327
|
|
| G
|
Hmgb2
|
high mobility group box 2
|
increases expression decreases expression
|
ISO EXP
|
Progesterone results in increased expression of HMGB2 mRNA Progesterone results in decreased expression of HMGB2 mRNA
|
CTD |
PMID:18070364 PMID:20726854 |
|
NCBI chr16:37,721,374...37,723,950
Ensembl chr16:37,721,379...37,723,860
|
|
| G
|
Hmgcl
|
3-hydroxy-3-methylglutaryl-CoA lyase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of HMGCL mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 5:153,461,738...153,475,552
Ensembl chr 5:153,461,769...153,475,604
|
|
| G
|
Hmgcr
|
3-hydroxy-3-methylglutaryl-CoA reductase
|
increases expression
|
ISO
|
Progesterone results in increased expression of HMGCR mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 2:29,732,163...29,754,276
Ensembl chr 2:29,720,553...29,754,533
|
|
| G
|
Hmgcs1
|
3-hydroxy-3-methylglutaryl-CoA synthase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of HMGCS1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 2:53,379,457...53,399,807
Ensembl chr 2:53,382,643...53,399,802
|
|
| G
|
Hmgcs2
|
3-hydroxy-3-methylglutaryl-CoA synthase 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of HMGCS2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:188,564,348...188,590,872
Ensembl chr 2:188,547,767...188,592,242
|
|
| G
|
Hmgn3
|
high mobility group nucleosomal binding domain 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of HMGN3 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 8:92,902,555...92,939,980
|
|
| G
|
Hmmr
|
hyaluronan-mediated motility receptor
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of HMMR mRNA Progesterone results in decreased expression of HMMR mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr10:25,635,249...25,665,389
Ensembl chr10:25,635,915...25,665,390
|
|
| G
|
Hmox1
|
heme oxygenase 1
|
multiple interactions increases expression affects expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of HMOX1 mRNA Progesterone results in increased expression of HMOX1 mRNA Progesterone affects the expression of HMOX1 mRNA HMOX1 protein inhibits the reaction [POMC protein results in increased abundance of Progesterone]
|
CTD |
PMID:17251523 PMID:17404688 PMID:18070364 PMID:19489000 PMID:21770760 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818
|
|
| G
|
Hnf4a
|
hepatocyte nuclear factor 4, alpha
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone promotes the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]]
|
CTD |
PMID:21768169 |
|
NCBI chr 3:172,606,220...172,667,758
Ensembl chr 3:172,606,220...172,667,758
|
|
| G
|
Hnrnpab
|
heterogeneous nuclear ribonucleoprotein A/B
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of HNRNPAB mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:36,358,004...36,363,898
Ensembl chr10:36,358,006...36,364,307
|
|
| G
|
Hnrnph1
|
heterogeneous nuclear ribonucleoprotein H1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of HNRNPH1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:35,187,412...35,203,909
Ensembl chr10:35,193,890...35,203,906
|
|
| G
|
Homer2
|
homer scaffold protein 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of HOMER2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:144,968,207...145,069,022
Ensembl chr 1:144,976,436...145,068,997
|
|
| G
|
Homer3
|
homer scaffold protein 3
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of HOMER3 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of HOMER3 mRNA
|
CTD |
PMID:19693291 PMID:20660070 |
|
NCBI chr16:19,166,141...19,176,701
Ensembl chr16:19,165,482...19,176,640
|
|
| G
|
Hopx
|
HOP homeobox
|
affects expression increases expression
|
ISO EXP
|
Progesterone affects the expression of HOPX mRNA Progesterone results in increased expression of HOPX mRNA
|
CTD |
PMID:17251523 PMID:20726854 |
|
NCBI chr14:31,410,235...31,437,189
Ensembl chr14:31,410,221...31,437,188
|
|
| G
|
Hoxa10
|
homeobox A10
|
decreases expression multiple interactions increases expression
|
ISO EXP
|
Progesterone results in decreased expression of HOXA10 mRNA [Progesterone co-treated with Estrogens] results in decreased expression of HOXA10 mRNA; Copper promotes the reaction [[Progesterone co-treated with Estrogens] results in decreased expression of HOXA10 mRNA]; HOXA10 protein affects the reaction [Progesterone affects the localization of GABRP protein]; HOXA10 protein affects the reaction [Progesterone results in increased expression of GABRP mRNA] [Estradiol co-treated with Progesterone] results in increased expression of HOXA10 mRNA; [Estradiol co-treated with Progesterone] results in increased expression of HOXA10 protein Progesterone results in increased expression of HOXA10
|
CTD |
PMID:15845616 PMID:18037150 PMID:18653720 PMID:20103740 PMID:32004626 |
|
NCBI chr 4:82,662,204...82,671,490
Ensembl chr 4:82,662,204...82,665,922
|
|
| G
|
Hoxa11
|
homeobox A11
|
multiple interactions
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of HOXA11 mRNA [Estradiol co-treated with Progesterone] results in increased expression of HOXA11 mRNA [Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of HOXA11 mRNA
|
CTD |
PMID:17404688 PMID:18653720 PMID:32186404 |
|
NCBI chr 4:82,673,139...82,676,801
Ensembl chr 4:82,673,140...82,676,844
|
|
| G
|
Hoxa11-as
|
HOXA11 antisense RNA
|
increases expression
|
ISO
|
Progesterone results in increased expression of HOXA11OS mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:82,677,028...82,680,802
Ensembl chr 4:82,677,028...82,680,791
|
|
| G
|
Hp
|
haptoglobin
|
affects expression multiple interactions
|
ISO
|
Progesterone affects the expression of HP mRNA [Estradiol co-treated with Progesterone] results in increased expression of HP mRNA
|
CTD |
PMID:17251523 PMID:20660070 |
|
NCBI chr19:54,449,151...54,453,701
Ensembl chr19:54,446,217...54,467,518
|
|
| G
|
Hras
|
HRas proto-oncogene, GTPase
|
increases expression
|
ISO
|
Progesterone results in increased expression of HRAS mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590
|
|
| G
|
Hrk
|
harakiri, BCL2 interacting protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of HRK mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr12:44,048,402...44,070,561
Ensembl chr12:44,048,402...44,070,561
|
|
| G
|
Hs3st3b1
|
heparan sulfate-glucosamine 3-sulfotransferase 3B1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of HS3ST3B1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:49,060,693...49,093,185
Ensembl chr10:49,060,693...49,093,185
|
|
| G
|
Hs6st1
|
heparan sulfate 6-O-sulfotransferase 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of HS6ST1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 9:45,779,402...45,818,583
Ensembl chr 9:45,779,019...45,818,582
|
|
| G
|
Hs6st2
|
heparan sulfate 6-O-sulfotransferase 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of HS6ST2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr X:135,887,224...136,182,388
Ensembl chr X:135,888,472...136,182,353
|
|
| G
|
Hsd11b1
|
hydroxysteroid 11-beta dehydrogenase 1
|
affects expression increases expression multiple interactions
|
EXP ISO
|
Progesterone affects the expression of HSD11B1 mRNA; Progesterone affects the expression of HSD11B1 protein Progesterone results in increased expression of HSD11B1 mRNA 4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of HSD11B1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA; Hydrocortisone promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of HSD11B1 mRNA]; Progesterone inhibits the reaction [HSD11B1 protein results in increased reduction of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]
|
CTD |
PMID:19208548 PMID:20726854 PMID:21795739 PMID:23275455 PMID:28257955 |
|
NCBI chr13:107,277,526...107,327,462
Ensembl chr13:107,257,239...107,327,432
|
|
| G
|
Hsd11b2
|
hydroxysteroid 11-beta dehydrogenase 2
|
multiple interactions decreases activity increases expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of HSD11B2 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Progesterone results in increased expression of HSD11B2 mRNA]; Masoprocol inhibits the reaction [Progesterone results in decreased activity of HSD11B2 protein]; Mifepristone inhibits the reaction [Progesterone results in decreased activity of HSD11B2 protein]; Mifepristone inhibits the reaction [Progesterone results in decreased expression of HSD11B2 mRNA]; Mifepristone inhibits the reaction [Progesterone results in decreased expression of HSD11B2 protein] Progesterone results in decreased expression of HSD11B2 mRNA; Progesterone results in decreased expression of HSD11B2 protein
|
CTD |
PMID:15857753 PMID:18032417 PMID:18070364 PMID:20660070 PMID:21540246 |
|
NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812
|
|
| G
|
Hsd17b10
|
hydroxysteroid (17-beta) dehydrogenase 10
|
multiple interactions
|
ISO
|
[Progesterone co-treated with NAD] binds to HSD17B10 protein
|
CTD |
PMID:25526675 |
|
NCBI chr X:24,568,551...24,571,012
Ensembl chr X:24,568,551...24,574,681
|
|
| G
|
Hsd17b11
|
hydroxysteroid (17-beta) dehydrogenase 11
|
increases expression
|
ISO
|
Progesterone results in increased expression of HSD17B11 mRNA
|
CTD |
PMID:18070364 PMID:20864642 |
|
NCBI chr14:5,997,893...6,047,816
Ensembl chr14:5,997,906...6,047,811
|
|
| G
|
Hsd17b2
|
hydroxysteroid (17-beta) dehydrogenase 2
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of HSD17B2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of HSD17B2 mRNA Progesterone results in decreased expression of HSD17B2 mRNA; Progesterone results in decreased expression of HSD17B2 protein
|
CTD |
PMID:17404688 PMID:20660070 PMID:23183084 |
|
NCBI chr19:62,662,320...62,733,944
Ensembl chr19:62,662,098...62,733,943
|
|
| G
|
Hsd3b1
|
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1
|
affects metabolic processing increases chemical synthesis increases expression multiple interactions
|
EXP ISO
|
HSD3B1 protein affects the metabolism of Progesterone HSD3B1 protein results in increased chemical synthesis of Progesterone Progesterone results in increased expression of HSD3B1 protein [HSD3B2 protein results in increased metabolism of Pregnenolone] which results in increased abundance of Progesterone
|
CTD |
PMID:15261307 PMID:16054388 PMID:21558439 PMID:31771930 |
|
NCBI chr 2:188,858,574...188,864,694
|
|
| G
|
Hsd3b2
|
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2
|
multiple interactions
|
ISO EXP
|
[galaxolide results in decreased expression of [HSD3B2 co-treated with CYP21A2]] which results in decreased chemical synthesis of Progesterone [FSHB protein results in increased expression of HSD3B2 mRNA] which results in increased abundance of Progesterone; GH1 protein promotes the reaction [[FSHB protein results in increased expression of HSD3B2 mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of HSD3B2 mRNA] which results in increased abundance of Progesterone]
|
CTD |
PMID:22067323 PMID:23084589 |
|
NCBI chr 2:188,784,614...188,812,535
Ensembl chr 2:188,784,614...188,790,569
|
|
| G
|
Hsp90aa1
|
heat shock protein 90 alpha family class A member 1
|
affects expression
|
ISO
|
Progesterone affects the expression of HSP90AA1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 6:135,523,604...135,529,687
Ensembl chr 6:135,523,616...135,528,499
|
|
| G
|
Hsp90b1
|
heat shock protein 90 beta family member 1
|
affects expression
|
ISO
|
Progesterone affects the expression of HSP90B1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:22,997,962...23,012,293
Ensembl chr 7:22,997,962...23,012,293
|
|
| G
|
Hspa1a
|
heat shock protein family A (Hsp70) member 1A
|
affects expression increases expression
|
EXP ISO
|
Progesterone affects the expression of HSPA1A protein Progesterone results in increased expression of HSPA1A mRNA
|
CTD |
PMID:16797538 PMID:21549006 |
|
NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979
|
|
| G
|
Hspa1b
|
heat shock protein family A (Hsp70) member 1B
|
increases expression affects expression
|
ISO
|
Progesterone results in increased expression of HSPA1B mRNA Progesterone affects the expression of HSPA1B mRNA
|
CTD |
PMID:17251523 PMID:18037150 |
|
NCBI chr20:3,859,756...3,863,800
Ensembl chr20:3,855,780...3,877,979
|
|
| G
|
Hspa4
|
heat shock protein family A (Hsp70) member 4
|
increases expression
|
EXP
|
Progesterone results in increased expression of HSPA4 mRNA
|
CTD |
PMID:16376865 |
|
NCBI chr10:37,908,866...37,951,994
Ensembl chr10:37,908,866...37,949,835
|
|
| G
|
Hspa4l
|
heat shock protein family A (Hsp70) member 4 like
|
affects expression
|
ISO
|
Progesterone affects the expression of HSPA4L mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:125,668,346...125,726,404
Ensembl chr 2:125,668,236...125,720,986
|
|
| G
|
Hspa5
|
heat shock protein family A (Hsp70) member 5
|
affects expression
|
ISO
|
Progesterone affects the expression of HSPA5 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790
|
|
| G
|
Hspa6l-ps1
|
heat shock protein family A (Hsp70) member 6 like, pseudogene 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of HSPA6 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr13:85,805,911...85,807,052
|
|
| G
|
Hspa8
|
heat shock protein family A (Hsp70) member 8
|
multiple interactions
|
EXP
|
[estradiol 3-benzoate co-treated with Progesterone] results in increased expression of HSPA8 mRNA; Progesterone promotes the reaction [estradiol 3-benzoate results in increased expression of HSPA8 mRNA]
|
CTD |
PMID:9990085 |
|
NCBI chr 8:50,080,514...50,084,376
Ensembl chr 8:50,080,199...50,084,372
|
|
| G
|
Hspb1
|
heat shock protein family B (small) member 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of HSPB1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301
|
|
| G
|
Hspb6
|
heat shock protein family B (small) member 6
|
increases expression
|
EXP
|
Progesterone results in increased expression of HSPB6 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:94,934,372...94,936,516
Ensembl chr 1:94,933,543...94,936,512
|
|
| G
|
Hspb8
|
heat shock protein family B (small) member 8
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of HSPB8 mRNA [Estradiol co-treated with Progesterone] results in increased expression of HSPB8 mRNA
|
CTD |
PMID:20660070 PMID:20726854 |
|
NCBI chr12:45,835,899...45,866,449
Ensembl chr12:45,837,066...45,851,937
|
|
| G
|
Htr2a
|
5-hydroxytryptamine receptor 2A
|
increases expression
|
ISO EXP
|
Progesterone results in increased expression of HTR2A mRNA
|
CTD |
PMID:20726854 PMID:21540246 |
|
NCBI chr15:56,360,647...56,428,703
Ensembl chr15:56,359,596...56,431,619
|
|
| G
|
Htr2b
|
5-hydroxytryptamine receptor 2B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of HTR2B mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 9:94,184,442...94,206,851
Ensembl chr 9:94,190,109...94,204,087
|
|
| G
|
Hyal2
|
hyaluronidase 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of HYAL2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 8:117,121,802...117,125,494
Ensembl chr 8:117,121,787...117,125,493
|
|
| G
|
Hyou1
|
hypoxia up-regulated 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of HYOU1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 8:53,602,882...53,614,998
Ensembl chr 8:53,602,604...53,614,997
|
|
| G
|
Icam1
|
intercellular adhesion molecule 1
|
multiple interactions decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of ICAM1 protein; [Progesterone co-treated with Estradiol] results in increased expression of ICAM1 mRNA; Mifepristone inhibits the reaction [Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]; MPO gene polymorphism affects the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of ICAM1 protein]; Org 31710 inhibits the reaction [Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] Progesterone results in decreased expression of ICAM1 mRNA; Progesterone results in decreased expression of ICAM1 protein [Progesterone co-treated with Halothane] results in increased expression of ICAM1 mRNA; gadolinium chloride inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of ICAM1 mRNA]; Mifepristone inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of ICAM1 mRNA]]; Progesterone promotes the reaction [Halothane results in increased expression of ICAM1 mRNA]; U 0126 inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of ICAM1 mRNA]
|
CTD |
PMID:15358673 PMID:17868700 PMID:20226447 PMID:21242819 PMID:21501669 PMID:22157104 PMID:22903158 More...
|
|
NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617
|
|
| G
|
Icmt
|
isoprenylcysteine carboxyl methyltransferase
|
affects expression
|
ISO
|
Progesterone affects the expression of ICMT mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:168,084,487...168,097,519
Ensembl chr 5:168,086,057...168,093,094
|
|
| G
|
Id1
|
inhibitor of DNA binding 1
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of ID1 mRNA Progesterone results in decreased expression of ID1 protein Progesterone results in decreased expression of ID1 mRNA
|
CTD |
PMID:18037150 PMID:18045962 PMID:22238285 |
|
NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685
|
|
| G
|
Id2
|
inhibitor of DNA binding 2
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of ID2 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of ID2 mRNA
|
CTD |
PMID:18037150 PMID:20660070 |
|
NCBI chr 6:47,469,162...47,470,995
Ensembl chr 6:47,457,554...47,472,961
|
|
| G
|
Id3
|
inhibitor of DNA binding 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of ID3 mRNA
|
CTD |
PMID:18037150 PMID:20864642 |
|
NCBI chr 5:153,656,253...153,657,860
Ensembl chr 5:153,630,498...153,657,856
|
|
| G
|
Id4
|
inhibitor of DNA binding 4
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ID4 mRNA Progesterone results in increased expression of ID4 mRNA
|
CTD |
PMID:20660070 PMID:20864642 |
|
NCBI chr17:16,595,724...16,598,293
Ensembl chr17:16,595,724...16,598,492
|
|
| G
|
Idh1
|
isocitrate dehydrogenase (NADP(+)) 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of IDH1 mRNA [Estradiol co-treated with Progesterone] results in increased expression of IDH1 mRNA
|
CTD |
PMID:18070364 PMID:20660070 |
|
NCBI chr 9:74,027,887...74,057,442
Ensembl chr 9:74,027,892...74,049,555
|
|
| G
|
Idi1
|
isopentenyl-diphosphate delta isomerase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of IDI1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr17:66,539,761...66,547,524
Ensembl chr17:66,539,763...66,547,524
|
|
| G
|
Ier3
|
immediate early response 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of IER3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377
|
|
| G
|
Ier5l
|
immediate early response 5-like
|
increases expression
|
ISO
|
Progesterone results in increased expression of IER5L mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:34,141,866...34,143,457
Ensembl chr 3:34,139,672...34,144,452
|
|
| G
|
Ifi44l
|
interferon-induced protein 44-like
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of IFI44L mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 2:243,328,629...243,366,404
Ensembl chr 2:243,328,723...243,366,404
|
|
| G
|
Ifit3
|
interferon-induced protein with tetratricopeptide repeats 3
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with TGFB1 protein] results in increased expression of IFIT3 mRNA Progesterone results in increased expression of IFIT3 mRNA
|
CTD |
PMID:21768398 |
|
NCBI chr 1:241,527,326...241,532,469
Ensembl chr 1:241,526,880...241,532,521
|
|
| G
|
Ifitm1
|
interferon induced transmembrane protein 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of IFITM1 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:205,496,807...205,498,776
|
|
| G
|
Ifitm2
|
interferon induced transmembrane protein 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of IFITM2 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 1:205,481,168...205,482,348
|
|
| G
|
Ifnar2
|
interferon alpha and beta receptor subunit 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of IFNAR2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr11:44,099,574...44,131,941
Ensembl chr11:44,099,753...44,131,937
|
|
| G
|
Ifnb1
|
interferon beta 1
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IFNB1 mRNA]; Progesterone inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA]
|
CTD |
PMID:22546503 |
|
NCBI chr 5:108,066,650...108,067,487
Ensembl chr 5:108,066,650...108,067,487
|
|
| G
|
Ifng
|
interferon gamma
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of IFNG protein Progesterone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide] [Progesterone co-treated with Estradiol] inhibits the reaction [Vaccines, Virus-Like Particle results in increased expression of IFNG protein]; Progesterone inhibits the reaction [Vaccines, Virus-Like Particle results in increased expression of IFNG protein]
|
CTD |
PMID:11063824 PMID:15804489 PMID:20130130 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216
|
|
| G
|
Ifngr1
|
interferon gamma receptor 1
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of IFNGR1 mRNA Progesterone results in increased expression of IFNGR1 mRNA
|
CTD |
PMID:18692832 PMID:21540246 |
|
NCBI chr 1:16,152,811...16,171,439
Ensembl chr 1:16,152,879...16,171,437
|
|
| G
|
Ifrd1
|
interferon-related developmental regulator 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of IFRD1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:62,996,560...63,044,996
Ensembl chr 6:62,996,562...63,016,131
|
|
| G
|
Ift70a2
|
intraflagellar transport 70A2
|
increases expression
|
ISO
|
Progesterone results in increased expression of IFT70A mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 3:81,306,455...81,308,896
Ensembl chr 3:81,307,245...81,320,093
|
|
| G
|
Ift74
|
intraflagellar transport 74
|
increases expression
|
ISO
|
Progesterone results in increased expression of IFT74 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 5:114,576,106...114,679,581
Ensembl chr 5:114,593,397...114,679,581
|
|
| G
|
Igf1
|
insulin-like growth factor 1
|
multiple interactions increases secretion affects expression increases expression increases abundance
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased secretion of IGF1 protein; [IGF1 protein co-treated with FSHB protein] results in increased abundance of Progesterone; ADIPOQ protein promotes the reaction [IGF1 protein results in increased abundance of Progesterone]; FGF9 protein inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased abundance of Progesterone]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]]; FGF9 protein inhibits the reaction [IGF1 protein results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]; Mifepristone inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of IGF1 protein]; Mifepristone inhibits the reaction [Progesterone results in increased secretion of IGF1 protein]; NAMPT protein promotes the reaction [IGF1 protein results in increased abundance of Progesterone]; Tamoxifen inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of IGF1 protein] Progesterone affects the expression of IGF1 mRNA [Estradiol co-treated with Progesterone] promotes the reaction [Cuprizone results in increased expression of IGF1 mRNA]; Estradiol promotes the reaction [Progesterone results in increased expression of IGF1 mRNA]; IGF1 protein affects the susceptibility to [Progesterone co-treated with Estrogens]; IGF1 protein inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased expression of IGFBP3 mRNA]; IGF1 protein inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased expression of RBP1 mRNA]; IGF1 protein inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased expression of TGFB1 mRNA]; IGF1 protein inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased expression of TRP53 mRNA]; Progesterone promotes the reaction [Estradiol results in increased expression of IGF1 mRNA] IGF1 protein inhibits the reaction [BMP15 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP2 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP4 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP6 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein inhibits the reaction [BMP7 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of CYP11A1 mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of CYP19A1 mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of HSD3B2 mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]; RETN protein promotes the reaction [IGF1 protein results in increased abundance of Progesterone]
|
CTD |
PMID:8390853 PMID:15809018 PMID:17251523 PMID:18562952 PMID:19031445 PMID:19081562 PMID:19853640 PMID:20726854 PMID:20864642 PMID:21239528 PMID:21770760 PMID:22067323 PMID:22798350 PMID:23315983 More...
|
|
NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764
|
|
| G
|
Igf1r
|
insulin-like growth factor 1 receptor
|
decreases expression multiple interactions increases expression
|
ISO EXP
|
Progesterone results in decreased expression of IGF1R mRNA [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of IGF1R mRNA; [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of IGF1R protein Progesterone results in increased expression of IGF1R mRNA
|
CTD |
PMID:18070364 PMID:19853640 PMID:22465879 |
|
NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664
|
|
| G
|
Igf2
|
insulin-like growth factor 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of IGF2 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667
|
|
| G
|
Igfbp1
|
insulin-like growth factor binding protein 1
|
affects expression multiple interactions increases expression increases secretion
|
ISO
|
Progesterone affects the expression of IGFBP1 mRNA; Progesterone affects the expression of IGFBP1 protein 4'-cyanobiphenyl-4-sulfonic acid (6-aminopyridin-2-yl)amide inhibits the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; [Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Progesterone] results in increased secretion of IGFBP1 protein; [Progesterone co-treated with bisphenol A] results in increased expression of IGFBP1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of IGFBP1 mRNA; [Progesterone co-treated with Triclosan] results in increased expression of IGFBP1 mRNA; BMP7 protein inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of IGFBP1 mRNA]; BMP7 protein inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of IGFBP1 protein]; Hydrocortisone promotes the reaction [Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]]; Mifepristone inhibits the reaction [Progesterone results in increased secretion of IGFBP1 protein]; Progesterone inhibits the reaction [Estradiol results in increased expression of IGFBP1 protein]; Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of IGFBP1 mRNA]; Progesterone promotes the reaction [Triclosan results in increased secretion of IGFBP1 protein] Progesterone results in increased expression of IGFBP1 mRNA
|
CTD |
PMID:15501902 PMID:17404688 PMID:17484513 PMID:18815356 PMID:20085912 PMID:20864642 PMID:23275455 PMID:26604029 PMID:32446389 More...
|
|
NCBI chr14:86,261,277...86,266,344
Ensembl chr14:86,261,277...86,266,344
|
|
| G
|
Igfbp2
|
insulin-like growth factor binding protein 2
|
multiple interactions decreases expression increases secretion increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased secretion of IGFBP2 protein Progesterone results in decreased expression of IGFBP2 mRNA Progesterone results in increased secretion of IGFBP2 protein Progesterone results in increased expression of IGFBP2 mRNA
|
CTD |
PMID:15809018 PMID:18070364 PMID:19853640 |
|
NCBI chr 9:81,864,811...81,892,179
Ensembl chr 9:81,864,783...81,892,171
|
|
| G
|
Igfbp3
|
insulin-like growth factor binding protein 3
|
multiple interactions decreases expression decreases secretion affects expression increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of IGFBP3 mRNA; [Estradiol co-treated with Progesterone] results in decreased secretion of IGFBP3 protein; [Progesterone affects the activity of PGR protein alternative form] which affects the expression of IGFBP3 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of IGFBP3 mRNA Progesterone results in decreased expression of IGFBP3 mRNA Progesterone results in decreased secretion of IGFBP3 protein Progesterone affects the expression of IGFBP3; Progesterone affects the expression of IGFBP3 mRNA Progesterone results in increased expression of IGFBP3 mRNA [Progesterone co-treated with Estrogens] results in increased expression of IGFBP3 mRNA; IGF1 protein inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased expression of IGFBP3 mRNA]
|
CTD |
PMID:15178747 PMID:15809018 PMID:15866122 PMID:17251523 PMID:17404688 PMID:18070364 PMID:18562952 PMID:19341330 PMID:20660070 PMID:20726854 PMID:22238285 More...
|
|
NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944
|
|
| G
|
Igfbp4
|
insulin-like growth factor binding protein 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of IGFBP4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473
|
|
| G
|
Igfbp5
|
insulin-like growth factor binding protein 5
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of IGFBP5 mRNA Progesterone results in decreased expression of IGFBP5 mRNA
|
CTD |
PMID:18070364 PMID:20660070 PMID:20864642 |
|
NCBI chr 9:81,901,605...81,914,187
Ensembl chr 9:81,897,616...81,914,390
|
|
| G
|
Igfbp6
|
insulin-like growth factor binding protein 6
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of IGFBP6 mRNA Progesterone results in increased expression of IGFBP6 mRNA
|
CTD |
PMID:19853640 PMID:20864642 PMID:22238285 |
|
NCBI chr 7:135,154,919...135,159,550
Ensembl chr 7:135,154,685...135,159,795
|
|
| G
|
Igkc
|
immunoglobulin kappa constant
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of IGKC mRNA [Estradiol co-treated with Progesterone] results in decreased expression of IGKC mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
|
|
| G
|
Ihh
|
Indian hedgehog signaling molecule
|
affects expression increases expression multiple interactions
|
ISO
|
Progesterone affects the expression of IHH Progesterone results in increased expression of IHH; Progesterone results in increased expression of IHH mRNA [Estradiol co-treated with Progesterone] results in decreased expression of IHH mRNA [Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of IHH mRNA; [Estradiol co-treated with Progesterone] results in increased expression of IHH mRNA; ESR1 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased expression of IHH mRNA]
|
CTD |
PMID:16794005 PMID:20232216 PMID:20660070 PMID:22238285 PMID:22958837 PMID:25210133 PMID:32186404 More...
|
|
NCBI chr 9:83,952,986...83,959,203
Ensembl chr 9:83,952,986...83,959,203
|
|
| G
|
Ikbkb
|
inhibitor of nuclear factor kappa B kinase subunit beta
|
increases expression
|
ISO
|
Progesterone results in increased expression of IKBKB mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911
|
|
| G
|
Ikbkg
|
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of IKBKG mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr X:157,358,279...157,397,563
Ensembl chr X:157,367,639...157,392,757
|
|
| G
|
Il10
|
interleukin 10
|
decreases expression increases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of IL10 protein Progesterone results in increased expression of IL10 protein [Progesterone co-treated with Estradiol] promotes the reaction [Vaccines, Virus-Like Particle results in increased expression of IL10 protein]; Progesterone promotes the reaction [Vaccines, Virus-Like Particle results in increased expression of IL10 protein] Progesterone results in increased expression of IL10 mRNA
|
CTD |
PMID:15804489 PMID:20130130 PMID:21856019 PMID:22615136 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580
|
|
| G
|
Il11
|
interleukin 11
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased secretion of IL11 protein; IL11 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]; IL11 protein promotes the reaction [INHBA protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]; INHBA protein promotes the reaction [IL11 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]
|
CTD |
PMID:20074812 |
|
NCBI chr 1:78,098,622...78,104,915
Ensembl chr 1:78,096,930...78,104,915
|
|
| G
|
Il12a
|
interleukin 12A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of IL12A mRNA [Progesterone co-treated with Estradiol] inhibits the reaction [Vaccines, Virus-Like Particle results in increased expression of [IL12A protein binds to IL12B protein]]; Progesterone inhibits the reaction [Vaccines, Virus-Like Particle results in increased expression of [IL12A protein binds to IL12B protein]]; Progesterone results in increased expression of [IL12A protein binds to IL12B protein]
|
CTD |
PMID:19693291 PMID:20130130 |
|
NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997
|
|
| G
|
Il12b
|
interleukin 12B
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with IL4 protein] results in increased expression of IL12B mRNA]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA] [Progesterone co-treated with Estradiol] inhibits the reaction [Vaccines, Virus-Like Particle results in increased expression of [IL12A protein binds to IL12B protein]]; Progesterone inhibits the reaction [Vaccines, Virus-Like Particle results in increased expression of [IL12A protein binds to IL12B protein]]; Progesterone results in increased expression of [IL12A protein binds to IL12B protein]
|
CTD |
PMID:20130130 PMID:21977998 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194
|
|
| G
|
Il13ra1
|
interleukin 13 receptor subunit alpha 1
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of IL13RA1 mRNA Progesterone results in increased expression of IL13RA1 mRNA
|
CTD |
PMID:21770760 PMID:21795739 |
|
NCBI chr X:120,213,670...120,294,777
Ensembl chr X:120,214,075...120,274,461
|
|
| G
|
Il13ra2
|
interleukin 13 receptor subunit alpha 2
|
multiple interactions decreases expression
|
ISO
|
4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of IL13RA2 mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of IL13RA2 mRNA; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of IL13RA2 mRNA]; U 0126 promotes the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of IL13RA2 mRNA] Progesterone results in decreased expression of IL13RA2 mRNA
|
CTD |
PMID:20660070 PMID:20864642 |
|
NCBI chr X:115,814,620...115,886,080
Ensembl chr X:115,814,622...115,841,455
|
|
| G
|
Il15
|
interleukin 15
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of IL15 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of IL15 mRNA Progesterone results in increased expression of IL15 mRNA
|
CTD |
PMID:17404688 PMID:18692832 PMID:20660070 |
|
NCBI chr19:42,536,160...42,611,349
Ensembl chr19:42,545,346...42,611,348
|
|
| G
|
Il15ra
|
interleukin 15 receptor subunit alpha
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of IL15RA mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr17:71,712,141...71,742,072
Ensembl chr17:71,712,141...71,742,149
|
|
| G
|
Il17a
|
interleukin 17A
|
multiple interactions
|
ISO
|
Mifepristone inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of IL17A protein]]; Progesterone promotes the reaction [Budesonide inhibits the reaction [Ozone results in increased expression of IL17A protein]]; Progesterone promotes the reaction [Halothane results in increased expression of IL17A protein]
|
CTD |
PMID:21501669 PMID:28279894 |
|
NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331
|
|
| G
|
Il17rb
|
interleukin 17 receptor B
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of IL17RB mRNA Progesterone results in decreased expression of IL17RB mRNA
|
CTD |
PMID:20660070 PMID:21273126 |
|
NCBI chr16:5,186,961...5,200,657
Ensembl chr16:5,186,961...5,200,694
|
|
| G
|
Il17rd
|
interleukin 17 receptor D
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of IL17RD mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr16:2,235,172...2,489,827
Ensembl chr16:2,235,169...2,301,850
|
|
| G
|
Il17re
|
interleukin 17 receptor E
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of IL17RE mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:148,160,384...148,173,830
Ensembl chr 4:148,159,475...148,173,827
|
|
| G
|
Il18
|
interleukin 18
|
multiple interactions
|
ISO
|
[fulvestrant co-treated with Mifepristone] inhibits the reaction [[Progesterone co-treated with Estrogens] inhibits the reaction [Lipopolysaccharides results in increased expression of IL18 mRNA]]; [Progesterone co-treated with Estrogens] inhibits the reaction [Lipopolysaccharides results in increased expression of IL18 mRNA]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of IL18 mRNA]
|
CTD |
PMID:17850464 |
|
NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286
|
|
| G
|
Il18r1
|
interleukin 18 receptor 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of IL18R1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 9:50,223,274...50,257,370
Ensembl chr 9:50,223,200...50,257,367
|
|
| G
|
Il1b
|
interleukin 1 beta
|
multiple interactions affects expression decreases expression decreases activity increases expression
|
ISO EXP
|
[[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the abundance of Lipids; [[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the abundance of Reactive Oxygen Species; [[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the expression of ALB protein; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the abundance of Lipids; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the abundance of Reactive Oxygen Species; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the expression of ALB protein; [Estrogens co-treated with Progesterone co-treated with IL1B protein] results in increased expression of MMP14 mRNA; [Estrogens co-treated with Progesterone co-treated with IL1B protein] results in increased expression of MMP3 mRNA; [IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]; [Progesterone co-treated with IL1B protein] results in increased expression of INHBA mRNA; [Progesterone co-treated with IL1B protein] results in increased secretion of [INHBA protein binds to INHBA protein]; [Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]; Progesterone inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein]; Progesterone inhibits the reaction [IL1B protein results in increased expression of MMP1 protein modified form]; Progesterone inhibits the reaction [IL1B protein results in increased expression of MMP2 protein modified form]; Progesterone inhibits the reaction [IL1B protein results in increased expression of MMP3 protein modified form]; Progesterone inhibits the reaction [IL1B protein results in increased expression of MMP9 protein modified form]; Progesterone inhibits the reaction [Vaccines, Virus-Like Particle results in increased expression of IL1B protein] Progesterone affects the expression of IL1B mRNA Progesterone results in decreased expression of IL1B protein Mifepristone inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of IL1B mRNA]]; Progesterone promotes the reaction [Halothane results in increased expression of IL1B mRNA] Progesterone results in decreased activity of IL1B protein Progesterone results in increased expression of IL1B mRNA; Progesterone results in increased expression of IL1B protein Progesterone results in decreased expression of IL1B mRNA
|
CTD |
PMID:17251523 PMID:17437195 PMID:17636213 PMID:17868700 PMID:18570937 PMID:20130130 PMID:20621171 PMID:21501669 PMID:21540246 PMID:21549006 PMID:22219637 PMID:22615136 More...
|
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601
|
|
| G
|
Il1r1
|
interleukin 1 receptor type 1
|
increases expression
|
ISO EXP
|
Progesterone results in increased expression of IL1R1 mRNA
|
CTD |
PMID:20726854 PMID:20864642 PMID:21795739 |
|
NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579
|
|
| G
|
Il1r2
|
interleukin 1 receptor type 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of IL1R2 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 9:49,879,928...49,920,374
Ensembl chr 9:49,877,266...49,920,374
|
|
| G
|
Il1rl1
|
interleukin 1 receptor-like 1
|
increases expression decreases expression multiple interactions
|
ISO EXP
|
Progesterone results in increased expression of IL1RL1 mRNA Progesterone results in decreased expression of IL1RL1 mRNA [Progesterone co-treated with Estradiol] results in increased expression of IL1RL1 mRNA
|
CTD |
PMID:17404688 PMID:18692832 PMID:19000923 PMID:20726854 |
|
NCBI chr 9:50,157,326...50,222,888
Ensembl chr 9:50,204,551...50,222,891
|
|
| G
|
Il1rn
|
interleukin 1 receptor antagonist
|
increases expression
|
EXP
|
Progesterone results in increased expression of IL1RN mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732
|
|
| G
|
Il2
|
interleukin 2
|
multiple interactions
|
ISO
|
Progesterone promotes the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]; Progesterone promotes the reaction [IL2 protein results in increased phosphorylation of STAT5B protein]
|
CTD |
PMID:21768398 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672
|
|
| G
|
Il20ra
|
interleukin 20 receptor subunit alpha
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of IL20RA mRNA; [Progesterone co-treated with Estradiol] results in increased expression of IL20RA mRNA Progesterone results in increased expression of IL20RA mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 1:16,243,683...16,313,229
Ensembl chr 1:16,243,801...16,313,221
|
|
| G
|
Il24
|
interleukin 24
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of IL24 mRNA Progesterone results in decreased expression of IL24 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr13:44,905,362...44,910,760
Ensembl chr13:44,905,363...44,910,760
|
|
| G
|
Il2rb
|
interleukin 2 receptor subunit beta
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of IL2RB mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 7:111,913,828...111,928,537
Ensembl chr 7:111,913,828...111,928,537
|
|
| G
|
Il33
|
interleukin 33
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of IL33 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of IL33 mRNA Progesterone results in decreased expression of IL33 mRNA Progesterone results in increased expression of IL33 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21770760 |
|
NCBI chr 1:237,115,478...237,149,897
Ensembl chr 1:237,115,572...237,150,901
|
|
| G
|
Il36a
|
interleukin 36, alpha
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of IL36A mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:27,395,146...27,399,695
Ensembl chr 3:27,395,146...27,399,695
|
|
| G
|
Il4
|
interleukin 4
|
decreases expression multiple interactions increases expression
|
ISO
|
Progesterone results in decreased expression of IL4 protein Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with IL4 protein] results in increased expression of ARG1 mRNA]; Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with IL4 protein] results in increased expression of IL12B mRNA]; Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with IL4 protein] results in increased expression of NOS2 mRNA]; Progesterone inhibits the reaction [IL4 protein results in increased expression of ARG1 mRNA]; Progesterone inhibits the reaction [IL4 protein results in increased expression of MRC1 mRNA]; Progesterone inhibits the reaction [IL4 protein results in increased expression of RETNLA mRNA]; Progesterone promotes the reaction [[IL4 protein co-treated with Lipopolysaccharides] results in increased expression of CHIL3 mRNA]; Progesterone promotes the reaction [[IL4 protein co-treated with Lipopolysaccharides] results in increased expression of RETNLA mRNA]; Progesterone promotes the reaction [IL4 protein results in increased expression of CHIL3 mRNA] Progesterone results in increased expression of IL4 mRNA
|
CTD |
PMID:15804489 PMID:21977998 PMID:22615136 |
|
NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549
|
|
| G
|
Il4r
|
interleukin 4 receptor
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of IL4R mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:189,544,988...189,570,636
|
|
| G
|
Il6
|
interleukin 6
|
decreases secretion multiple interactions affects expression decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased secretion of IL6 protein [[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the abundance of Lipids; [[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the abundance of Reactive Oxygen Species; [[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the expression of ALB protein; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the abundance of Lipids; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the abundance of Reactive Oxygen Species; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the expression of ALB protein; [IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]; [Proteoglycans co-treated with Progesterone] inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; [Proteoglycans co-treated with Progesterone] inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; [Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]; Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of IL6 protein]; Progesterone inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; Progesterone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; Progesterone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 protein]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Progesterone affects the expression of IL6 mRNA Progesterone results in decreased expression of IL6 protein Mifepristone inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of IL6 mRNA]]; MIR155 mRNA inhibits the reaction [Progesterone inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]]; Progesterone inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]; Progesterone promotes the reaction [Budesonide inhibits the reaction [Ozone results in increased expression of IL6 protein]]; Progesterone promotes the reaction [Halothane results in increased expression of IL6 mRNA] Progesterone results in increased expression of IL6 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of IL6 mRNA; [Estradiol co-treated with Progesterone] results in decreased expression of IL6 protein
|
CTD |
PMID:15804489 PMID:16134523 PMID:17000234 PMID:17251523 PMID:20621171 PMID:21277368 PMID:21501669 PMID:21768398 PMID:21795739 PMID:22014880 PMID:22122352 PMID:22314502 PMID:22546503 PMID:28279894 More...
|
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610
|
|
| G
|
Il6r
|
interleukin 6 receptor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of IL6R mRNA; Progesterone results in decreased expression of IL6R protein
|
CTD |
PMID:21768398 |
|
NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221
|
|
| G
|
Il6st
|
interleukin 6 cytokine family signal transducer
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of IL6ST mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182
|
|
| G
|
Il7r
|
interleukin 7 receptor
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of IL7R mRNA Progesterone results in increased expression of IL7R mRNA
|
CTD |
PMID:21770760 PMID:21795739 |
|
NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:60,181,382...60,211,027
|
|
| G
|
Impa2
|
inositol monophosphatase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of IMPA2 mRNA
|
CTD |
PMID:20864642 PMID:21540246 PMID:21795739 |
|
NCBI chr18:63,104,113...63,135,232
Ensembl chr18:63,104,083...63,137,543
|
|
| G
|
Inha
|
inhibin subunit alpha
|
multiple interactions decreases abundance increases expression
|
ISO EXP
|
INHA mutant form inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; INHA mutant form inhibits the reaction [GDF9 protein inhibits the reaction [INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]]] INHA protein results in decreased abundance of Progesterone Progesterone results in increased expression of INHA mRNA
|
CTD |
PMID:18992787 PMID:20660033 PMID:22285243 |
|
NCBI chr 9:84,443,109...84,446,010
Ensembl chr 9:84,443,109...84,446,009
|
|
| G
|
Inhba
|
inhibin subunit beta A
|
multiple interactions increases expression decreases secretion decreases expression
|
ISO EXP
|
4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA; [Progesterone co-treated with IL1B protein] results in increased expression of INHBA mRNA; [Progesterone co-treated with IL1B protein] results in increased secretion of [INHBA protein binds to INHBA protein]; FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; GDF9 protein inhibits the reaction [INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]]; GDF9 protein inhibits the reaction [INHBA protein results in decreased secretion of Progesterone]; IL11 protein promotes the reaction [INHBA protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]; INHA mutant form inhibits the reaction [GDF9 protein inhibits the reaction [INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]]]; INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]; INHBA protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]; INHBA protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]; INHBA protein promotes the reaction [IL11 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]; pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of INHBA mRNA]; Progesterone results in increased secretion of [INHBA protein binds to INHBA protein] Progesterone results in increased expression of INHBA mRNA Progesterone results in decreased expression of INHBA mRNA
|
CTD |
PMID:17636213 PMID:17954979 PMID:18070364 PMID:18936084 PMID:20074812 PMID:20660033 PMID:20660070 PMID:22285243 More...
|
|
NCBI chr17:53,787,159...53,810,942
Ensembl chr17:53,791,444...53,804,508
|
|
| G
|
Inhbb
|
inhibin subunit beta B
|
increases expression
|
ISO
|
Progesterone results in increased expression of INHBB mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:33,083,671...33,089,373
Ensembl chr13:33,083,671...33,089,609
|
|
| G
|
Inmt
|
indolethylamine N-methyltransferase
|
affects expression increases expression
|
ISO
|
Progesterone affects the expression of INMT mRNA Progesterone results in increased expression of INMT mRNA
|
CTD |
PMID:17251523 PMID:22238285 |
|
NCBI chr 4:85,648,459...85,652,755
Ensembl chr 4:85,648,459...85,652,755
|
|
| G
|
Inpp4b
|
inositol polyphosphate-4-phosphatase type II B
|
multiple interactions decreases expression
|
ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of INPP4B mRNA] Progesterone results in decreased expression of INPP4B mRNA
|
CTD |
PMID:20864642 PMID:21795739 |
|
NCBI chr19:42,824,710...43,575,039
Ensembl chr19:42,829,871...43,185,091
|
|
| G
|
Ins1
|
insulin 1
|
multiple interactions
|
ISO
|
1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [[Progesterone co-treated with Estradiol] results in increased expression of INS1 protein]; [Progesterone co-treated with Estradiol] results in increased expression of INS1 protein; Progesterone inhibits the reaction [INS1 protein results in increased transport of Glucose]
|
CTD |
PMID:18615583 PMID:21768169 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682
|
|
| G
|
Ins2
|
insulin 2
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of INS2 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805
|
|
| G
|
Insig1
|
insulin induced gene 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of INSIG1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 4:8,049,339...8,057,812
Ensembl chr 4:8,049,556...8,057,778
|
|
| G
|
Insr
|
insulin receptor
|
decreases phosphorylation multiple interactions increases expression
|
EXP ISO
|
Progesterone results in decreased phosphorylation of INSR protein Progesterone affects the reaction [Streptozocin affects the expression of INSR protein] Progesterone results in increased expression of INSR mRNA
|
CTD |
PMID:17068109 PMID:20864642 |
|
NCBI chr12:5,991,135...6,129,275
Ensembl chr12:5,981,835...6,128,803
|
|
| G
|
Insyn1
|
inhibitory synaptic factor 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of INSYN1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 8:67,799,989...67,810,685
Ensembl chr 8:67,799,304...67,814,536
|
|
| G
|
Ipo4
|
importin 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of IPO4 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr15:33,087,321...33,097,241
Ensembl chr15:33,087,321...33,097,241
|
|
| G
|
Iqgap2
|
IQ motif containing GTPase activating protein 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of IQGAP2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:28,629,558...28,904,649
Ensembl chr 2:28,629,558...28,904,649
|
|
| G
|
Iqgap3
|
IQ motif containing GTPase activating protein 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of IQGAP3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:175,840,001...175,881,799
Ensembl chr 2:175,839,949...175,881,797
|
|
| G
|
Irak1
|
interleukin-1 receptor-associated kinase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of IRAK1 mRNA
|
CTD |
PMID:17701593 |
|
NCBI chr X:156,919,927...156,929,825
Ensembl chr X:156,920,081...156,929,825
|
|
| G
|
Irak2
|
interleukin-1 receptor-associated kinase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of IRAK2 protein Progesterone results in increased expression of IRAK2 mRNA
|
CTD |
PMID:17701593 PMID:21549006 |
|
NCBI chr 4:148,341,704...148,398,211
Ensembl chr 4:148,341,719...148,398,210
|
|
| G
|
Irak3
|
interleukin-1 receptor-associated kinase 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of IRAK3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 7:57,538,522...57,600,166
Ensembl chr 7:57,539,557...57,598,706
|
|
| G
|
Irak4
|
interleukin-1 receptor-associated kinase 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of IRAK4 protein
|
CTD |
PMID:17701593 |
|
NCBI chr 7:127,561,777...127,588,762
Ensembl chr 7:127,561,717...127,597,109
|
|
| G
|
Irf1
|
interferon regulatory factor 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of IRF1 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr10:38,417,935...38,424,946
Ensembl chr10:38,417,148...38,424,947
|
|
| G
|
Irf6
|
interferon regulatory factor 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of IRF6 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr13:107,200,876...107,220,083
Ensembl chr13:107,200,731...107,220,049
|
|
| G
|
Irs1
|
insulin receptor substrate 1
|
decreases phosphorylation increases phosphorylation
|
ISO
|
Progesterone results in decreased phosphorylation of IRS1 protein Progesterone results in increased phosphorylation of IRS1 protein
|
CTD |
PMID:15604210 PMID:15949379 |
|
NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538
|
|
| G
|
Irs2
|
insulin receptor substrate 2
|
multiple interactions increases phosphorylation increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of IRS2 mRNA; Estradiol promotes the reaction [Progesterone results in increased expression of IRS2 mRNA]; Estradiol promotes the reaction [Progesterone results in increased expression of IRS2 protein]; Estradiol promotes the reaction [Progesterone results in increased phosphorylation of IRS2 protein] Progesterone results in increased expression of IRS2 mRNA; Progesterone results in increased expression of IRS2 protein
|
CTD |
PMID:15949379 PMID:17404688 PMID:20864642 PMID:21795739 |
|
NCBI chr16:85,190,310...85,214,543
Ensembl chr16:85,190,111...85,214,543
|
|
| G
|
Irs3
|
insulin receptor substrate 3
|
increases expression
|
EXP
|
Progesterone results in increased expression of IRS3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr12:24,689,930...24,692,068
Ensembl chr12:24,689,909...24,692,068
|
|
| G
|
Irx2
|
iroquois homeobox 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of IRX2 mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 1:32,489,512...32,494,930
Ensembl chr 1:32,489,512...32,494,930
|
|
| G
|
Irx4
|
iroquois homeobox 4
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of IRX4 mRNA Progesterone results in increased expression of IRX4 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:31,859,101...31,868,089
Ensembl chr 1:31,859,101...31,868,089
|
|
| G
|
Isg20
|
interferon stimulated exonuclease gene 20
|
affects expression
|
ISO
|
Progesterone affects the expression of ISG20 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:142,234,729...142,246,403
Ensembl chr 1:142,236,137...142,246,401
|
|
| G
|
Ism1
|
isthmin 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ISM1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:147,476,983...147,555,900
Ensembl chr 3:147,475,533...147,555,908
|
|
| G
|
Isoc1
|
isochorismatase domain containing 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ISOC1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr18:54,356,757...54,377,170
Ensembl chr18:54,356,734...54,377,170
|
|
| G
|
Itga1
|
integrin subunit alpha 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ITGA1 protein; PGR protein affects the reaction [[Estradiol co-treated with Progesterone] results in increased expression of ITGA1]; resveratrol inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of ITGA1 protein]; resveratrol inhibits the reaction [PGR protein affects the reaction [[Estradiol co-treated with Progesterone] results in increased expression of ITGA1]]
|
CTD |
PMID:11507064 |
|
NCBI chr 2:48,379,181...48,545,336
Ensembl chr 2:48,386,249...48,545,284
|
|
| G
|
Itga10
|
integrin subunit alpha 10
|
increases expression
|
ISO
|
Progesterone results in increased expression of ITGA10 mRNA
|
CTD |
PMID:20864642 PMID:21795739 |
|
NCBI chr 2:186,871,711...186,891,012
Ensembl chr 2:186,871,711...186,891,012
|
|
| G
|
Itga2
|
integrin subunit alpha 2
|
multiple interactions decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of ITGA2 mRNA Progesterone results in decreased expression of ITGA2 protein Mifepristone inhibits the reaction [Progesterone results in decreased expression of ITGA2 protein]
|
CTD |
PMID:20660070 PMID:20959644 |
|
NCBI chr 2:48,253,412...48,354,509
Ensembl chr 2:48,253,412...48,354,509
|
|
| G
|
Itga3
|
integrin subunit alpha 3
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of ITGA3 mRNA Progesterone results in increased expression of ITGA3 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr10:80,486,998...80,522,548
Ensembl chr10:80,486,999...80,518,901
|
|
| G
|
Itga4
|
integrin subunit alpha 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ITGA4 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:84,569,487...84,646,276
Ensembl chr 3:84,560,369...84,641,039
|
|
| G
|
Itga5
|
integrin subunit alpha 5
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of ITGA5 mRNA Progesterone results in increased expression of ITGA5 mRNA
|
CTD |
PMID:20226447 PMID:21795739 |
|
NCBI chr 7:136,358,097...136,381,305
Ensembl chr 7:136,358,097...136,381,305
|
|
| G
|
Itga6
|
integrin subunit alpha 6
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ITGA6 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076
|
|
| G
|
Itga7
|
integrin subunit alpha 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of ITGA7 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 7:1,944,447...1,973,347
Ensembl chr 7:1,944,460...1,973,339
|
|
| G
|
Itga8
|
integrin subunit alpha 8
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of ITGA8 mRNA Progesterone results in increased expression of ITGA8 mRNA
|
CTD |
PMID:20226447 PMID:20726854 |
|
NCBI chr17:80,213,139...80,410,633
Ensembl chr17:80,213,143...80,410,633
|
|
| G
|
Itgam
|
integrin subunit alpha M
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ITGAM protein
|
CTD |
PMID:21558462 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:192,089,542...192,139,943
|
|
| G
|
Itgb1
|
integrin subunit beta 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of ITGB1 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269
|
|
| G
|
Itgb1bp1
|
integrin subunit beta 1 binding protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ITGB1BP1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:46,549,994...46,564,735
Ensembl chr 6:46,549,999...46,564,398
|
|
| G
|
Itgb2
|
integrin subunit beta 2
|
affects expression multiple interactions increases expression
|
ISO
|
Progesterone affects the expression of ITGB2 mRNA [Progesterone co-treated with Estradiol] results in increased expression of ITGB2 mRNA Progesterone results in increased expression of ITGB2 mRNA
|
CTD |
PMID:17251523 PMID:20226447 PMID:21540246 |
|
NCBI chr20:11,061,009...11,097,242
Ensembl chr20:11,058,492...11,097,182
|
|
| G
|
Itgb3
|
integrin subunit beta 3
|
multiple interactions increases expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ITGB3 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of ITGB3 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of ITGB3 mRNA Progesterone results in increased expression of ITGB3 mRNA Progesterone results in decreased expression of ITGB3 mRNA
|
CTD |
PMID:16403803 PMID:17404688 PMID:20226447 PMID:20660070 |
|
NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800
|
|
| G
|
Itgb4
|
integrin subunit beta 4
|
multiple interactions increases expression
|
ISO
|
[Progesterone affects the activity of PGR protein alternative form] which affects the expression of ITGB4 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of ITGB4 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of ITGB4 mRNA Progesterone results in increased expression of ITGB4 mRNA
|
CTD |
PMID:15866122 PMID:20226447 |
|
NCBI chr10:101,705,592...101,741,933
Ensembl chr10:101,705,587...101,741,932
|
|
| G
|
Itgb6
|
integrin subunit beta 6
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ITGB6 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of ITGB6 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 3:65,454,964...65,579,179
Ensembl chr 3:65,456,713...65,530,333
|
|
| G
|
Itgb8
|
integrin subunit beta 8
|
multiple interactions affects expression
|
ISO
|
perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of ITGB8 mRNA]; Progesterone inhibits the reaction [perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of ITGB8 mRNA]]
|
CTD |
PMID:31896193 |
|
NCBI chr 6:146,267,982...146,351,245
Ensembl chr 6:146,165,484...146,351,245
|
|
| G
|
Itgbl1
|
integrin subunit beta like 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ITGBL1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of ITGBL1 mRNA; Progesterone inhibits the reaction [Estradiol results in decreased expression of ITGBL1 mRNA] Progesterone results in increased expression of ITGBL1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21795739 |
|
NCBI chr15:107,186,792...107,448,335
Ensembl chr15:107,186,689...107,451,098
|
|
| G
|
Itm2a
|
integral membrane protein 2A
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ITM2A mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr X:76,559,183...76,565,144
Ensembl chr X:76,559,181...76,565,437
|
|
| G
|
Itm2c
|
integral membrane protein 2C
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ITM2C mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 9:93,993,922...94,007,737
Ensembl chr 9:93,993,895...94,007,704
|
|
| G
|
Itpr1
|
inositol 1,4,5-trisphosphate receptor, type 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ITPR1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504
|
|
| G
|
Ivd
|
isovaleryl-CoA dehydrogenase
|
increases expression
|
EXP
|
Progesterone results in increased expression of IVD mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 3:126,305,584...126,326,016
Ensembl chr 3:126,305,364...126,328,160
|
|
| G
|
Ivns1abp
|
influenza virus NS1A binding protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of IVNS1ABP mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:65,977,069...65,996,685
Ensembl chr13:65,977,045...65,997,547
|
|
| G
|
Jade1
|
jade family PHD finger 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of JADE1 mRNA
|
CTD |
PMID:20864642 PMID:21795739 |
|
NCBI chr 2:126,471,124...126,524,252
Ensembl chr 2:126,471,124...126,524,252
|
|
| G
|
Jak2
|
Janus kinase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of JAK2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 1:236,408,905...236,468,769
Ensembl chr 1:236,408,662...236,468,762
|
|
| G
|
Jam2
|
junctional adhesion molecule 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of JAM2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr11:37,316,287...37,366,517
Ensembl chr11:37,317,511...37,367,510
|
|
| G
|
Jchain
|
joining chain of multimeric IgA and IgM
|
affects expression
|
ISO
|
Progesterone affects the expression of JCHAIN mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr14:19,822,976...19,831,072
Ensembl chr14:19,822,976...19,838,307
|
|
| G
|
Jdp2
|
Jun dimerization protein 2
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of JDP2 mRNA [Estradiol co-treated with Progesterone] results in increased expression of JDP2 mRNA
|
CTD |
PMID:18037150 PMID:18556351 |
|
NCBI chr 6:110,988,927...111,033,392
Ensembl chr 6:110,992,806...111,033,392
|
|
| G
|
Jmy
|
junction mediating and regulatory protein, p53 cofactor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of JMY mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:26,401,047...26,465,959
Ensembl chr 2:26,409,969...26,465,649
|
|
| G
|
Jun
|
Jun proto-oncogene, AP-1 transcription factor subunit
|
multiple interactions decreases expression increases expression
|
EXP ISO
|
[Estrogens co-treated with Progesterone] results in increased phosphorylation of JUN protein; Progesterone promotes the reaction [Hydrogen Peroxide results in increased activity of JUN protein] Progesterone results in decreased expression of JUN mRNA Progesterone results in increased expression of JUN mRNA
|
CTD |
PMID:16284289 PMID:17170212 PMID:21258428 PMID:21549006 |
|
NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285
|
|
| G
|
Jund
|
JunD proto-oncogene, AP-1 transcription factor subunit
|
increases expression
|
ISO
|
Progesterone results in increased expression of JUND mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148
|
|
| G
|
Jup
|
junction plakoglobin
|
affects expression multiple interactions
|
ISO
|
Progesterone affects the expression of JUP mRNA [Estradiol co-treated with Progesterone] results in decreased expression of JUP mRNA
|
CTD |
PMID:17251523 PMID:20660070 |
|
NCBI chr10:85,800,812...85,827,881
Ensembl chr10:85,800,814...85,827,429
|
|
| G
|
Kansl1l
|
KAT8 regulatory NSL complex subunit 1-like
|
increases expression
|
ISO
|
Progesterone results in increased expression of KANSL1L mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 9:75,660,865...75,766,730
Ensembl chr 9:75,661,233...75,766,745
|
|
| G
|
Kazald1
|
Kazal-type serine peptidase inhibitor domain 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KAZALD1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 1:253,888,639...253,892,211
Ensembl chr 1:253,888,783...253,892,305
|
|
| G
|
Kazn
|
kazrin, periplakin interacting protein
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of KAZN mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:159,675,803...160,666,084
Ensembl chr 5:159,675,803...160,664,154
|
|
| G
|
Kbtbd11
|
kelch repeat and BTB domain containing 11
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of KBTBD11 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr16:81,318,596...81,340,334
Ensembl chr16:81,313,093...81,340,390
|
|
| G
|
Kcna5
|
potassium voltage-gated channel subfamily A member 5
|
decreases activity
|
ISO
|
Progesterone results in decreased activity of KCNA5 protein
|
CTD |
PMID:18068743 |
|
NCBI chr 4:161,040,853...161,044,311
Ensembl chr 4:160,996,950...161,044,408
|
|
| G
|
Kcnd2
|
potassium voltage-gated channel subfamily D member 2
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of KCND2 mRNA Progesterone results in increased expression of KCND2 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 4:50,741,595...51,243,540
Ensembl chr 4:50,742,839...51,243,522
|
|
| G
|
Kcnd3
|
potassium voltage-gated channel subfamily D member 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of KCND3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:195,626,316...195,843,690
Ensembl chr 2:195,626,316...195,843,690
|
|
| G
|
Kcne1
|
potassium voltage-gated channel subfamily E regulatory subunit 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of KCNE1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr11:45,066,875...45,080,024
Ensembl chr11:45,064,162...45,081,247
|
|
| G
|
Kcne3
|
potassium voltage-gated channel subfamily E regulatory subunit 3
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of KCNE3 mRNA Progesterone results in decreased expression of KCNE3 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 1:163,936,035...163,942,998
Ensembl chr 1:163,935,991...163,950,162
|
|
| G
|
Kcne4
|
potassium voltage-gated channel subfamily E regulatory subunit 4
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of KCNE4 mRNA Progesterone results in increased expression of KCNE4 mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr 9:87,674,264...87,699,088
Ensembl chr 9:87,650,462...87,704,131
|
|
| G
|
Kcng1
|
potassium voltage-gated channel modifier subfamily G member 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of KCNG1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of KCNG1 mRNA Progesterone results in increased expression of KCNG1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21795739 |
|
NCBI chr 3:177,379,593...177,412,986
Ensembl chr 3:177,392,031...177,411,507
|
|
| G
|
Kcnh2
|
potassium voltage-gated channel subfamily H member 2
|
multiple interactions
|
EXP
|
2-Hydroxypropyl-beta-cyclodextrin inhibits the reaction [Progesterone results in decreased localization of KCNH2 protein]; E 4031 inhibits the reaction [Progesterone results in decreased localization of KCNH2 protein]; Progesterone results in decreased glycosylation of and results in decreased localization of and results in decreased activity of KCNH2 protein
|
CTD |
PMID:21525004 |
|
NCBI chr 4:11,719,357...11,751,424
Ensembl chr 4:11,692,980...11,751,421
|
|
| G
|
Kcnip4
|
potassium voltage-gated channel interacting protein 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of KCNIP4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr14:65,593,297...66,743,994
Ensembl chr14:65,593,366...66,743,993
|
|
| G
|
Kcnj13
|
potassium inwardly-rectifying channel, subfamily J, member 13
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of KCNJ13 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 9:95,509,228...95,528,400
Ensembl chr 9:95,510,877...95,520,817
|
|
| G
|
Kcnj16
|
potassium inwardly-rectifying channel, subfamily J, member 16
|
increases expression
|
ISO
|
Progesterone results in increased expression of KCNJ16 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:96,489,329...96,520,745
Ensembl chr10:96,460,331...96,566,075
|
|
| G
|
Kcnj8
|
potassium inwardly-rectifying channel, subfamily J, member 8
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of KCNJ8 mRNA Progesterone results in increased expression of KCNJ8 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 4:177,240,692...177,246,548
Ensembl chr 4:177,239,908...177,246,531
|
|
| G
|
Kcnk3
|
potassium two pore domain channel subfamily K member 3
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of KCNK3 mRNA Progesterone results in increased expression of KCNK3 mRNA
|
CTD |
PMID:18070364 PMID:20726854 |
|
NCBI chr 6:31,483,129...31,519,061
Ensembl chr 6:31,483,140...31,519,061
|
|
| G
|
Kcnk6
|
potassium two pore domain channel subfamily K member 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of KCNK6 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 1:93,652,888...93,661,419
|
|
| G
|
Kcnma1
|
potassium calcium-activated channel subfamily M alpha 1
|
multiple interactions increases expression decreases activity
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of KCNMA1 mRNA; Progesterone inhibits the reaction [Estradiol results in increased activity of KCNMA1 protein] Progesterone results in increased expression of KCNMA1 mRNA; Progesterone results in increased expression of KCNMA1 mRNA alternative form Progesterone results in decreased activity of KCNMA1 protein Progesterone results in increased expression of KCNMA1 mRNA; Progesterone results in increased expression of KCNMA1 protein
|
CTD |
PMID:16102753 PMID:18068743 PMID:20660070 PMID:21795739 |
|
NCBI chr15:351,065...1,057,117
Ensembl chr15:351,659...1,057,117
|
|
| G
|
Kcnmb2
|
potassium calcium-activated channel subfamily M regulatory beta subunit 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KCNMB2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:116,598,511...116,903,886
Ensembl chr 2:116,599,387...116,903,854
|
|
| G
|
Kcnn4
|
potassium calcium-activated channel subfamily N member 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of KCNN4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:89,084,306...89,102,279
Ensembl chr 1:89,086,814...89,102,275
|
|
| G
|
Kcns3
|
potassium voltage-gated channel, modifier subfamily S, member 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of KCNS3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 6:39,527,410...39,584,105
Ensembl chr 6:39,523,777...39,618,848
|
|
| G
|
Kcnt2
|
potassium sodium-activated channel subfamily T member 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of KCNT2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:54,214,831...54,609,889
Ensembl chr13:54,215,307...54,607,924
|
|
| G
|
Kctd12
|
potassium channel tetramerization domain containing 12
|
increases expression
|
ISO
|
Progesterone results in increased expression of KCTD12 mRNA
|
CTD |
PMID:21795739 PMID:22238285 |
|
NCBI chr15:86,214,786...86,220,725
Ensembl chr15:86,214,840...86,224,539
|
|
| G
|
Kdm4a
|
lysine demethylase 4A
|
increases expression
|
ISO
|
Progesterone results in increased expression of KDM4A mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:136,958,178...137,004,942
Ensembl chr 5:136,958,178...137,004,951
|
|
| G
|
Kdr
|
kinase insert domain receptor
|
increases expression
|
EXP ISO
|
Progesterone results in increased expression of KDR mRNA
|
CTD |
PMID:18692832 PMID:20726854 |
|
NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192
|
|
| G
|
Kdsr
|
3-ketodihydrosphingosine reductase
|
increases expression
|
ISO
|
Progesterone results in increased expression of KDSR mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr13:23,374,101...23,408,779
Ensembl chr13:23,376,779...23,408,897
|
|
| G
|
Khdrbs1
|
KH RNA binding domain containing, signal transduction associated 1
|
affects expression
|
ISO
|
Progesterone affects the expression of KHDRBS1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:147,337,048...147,374,604
Ensembl chr 5:147,347,904...147,373,448
|
|
| G
|
Kif13b
|
kinesin family member 13B
|
increases expression
|
ISO
|
Progesterone results in increased expression of KIF13B mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr15:43,084,059...43,241,719
Ensembl chr15:43,080,910...43,241,719
|
|
| G
|
Kif14
|
kinesin family member 14
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KIF14 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:50,478,646...50,542,256
Ensembl chr13:50,478,721...50,542,248
|
|
| G
|
Kif20a
|
kinesin family member 20A
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of KIF20A mRNA Progesterone results in decreased expression of KIF20A mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr18:26,504,422...26,512,908
Ensembl chr18:26,504,072...26,512,909
|
|
| G
|
Kif4a
|
kinesin family member 4A
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of KIF4A mRNA Progesterone results in decreased expression of KIF4A mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr X:69,761,803...69,864,335
Ensembl chr X:69,761,883...69,864,335
|
|
| G
|
Kiss1
|
KiSS-1 metastasis-suppressor
|
multiple interactions increases abundance
|
EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [KISS1 protein results in increased abundance of Progesterone]; KISS1 protein promotes the reaction [CGB3 protein results in increased abundance of Progesterone]
|
CTD |
PMID:23312234 |
|
NCBI chr13:47,327,159...47,332,759
Ensembl chr13:47,327,004...47,332,906
|
|
| G
|
Kiz
|
kizuna centrosomal protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of KIZ mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:154,730,873...154,838,410
Ensembl chr 3:154,730,634...154,838,410
|
|
| G
|
Klf10
|
KLF transcription factor 10
|
decreases expression
|
ISO EXP
|
Progesterone results in decreased expression of KLF10 mRNA
|
CTD |
PMID:18037150 PMID:20726854 |
|
NCBI chr 7:71,352,612...71,358,680
Ensembl chr 7:71,350,573...71,358,948
|
|
| G
|
Klf15
|
KLF transcription factor 15
|
increases expression
|
EXP
|
Progesterone results in increased expression of KLF15 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:124,522,652...124,535,613
Ensembl chr 4:124,522,909...124,542,373
|
|
| G
|
Klf4
|
KLF transcription factor 4
|
multiple interactions
|
ISO
|
Progesterone promotes the reaction [Estradiol results in increased expression of KLF4 mRNA]
|
CTD |
PMID:21795739 |
|
NCBI chr 5:75,074,107...75,079,182
Ensembl chr 5:75,074,236...75,078,592
|
|
| G
|
Klf5
|
KLF transcription factor 5
|
increases expression affects expression multiple interactions
|
ISO
|
Progesterone results in increased expression of KLF5 mRNA Progesterone affects the expression of KLF5 mRNA perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of KLF5 mRNA]; Progesterone inhibits the reaction [perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of KLF5 mRNA]]
|
CTD |
PMID:18037150 PMID:18070364 PMID:31896193 |
|
NCBI chr15:82,472,081...82,487,267
Ensembl chr15:82,472,065...82,487,262
|
|
| G
|
Klf6
|
KLF transcription factor 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of KLF6 mRNA
|
CTD |
PMID:18070364 PMID:20864642 PMID:21795739 |
|
NCBI chr17:69,449,483...69,458,478
Ensembl chr17:69,441,493...69,498,601
|
|
| G
|
Klf9
|
KLF transcription factor 9
|
increases expression
|
EXP
|
Progesterone results in increased expression of KLF9 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641
|
|
| G
|
Klhl14
|
kelch-like family member 14
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KLHL14 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr18:13,079,159...13,192,728
Ensembl chr18:13,079,159...13,193,557
|
|
| G
|
Klhl24
|
kelch-like family member 24
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of KLHL24 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:94,348,024...94,382,085
Ensembl chr11:94,351,157...94,382,050
|
|
| G
|
Klhl29
|
kelch-like family member 29
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of KLHL29 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:33,805,922...34,110,055
Ensembl chr 6:33,805,922...34,110,055
|
|
| G
|
Klhl31
|
kelch-like family member 31
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of KLHL31 mRNA Progesterone results in decreased expression of KLHL31 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 8:87,395,878...87,419,236
Ensembl chr 8:87,395,869...87,419,258
|
|
| G
|
Klk10
|
kallikrein related-peptidase 10
|
multiple interactions
|
ISO
|
[Estrogens co-treated with Progesterone] results in increased expression of KLK10 mRNA
|
CTD |
PMID:20686372 |
|
NCBI chr 1:103,371,638...103,375,918
Ensembl chr 1:103,371,638...103,375,918
|
|
| G
|
Klk11
|
kallikrein related-peptidase 11
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KLK11 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:103,365,290...103,369,830
Ensembl chr 1:103,365,290...103,369,830
|
|
| G
|
Klk5
|
kallikrein related-peptidase 5
|
multiple interactions
|
ISO
|
[Progesterone results in increased activity of PGR protein] which results in increased expression of KLK5 mRNA
|
CTD |
PMID:15845616 |
|
NCBI chr 1:103,432,743...103,442,011
Ensembl chr 1:103,433,065...103,441,305
|
|
| G
|
Klk6
|
kallikrein related-peptidase 6
|
multiple interactions
|
ISO
|
[Progesterone results in increased activity of PGR protein] which results in increased expression of KLK6 mRNA
|
CTD |
PMID:15845616 |
|
NCBI chr 1:103,415,411...103,422,682
Ensembl chr 1:103,416,886...103,422,690
|
|
| G
|
Klrb1a
|
killer cell lectin like receptor B1A
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of KLRB1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 4:163,576,672...163,590,201
Ensembl chr 4:163,576,672...163,619,374
|
|
| G
|
Klrc3
|
killer cell lectin like receptor C3
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of KLRC3 mRNA Progesterone results in increased expression of KLRC3 mRNA
|
CTD |
PMID:17404688 PMID:21540246 |
|
NCBI chr 4:164,791,102...164,798,758
Ensembl chr 4:164,791,128...164,798,758
|
|
| G
|
Kng1
|
kininogen 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of KNG1 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr11:91,317,354...91,340,148
Ensembl chr11:91,317,355...91,340,148
|
|
| G
|
Knl1
|
kinetochore scaffold 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KNL1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:126,483,498...126,545,774
Ensembl chr 3:126,483,544...126,545,774
|
|
| G
|
Krt12
|
keratin 12
|
increases expression
|
ISO
|
Progesterone results in increased expression of KRT12 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:84,866,965...84,874,265
Ensembl chr10:84,866,965...84,874,265
|
|
| G
|
Krt15
|
keratin 15
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KRT15 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:85,567,197...85,571,014
Ensembl chr10:85,567,202...85,571,142
|
|
| G
|
Krt17
|
keratin 17
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KRT17 mRNA
|
CTD |
PMID:18037150 PMID:22238285 |
|
NCBI chr10:85,679,068...85,683,792
Ensembl chr10:85,679,070...85,683,787
|
|
| G
|
Krt18
|
keratin 18
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of KRT18 mRNA]
|
CTD |
PMID:17556502 PMID:21795739 |
|
NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848 Ensembl chr10:135,035,982...135,039,848
|
|
| G
|
Krt23
|
keratin 23
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of KRT23 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of KRT23 mRNA Progesterone results in decreased expression of KRT23 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21540246 |
|
NCBI chr10:84,930,603...84,946,929
Ensembl chr10:84,930,603...84,946,929
|
|
| G
|
Krt34
|
keratin 34
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KRT34 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr10:85,470,391...85,474,501
Ensembl chr10:85,470,391...85,474,501
|
|
| G
|
Krt7
|
keratin 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of KRT7 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 7:134,407,626...134,423,787
Ensembl chr 7:134,407,584...134,423,786
|
|
| G
|
Krt8
|
keratin 8
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KRT8 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 7:135,002,886...135,010,339
Ensembl chr 7:135,002,894...135,010,403
|
|
| G
|
Krt86
|
keratin 86
|
increases expression
|
ISO
|
Progesterone results in increased expression of KRT86 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 7:134,470,224...134,476,873
Ensembl chr 7:134,470,224...134,476,873
|
|
| G
|
Krtcap3
|
keratinocyte associated protein 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of KRTCAP3 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 6:30,840,906...30,842,500
Ensembl chr 6:30,840,906...30,842,475
|
|
| G
|
Kynu
|
kynureninase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of KYNU mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:48,188,286...48,338,996
Ensembl chr 3:48,188,182...48,339,014
|
|
| G
|
L1cam
|
L1 cell adhesion molecule
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of L1CAM mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr X:156,748,597...156,775,116
Ensembl chr X:156,748,597...156,775,077
|
|
| G
|
L2hgdh
|
L-2-hydroxyglutarate dehydrogenase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of L2HGDH mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:93,900,427...93,941,534
Ensembl chr 6:93,900,427...93,941,534
|
|
| G
|
Lama2
|
laminin subunit alpha 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of LAMA2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:19,492,126...20,140,056
Ensembl chr 1:19,244,599...20,140,056
|
|
| G
|
Lama3
|
laminin subunit alpha 3
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of LAMA3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr18:3,797,898...4,033,021
Ensembl chr18:3,797,939...4,026,449
|
|
| G
|
Lama4
|
laminin subunit alpha 4
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LAMA4 mRNA Progesterone results in increased expression of LAMA4 mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr20:43,946,898...44,087,972
Ensembl chr20:43,946,898...44,087,972
|
|
| G
|
Lamb3
|
laminin subunit beta 3
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LAMB3 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of LAMB3 mRNA Progesterone results in increased expression of LAMB3 mRNA
|
CTD |
PMID:20226447 PMID:20660070 |
|
NCBI chr13:107,362,514...107,404,081
Ensembl chr13:107,322,526...107,404,081
|
|
| G
|
Lamc1
|
laminin subunit gamma 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of LAMC1 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr13:67,924,872...68,051,986
Ensembl chr13:67,924,872...68,051,986
|
|
| G
|
Lamc2
|
laminin subunit gamma 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LAMC2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr13:67,835,199...67,894,694
Ensembl chr13:67,835,199...67,895,102
|
|
| G
|
Lamc3
|
laminin subunit gamma 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of LAMC3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:35,562,989...35,624,460
Ensembl chr 3:35,562,713...35,624,460
|
|
| G
|
Lap3
|
leucine aminopeptidase 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of LAP3 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr14:69,820,907...69,839,891
Ensembl chr14:69,820,908...69,839,891
|
|
| G
|
Large2
|
LARGE xylosyl- and glucuronyltransferase 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LARGE2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 3:98,791,543...98,800,251
Ensembl chr 3:98,791,543...98,797,782
|
|
| G
|
Larp4
|
La ribonucleoprotein 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of LARP4 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 7:132,983,276...133,031,514
Ensembl chr 7:132,980,385...133,029,633
|
|
| G
|
Lbp
|
lipopolysaccharide binding protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of LBP mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 3:167,373,786...167,400,941
Ensembl chr 3:167,373,924...167,401,518
|
|
| G
|
Lce3e
|
late cornified envelope 3E
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LCE3B mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:181,274,092...181,275,265
Ensembl chr 2:181,274,092...181,275,265
|
|
| G
|
Lck
|
LCK proto-oncogene, Src family tyrosine kinase
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of LCK mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267
|
|
| G
|
Lcn2
|
lipocalin 2
|
affects expression
|
ISO
|
Progesterone affects the expression of LCN2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842
|
|
| G
|
Lcp1
|
lymphocyte cytosolic protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of LCP1 mRNA
|
CTD |
PMID:20864642 PMID:21540246 |
|
NCBI chr15:56,846,375...56,954,090
Ensembl chr15:56,847,433...56,954,092
|
|
| G
|
Lct
|
lactase
|
increases expression
|
ISO
|
Progesterone results in increased expression of LCT mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr13:42,334,347...42,376,872
Ensembl chr13:42,334,347...42,376,872
|
|
| G
|
Ldb2
|
LIM domain binding 2
|
decreases expression multiple interactions increases expression
|
ISO
|
Progesterone results in decreased expression of LDB2 mRNA NCOA2 protein affects the reaction [Progesterone results in decreased expression of LDB2 mRNA] Progesterone results in increased expression of LDB2 mRNA
|
CTD |
PMID:17556502 PMID:22238285 |
|
NCBI chr14:70,489,243...70,810,573
Ensembl chr14:70,489,620...70,810,574
|
|
| G
|
Ldha
|
lactate dehydrogenase A
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of LDHA mRNA Progesterone results in increased expression of LDHA mRNA
|
CTD |
PMID:18037150 PMID:21770760 |
|
NCBI chr 1:106,508,092...106,517,512
Ensembl chr 1:106,502,182...106,517,521
|
|
| G
|
Ldhb
|
lactate dehydrogenase B
|
increases expression
|
EXP
|
Progesterone results in increased expression of LDHB mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:177,159,389...177,177,408
Ensembl chr 4:177,159,392...177,177,408
|
|
| G
|
Ldlr
|
low density lipoprotein receptor
|
affects expression increases expression
|
ISO EXP
|
Progesterone affects the expression of LDLR mRNA Progesterone results in increased expression of LDLR mRNA
|
CTD |
PMID:17170212 PMID:17251523 PMID:18037150 PMID:18070364 |
|
NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675
|
|
| G
|
Ldlrad4
|
low density lipoprotein receptor class A domain containing 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of LDLRAD4 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr18:63,789,089...64,118,166
Ensembl chr18:63,790,440...64,113,064
|
|
| G
|
Lefty1
|
left right determination factor 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of LEFTY1 mRNA [Progesterone co-treated with Triclosan] results in increased expression of LEFTY1 mRNA
|
CTD |
PMID:26604029 |
|
NCBI chr13:95,188,091...95,191,488
Ensembl chr13:95,188,091...95,191,488
|
|
| G
|
Lemd1
|
LEM domain containing 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LEMD1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr13:46,183,860...46,250,105
Ensembl chr13:46,218,085...46,250,562
|
|
| G
|
Lep
|
leptin
|
decreases secretion increases expression multiple interactions
|
ISO
|
Progesterone results in decreased secretion of LEP protein Progesterone results in increased expression of LEP mRNA LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]; LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]]
|
CTD |
PMID:15713686 PMID:16048798 PMID:19849856 |
|
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661
|
|
| G
|
Lepr
|
leptin receptor
|
multiple interactions
|
ISO
|
LEPR protein affects the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased chemical synthesis of Progesterone]]
|
CTD |
PMID:19849856 |
|
NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215
|
|
| G
|
Lfng
|
LFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LFNG mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr12:19,144,474...19,152,951
Ensembl chr12:19,124,662...19,152,918
|
|
| G
|
Lgals1
|
galectin 1
|
affects metabolic processing
|
ISO
|
LGALS1 protein affects the metabolism of Progesterone
|
CTD |
PMID:17242467 |
|
NCBI chr 7:112,365,695...112,368,801
Ensembl chr 7:112,361,850...112,368,800
|
|
| G
|
Lgals3
|
galectin 3
|
affects metabolic processing multiple interactions
|
ISO
|
LGALS3 protein affects the metabolism of Progesterone [Estradiol co-treated with Progesterone] results in decreased expression of LGALS3 mRNA
|
CTD |
PMID:17242467 PMID:20660070 |
|
NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737
|
|
| G
|
Lgals8
|
galectin 8
|
increases expression
|
ISO
|
Progesterone results in increased expression of LGALS8 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr17:62,716,368...62,744,272
Ensembl chr17:62,719,828...62,744,482
|
|
| G
|
Lgalsl
|
galectin-like
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LGALSL mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr14:99,198,340...99,205,846
Ensembl chr14:99,198,339...99,206,487
|
|
| G
|
Lgi1
|
leucine-rich, glioma inactivated 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LGI1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:245,455,691...245,497,036
Ensembl chr 1:245,455,599...245,499,095
|
|
| G
|
Lgr5
|
leucine rich repeat containing G protein coupled receptor 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LGR5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 7:52,973,151...53,107,964
Ensembl chr 7:52,974,332...53,108,163
|
|
| G
|
Lhb
|
luteinizing hormone subunit beta
|
multiple interactions increases secretion increases abundance decreases abundance increases chemical synthesis
|
EXP ISO
|
2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane inhibits the reaction [CGB3 protein results in increased chemical synthesis of Progesterone]; 7-Ala-angiotensin (1-7) inhibits the reaction [LHB protein results in increased secretion of Progesterone]; [Estradiol co-treated with Progesterone] results in decreased secretion of LHB protein; [Estradiol co-treated with Progesterone] results in increased expression of LHB protein; [FSHB protein co-treated with CGB3 protein] inhibits the reaction [Puromycin Aminonucleoside results in decreased abundance of Progesterone]; Atrazine inhibits the reaction [[estradiol 3-benzoate co-treated with Progesterone] results in increased secretion of LHB protein]; KISS1 protein promotes the reaction [CGB3 protein results in increased abundance of Progesterone]; nociceptin (1-13) amide inhibits the reaction [PNOC protein inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of LHB protein]]; PNOC protein inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of LHB protein] [LHB protein affects the secretion of Cyclic AMP] which results in increased secretion of Progesterone; ADCYAP1R1 protein promotes the reaction [LHB protein results in increased abundance of Progesterone]; DDT inhibits the reaction [LHB protein results in increased secretion of Progesterone]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [LHB protein results in increased secretion of Progesterone] [estradiol 3-benzoate co-treated with Progesterone] results in increased abundance of LHB protein; mono-(2-ethylhexyl)phthalate inhibits the reaction [LHB protein results in increased secretion of Progesterone]; Reactive Oxygen Species promotes the reaction [LHB protein results in increased abundance of Progesterone] LHB protein results in decreased abundance of Progesterone
|
CTD |
PMID:15056801 PMID:15525572 PMID:15967414 PMID:16574160 PMID:17640482 PMID:19215433 PMID:19926922 PMID:21220312 PMID:21664964 PMID:22247282 PMID:22577852 PMID:23071612 PMID:23312234 PMID:23433069 PMID:33638691 PMID:34627990 More...
|
|
NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445
|
|
| G
|
Lhfpl6
|
LHFPL tetraspan subfamily member 6
|
increases expression
|
ISO
|
Progesterone results in increased expression of LHFPL6 mRNA
|
CTD |
PMID:20864642 PMID:21540246 |
|
NCBI chr 2:139,276,810...139,474,740
Ensembl chr 2:139,276,789...139,474,737
|
|
| G
|
Lif
|
LIF, interleukin 6 family cytokine
|
affects expression affects response to substance increases expression multiple interactions
|
ISO
|
Progesterone affects the expression of LIF; Progesterone affects the expression of LIF mRNA LIF protein affects the susceptibility to Progesterone Progesterone results in increased expression of LIF mRNA [Estradiol co-treated with Progesterone] results in decreased expression of LIF mRNA [Estradiol co-treated with Progesterone] results in increased expression of LIF mRNA; [NR5A1 protein co-treated with LIF protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Tretinoin] results in increased abundance of Progesterone; [Progesterone co-treated with Estradiol] affects the expression of LIF; ESR1 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased expression of LIF mRNA]; LIF protein affects the reaction [Progesterone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased abundance of Nitric Oxide]]
|
CTD |
PMID:15639816 PMID:17307916 PMID:20660070 PMID:21610156 PMID:23407384 PMID:23409146 PMID:25210133 More...
|
|
NCBI chr14:83,354,602...83,364,053
Ensembl chr14:83,358,164...83,364,053
|
|
| G
|
Lifr
|
LIF receptor subunit alpha
|
increases expression
|
EXP
|
Progesterone results in increased expression of LIFR mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 2:57,951,787...58,020,357
Ensembl chr 2:57,952,975...58,020,364
|
|
| G
|
Lig1
|
DNA ligase 1
|
decreases expression
|
ISO EXP
|
Progesterone results in decreased expression of LIG1 mRNA
|
CTD |
PMID:16966611 PMID:20726854 |
|
NCBI chr 1:83,243,043...83,281,707
Ensembl chr 1:83,219,545...83,281,708
|
|
| G
|
Lima1
|
LIM domain and actin binding 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LIMA1 mRNA
|
CTD |
PMID:18037150 PMID:20864642 |
|
NCBI chr 7:132,780,556...132,880,343
Ensembl chr 7:132,780,556...132,880,386
|
|
| G
|
Lin7b
|
lin-7 homolog B, crumbs cell polarity complex component
|
increases expression
|
ISO
|
Progesterone results in increased expression of LIN7B mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:104,983,368...104,986,795
Ensembl chr 1:104,982,771...104,986,078
|
|
| G
|
Lipa
|
lipase A, lysosomal acid type
|
increases expression
|
EXP
|
Progesterone results in increased expression of LIPA mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 1:241,437,524...241,470,936
Ensembl chr 1:241,437,524...241,470,740
|
|
| G
|
Lipg
|
lipase G, endothelial type
|
increases expression
|
ISO
|
Progesterone results in increased expression of LIPG mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr18:70,790,077...70,811,259
Ensembl chr18:70,790,077...70,812,260
|
|
| G
|
Lmcd1
|
LIM and cysteine-rich domains 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of LMCD1 mRNA [Estradiol co-treated with Progesterone] results in increased expression of LMCD1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21795739 |
|
NCBI chr 4:146,948,993...147,007,878
Ensembl chr 4:146,948,958...147,007,875
|
|
| G
|
Lmnb1
|
lamin B1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LMNB1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr18:52,373,939...52,413,284
Ensembl chr18:52,373,757...52,413,283
|
|
| G
|
Lmo4
|
LIM domain only 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of LMO4 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:235,924,574...235,941,609
Ensembl chr 2:235,924,403...235,941,275
|
|
| G
|
Lmod1
|
leiomodin 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of LMOD1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr13:49,305,693...49,347,970
Ensembl chr13:49,305,830...49,348,116
|
|
| G
|
Lox
|
lysyl oxidase
|
increases expression
|
ISO
|
Progesterone results in increased expression of LOX mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr18:48,162,889...48,175,640
Ensembl chr18:48,165,688...48,239,810
|
|
| G
|
Loxl2
|
lysyl oxidase-like 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LOXL2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr15:51,091,547...51,182,843
Ensembl chr15:51,069,997...51,182,842
|
|
| G
|
Loxl4
|
lysyl oxidase-like 4
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LOXL4 mRNA; [Estradiol co-treated with Progesterone] results in increased expression of LOXL4 mRNA; Progesterone inhibits the reaction [Estradiol results in increased expression of LOXL4 mRNA] Progesterone results in decreased expression of LOXL4 mRNA
|
CTD |
PMID:20660070 PMID:20864642 PMID:21795739 |
|
NCBI chr 1:251,345,445...251,365,640
Ensembl chr 1:251,347,238...251,365,577
|
|
| G
|
Lpar1
|
lysophosphatidic acid receptor 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of LPAR1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 5:78,024,139...78,147,071
Ensembl chr 5:78,024,139...78,142,188
|
|
| G
|
Lpar3
|
lysophosphatidic acid receptor 3
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of LPAR3 mRNA Estrogens inhibits the reaction [Progesterone results in increased expression of LPAR3 mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of LPAR3 mRNA]
|
CTD |
PMID:16815476 PMID:17404688 |
|
NCBI chr 2:237,785,371...237,854,199
Ensembl chr 2:237,787,766...237,854,197
|
|
| G
|
Lpcat3
|
lysophosphatidylcholine acyltransferase 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of LPCAT3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:159,154,690...159,196,176
Ensembl chr 4:159,154,158...159,196,358
|
|
| G
|
Lpin1
|
lipin 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of LPIN1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 6:45,039,110...45,145,845
Ensembl chr 6:45,041,522...45,145,991
|
|
| G
|
Lpl
|
lipoprotein lipase
|
affects expression multiple interactions decreases expression increases expression
|
ISO EXP
|
Progesterone affects the expression of LPL mRNA Progesterone inhibits the reaction [ESR1 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]]; Progesterone inhibits the reaction [ESR2 protein promotes the reaction [Estradiol results in increased expression of LPL mRNA]]; Progesterone inhibits the reaction [Estradiol results in increased expression of LPL mRNA] Progesterone results in decreased expression of LPL mRNA Progesterone inhibits the reaction [Dexamethasone results in increased activity of LPL protein] Progesterone results in increased expression of LPL mRNA
|
CTD |
PMID:12906939 PMID:17251523 PMID:17974624 PMID:20726854 |
|
NCBI chr16:25,596,205...25,621,928
Ensembl chr16:25,596,211...25,622,107
|
|
| G
|
Lrig1
|
leucine-rich repeats and immunoglobulin-like domains 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of LRIG1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 4:128,687,723...128,788,219
Ensembl chr 4:128,687,723...128,788,219
|
|
| G
|
Lrp2
|
LDL receptor related protein 2
|
affects expression
|
ISO
|
Progesterone affects the expression of LRP2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:74,597,148...74,754,535
Ensembl chr 3:74,597,148...74,754,535
|
|
| G
|
Lrp4
|
LDL receptor related protein 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of LRP4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:97,885,373...97,939,366
Ensembl chr 3:97,885,400...97,939,370
|
|
| G
|
Lrp8
|
LDL receptor related protein 8
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LRP8 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:127,792,236...127,864,207
Ensembl chr 5:127,792,299...127,864,207
|
|
| G
|
Lrrc1
|
leucine rich repeat containing 1
|
increases expression multiple interactions decreases expression
|
ISO
|
Progesterone results in increased expression of LRRC1 mRNA [Estradiol co-treated with Progesterone] results in increased expression of LRRC1 mRNA Progesterone results in decreased expression of LRRC1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21540246 |
|
NCBI chr 8:87,120,281...87,289,748
Ensembl chr 8:87,119,975...87,286,853
|
|
| G
|
Lrrc17
|
leucine rich repeat containing 17
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LRRC17 mRNA Progesterone results in decreased expression of LRRC17 mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr 4:14,393,632...14,424,048
Ensembl chr 4:14,393,640...14,424,048
|
|
| G
|
Lrrc32
|
leucine rich repeat containing 32
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of LRRC32 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:162,196,995...162,209,563
Ensembl chr 1:162,197,653...162,209,563
|
|
| G
|
Lrrc36
|
leucine rich repeat containing 36
|
increases expression
|
ISO
|
Progesterone results in increased expression of LRRC36 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr19:50,201,944...50,252,338
Ensembl chr19:50,201,987...50,252,338
|
|
| G
|
Lrrc8c
|
leucine rich repeat containing 8 VRAC subunit C
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LRRC8C mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:4,528,721...4,621,259
Ensembl chr14:4,531,823...4,620,049
|
|
| G
|
Lrrc8d
|
leucine rich repeat containing 8 VRAC subunit D
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of LRRC8D mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr14:4,335,114...4,411,549
Ensembl chr14:4,332,130...4,445,639
|
|
| G
|
Lrrn1
|
leucine rich repeat neuronal 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LRRN1 mRNA Progesterone results in increased expression of LRRN1 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 4:142,032,805...142,072,320
Ensembl chr 4:142,032,041...142,074,760
|
|
| G
|
Lrrtm1
|
leucine rich repeat transmembrane neuronal 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LRRTM1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:111,246,213...111,295,638
Ensembl chr 4:111,235,054...111,276,818
|
|
| G
|
Lsr
|
lipolysis stimulated lipoprotein receptor
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of LSR mRNA Progesterone results in decreased expression of LSR mRNA
|
CTD |
PMID:18556351 PMID:22238285 |
|
NCBI chr 1:95,313,830...95,329,471
Ensembl chr 1:95,313,033...95,329,354
|
|
| G
|
Lss
|
lanosterol synthase
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of LSS mRNA [Estradiol co-treated with Progesterone] results in increased expression of LSS mRNA
|
CTD |
PMID:18070364 PMID:20660070 |
|
NCBI chr20:12,090,641...12,118,230
Ensembl chr20:12,073,543...12,118,253
|
|
| G
|
Lta
|
lymphotoxin alpha
|
increases expression
|
ISO
|
Progesterone results in increased expression of LTA mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr20:3,622,291...3,625,852
Ensembl chr20:3,623,527...3,625,533
|
|
| G
|
Ltb
|
lymphotoxin beta
|
increases expression
|
ISO
|
Progesterone results in increased expression of LTB mRNA
|
CTD |
PMID:22615136 |
|
NCBI chr20:3,632,209...3,634,054
Ensembl chr20:3,632,210...3,634,054
|
|
| G
|
Ltbp1
|
latent transforming growth factor beta binding protein 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of LTBP1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of LTBP1 mRNA Progesterone results in increased expression of LTBP1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21795739 |
|
NCBI chr 6:25,781,625...26,177,346
Ensembl chr 6:25,781,638...26,454,036
|
|
| G
|
Ltf
|
lactotransferrin
|
affects expression
|
ISO
|
Progesterone affects the expression of LTF mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:119,878,344...119,901,189
|
|
| G
|
Lum
|
lumican
|
increases expression
|
ISO
|
Progesterone results in increased expression of LUM mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 7:34,245,323...34,252,510
Ensembl chr 7:34,245,360...34,252,508
|
|
| G
|
Lxn
|
latexin
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of LXN mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 2:154,037,604...154,043,473
Ensembl chr 2:154,037,292...154,043,488
|
|
| G
|
Ly6e
|
lymphocyte antigen 6 family member E
|
multiple interactions decreases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in decreased expression of LY6E mRNA]
|
CTD |
PMID:27264040 PMID:31566189 |
|
NCBI chr 7:108,815,970...108,820,444
Ensembl chr 7:108,816,887...108,820,443
|
|
| G
|
Ly86
|
lymphocyte antigen 86
|
increases expression
|
ISO
|
Progesterone results in increased expression of LY86 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr17:27,621,313...27,705,336
Ensembl chr17:27,621,313...27,692,743
|
|
| G
|
Lypd1
|
Ly6/Plaur domain containing 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of LYPD1 mRNA Progesterone results in increased expression of LYPD1 mRNA
|
CTD |
PMID:17404688 PMID:22238285 |
|
NCBI chr13:39,874,937...39,922,385
Ensembl chr13:39,879,096...39,922,338
|
|
| G
|
Lypd2
|
Ly6/Plaur domain containing 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of LYPD2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 7:108,506,545...108,508,582
Ensembl chr 7:108,506,545...108,508,582
|
|
| G
|
Lyset
|
lysosomal enzyme trafficking factor
|
increases expression
|
ISO
|
Progesterone results in increased expression of LYSET mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 6:127,649,401...127,651,143
Ensembl chr 6:127,649,450...127,652,661
|
|
| G
|
Lyz2
|
lysozyme 2
|
multiple interactions affects expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of LYZ mRNA Progesterone affects the expression of LYZ mRNA
|
CTD |
PMID:17251523 PMID:20660070 |
|
NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011
|
|
| G
|
Lztfl1
|
leucine zipper transcription factor-like 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with TGFB1 protein] results in increased expression of LZTFL1 mRNA Progesterone results in increased expression of LZTFL1 mRNA
|
CTD |
PMID:21768398 |
|
NCBI chr 8:132,222,339...132,237,757
Ensembl chr 8:132,222,342...132,237,684
|
|
| G
|
Macc1
|
MET transcriptional regulator MACC1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MACC1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:146,495,544...146,574,254
Ensembl chr 6:146,495,861...146,574,260
|
|
| G
|
Mad2l1
|
mitotic arrest deficient 2 like 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MAD2L1 mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr 4:97,236,419...97,247,603
Ensembl chr 4:97,236,503...97,243,222
|
|
| G
|
Maf
|
MAF bZIP transcription factor
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of MAF mRNA [Estradiol co-treated with Progesterone] results in increased expression of MAF mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr19:60,259,200...60,622,145
Ensembl chr19:60,269,541...60,621,378
|
|
| G
|
Mafb
|
MAF bZIP transcription factor B
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MAFB mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:169,417,890...169,419,810
Ensembl chr 3:169,416,945...169,419,975
|
|
| G
|
Mal
|
mal, T-cell differentiation protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MAL mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:135,317,664...135,341,423
Ensembl chr 3:135,317,664...135,341,423
|
|
| G
|
Mal2
|
mal, T-cell differentiation protein 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MAL2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 7:87,790,239...87,823,219
Ensembl chr 7:87,790,239...87,850,403
|
|
| G
|
Mamdc2
|
MAM domain containing 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of MAMDC2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 1:230,290,482...230,443,014
Ensembl chr 1:230,290,499...230,442,711
|
|
| G
|
Man2b2
|
mannosidase, alpha, class 2B, member 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MAN2B2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr14:78,193,797...78,218,802
Ensembl chr14:78,193,725...78,227,724
|
|
| G
|
Manf
|
mesencephalic astrocyte-derived neurotrophic factor
|
affects expression increases expression
|
ISO
|
Progesterone affects the expression of MANF mRNA Progesterone results in increased expression of MANF mRNA
|
CTD |
PMID:17251523 PMID:18037150 |
|
NCBI chr 8:116,427,053...116,430,259
Ensembl chr 8:116,427,048...116,429,910
|
|
| G
|
Maoa
|
monoamine oxidase A
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MAOA mRNA; [Progesterone co-treated with Estradiol] results in increased expression of MAOA mRNA Progesterone results in increased expression of MAOA mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20864642 |
|
NCBI chr X:8,615,239...8,681,372
Ensembl chr X:8,615,239...8,682,631
|
|
| G
|
Maob
|
monoamine oxidase B
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MAOB mRNA; [Progesterone co-treated with Estradiol] results in increased expression of MAOB mRNA Progesterone results in increased expression of MAOB mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20864642 PMID:22238285 |
|
NCBI chr X:8,490,405...8,594,065
Ensembl chr X:8,490,344...8,594,375
|
|
| G
|
Map1b
|
microtubule-associated protein 1B
|
increases expression
|
EXP
|
Progesterone results in increased expression of MAP1B mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:32,551,423...32,644,471
Ensembl chr 2:32,551,423...32,657,094
|
|
| G
|
Map2
|
microtubule-associated protein 2
|
increases expression decreases expression
|
ISO EXP
|
Progesterone results in increased expression of MAP2 mRNA Progesterone results in increased expression of MAP2 protein Progesterone results in decreased expression of MAP2 mRNA
|
CTD |
PMID:16054770 PMID:18037150 PMID:21795739 |
|
NCBI chr 9:75,173,038...75,431,606
Ensembl chr 9:75,288,262...75,428,459
|
|
| G
|
Map2k6
|
mitogen-activated protein kinase kinase 6
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of MAP2K6 mRNA Progesterone results in increased expression of MAP2K6 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:95,872,747...95,987,747
Ensembl chr10:95,872,546...95,987,721
|
|
| G
|
Map3k4
|
mitogen activated protein kinase kinase kinase 4
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of MAP3K4 mRNA [Progesterone co-treated with Estradiol] results in increased expression of MAP3K4 mRNA
|
CTD |
PMID:18692832 PMID:20864642 |
|
NCBI chr 1:50,977,870...51,067,117
Ensembl chr 1:50,979,586...51,067,117
|
|
| G
|
Map3k7cl
|
MAP3K7 C-terminal like
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MAP3K7CL mRNA Progesterone results in decreased expression of MAP3K7CL mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr11:40,276,839...40,321,848
Ensembl chr11:40,277,688...40,321,847
|
|
| G
|
Map3k8
|
mitogen-activated protein kinase kinase kinase 8
|
increases expression
|
ISO
|
Progesterone results in increased expression of MAP3K8 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr17:58,078,175...58,098,455
Ensembl chr17:58,078,320...58,098,452
|
|
| G
|
Map4k4
|
mitogen-activated protein kinase kinase kinase kinase 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MAP4K4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:49,696,573...49,822,353
Ensembl chr 9:49,696,700...49,822,353
|
|
| G
|
Map7
|
microtubule-associated protein 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of MAP7 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:16,730,000...16,857,173
Ensembl chr 1:16,730,075...16,857,170
|
|
| G
|
Mapk1
|
mitogen activated protein kinase 1
|
multiple interactions decreases phosphorylation increases phosphorylation
|
ISO EXP
|
Mifepristone inhibits the reaction [Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]]; Mifepristone inhibits the reaction [Progesterone promotes the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]]; Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Progesterone promotes the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]] Progesterone results in decreased phosphorylation of MAPK1 protein [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased phosphorylation of MAPK1 protein; [Progesterone co-treated with Estrogens] results in increased phosphorylation of MAPK1 protein; Progesterone promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein] Progesterone results in increased phosphorylation of MAPK1 protein [Progesterone co-treated with Halothane] results in increased phosphorylation of MAPK1 protein; U 0126 inhibits the reaction [[Progesterone co-treated with Halothane] results in increased phosphorylation of MAPK1 protein]
|
CTD |
PMID:15358673 PMID:16175315 PMID:16284289 PMID:17492661 PMID:21258428 PMID:22157104 PMID:22345431 PMID:22465879 More...
|
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825
|
|
| G
|
Mapk14
|
mitogen activated protein kinase 14
|
multiple interactions
|
EXP ISO
|
Progesterone promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK14 protein] Progesterone inhibits the reaction [Ozone results in increased phosphorylation of MAPK14 protein]
|
CTD |
PMID:16284289 PMID:28279894 |
|
NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294
|
|
| G
|
Mapk3
|
mitogen activated protein kinase 3
|
multiple interactions decreases phosphorylation increases phosphorylation
|
ISO EXP
|
Mifepristone inhibits the reaction [Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]]; Mifepristone inhibits the reaction [Progesterone promotes the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]]; Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Progesterone promotes the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Progesterone promotes the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]] Progesterone results in decreased phosphorylation of MAPK3 protein [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased phosphorylation of MAPK3 protein; [Progesterone co-treated with Estrogens] results in increased phosphorylation of MAPK3 protein; Progesterone promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein] Progesterone results in increased phosphorylation of MAPK3 protein [Progesterone co-treated with Halothane] results in increased phosphorylation of MAPK3 protein; U 0126 inhibits the reaction [[Progesterone co-treated with Halothane] results in increased phosphorylation of MAPK3 protein]
|
CTD |
PMID:15358673 PMID:16175315 PMID:16284289 PMID:17492661 PMID:21258428 PMID:22157104 PMID:22345431 PMID:22465879 More...
|
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411
|
|
| G
|
Mapk8
|
mitogen-activated protein kinase 8
|
multiple interactions
|
EXP
|
Progesterone promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]
|
CTD |
PMID:16284289 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,645,198...8,728,427
|
|
| G
|
Mapk9
|
mitogen-activated protein kinase 9
|
increases expression
|
EXP
|
Progesterone results in increased expression of MAPK9 mRNA
|
CTD |
PMID:17170212 |
|
NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228
|
|
| G
|
Mapt
|
microtubule-associated protein tau
|
increases phosphorylation decreases expression
|
EXP
|
Progesterone results in increased phosphorylation of MAPT protein Progesterone results in decreased expression of MAPT protein
|
CTD |
PMID:17443805 |
|
NCBI chr10:89,638,618...89,736,108
Ensembl chr10:89,638,599...89,736,108
|
|
| G
|
Marcks
|
myristoylated alanine rich protein kinase C substrate
|
multiple interactions decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of MARCKS mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of MARCKS mRNA Progesterone results in decreased expression of MARCKS mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20726854 |
|
NCBI chr20:42,240,185...42,245,882
Ensembl chr20:42,240,185...42,245,882
|
|
| G
|
Marcksl1
|
MARCKS-like 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MARCKSL1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 5:147,135,827...147,138,150
Ensembl chr 5:147,134,514...147,138,417
|
|
| G
|
Mars1
|
methionyl-tRNA synthetase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of MARS1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 7:65,006,456...65,023,880
Ensembl chr 7:64,998,544...65,023,753
|
|
| G
|
Mat2a
|
methionine adenosyltransferase 2A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MAT2A mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 4:106,048,043...106,053,612
Ensembl chr 4:106,038,254...106,053,645
|
|
| G
|
Matcap2
|
microtubule associated tyrosine carboxypeptidase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of MATCAP2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 8:29,197,154...29,247,056
Ensembl chr 8:29,196,927...29,247,058
|
|
| G
|
Matk
|
megakaryocyte-associated tyrosine kinase
|
increases expression
|
ISO
|
Progesterone results in increased expression of MATK mRNA; Progesterone results in increased expression of MATK protein
|
CTD |
PMID:17492661 |
|
NCBI chr 7:9,107,711...9,116,864
Ensembl chr 7:9,107,722...9,112,746
|
|
| G
|
Matn2
|
matrilin 2
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MATN2 mRNA Progesterone results in increased expression of MATN2 mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr 7:67,380,140...67,529,767
Ensembl chr 7:67,380,168...67,530,153
|
|
| G
|
Matn4
|
matrilin 4
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MATN4 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 3:173,539,966...173,554,984
Ensembl chr 3:173,539,966...173,554,984
|
|
| G
|
Mboat1
|
membrane bound O-acyltransferase domain containing 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MBOAT1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:34,540,032...34,653,705
Ensembl chr17:34,540,041...34,653,698
|
|
| G
|
Mbp
|
myelin basic protein
|
multiple interactions
|
ISO EXP
|
[Progesterone co-treated with Estradiol] inhibits the reaction [Cuprizone results in decreased expression of MBP mRNA] Progesterone inhibits the reaction [Streptozocin results in decreased expression of MBP mRNA]
|
CTD |
PMID:19031445 PMID:20349157 |
|
NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174
|
|
| G
|
Mc2r
|
melanocortin 2 receptor
|
multiple interactions increases secretion
|
EXP
|
MC2R protein promotes the reaction [PRL protein results in increased secretion of Progesterone]; PRL protein promotes the reaction [MC2R protein results in increased secretion of Progesterone]
|
CTD |
PMID:18609294 |
|
NCBI chr18:64,279,878...64,291,775
Ensembl chr18:64,277,360...64,291,881
|
|
| G
|
Mc4r
|
melanocortin 4 receptor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MC4R mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr18:62,689,798...62,691,685
|
|
| G
|
Mcm2
|
minichromosome maintenance complex component 2
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] affects the localization of MCM2 protein; [Progesterone co-treated with Estradiol] results in decreased expression of MCM2 protein Progesterone results in decreased expression of MCM2 mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr 4:122,903,679...122,918,205
Ensembl chr 4:122,903,682...122,918,094
|
|
| G
|
Mcm3
|
minichromosome maintenance complex component 3
|
multiple interactions affects localization decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MCM3 protein; Estradiol promotes the reaction [Progesterone affects the localization of MCM3 protein] Progesterone results in decreased expression of MCM3 mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746
|
|
| G
|
Mcm4
|
minichromosome maintenance complex component 4
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MCM4 protein Progesterone results in decreased expression of MCM4 mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr11:98,762,599...98,776,300
Ensembl chr11:98,762,634...98,776,536
|
|
| G
|
Mcm5
|
minichromosome maintenance complex component 5
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of MCM5 mRNA Progesterone results in decreased expression of MCM5 mRNA
|
CTD |
PMID:16966611 PMID:17251523 PMID:21795739 |
|
NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758
|
|
| G
|
Mcm6
|
minichromosome maintenance complex component 6
|
multiple interactions affects localization decreases expression
|
ISO EXP
|
Estradiol inhibits the reaction [Progesterone affects the localization of MCM6 protein] Progesterone results in decreased expression of MCM6 mRNA
|
CTD |
PMID:16966611 PMID:20726854 |
|
NCBI chr13:42,379,161...42,404,352
Ensembl chr13:42,379,162...42,465,467
|
|
| G
|
Mcm7
|
minichromosome maintenance complex component 7
|
multiple interactions affects localization
|
ISO
|
Estradiol inhibits the reaction [Progesterone affects the localization of MCM7 protein]
|
CTD |
PMID:16966611 |
|
NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771
|
|
| G
|
Mcub
|
mitochondrial calcium uniporter dominant negative subunit beta
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MCUB mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:221,153,525...221,223,814
Ensembl chr 2:221,153,525...221,223,814
|
|
| G
|
Mdm1
|
Mdm1 nuclear protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of MDM1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 7:55,615,459...55,651,889
Ensembl chr 7:55,615,608...55,651,888
|
|
| G
|
Mdn1
|
midasin AAA ATPase 1
|
affects expression
|
ISO
|
Progesterone affects the expression of MDN1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:51,851,785...51,982,688
Ensembl chr 5:51,851,809...51,982,688
|
|
| G
|
Meak7
|
MTOR associated protein, eak-7 homolog
|
increases expression
|
ISO
|
Progesterone results in increased expression of MEAK7 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr19:64,722,528...64,745,443
Ensembl chr19:64,722,528...64,751,330
|
|
| G
|
Med27
|
mediator complex subunit 27
|
affects expression
|
ISO
|
Progesterone affects the expression of MED27 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:33,027,240...33,201,240
Ensembl chr 3:33,027,525...33,201,240
|
|
| G
|
Medag
|
mesenteric estrogen-dependent adipogenesis
|
increases expression
|
ISO
|
Progesterone results in increased expression of MEDAG mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr12:10,649,526...10,670,913
Ensembl chr12:10,649,526...10,692,756
|
|
| G
|
Megf10
|
multiple EGF-like domains 10
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MEGF10 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr18:52,803,292...52,953,431
Ensembl chr18:52,847,781...52,950,675
|
|
| G
|
Meig1
|
meiosis/spermiogenesis associated 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of MEIG1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:79,718,630...79,737,604
Ensembl chr17:79,723,811...79,737,533
|
|
| G
|
Meltf
|
melanotransferrin
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MELTF mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr11:82,389,420...82,411,270
Ensembl chr11:82,389,420...82,411,270
|
|
| G
|
Metap2
|
methionyl aminopeptidase 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of METAP2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 7:30,299,433...30,327,477
Ensembl chr 7:30,299,433...30,327,521
|
|
| G
|
Mex3a
|
mex-3 RNA binding family member A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MEX3A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:176,287,900...176,297,369
Ensembl chr 2:176,287,900...176,297,369
|
|
| G
|
Mfap2
|
microfibril associated protein 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MFAP2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 5:158,595,121...158,603,283
Ensembl chr 5:158,597,512...158,610,656
|
|
| G
|
Mfap4
|
microfibril associated protein 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of MFAP4 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr10:46,666,552...46,669,613
Ensembl chr10:46,655,722...46,669,740
|
|
| G
|
Mfap5
|
microfibril associated protein 5
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MFAP5 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 4:157,399,919...157,422,448
Ensembl chr 4:157,395,597...157,422,448
|
|
| G
|
Mfng
|
MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase
|
increases expression
|
ISO
|
Progesterone results in increased expression of MFNG mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 7:112,191,288...112,209,129
Ensembl chr 7:112,161,071...112,209,129
|
|
| G
|
Mgat3
|
beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MGAT3 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 7:113,614,011...113,640,201
Ensembl chr 7:113,598,059...113,643,481
|
|
| G
|
Mgp
|
matrix Gla protein
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of MGP mRNA Progesterone results in increased expression of MGP mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr 4:171,497,472...171,500,888
Ensembl chr 4:171,497,471...171,500,859
|
|
| G
|
Mgst1
|
microsomal glutathione S-transferase 1
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of MGST1 mRNA Progesterone results in increased expression of MGST1 mRNA
|
CTD |
PMID:20660070 PMID:20726854 |
|
NCBI chr 4:172,760,930...172,776,157
Ensembl chr 4:172,760,886...172,776,875
|
|
| G
|
Mia
|
MIA SH3 domain containing
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIA mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:91,601,326...91,603,019
Ensembl chr 1:91,601,327...91,603,019
|
|
| G
|
Mical2
|
microtubule associated monooxygenase, calponin and LIM domain containing 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MICAL2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:175,780,441...175,965,157
Ensembl chr 1:175,825,596...175,905,155
|
|
| G
|
Mid1
|
midline 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MID1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr X:27,678,248...28,053,049
Ensembl chr X:27,681,867...27,906,105
|
|
| G
|
Mir100
|
microRNA 100
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of MIR100 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of MIR100 mRNA
|
CTD |
PMID:22950660 PMID:30328349 |
|
NCBI chr 8:50,798,295...50,798,374
Ensembl chr 8:50,798,295...50,798,374
|
|
| G
|
Mir106b
|
microRNA 106b
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR106B mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr12:22,157,053...22,157,134
|
|
| G
|
Mir10a
|
microRNA 10a
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MIR10A mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr10:81,779,709...81,779,818
Ensembl chr10:81,779,709...81,779,818
|
|
| G
|
Mir122
|
microRNA 122
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR122 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr18:61,028,817...61,028,901
|
|
| G
|
Mir128-2
|
microRNA 128-2
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR128-2 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 8:120,963,795...120,963,878
|
|
| G
|
Mir134
|
microRNA 134
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MIR134 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 6:134,570,313...134,570,385
|
|
| G
|
Mir135b
|
microRNA 135b
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MIR135B mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr13:46,191,018...46,191,114
Ensembl chr13:46,191,018...46,191,114
|
|
| G
|
Mir142
|
microRNA 142
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR142 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr10:73,055,104...73,055,190
Ensembl chr10:73,055,097...73,055,207
|
|
| G
|
Mir144
|
microRNA 144
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of MIR144 mRNA [Progesterone co-treated with Estradiol] results in increased expression of MIR144 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr10:63,459,397...63,459,479
Ensembl chr10:63,459,397...63,459,479
|
|
| G
|
Mir145
|
microRNA 145
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MIR145 mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr18:57,369,983...57,370,070
|
|
| G
|
Mir146a
|
microRNA 146a
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of MIR146A mRNA Progesterone promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MIR146 mRNA]
|
CTD |
PMID:22546503 PMID:22950660 |
|
NCBI chr10:28,349,996...28,350,090
|
|
| G
|
Mir146b
|
microRNA 146b
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR146B mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 1:255,144,860...255,144,947
Ensembl chr 1:255,144,860...255,144,947
|
|
| G
|
Mir148a
|
microRNA 148a
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of MIR148A mRNA [Estradiol co-treated with Progesterone] results in decreased expression of MIR148A mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr 4:81,664,431...81,664,527
|
|
| G
|
Mir148b
|
microRNA 148b
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR148B mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr 7:136,299,870...136,299,966
Ensembl chr 7:136,299,870...136,299,966
|
|
| G
|
Mir151
|
microRNA 151
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR151A mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr 7:107,061,380...107,061,476
|
|
| G
|
Mir151b
|
microRNA 151b
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR151B mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr 7:107,061,380...107,061,499
Ensembl chr 7:107,061,380...107,061,499
|
|
| G
|
Mir155
|
microRNA 155
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of MIR155 mRNA Progesterone results in increased expression of MIR155 mRNA MIR155 mRNA inhibits the reaction [Progesterone inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL6 protein]]; MIR155 mRNA inhibits the reaction [Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA]]; Progesterone inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of MIR155 mRNA]; Progesterone inhibits the reaction [Poly I-C results in increased expression of MIR155 mRNA]
|
CTD |
PMID:22546503 PMID:22950660 |
|
NCBI chr11:37,261,114...37,261,178
Ensembl chr11:37,261,114...37,261,178
|
|
| G
|
Mir155hg
|
Mir155 host gene
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of BIC mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:37,259,928...37,262,157
|
|
| G
|
Mir15b
|
microRNA 15b
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of MIR15B mRNA Progesterone results in increased expression of MIR15B mRNA
|
CTD |
PMID:22950660 PMID:30328349 |
|
NCBI chr 2:155,555,178...155,555,275
Ensembl chr 2:155,555,178...155,555,275
|
|
| G
|
Mir181c
|
microRNA 181c
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR181C mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr19:40,888,291...40,888,396
Ensembl chr19:40,888,291...40,888,396
|
|
| G
|
Mir181d
|
microRNA 181d
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of MIR181D mRNA [Estradiol co-treated with Progesterone] results in decreased expression of MIR181D mRNA
|
CTD |
PMID:22950660 PMID:30328349 |
|
NCBI chr19:40,888,474...40,888,556
Ensembl chr19:40,888,474...40,888,556
|
|
| G
|
Mir186
|
microRNA 186
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of MIR186 mRNA Progesterone results in decreased expression of MIR186 mRNA
|
CTD |
PMID:22950660 PMID:30328349 |
|
NCBI chr 2:249,241,650...249,241,735
Ensembl chr 2:249,241,650...249,241,735
|
|
| G
|
Mir191
|
microRNA 191
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR191 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 8:118,142,627...118,142,717
|
|
| G
|
Mir195
|
microRNA 195
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR195 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr10:55,450,495...55,450,581
Ensembl chr10:55,450,495...55,450,581
|
|
| G
|
Mir196b
|
microRNA 196b
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MIR196B mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 4:82,661,101...82,661,185
|
|
| G
|
Mir202
|
microRNA 202
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR202 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 1:204,184,345...204,184,416
|
|
| G
|
Mir204
|
microRNA 204
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR204 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 1:229,743,461...229,743,570
Ensembl chr 1:229,743,461...229,743,570
|
|
| G
|
Mir206
|
microRNA 206
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR206 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 9:30,590,697...30,590,780
Ensembl chr 9:30,590,697...30,590,780
|
|
| G
|
Mir20b
|
microRNA 20b
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR20B mRNA
|
CTD |
PMID:22950660 PMID:30328349 |
|
NCBI chr X:137,343,197...137,343,268
|
|
| G
|
Mir21
|
microRNA 21
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR21 mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr10:71,902,600...71,902,691
|
|
| G
|
Mir22
|
microRNA 22
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR22 mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr10:60,805,331...60,805,425
Ensembl chr10:60,805,331...60,805,425
|
|
| G
|
Mir221
|
microRNA 221
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR221 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr X:6,023,182...6,023,290
Ensembl chr X:6,023,182...6,023,290
|
|
| G
|
Mir23a
|
microRNA 23a
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR23A mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr19:40,859,769...40,859,843
|
|
| G
|
Mir23b
|
microRNA 23b
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR23B mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr17:1,819,386...1,819,482
|
|
| G
|
Mir25
|
microRNA 25
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR25 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr12:22,156,641...22,156,724
|
|
| G
|
Mir26b
|
microRNA 26b
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of MIR26B mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 9:83,425,709...83,425,793
Ensembl chr 9:83,425,709...83,425,793
|
|
| G
|
Mir27a
|
microRNA 27a
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MIR27A mRNA Progesterone results in decreased expression of MIR27A mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr19:40,859,603...40,859,689
|
|
| G
|
Mir27b
|
microRNA 27b
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR27B mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr17:1,819,147...1,819,243
|
|
| G
|
Mir296
|
microRNA 296
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR296 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 3:183,470,069...183,470,146
|
|
| G
|
Mir299a
|
microRNA 299B
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR299 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 6:134,545,040...134,545,157
|
|
| G
|
Mir29a
|
microRNA 29a
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR29A mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr 4:60,617,955...60,618,042
|
|
| G
|
Mir30d
|
microRNA 30d
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR30D mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 7:102,025,345...102,025,426
|
|
| G
|
Mir30e
|
microRNA 30e
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR30E mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 5:139,637,450...139,637,541
Ensembl chr 5:139,637,450...139,637,541
|
|
| G
|
Mir320a
|
microRNA 320a
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR320A mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr15:51,926,088...51,926,169
Ensembl chr15:51,926,088...51,926,169
|
|
| G
|
Mir322
|
microRNA 322
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MIR424 mRNA Progesterone results in decreased expression of MIR424 mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr X:137,726,147...137,726,241
|
|
| G
|
Mir328
|
microRNA 328
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR328 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr19:50,094,691...50,094,774
|
|
| G
|
Mir337
|
microRNA 337
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR337 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 6:134,321,142...134,321,238
Ensembl chr 6:134,321,141...134,321,237
|
|
| G
|
Mir345
|
microRNA 345
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR345 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 6:133,518,403...133,518,498
Ensembl chr 6:133,518,403...133,518,498
|
|
| G
|
Mir346
|
microRNA 346
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of MIR346 mRNA Progesterone results in increased expression of MIR346 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr16:10,224,300...10,224,397
Ensembl chr16:10,224,300...10,224,397
|
|
| G
|
Mir34b
|
microRNA 34b
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MIR34B mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 8:60,306,609...60,306,692
|
|
| G
|
Mir361
|
microRNA 361
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR361 mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr X:82,438,463...82,438,532
|
|
| G
|
Mir363
|
microRNA 363
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR363 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr X:137,342,777...137,342,863
|
|
| G
|
Mir411
|
microRNA 411
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of MIR411 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of MIR411 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 6:134,544,594...134,544,669
Ensembl chr 6:134,544,589...134,544,684
|
|
| G
|
Mir412
|
microRNA 412
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR412 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 6:134,579,337...134,579,406
Ensembl chr 6:134,579,331...134,579,410
|
|
| G
|
Mir423
|
microRNA 423
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MIR423 mRNA Progesterone results in increased expression of MIR423 mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr10:62,412,272...62,412,350
|
|
| G
|
Mir425
|
microRNA 425
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of MIR425 mRNA Progesterone results in decreased expression of MIR425 mRNA
|
CTD |
PMID:22950660 PMID:30328349 |
|
NCBI chr 8:118,143,084...118,143,166
Ensembl chr 8:118,143,084...118,143,166
|
|
| G
|
Mir448
|
microRNA 448
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR448 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr X:115,641,955...115,642,066
Ensembl chr X:115,641,955...115,642,066
|
|
| G
|
Mir449a
|
microRNA 449a
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MIR449A mRNA Progesterone results in decreased expression of MIR449A mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 2:46,403,910...46,404,000
Ensembl chr 2:46,403,910...46,404,000
|
|
| G
|
Mir455
|
microRNA 455
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MIR455 mRNA Progesterone results in decreased expression of MIR455 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 5:81,704,834...81,704,911
Ensembl chr 5:81,704,834...81,704,911
|
|
| G
|
Mir486
|
microRNA 486
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR486-1 mRNA
|
CTD |
PMID:22950660 |
|
|
|
| G
|
Mir500
|
microRNA 500
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MIR502 mRNA Progesterone results in increased expression of MIR502 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr X:17,930,647...17,930,726
Ensembl chr X:17,930,637...17,930,728
|
|
| G
|
Mir503
|
microRNA 503
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of MIR503 mRNA Progesterone results in increased expression of MIR503 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr X:137,725,856...137,725,926
|
|
| G
|
Mir504
|
microRNA 504
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR504 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr X:142,354,419...142,354,495
|
|
| G
|
Mir542
|
microRNA 542
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MIR542 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr X:137,722,176...137,722,254
|
|
| G
|
Mir592
|
microRNA 592
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR592 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 4:57,470,748...57,470,843
|
|
| G
|
Mir632
|
microRNA 632
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR632 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr10:65,883,580...65,883,657
Ensembl chr10:65,883,580...65,883,657
|
|
| G
|
Mir671
|
microRNA 671
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR671 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 4:11,473,194...11,473,274
|
|
| G
|
Mir675
|
microRNA 675
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MIR675 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 1:207,161,752...207,161,835
|
|
| G
|
Mir876
|
microRNA 876
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of MIR876 mRNA [Progesterone co-treated with Estradiol] results in increased expression of MIR876 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 5:56,133,376...56,133,454
|
|
| G
|
Mir92b
|
microRNA 92b
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIR92B mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr 2:176,931,653...176,931,735
|
|
| G
|
Mir93
|
microRNA 93
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR93 mRNA
|
CTD |
PMID:22950660 |
|
NCBI chr12:22,156,844...22,156,930
|
|
| G
|
Mir99a
|
microRNA 99a
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MIR99A mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of MIR99A mRNA Progesterone results in decreased expression of MIR99A mRNA
|
CTD |
PMID:22950660 PMID:30328349 |
|
NCBI chr11:29,687,392...29,687,472
Ensembl chr11:29,687,392...29,687,472
|
|
| G
|
Mir99b
|
microRNA 99b
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MIR99B mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr 1:67,350,064...67,350,133
Ensembl chr 1:67,350,060...67,350,139
|
|
| G
|
Mirlet7b
|
microRNA let-7b
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIRLET7B mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr 7:118,684,038...118,684,122
Ensembl chr 7:118,684,038...118,684,122
|
|
| G
|
Mirlet7c-1
|
microRNA let-7c
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIRLET7C mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr11:29,688,112...29,688,205
Ensembl chr11:29,688,107...29,688,214
|
|
| G
|
Mirlet7d
|
microRNA let-7d
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIRLET7D mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr17:16,322,260...16,322,357
Ensembl chr17:16,322,260...16,322,357
|
|
| G
|
Mirlet7i
|
microRNA let-7i
|
increases expression
|
ISO
|
Progesterone results in increased expression of MIRLET7I mRNA
|
CTD |
PMID:30328349 |
|
NCBI chr 7:60,527,877...60,527,961
|
|
| G
|
Mitf
|
melanocyte inducing transcription factor
|
increases expression
|
ISO
|
Progesterone results in increased expression of MITF mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790
|
|
| G
|
Mki67
|
marker of proliferation Ki-67
|
increases expression multiple interactions decreases expression affects expression
|
ISO EXP
|
Progesterone results in increased expression of MKI67 mRNA Lithium Chloride inhibits the reaction [Progesterone inhibits the reaction [Estradiol results in increased expression of MKI67 protein]]; Progesterone inhibits the reaction [Estradiol results in increased expression of MKI67 protein] Progesterone results in decreased expression of MKI67 mRNA Progesterone affects the expression of MKI67 mRNA; Progesterone affects the expression of MKI67 protein [Estrogens co-treated with Progesterone] results in increased expression of MKI67 protein Copper promotes the reaction [[Progesterone co-treated with Estrogens] results in decreased expression of MKI67 protein]; Lead inhibits the reaction [[Progesterone co-treated with Estrogens] results in decreased expression of MKI67 protein]
|
CTD |
PMID:15845746 PMID:16800253 PMID:16888808 PMID:16966611 PMID:17251523 PMID:22238285 PMID:32004626 More...
|
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593
|
|
| G
|
Mknk2
|
MAPK interacting serine/threonine kinase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of MKNK2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 7:9,690,385...9,701,527
Ensembl chr 7:9,690,421...9,701,529
|
|
| G
|
Mllt11
|
MLLT11, transcription factor 7 cofactor
|
increases expression
|
ISO
|
Progesterone results in increased expression of MLLT11 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 2:185,484,791...185,493,961
Ensembl chr 2:185,484,793...185,493,961
|
|
| G
|
Mlph
|
melanophilin
|
increases expression
|
ISO
|
Progesterone results in increased expression of MLPH mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 9:98,955,036...98,990,566
Ensembl chr 9:98,955,141...98,990,556
|
|
| G
|
Mmd
|
monocyte to macrophage differentiation-associated
|
increases expression
|
ISO
|
Progesterone results in increased expression of MMD mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr10:75,570,366...75,598,610
Ensembl chr10:75,570,397...75,598,609
|
|
| G
|
Mme
|
membrane metallo-endopeptidase
|
decreases expression affects expression increases expression
|
ISO
|
Progesterone results in decreased expression of MME mRNA Progesterone affects the expression of MME mRNA Progesterone results in increased expression of MME mRNA
|
CTD |
PMID:17251523 PMID:18070364 PMID:21795739 |
|
NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:149,872,291...149,953,463
|
|
| G
|
Mmp1
|
matrix metallopeptidase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MMP1 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of MMP1 mRNA; Progesterone inhibits the reaction [IL1B protein results in increased expression of MMP1 protein modified form]
|
CTD |
PMID:17404688 PMID:20660070 PMID:22219637 |
|
NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964
|
|
| G
|
Mmp10
|
matrix metallopeptidase 10
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MMP10 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of MMP10 mRNA Progesterone results in increased expression of MMP10 mRNA
|
CTD |
PMID:20226447 PMID:20660070 |
|
NCBI chr 8:12,974,707...12,982,613
Ensembl chr 8:12,974,707...12,982,613
|
|
| G
|
Mmp11
|
matrix metallopeptidase 11
|
multiple interactions affects expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MMP11 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of MMP11 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of MMP11 mRNA; Progesterone inhibits the reaction [Estradiol results in increased expression of MMP11 mRNA] Progesterone affects the expression of MMP11 mRNA Progesterone results in decreased expression of MMP11 mRNA
|
CTD |
PMID:17251523 PMID:17404688 PMID:20226447 PMID:20660070 PMID:20864642 PMID:21795739 More...
|
|
NCBI chr20:12,730,284...12,739,067
Ensembl chr20:12,730,277...12,739,290
|
|
| G
|
Mmp12
|
matrix metallopeptidase 12
|
affects expression
|
ISO
|
Progesterone affects the expression of MMP12 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 8:12,866,652...12,876,554
Ensembl chr 8:12,866,641...12,884,478
|
|
| G
|
Mmp13
|
matrix metallopeptidase 13
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of MMP13 mRNA]
|
CTD |
PMID:19416213 |
|
NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105
|
|
| G
|
Mmp14
|
matrix metallopeptidase 14
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MMP14 protein; [Estrogens co-treated with Progesterone co-treated with IL1B protein] results in increased expression of MMP14 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of MMP14 mRNA; Estradiol inhibits the reaction [Progesterone results in increased expression of MMP14 mRNA]
|
CTD |
PMID:17404688 PMID:18570937 PMID:18692832 PMID:18829229 PMID:26604029 |
|
NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893
|
|
| G
|
Mmp16
|
matrix metallopeptidase 16
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MMP16 mRNA Progesterone results in decreased expression of MMP16 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr 5:36,109,265...36,353,252
Ensembl chr 5:36,109,265...36,353,252
|
|
| G
|
Mmp2
|
matrix metallopeptidase 2
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of MMP2 mRNA [Estradiol co-treated with Progesterone] results in increased expression of and results in increased activity of MMP2 protein; Progesterone inhibits the reaction [IL1B protein results in increased expression of MMP2 protein modified form]
|
CTD |
PMID:18070364 PMID:18829229 PMID:22219637 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856
|
|
| G
|
Mmp27
|
matrix metallopeptidase 27
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MMP27 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of MMP27 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 8:13,030,752...13,040,671
Ensembl chr 8:13,030,746...13,040,671
|
|
| G
|
Mmp3
|
matrix metallopeptidase 3
|
multiple interactions decreases secretion decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased secretion of MMP3 protein; [Estrogens co-treated with Progesterone co-treated with IL1B protein] results in increased expression of MMP3 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of MMP3 mRNA; Progesterone inhibits the reaction [IL1B protein results in increased expression of MMP3 protein modified form]; Tetrachlorodibenzodioxin inhibits the reaction [Progesterone results in decreased secretion of MMP3 protein]; Triclosan inhibits the reaction [Progesterone results in decreased expression of MMP3 mRNA] Mifepristone inhibits the reaction [Progesterone results in decreased expression of MMP3 mRNA]; Progesterone inhibits the reaction [Estradiol results in increased expression of MMP3 mRNA]
|
CTD |
PMID:16009159 PMID:17404688 PMID:18570937 PMID:19416213 PMID:22219637 PMID:26604029 PMID:27264040 More...
|
|
NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826
|
|
| G
|
Mmp7
|
matrix metallopeptidase 7
|
multiple interactions decreases secretion affects expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MMP7 mRNA; [Estradiol co-treated with Progesterone] results in decreased secretion of MMP7 protein; Tetrachlorodibenzodioxin inhibits the reaction [Progesterone results in decreased secretion of MMP7 protein] Progesterone affects the expression of MMP7 mRNA Progesterone results in decreased expression of MMP7 mRNA
|
CTD |
PMID:16009159 PMID:17251523 PMID:20660070 PMID:22238285 |
|
NCBI chr 8:13,133,043...13,140,761
Ensembl chr 8:13,133,043...13,140,755
|
|
| G
|
Mmp8
|
matrix metallopeptidase 8
|
increases expression
|
EXP
|
Progesterone results in increased expression of MMP8 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 8:13,008,873...13,018,729
Ensembl chr 8:13,008,890...13,018,729
|
|
| G
|
Mmp9
|
matrix metallopeptidase 9
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of MMP9 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of MMP9 mRNA; [Progesterone co-treated with Triclosan] results in increased expression of MMP9 mRNA; Progesterone inhibits the reaction [IL1B protein results in increased expression of MMP9 protein modified form] Progesterone inhibits the reaction [Estradiol results in increased expression of MMP9 mRNA] Progesterone results in increased expression of MMP9 mRNA
|
CTD |
PMID:17404688 PMID:19416213 PMID:20226447 PMID:21770760 PMID:22219637 PMID:26604029 More...
|
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442
|
|
| G
|
Mmrn1
|
multimerin 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of MMRN1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 4:91,205,462...91,280,862
Ensembl chr 4:91,233,240...91,280,861
|
|
| G
|
Mob3b
|
MOB kinase activator 3B
|
increases expression
|
ISO
|
Progesterone results in increased expression of MOB3B mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 5:54,342,509...54,534,164
Ensembl chr 5:54,338,056...54,454,678
|
|
| G
|
Mogat1
|
monoacylglycerol O-acyltransferase 1
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MOGAT1 mRNA Progesterone results in decreased expression of MOGAT1 mRNA
|
CTD |
PMID:19693291 PMID:22238285 |
|
NCBI chr 9:87,429,427...87,436,977
Ensembl chr 9:87,405,119...87,436,977
|
|
| G
|
Mogat2
|
monoacylglycerol O-acyltransferase 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MOGAT2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:162,933,964...162,957,896
Ensembl chr 1:162,933,966...162,957,896
|
|
| G
|
Mok
|
MOK protein kinase
|
increases expression
|
ISO
|
Progesterone results in increased expression of MOK mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:135,645,018...135,675,894
Ensembl chr 6:135,645,018...135,676,174
|
|
| G
|
Mon2
|
MON2 homolog, regulator of endosome-to-Golgi trafficking
|
increases expression
|
ISO
|
Progesterone results in increased expression of MON2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 7:60,534,772...60,613,467
Ensembl chr 7:60,534,772...60,613,467
|
|
| G
|
Mpc1
|
mitochondrial pyruvate carrier 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of MPC1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:54,985,305...54,996,979
Ensembl chr 1:54,985,301...54,997,064
|
|
| G
|
Mpo
|
myeloperoxidase
|
multiple interactions
|
ISO
|
MPO gene polymorphism affects the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of ICAM1 protein]
|
CTD |
PMID:21242819 |
|
NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056
|
|
| G
|
Mpp1
|
MAGUK p55 scaffold protein 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MPP1 mRNA
|
CTD |
PMID:20660070 |
|
|
|
| G
|
Mpz
|
myelin protein zero
|
increases expression multiple interactions
|
EXP
|
Progesterone results in increased expression of MPZ mRNA Progesterone inhibits the reaction [Streptozocin results in decreased expression of MPZ mRNA]
|
CTD |
PMID:16787508 PMID:17187935 |
|
NCBI chr13:86,103,290...86,109,156
Ensembl chr13:86,103,290...86,109,155
|
|
| G
|
Mpzl2
|
myelin protein zero-like 2
|
increases expression multiple interactions decreases expression
|
ISO
|
Progesterone results in increased expression of MPZL2 mRNA NCOA2 protein affects the reaction [Progesterone results in decreased expression of MPZL2 mRNA]
|
CTD |
PMID:17404688 PMID:17556502 PMID:21540246 |
|
NCBI chr 8:54,244,920...54,256,064
Ensembl chr 8:54,243,556...54,256,074
|
|
| G
|
Mrap
|
melanocortin 2 receptor accessory protein
|
affects expression
|
ISO
|
Progesterone affects the expression of MRAP mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr11:43,477,382...43,489,118
Ensembl chr11:43,478,001...43,489,118
|
|
| G
|
Mras
|
muscle RAS oncogene homolog
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MRAS mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:108,823,374...108,886,104
Ensembl chr 8:108,823,374...108,875,911
|
|
| G
|
Mrc1
|
mannose receptor, C type 1
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [IL4 protein results in increased expression of MRC1 mRNA]
|
CTD |
PMID:21977998 |
|
NCBI chr17:82,157,725...82,239,411
Ensembl chr17:82,157,705...82,239,410
|
|
| G
|
Mrpl27
|
mitochondrial ribosomal protein L27
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of MRPL27 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of MRPL27 mRNA
|
CTD |
PMID:18037150 PMID:21453500 |
|
NCBI chr10:80,092,327...80,098,105
Ensembl chr10:80,092,324...80,098,085
|
|
| G
|
Mrpl30
|
mitochondrial ribosomal protein L30
|
affects expression
|
ISO
|
Progesterone affects the expression of MRPL30 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 9:47,621,226...47,631,986
Ensembl chr 9:47,621,227...47,633,484
|
|
| G
|
Mrpl49
|
mitochondrial ribosomal protein L49
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MRPL49 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 1:212,775,357...212,779,364
Ensembl chr 1:212,775,357...212,779,888
|
|
| G
|
Mrps28
|
mitochondrial ribosomal protein S28
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MRPS28 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:94,728,034...94,858,641
Ensembl chr 2:94,762,904...94,766,152
|
|
| G
|
Mrps6
|
mitochondrial ribosomal protein S6
|
increases expression
|
ISO
|
Progesterone results in increased expression of MRPS6 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr11:44,778,667...44,834,420
Ensembl chr11:44,781,554...44,834,962
|
|
| G
|
Mrto4
|
MRT4 homolog, ribosome maturation factor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MRTO4 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:156,884,985...156,891,738
Ensembl chr 5:156,884,985...156,891,738
|
|
| G
|
Msln
|
mesothelin
|
increases expression
|
ISO
|
Progesterone results in increased expression of MSLN mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:15,276,489...15,285,921
Ensembl chr10:15,275,659...15,282,153
|
|
| G
|
Msmo1
|
methylsterol monooxygenase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of MSMO1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr16:29,747,113...29,764,360
Ensembl chr16:29,747,137...29,764,445
|
|
| G
|
Mstn
|
myostatin
|
multiple interactions decreases expression
|
EXP
|
estradiol 3-benzoate promotes the reaction [Progesterone results in decreased expression of MSTN mRNA]
|
CTD |
PMID:18845635 |
|
NCBI chr 9:55,944,513...55,950,913
Ensembl chr 9:55,944,513...55,950,913
|
|
| G
|
Msx2
|
msh homeobox 2
|
multiple interactions increases expression decreases expression
|
ISO
|
[Estrogens co-treated with Progesterone] results in increased expression of MSX2 mRNA Progesterone results in increased expression of MSX2 mRNA Progesterone results in decreased expression of MSX2 mRNA
|
CTD |
PMID:17546050 PMID:22238285 |
|
NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,102,247...11,107,945
|
|
| G
|
Mt-atp8
|
mitochondrially encoded ATP synthase membrane subunit 8
|
increases expression
|
EXP
|
Progesterone results in increased expression of ATP8 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr MT:7,758...7,961
Ensembl chr MT:7,743...7,946
|
|
| G
|
Mt1-ps3
|
metallothionein 1, pseudogene 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of MT1E mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr17:79,695,812...79,696,200
Ensembl chr17:79,695,809...79,696,200
|
|
| G
|
Mt1a
|
metallothionein 1A
|
increases expression affects expression
|
EXP ISO
|
Progesterone results in increased expression of MT1A mRNA Progesterone affects the expression of MT1 mRNA
|
CTD |
PMID:17251523 PMID:18037150 PMID:20726854 |
|
NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200 Ensembl chr X:79,695,809...79,696,200 Ensembl chr19:79,695,809...79,696,200
|
|
| G
|
Mt2
|
metallothionein 2
|
increases expression affects expression
|
ISO
|
Progesterone results in increased expression of MT2A mRNA Progesterone affects the expression of MT2 mRNA Progesterone results in increased expression of MT2 mRNA
|
CTD |
PMID:17251523 PMID:18037150 PMID:21795739 PMID:22238285 |
|
NCBI chr19:10,837,934...10,838,708
Ensembl chr19:10,837,927...10,838,709
|
|
| G
|
Mta1
|
metastasis associated 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of MTA1 mRNA
|
CTD |
PMID:16888808 |
|
NCBI chr 6:137,999,845...138,038,696
Ensembl chr 6:137,999,915...138,038,696
|
|
| G
|
Mtarc1
|
mitochondrial amidoxime reducing component 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MTARC1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr13:98,854,235...98,894,208
Ensembl chr13:98,871,289...98,894,252
|
|
| G
|
Mtf2
|
metal response element binding transcription factor 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of MTF2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr14:1,784,218...1,828,463
Ensembl chr14:1,783,627...1,828,414
|
|
| G
|
Mthfd2
|
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase
|
increases expression affects expression
|
ISO
|
Progesterone results in increased expression of MTHFD2 mRNA Progesterone affects the expression of MTHFD2 mRNA
|
CTD |
PMID:17251523 PMID:18037150 |
|
NCBI chr 4:117,368,833...117,380,350
Ensembl chr 4:117,368,835...117,380,350
|
|
| G
|
Mtor
|
mechanistic target of rapamycin kinase
|
decreases expression multiple interactions
|
ISO EXP
|
Progesterone results in decreased expression of MTOR mRNA [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased phosphorylation of MTOR protein
|
CTD |
PMID:22465879 PMID:23541542 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435
|
|
| G
|
Mtr
|
5-methyltetrahydrofolate-homocysteine methyltransferase
|
increases expression
|
ISO
|
Progesterone results in increased expression of MTR mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr17:62,911,705...62,996,544
Ensembl chr17:62,911,771...62,996,541
|
|
| G
|
Mtus1
|
microtubule associated scaffold protein 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of MTUS1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr16:57,905,991...58,051,466
Ensembl chr16:57,906,128...58,051,474
|
|
| G
|
Mtx1
|
Metaxin 1
|
affects expression
|
ISO
|
Progesterone affects the expression of MTX1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:176,913,225...176,919,148
Ensembl chr 2:176,913,225...176,918,824
|
|
| G
|
Muc1
|
mucin 1, cell surface associated
|
affects expression
|
ISO
|
Progesterone affects the expression of MUC1 protein
|
CTD |
PMID:15971251 |
|
NCBI chr 2:176,933,312...176,938,497
Ensembl chr 2:176,933,047...176,938,491
|
|
| G
|
Muc20
|
mucin 20, cell surface associated
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MUC20 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr11:81,492,844...81,506,571
Ensembl chr11:81,492,891...81,506,571
|
|
| G
|
Muc4
|
mucin 4, cell surface associated
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MUC4 mRNA Progesterone results in decreased expression of MUC4 mRNA
|
CTD |
PMID:17404688 PMID:22238285 |
|
NCBI chr11:81,513,321...81,575,200
|
|
| G
|
Muc5b
|
mucin 5B, oligomeric mucus/gel-forming
|
increases expression
|
ISO
|
Progesterone results in increased expression of MUC5B mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:206,346,400...206,378,367
Ensembl chr 1:206,346,400...206,378,367
|
|
| G
|
Mvk
|
mevalonate kinase
|
increases expression
|
ISO
|
Progesterone results in increased expression of MVK mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr12:47,802,002...47,819,503
Ensembl chr12:47,802,002...47,819,503
|
|
| G
|
Myadm
|
myeloid-associated differentiation marker
|
increases expression
|
ISO
|
Progesterone results in increased expression of MYADM mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 1:74,779,616...74,796,752
Ensembl chr 1:74,775,698...74,789,710
|
|
| G
|
Myb
|
MYB proto-oncogene, transcription factor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MYB mRNA
|
CTD |
PMID:16966611 PMID:18497975 PMID:22238285 |
|
NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:17,759,309...17,792,547
|
|
| G
|
Mybl1
|
MYB proto-oncogene like 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of MYBL1 mRNA Fulvestrant inhibits the reaction [Progesterone results in increased expression of MYBL1 mRNA]
|
CTD |
PMID:33405908 |
|
NCBI chr 5:14,365,768...14,401,012
Ensembl chr 5:14,365,768...14,399,588
|
|
| G
|
Mybl2
|
MYB proto-oncogene like 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MYBL2 mRNA
|
CTD |
PMID:16966611 |
|
NCBI chr 3:172,124,765...172,153,221
Ensembl chr 3:172,116,550...172,153,221
|
|
| G
|
Mybpc1
|
myosin binding protein C1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MYBPC1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 7:24,817,770...24,903,681
Ensembl chr 7:24,817,561...24,903,544
|
|
| G
|
Mybpc2
|
myosin binding protein C2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MYBPC2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:104,130,642...104,154,101
Ensembl chr 1:104,131,323...104,154,101
|
|
| G
|
Myc
|
MYC proto-oncogene, bHLH transcription factor
|
decreases expression multiple interactions increases expression
|
ISO
|
Progesterone results in decreased expression of MYC protein [5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one results in decreased activity of MYC protein] inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]; [Estradiol co-treated with Progesterone] results in increased expression of MYC mRNA; MYC protein promotes the reaction [Progesterone results in increased expression of RRM2 mRNA]; Progesterone promotes the reaction [Estradiol results in increased expression of MYC mRNA] Progesterone results in increased expression of MYC mRNA Progesterone results in increased expression of MYC mRNA; Progesterone results in increased expression of MYC protein
|
CTD |
PMID:8390853 PMID:18045962 PMID:18556351 PMID:19847363 PMID:21795739 PMID:22403396 More...
|
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028
|
|
| G
|
Mycl
|
MYCL proto-oncogene, bHLH transcription factor
|
affects expression
|
ISO
|
Progesterone affects the expression of MYCL mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:140,559,843...140,566,704
Ensembl chr 5:140,560,152...140,566,699
|
|
| G
|
Mycn
|
MYCN proto-oncogene, bHLH transcription factor
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of MYCN mRNA Progesterone results in decreased expression of MYCN mRNA
|
CTD |
PMID:17404688 PMID:22238285 |
|
NCBI chr 6:41,446,683...41,452,584
Ensembl chr 6:41,446,684...41,452,508
|
|
| G
|
Myd88
|
MYD88, innate immune signal transduction adaptor
|
increases expression
|
ISO
|
Progesterone results in increased expression of MYD88 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230
|
|
| G
|
Myh1
|
myosin heavy chain 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MYH1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:52,384,810...52,408,698
Ensembl chr10:52,384,908...52,409,047
|
|
| G
|
Myh10
|
myosin heavy chain 10
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MYH10 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr10:53,891,955...54,024,032
Ensembl chr10:53,893,166...54,024,036
|
|
| G
|
Myh11
|
myosin heavy chain 11
|
increases expression
|
EXP
|
Progesterone results in increased expression of MYH11 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:1,250,554...1,345,681
Ensembl chr10:1,263,194...1,345,678
|
|
| G
|
Myh3
|
myosin heavy chain 3
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of MYH3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:52,269,185...52,293,000
Ensembl chr10:52,269,185...52,293,000
|
|
| G
|
Myh6
|
myosin heavy chain 6
|
increases expression
|
EXP ISO
|
Progesterone results in increased expression of MYH6 mRNA
|
CTD |
PMID:20726854 PMID:22238285 |
|
NCBI chr15:32,388,102...32,413,663
Ensembl chr15:32,387,487...32,411,333
|
|
| G
|
Myh7
|
myosin heavy chain 7
|
increases expression
|
EXP
|
Progesterone results in increased expression of MYH7 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr15:32,416,525...32,439,851
Ensembl chr15:32,416,527...32,438,194
|
|
| G
|
Myl1
|
myosin, light chain 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of MYL1 mRNA
|
CTD |
PMID:20726854 |
|
Ensembl chr 9:75,887,227...75,907,971
|
|
| G
|
Myl6b
|
myosin light chain 6B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MYL6B mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr X:44,450,733...44,451,711
|
|
| G
|
Myl9
|
myosin light chain 9
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MYL9 mRNA
|
CTD |
PMID:18037150 PMID:18070364 |
|
NCBI chr 3:165,742,020...165,748,409
Ensembl chr 3:165,742,046...165,748,410
|
|
| G
|
Mylip
|
myosin regulatory light chain interacting protein
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of MYLIP mRNA Progesterone results in decreased expression of MYLIP mRNA
|
CTD |
PMID:18037150 PMID:21795739 |
|
NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,492,826...19,514,471
|
|
| G
|
Mylk
|
myosin light chain kinase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of MYLK mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of MYLK mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659
|
|
| G
|
Mylk3
|
myosin light chain kinase 3
|
multiple interactions decreases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in decreased expression of MYLK3 mRNA]
|
CTD |
PMID:27264040 PMID:31566189 |
|
NCBI chr19:37,858,298...37,916,805
Ensembl chr19:37,865,141...37,915,827
|
|
| G
|
Myo16
|
myosin XVI
|
increases expression
|
ISO
|
Progesterone results in increased expression of MYO16 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr16:85,586,428...86,066,537
Ensembl chr16:85,586,429...85,973,879
|
|
| G
|
Myo1b
|
myosin Ib
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of MYO1B mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 9:57,182,059...57,344,335
Ensembl chr 9:57,181,987...57,344,328
|
|
| G
|
Myocd
|
myocardin
|
increases expression
|
ISO
|
Progesterone results in increased expression of MYOCD mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr10:50,332,356...50,426,819
Ensembl chr10:50,332,356...50,426,819
|
|
| G
|
Myof
|
myoferlin
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of MYOF mRNA [Estradiol co-treated with Progesterone] results in increased expression of MYOF mRNA
|
CTD |
PMID:18037150 PMID:20660070 |
|
NCBI chr 1:245,086,109...245,234,768
Ensembl chr 1:245,086,109...245,234,768
|
|
| G
|
Myrip
|
myosin VIIA and Rab interacting protein
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of MYRIP mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:128,895,371...129,062,420
Ensembl chr 8:128,895,371...129,062,420
|
|
| G
|
Naaa
|
N-acylethanolamine acid amidase
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of NAAA mRNA [Estradiol co-treated with Progesterone] results in increased expression of NAAA mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr14:16,061,599...16,080,703
Ensembl chr14:16,061,583...16,080,702
|
|
| G
|
Nacc2
|
NACC family member 2
|
affects expression increases expression
|
ISO
|
Progesterone affects the expression of NACC2 mRNA Progesterone results in increased expression of NACC2 mRNA
|
CTD |
PMID:17251523 PMID:22238285 |
|
NCBI chr 3:29,278,077...29,345,098
Ensembl chr 3:29,281,190...29,344,840
|
|
| G
|
Nalcn
|
sodium leak channel, non-selective
|
increases expression
|
ISO
|
Progesterone results in increased expression of NALCN mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr15:106,805,209...107,148,837
Ensembl chr15:106,805,209...107,147,858
|
|
| G
|
Nalf1
|
NALCN channel auxiliary factor 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of NALF1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr16:86,415,540...86,938,150
Ensembl chr16:86,415,488...86,938,150
|
|
| G
|
Nampt
|
nicotinamide phosphoribosyltransferase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] promotes the reaction [Estriol results in increased expression of NAMPT mRNA] NAMPT protein promotes the reaction [IGF1 protein results in increased abundance of Progesterone]
|
CTD |
PMID:20004694 PMID:23315983 |
|
NCBI chr 6:55,152,756...55,189,547
Ensembl chr 6:55,151,926...55,189,544
|
|
| G
|
Nanos1
|
nanos C2HC-type zinc finger 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NANOS1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:269,883,713...269,887,611
Ensembl chr 1:269,883,536...269,895,417
|
|
| G
|
Napsa
|
napsin A aspartic peptidase
|
affects expression
|
ISO
|
Progesterone affects the expression of NAPSA mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:104,200,967...104,213,603
Ensembl chr 1:104,200,960...104,213,608
|
|
| G
|
Nat1
|
N-acetyltransferase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NAT1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr16:26,984,882...27,005,194
Ensembl chr16:26,982,625...26,986,527
|
|
| G
|
Nav3
|
neuron navigator 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NAV3 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893
|
|
| G
|
Ncapg
|
non-SMC condensin I complex, subunit G
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of NCAPG mRNA Progesterone results in decreased expression of NCAPG mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr14:69,616,473...69,645,445
Ensembl chr14:69,616,473...69,645,445
|
|
| G
|
Ncf2
|
neutrophil cytosolic factor 2
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of NCF2 mRNA Estradiol inhibits the reaction [Progesterone results in increased expression of NCF2 mRNA]
|
CTD |
PMID:16195479 |
|
NCBI chr13:67,505,492...67,536,015
Ensembl chr13:67,505,375...67,536,149
|
|
| G
|
Nck1
|
NCK adaptor protein 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of NCK1 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 8:109,897,723...109,958,247
Ensembl chr 8:109,897,724...109,958,247
|
|
| G
|
Ncmap
|
noncompact myelin associated protein
|
multiple interactions decreases expression
|
ISO
|
Mifepristone promotes the reaction [Progesterone affects the expression of NCMAP mRNA] Progesterone results in decreased expression of NCMAP mRNA
|
CTD |
PMID:22238285 PMID:22414680 |
|
NCBI chr 5:152,893,173...152,921,175
Ensembl chr 5:152,894,316...152,902,414
|
|
| G
|
Ncoa1
|
nuclear receptor coactivator 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of NCOA1 protein [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]
|
CTD |
PMID:17556502 PMID:21768169 |
|
NCBI chr 6:32,952,090...33,229,829
Ensembl chr 6:32,952,090...33,195,924
|
|
| G
|
Ncoa2
|
nuclear receptor coactivator 2
|
multiple interactions increases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of BMP2 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of BMP5 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of CALB1 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of CDKL1 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of CLMN mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of DSP mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of EMB mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of HMGA2 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of KRT18 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of LDB2 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of MPZL2 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of POF1B mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of RHPN2 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of S100G mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of SLC44A3 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of SOX7 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of TJP3 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of TSPAN8 mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of WNT7A mRNA]; NCOA2 protein affects the reaction [Progesterone results in increased expression of ATP2C2 mRNA]; NCOA2 protein affects the reaction [Progesterone results in increased expression of CLDN23 mRNA]; NCOA2 protein affects the reaction [Progesterone results in increased expression of SLCO5A1 mRNA]; NCOA2 protein affects the reaction [Progesterone results in increased expression of TTR mRNA]; NCOA2 protein affects the reaction [Progesterone results in increased expression of TUBB2A mRNA] Progesterone results in increased expression of NCOA2 protein
|
CTD |
PMID:17556502 |
|
NCBI chr 5:10,618,712...10,852,776
Ensembl chr 5:10,618,722...10,852,776
|
|
| G
|
Ncoa4
|
nuclear receptor coactivator 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NCOA4 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr16:7,395,502...7,415,846
Ensembl chr16:7,401,802...7,415,840
|
|
| G
|
Ncr2
|
natural cytotoxicity triggering receptor 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of NCR2 mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr 9:20,274,057...20,324,708
|
|
| G
|
Ndc80
|
NDC80 kinetochore complex component
|
increases expression
|
ISO
|
Progesterone results in increased expression of NDC80 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 9:118,853,806...118,887,582
Ensembl chr 9:118,853,806...118,887,568
|
|
| G
|
Ndp
|
norrin cystine knot growth factor NDP
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NDP mRNA; [Progesterone co-treated with Estradiol] results in increased expression of NDP mRNA Progesterone results in increased expression of NDP mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:22238285 |
|
NCBI chr X:8,379,569...8,404,019
Ensembl chr X:8,379,569...8,406,802
|
|
| G
|
Ndrg1
|
N-myc downstream regulated 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of NDRG1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913
|
|
| G
|
Ndrg2
|
NDRG family member 2
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of NDRG2 mRNA Progesterone results in increased expression of NDRG2 mRNA
|
CTD |
PMID:20726854 PMID:21540246 |
|
NCBI chr15:27,074,481...27,087,376
Ensembl chr15:27,074,481...27,083,125
|
|
| G
|
Ndrg4
|
NDRG family member 4
|
increases expression
|
EXP
|
Progesterone results in increased expression of NDRG4 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr19:9,357,470...9,393,465
Ensembl chr19:9,357,470...9,392,972
|
|
| G
|
Ndufb7
|
NADH:ubiquinone oxidoreductase subunit B7
|
increases expression
|
ISO
|
Progesterone results in increased expression of NDUFB7 mRNA
|
CTD |
PMID:38992643 |
|
NCBI chr19:41,472,953...41,477,291
Ensembl chr19:41,472,953...41,477,291
|
|
| G
|
Nebl
|
nebulette
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NEBL mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:85,022,953...85,374,848
Ensembl chr17:85,022,963...85,374,172
|
|
| G
|
Nefh
|
neurofilament heavy chain
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NEFH mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr14:84,044,428...84,054,413
Ensembl chr14:84,044,023...84,054,417
|
|
| G
|
Nefm
|
neurofilament medium chain
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NEFM mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163
|
|
| G
|
Negr1
|
neuronal growth regulator 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of NEGR1 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 2:248,283,164...249,015,538
Ensembl chr 2:248,283,353...249,018,410
|
|
| G
|
Nek2
|
NIMA-related kinase 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NEK2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:105,936,809...105,950,054
Ensembl chr13:105,936,788...105,950,056
|
|
| G
|
Nell2
|
neural EGFL like 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NELL2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:128,222,333...128,542,127
Ensembl chr 7:128,078,103...128,651,917
|
|
| G
|
Neo1
|
neogenin 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NEO1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:68,169,711...68,322,158
Ensembl chr 8:68,169,716...68,322,152
|
|
| G
|
Nes
|
nestin
|
decreases expression
|
ISO EXP
|
Progesterone results in decreased expression of NES mRNA
|
CTD |
PMID:20726854 PMID:21795739 |
|
NCBI chr 2:175,735,715...175,745,631
Ensembl chr 2:175,736,551...175,746,228
|
|
| G
|
Neu3
|
neuraminidase 3
|
increases expression
|
EXP
|
Progesterone results in increased expression of NEU3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:163,549,834...163,560,997
Ensembl chr 1:163,549,738...163,561,049
|
|
| G
|
Nexn
|
nexilin (F actin binding protein)
|
increases expression
|
EXP
|
Progesterone results in increased expression of NEXN mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:243,846,736...243,878,268
Ensembl chr 2:243,846,433...243,887,114
|
|
| G
|
Nfat5
|
nuclear factor of activated T-cells 5
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of NFAT5 mRNA
|
CTD |
PMID:21371490 |
|
NCBI chr19:52,108,982...52,196,418
Ensembl chr19:52,109,483...52,196,418
|
|
| G
|
Nfe2l2
|
NFE2 like bZIP transcription factor 2
|
affects expression
|
EXP
|
Progesterone affects the expression of NFE2L2 mRNA
|
CTD |
PMID:24777823 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090
|
|
| G
|
Nfib
|
nuclear factor I/B
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NFIB mRNA; [Progesterone co-treated with Estradiol] results in increased expression of NFIB mRNA Progesterone results in increased expression of NFIB mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 5:101,805,168...102,020,618
Ensembl chr 5:101,805,168...102,019,945
|
|
| G
|
Nfic
|
nuclear factor I/C
|
affects expression
|
ISO
|
Progesterone affects the expression of NFIC mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:8,928,423...8,963,455
Ensembl chr 7:8,904,117...8,963,409
|
|
| G
|
Nfil3
|
nuclear factor, interleukin 3 regulated
|
increases expression
|
ISO
|
Progesterone results in increased expression of NFIL3 mRNA
|
CTD |
PMID:20864642 PMID:21795739 |
|
NCBI chr17:12,432,376...12,447,605
Ensembl chr17:12,432,198...12,450,826
|
|
| G
|
Nfix
|
nuclear factor I X
|
affects expression
|
ISO
|
Progesterone affects the expression of NFIX mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr19:40,259,873...40,356,966
Ensembl chr19:40,260,084...40,353,092
|
|
| G
|
Nfkb1
|
nuclear factor kappa B subunit 1
|
multiple interactions
|
ISO
|
Mifepristone inhibits the reaction [Progesterone inhibits the reaction [[Estradiol co-treated with TNF protein] results in increased activity of NFKB1 protein]]; Progesterone inhibits the reaction [[Estradiol co-treated with TNF protein] results in increased activity of NFKB1 protein]
|
CTD |
PMID:15866594 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088
|
|
| G
|
Nfkb2
|
nuclear factor kappa B subunit 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of NFKB2 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr 1:255,106,010...255,114,649
Ensembl chr 1:255,107,374...255,114,637
|
|
| G
|
Nfkbia
|
NFKB inhibitor alpha
|
multiple interactions increases expression
|
ISO EXP
|
Progesterone inhibits the reaction [IL1B protein results in increased degradation of NFKBIA protein] Progesterone promotes the reaction [Hydrogen Peroxide results in increased degradation of NFKBIA protein] Progesterone results in increased expression of NFKBIA mRNA
|
CTD |
PMID:16284289 PMID:17437195 PMID:18037150 PMID:21795739 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072
|
|
| G
|
Nfkbil1
|
NFKB inhibitor like 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of NFKBIL1 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr20:3,595,319...3,610,295
Ensembl chr20:3,595,284...3,610,294
|
|
| G
|
Nfkbiz
|
NFKB inhibitor zeta
|
increases expression
|
ISO
|
Progesterone results in increased expression of NFKBIZ mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr11:58,251,720...58,279,767
Ensembl chr11:58,251,721...58,279,767
|
|
| G
|
Nfxl1
|
nuclear transcription factor, X-box binding-like 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of NFXL1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr14:35,980,058...36,021,478
Ensembl chr14:35,980,057...36,023,281
|
|
| G
|
Ngf
|
nerve growth factor
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of NGF mRNA; [VIP protein results in increased secretion of Progesterone] which results in decreased expression of NGF mRNA; Progesterone inhibits the reaction [Estradiol results in increased expression of NGF protein]
|
CTD |
PMID:15570173 PMID:20150881 PMID:21277368 |
|
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834
|
|
| G
|
Ngly1
|
N-glycanase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of NGLY1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:11,584,475...11,640,977
Ensembl chr15:11,584,475...11,635,328
|
|
| G
|
Nherf1
|
NHERF family PDZ scaffold protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NHERF1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr10:100,902,165...100,919,265
Ensembl chr10:100,901,227...100,919,579
|
|
| G
|
Niban1
|
niban apoptosis regulator 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NIBAN1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr13:66,224,219...66,377,728
Ensembl chr13:66,224,021...66,377,724
|
|
| G
|
Nid1
|
nidogen 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NID1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr17:93,069,013...93,142,416
Ensembl chr17:93,069,278...93,142,386
|
|
| G
|
Nit1
|
nitrilase 1
|
affects expression
|
ISO
|
Progesterone affects the expression of NIT1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr13:86,302,334...86,305,770
Ensembl chr13:86,298,387...86,305,770
|
|
| G
|
Nkg7
|
natural killer cell granule protein 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of NKG7 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:102,981,497...102,982,564
Ensembl chr 1:102,981,450...102,982,562
|
|
| G
|
Nlrp5
|
NLR family, pyrin domain containing 5
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NLRP5 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:76,811,044...76,872,964
Ensembl chr 1:76,810,108...77,077,580
|
|
| G
|
Nmb
|
neuromedin B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NMB mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:144,278,678...144,290,523
Ensembl chr 1:144,278,453...144,281,422
|
|
| G
|
Nme2
|
NME/NM23 nucleoside diphosphate kinase 2
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of NME2 mRNA Mifepristone inhibits the reaction [Progesterone results in increased expression of NME2 mRNA]
|
CTD |
PMID:15674352 |
|
NCBI chr10:79,394,999...79,400,418
Ensembl chr20:11,179,066...11,179,497 Ensembl chr10:11,179,066...11,179,497
|
|
| G
|
Nmt1
|
N-myristoyltransferase 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of NMT1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:88,488,918...88,525,496
Ensembl chr10:88,488,990...88,522,729
|
|
| G
|
Nmu
|
neuromedin U
|
increases abundance
|
EXP
|
NMU protein results in increased abundance of Progesterone
|
CTD |
PMID:23423171 |
|
NCBI chr14:32,198,789...32,226,397
Ensembl chr14:32,198,943...32,226,632
|
|
| G
|
Nodal
|
nodal growth differentiation factor
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of NODAL mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr20:29,911,258...29,919,659
Ensembl chr20:29,911,258...29,919,659
|
|
| G
|
Nog
|
noggin
|
multiple interactions
|
ISO EXP
|
NOG protein inhibits the reaction [BMP2 protein results in decreased abundance of Progesterone]; Progesterone promotes the reaction [Estradiol results in increased expression of NOG mRNA] NOG protein inhibits the reaction [Octreotide inhibits the reaction [FSHB protein results in increased abundance of Progesterone]]; NOG protein inhibits the reaction [pasireotide inhibits the reaction [FSHB protein results in increased abundance of Progesterone]] NOG protein promotes the reaction [GH1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]]
|
CTD |
PMID:20639315 PMID:21795739 PMID:22067323 PMID:23137853 |
|
NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,625,875...74,628,103
|
|
| G
|
Nop56
|
NOP56 ribonucleoprotein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NOP56 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:137,926,187...137,934,971
Ensembl chr 3:137,929,646...137,934,959
|
|
| G
|
Nos1
|
nitric oxide synthase 1
|
multiple interactions decreases expression
|
EXP ISO
|
[Progesterone co-treated with estradiol 3-benzoate] results in increased expression of NOS1 protein Progesterone results in decreased expression of NOS1 protein
|
CTD |
PMID:15347845 PMID:22486171 |
|
NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837
|
|
| G
|
Nos2
|
nitric oxide synthase 2
|
multiple interactions increases expression affects response to substance decreases expression
|
ISO EXP
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of NOS2 mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of NOS2 protein] Progesterone results in increased expression of NOS2 mRNA; Progesterone results in increased expression of NOS2 protein NOS2 protein affects the susceptibility to Progesterone Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with IL4 protein] results in increased expression of NOS2 mRNA]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] [VIP protein results in increased secretion of Progesterone] which results in decreased expression of NOS2 protein Progesterone results in decreased expression of NOS2 mRNA
|
CTD |
PMID:11063824 PMID:15869954 PMID:16399999 PMID:18710710 PMID:20150881 PMID:21977998 More...
|
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880
|
|
| G
|
Nos3
|
nitric oxide synthase 3
|
multiple interactions increases activity increases expression increases phosphorylation decreases expression
|
ISO EXP
|
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Progesterone promotes the reaction [Estradiol results in increased activity of NOS3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Progesterone results in increased activity of NOS3 protein]; Mifepristone inhibits the reaction [Progesterone promotes the reaction [Estradiol results in increased activity of NOS3 protein]]; Mifepristone inhibits the reaction [Progesterone results in increased expression of and results in increased phosphorylation of NOS3 protein]; Mifepristone inhibits the reaction [Progesterone results in increased expression of NOS3 mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of NOS3 protein]; Org 31710 inhibits the reaction [Progesterone results in increased expression of NOS3 protein]; Org 31710 inhibits the reaction [Progesterone results in increased phosphorylation of NOS3 protein]; Progesterone promotes the reaction [Estradiol results in increased activity of NOS3 protein]; Progesterone results in increased expression of and results in increased phosphorylation of NOS3 protein; U 0126 inhibits the reaction [Progesterone results in increased phosphorylation of NOS3 protein]; Wortmannin inhibits the reaction [Progesterone promotes the reaction [Estradiol results in increased activity of NOS3 protein]]; Wortmannin inhibits the reaction [Progesterone results in increased activity of NOS3 protein]; Wortmannin inhibits the reaction [Progesterone results in increased phosphorylation of NOS3 protein] Progesterone results in increased expression of NOS3 mRNA; Progesterone results in increased expression of NOS3 protein Progesterone results in decreased expression of NOS3 protein
|
CTD |
PMID:15358673 PMID:18710710 PMID:21558462 |
|
NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664
|
|
| G
|
Notch1
|
notch receptor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of NOTCH1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 3:29,676,040...29,721,613
Ensembl chr 3:29,676,171...29,721,613
|
|
| G
|
Notch2
|
notch receptor 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NOTCH2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 2:188,299,336...188,432,823
Ensembl chr 2:188,299,336...188,432,823
|
|
| G
|
Nox3
|
NADPH oxidase 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NOX3 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:46,643,277...46,708,109
Ensembl chr 1:46,642,564...46,708,109
|
|
| G
|
Noxa1
|
NADPH oxidase activator 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NOXA1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:28,293,643...28,309,828
Ensembl chr 3:28,293,658...28,304,022
|
|
| G
|
Npas2
|
neuronal PAS domain protein 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of NPAS2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 9:48,959,225...49,138,036
Ensembl chr 9:48,959,148...49,138,037
|
|
| G
|
Npc1
|
NPC intracellular cholesterol transporter 1
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Cholesterol]; Progesterone inhibits the reaction [NPC1 protein results in increased secretion of Daunorubicin]
|
CTD |
PMID:16174794 |
|
NCBI chr18:3,654,237...3,699,853
Ensembl chr18:3,654,237...3,699,800
|
|
| G
|
Npl
|
N-acetylneuraminate pyruvate lyase
|
affects expression
|
ISO
|
Progesterone affects the expression of NPL mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr13:68,205,602...68,247,940
Ensembl chr13:68,205,603...68,247,999
|
|
| G
|
Npm3
|
nucleophosmin/nucleoplasmin, 3
|
affects expression
|
ISO
|
Progesterone affects the expression of NPM3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:254,544,664...254,546,649
Ensembl chr 1:254,544,664...254,546,649
|
|
| G
|
Nppa
|
natriuretic peptide A
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of NPPA mRNA [Progesterone co-treated with Estradiol] results in increased expression of NPPA mRNA
|
CTD |
PMID:18692832 PMID:20726854 |
|
NCBI chr 5:163,712,184...163,713,493
Ensembl chr 5:163,712,184...163,713,493
|
|
| G
|
Nppb
|
natriuretic peptide B
|
increases expression
|
EXP
|
Progesterone results in increased expression of NPPB mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310
|
|
| G
|
Nppc
|
natriuretic peptide C
|
multiple interactions increases expression
|
ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of NPPC protein] Progesterone results in increased expression of NPPC mRNA
|
CTD |
PMID:9435603 PMID:22238285 |
|
NCBI chr 9:94,767,986...94,772,186
Ensembl chr 9:94,767,986...94,772,186
|
|
| G
|
Npr3
|
natriuretic peptide receptor 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of NPR3 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 2:62,592,557...62,660,497
Ensembl chr 2:62,597,668...62,660,066
|
|
| G
|
Nptx2
|
neuronal pentraxin 2
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NPTX2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of NPTX2 mRNA Progesterone results in increased expression of NPTX2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr12:15,151,136...15,162,045
Ensembl chr12:15,151,136...15,162,045
|
|
| G
|
Npy
|
neuropeptide Y
|
increases expression increases secretion decreases expression
|
ISO EXP
|
Progesterone results in increased expression of NPY mRNA NPY protein results in increased secretion of Progesterone Progesterone results in decreased expression of NPY mRNA
|
CTD |
PMID:18070364 PMID:20150881 PMID:22238285 |
|
NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310
|
|
| G
|
Npy1r
|
neuropeptide Y receptor Y1
|
increases expression
|
ISO
|
Progesterone results in increased expression of NPY1R mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387
|
|
| G
|
Nqo1
|
NAD(P)H quinone dehydrogenase 1
|
multiple interactions increases expression
|
EXP
|
Dicumarol inhibits the reaction [Progesterone results in increased activity of NQO1 protein]; Progesterone results in increased expression of and results in increased activity of NQO1 protein Progesterone results in increased expression of NQO1 mRNA
|
CTD |
PMID:20726854 PMID:21770760 PMID:21947872 |
|
NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260
|
|
| G
|
Nr0b1
|
nuclear receptor subfamily 0, group B, member 1
|
multiple interactions
|
ISO
|
[[NR0B1 protein binds to STAR promoter] which results in decreased expression of STAR mRNA] which results in decreased abundance of Progesterone; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of STAR protein] which results in increased abundance of Progesterone]
|
CTD |
PMID:18787026 |
|
NCBI chr X:54,707,658...54,711,786
Ensembl chr X:54,707,639...54,712,083
|
|
| G
|
Nr1d1
|
nuclear receptor subfamily 1, group D, member 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of NR1D1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:84,224,599...84,231,812
Ensembl chr10:84,224,540...84,231,812
|
|
| G
|
Nr1d2
|
nuclear receptor subfamily 1, group D, member 2
|
affects expression
|
ISO
|
Progesterone affects the expression of NR1D2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr15:9,955,034...9,981,329
Ensembl chr15:9,954,906...9,981,330
|
|
| G
|
Nr1i2
|
nuclear receptor subfamily 1, group I, member 2
|
multiple interactions increases activity
|
ISO EXP
|
[Progesterone co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; Progesterone binds to and results in increased activity of NR1I2 protein Progesterone results in increased activity of NR1I2 protein Progesterone metabolite results in increased activity of NR1I2 protein
|
CTD |
PMID:14613717 PMID:15650019 PMID:15846226 PMID:16054614 PMID:18098064 |
|
NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380
|
|
| G
|
Nr1i3
|
nuclear receptor subfamily 1, group I, member 3
|
multiple interactions decreases activity
|
ISO
|
Estradiol inhibits the reaction [Progesterone results in decreased activity of NR1I3 protein]; Estrone inhibits the reaction [Progesterone results in decreased activity of NR1I3 protein] [Estradiol co-treated with Progesterone] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein]; [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; [Progesterone co-treated with Estradiol] inhibits the reaction [Phenobarbital results in increased activity of NR1I3 protein]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of G6PC1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2B6 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased expression of CYP2C9 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [Phenobarbital results in decreased expression of G6PC1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [Phenobarbital results in decreased expression of SREBF1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [Phenobarbital results in increased expression of CYP2B6 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [Phenobarbital results in increased expression of CYP2C9 mRNA]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime promotes the reaction [[NR1I3 protein co-treated with FOXO1 protein co-treated with HNF4A protein co-treated with NCOA1 protein] binds to CYP2C9 promoter]]; Progesterone inhibits the reaction [Phenobarbital results in increased activity of NR1I3 protein]
|
CTD |
PMID:11075820 PMID:21768169 |
|
NCBI chr13:86,165,327...86,170,362
Ensembl chr13:86,165,349...86,170,370
|
|
| G
|
Nr2c2
|
nuclear receptor subfamily 2, group C, member 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of NR2C2 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr 4:126,167,350...126,223,942
Ensembl chr 4:126,168,085...126,223,942
|
|
| G
|
Nr3c1
|
nuclear receptor subfamily 3, group C, member 1
|
multiple interactions increases phosphorylation affects binding affects expression increases expression
|
ISO EXP
|
[Hydrocortisone co-treated with Progesterone] results in increased expression of NR3C1 mRNA; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of NR3C1 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in decreased expression of NR3C1 mRNA; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C1 protein inhibits the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of ZNF486 mRNA]; NR3C1 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA]; Progesterone binds to and results in increased activity of NR3C1 protein Progesterone results in increased phosphorylation of NR3C1 protein Progesterone binds to and results in increased activity of NR3C1 protein; Progesterone inhibits the reaction [Ozone results in decreased expression of NR3C1 protein] Progesterone binds to NR3C1 protein Progesterone affects the expression of NR3C1 mRNA NR3C1 protein binds to Progesterone Progesterone results in increased expression of NR3C1 mRNA
|
CTD |
PMID:1597467 PMID:16507850 PMID:17509631 PMID:18060946 PMID:18483179 PMID:19208548 PMID:23275455 PMID:25056680 PMID:28279894 More...
|
|
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843
|
|
| G
|
Nr3c2
|
nuclear receptor subfamily 3, group C, member 2
|
affects binding increases activity multiple interactions
|
EXP ISO
|
Progesterone binds to NR3C2 protein Progesterone results in increased activity of NR3C2 protein [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of NR3C2 protein; [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased expression of NR3C2 mRNA; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in decreased expression of GRIA1 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of DHRS3 mRNA]; NR3C2 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of FBXO32 mRNA]
|
CTD |
PMID:14667981 PMID:15362971 PMID:23275455 |
|
NCBI chr19:47,619,853...47,964,089
Ensembl chr19:47,619,853...47,964,078
|
|
| G
|
Nr4a1
|
nuclear receptor subfamily 4, group A, member 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of NR4A1 mRNA NR4A1 protein mutant form inhibits the reaction [bisphenol A results in increased abundance of Progesterone]; NR4A1 protein promotes the reaction [bisphenol A diglycidyl ether affects the abundance of Progesterone]; NR4A1 protein promotes the reaction [bisphenol A results in increased abundance of Progesterone]
|
CTD |
PMID:12021184 PMID:18037150 PMID:18525235 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041
|
|
| G
|
Nr5a1
|
nuclear receptor subfamily 5, group A, member 1
|
multiple interactions increases abundance
|
ISO
|
[NR5A1 protein co-treated with 20-hydroxycholesterol co-treated with Tretinoin co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate] results in increased abundance of Progesterone; [NR5A1 protein co-treated with LIF protein co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Tretinoin] results in increased abundance of Progesterone NR5A1 protein results in increased abundance of Progesterone
|
CTD |
PMID:20045459 PMID:21610156 |
|
NCBI chr 3:42,874,505...42,896,109
Ensembl chr 3:42,875,221...42,896,046
|
|
| G
|
Nr5a2
|
nuclear receptor subfamily 5, group A, member 2
|
decreases abundance increases abundance
|
ISO
|
NR5A2 gene mutant form results in decreased abundance of Progesterone NR5A2 protein results in increased abundance of Progesterone
|
CTD |
PMID:17409375 PMID:18628394 |
|
NCBI chr13:50,865,253...50,985,107
Ensembl chr13:50,867,920...50,984,938
|
|
| G
|
Nrg1
|
neuregulin 1
|
multiple interactions
|
ISO
|
NRG1 protein promotes the reaction [AREG protein results in increased abundance of Progesterone]
|
CTD |
PMID:21047912 |
|
NCBI chr16:65,954,084...67,007,484
Ensembl chr16:65,953,865...66,999,849
|
|
| G
|
Nrp1
|
neuropilin 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of NRP1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702
|
|
| G
|
Nrxn3
|
neurexin 3
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NRXN3 mRNA Progesterone results in decreased expression of NRXN3 mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr 6:113,372,667...115,004,073
Ensembl chr 6:113,443,524...115,002,540
|
|
| G
|
Nsdhl
|
NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL
|
increases expression
|
ISO
|
Progesterone results in increased expression of NSDHL mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr X:155,817,301...155,848,224
Ensembl chr X:155,817,340...155,848,220
|
|
| G
|
Nsg1
|
neuronal vesicle trafficking associated 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of NSG1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr14:76,861,079...76,882,822
Ensembl chr14:76,860,746...76,883,390
|
|
| G
|
Nt5c3b
|
5'-nucleotidase, cytosolic IIIB
|
affects expression
|
ISO
|
Progesterone affects the expression of NT5C3B mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:85,859,509...85,876,731
Ensembl chr10:85,862,512...85,875,992
|
|
| G
|
Nt5e
|
5' nucleotidase, ecto
|
increases expression decreases expression
|
EXP ISO
|
Progesterone results in increased expression of NT5E mRNA Progesterone results in decreased expression of NT5E mRNA
|
CTD |
PMID:20726854 PMID:20864642 |
|
NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645
|
|
| G
|
Ntf3
|
neurotrophin 3
|
multiple interactions
|
EXP
|
Progesterone inhibits the reaction [Estradiol results in increased expression of NTF3 protein]
|
CTD |
PMID:15570173 |
|
NCBI chr 4:160,601,161...160,670,623
Ensembl chr 4:160,600,770...160,676,349
|
|
| G
|
Ntm
|
neurotrimin
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NTM mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 8:35,634,929...36,625,081
Ensembl chr 8:35,635,640...36,624,807
|
|
| G
|
Ntng1
|
netrin G1
|
increases expression
|
ISO
|
Progesterone results in increased expression of NTNG1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:200,151,979...200,515,031
Ensembl chr 2:200,151,979...200,515,031
|
|
| G
|
Ntrk1
|
neurotrophic receptor tyrosine kinase 1
|
multiple interactions
|
EXP
|
[VIP protein results in increased secretion of Progesterone] which results in decreased expression of NTRK1 mRNA
|
CTD |
PMID:20150881 |
|
NCBI chr 2:175,534,844...175,551,664
Ensembl chr 2:175,534,844...175,551,787
|
|
| G
|
Ntrk3
|
neurotrophic receptor tyrosine kinase 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of NTRK3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:141,526,192...141,913,575
Ensembl chr 1:141,542,569...141,913,004
|
|
| G
|
Nts
|
neurotensin
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of NTS mRNA]
|
CTD |
PMID:21795739 |
|
NCBI chr 7:39,451,484...39,460,888
Ensembl chr 7:39,451,073...39,460,961
|
|
| G
|
Nudt6
|
nudix hydrolase 6
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of NUDT6 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 2:122,218,031...122,234,488
Ensembl chr 2:122,217,861...122,234,344
|
|
| G
|
Nuf2
|
NUF2 component of NDC80 kinetochore complex
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of NUF2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:84,226,448...84,290,957
Ensembl chr13:84,226,509...84,255,598
|
|
| G
|
Numa1
|
nuclear mitotic apparatus protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of NUMA1 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 1:165,709,893...165,784,848
Ensembl chr 1:165,709,905...165,784,848
|
|
| G
|
Nup153
|
nucleoporin 153
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of NUP153 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr17:18,178,434...18,231,109
Ensembl chr17:18,178,456...18,231,109
|
|
| G
|
Nup160
|
nucleoporin 160
|
increases expression
|
ISO
|
Progesterone results in increased expression of NUP160 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 3:97,120,723...97,183,227
Ensembl chr 3:97,121,628...97,180,720
|
|
| G
|
Nup54
|
nucleoporin 54
|
increases expression
|
ISO
|
Progesterone results in increased expression of NUP54 mRNA
|
CTD |
PMID:19000923 |
|
NCBI chr14:15,901,936...15,920,335
Ensembl chr14:15,901,991...15,920,334
|
|
| G
|
Nusap1
|
nucleolar and spindle associated protein 1
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of NUSAP1 mRNA Progesterone results in decreased expression of NUSAP1 mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr 3:127,057,220...127,092,779
Ensembl chr 3:127,057,265...127,087,237
|
|
| G
|
Oas1a
|
2'-5' oligoadenylate synthetase 1A
|
multiple interactions increases expression
|
ISO
|
TGFB1 protein promotes the reaction [Progesterone results in increased expression of OAS1 mRNA]
|
CTD |
PMID:21768398 |
|
NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128
|
|
| G
|
Ociad2
|
OCIA domain containing 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of OCIAD2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr14:35,225,291...35,243,306
Ensembl chr14:35,225,255...35,243,311
|
|
| G
|
Ocln
|
occludin
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of OCLN mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411
|
|
| G
|
Odc1
|
ornithine decarboxylase 1
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of ODC1 mRNA Progesterone results in increased expression of ODC1 mRNA
|
CTD |
PMID:18037150 PMID:21770760 |
|
NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146
|
|
| G
|
Ogfod1
|
2-oxoglutarate and iron-dependent oxygenase domain containing 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of OGFOD1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr19:10,950,950...10,980,519
Ensembl chr19:10,950,060...10,980,519
|
|
| G
|
Ogt
|
O-linked N-acetylglucosamine (GlcNAc) transferase
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of OGT mRNA Progesterone results in increased expression of OGT mRNA
|
CTD |
PMID:18037150 PMID:18070364 |
|
NCBI chr X:70,811,317...70,856,123
Ensembl chr X:70,811,319...70,856,123
|
|
| G
|
Olah
|
oleoyl-ACP hydrolase
|
increases expression
|
ISO
|
Progesterone results in increased expression of OLAH mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:79,786,441...79,811,692
Ensembl chr17:79,786,832...79,811,688
|
|
| G
|
Olfm1
|
olfactomedin 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of OLFM1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:31,918,512...31,956,261
Ensembl chr 3:31,918,573...31,956,260
|
|
| G
|
Olfml1
|
olfactomedin-like 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of OLFML1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:170,889,912...170,914,300
Ensembl chr 1:170,889,980...170,915,762
|
|
| G
|
Olfml2b
|
olfactomedin-like 2B
|
increases expression
|
ISO
|
Progesterone results in increased expression of OLFML2B mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr13:85,402,151...85,439,342
Ensembl chr13:85,402,169...85,439,342
|
|
| G
|
Olfml3
|
olfactomedin-like 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of OLFML3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:193,932,665...193,935,494
Ensembl chr 2:193,932,665...193,935,494
|
|
| G
|
Olr1
|
oxidized low density lipoprotein receptor 1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of OLR1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:164,612,460...164,635,082
Ensembl chr 4:164,612,463...164,634,598
|
|
| G
|
Omd
|
osteomodulin
|
increases expression
|
ISO EXP
|
Progesterone results in increased expression of OMD mRNA
|
CTD |
PMID:20726854 PMID:20864642 PMID:21795739 |
|
NCBI chr17:15,266,646...15,274,870
Ensembl chr17:15,266,646...15,274,870
|
|
| G
|
Oplah
|
5-oxoprolinase (ATP-hydrolysing)
|
increases expression
|
EXP
|
Progesterone results in increased expression of OPLAH mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 7:109,892,136...109,932,403
Ensembl chr 7:109,891,405...109,915,979
|
|
| G
|
Opn3
|
opsin 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of OPN3 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr13:90,121,560...90,152,076
Ensembl chr13:90,121,560...90,152,076
|
|
| G
|
Oprk1
|
opioid receptor, kappa 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of OPRK1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671
|
|
| G
|
Orai2
|
ORAI calcium release-activated calcium modulator 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ORAI2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr12:26,136,922...26,157,041
Ensembl chr12:26,132,193...26,157,041
|
|
| G
|
Orc2
|
origin recognition complex, subunit 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of ORC2 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 9:67,496,097...67,532,548
Ensembl chr 9:67,496,825...67,526,649
|
|
| G
|
Orc4
|
origin recognition complex, subunit 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of ORC4 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 3:53,700,046...53,743,293
Ensembl chr 3:53,703,615...53,742,264
|
|
| G
|
Orm1
|
orosomucoid 1
|
multiple interactions affects binding decreases expression affects expression increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ORM1 mRNA; Progesterone inhibits the reaction [Warfarin binds to ORM1 protein alternative form] Progesterone binds to ORM1 protein; Progesterone binds to ORM1 protein alternative form Progesterone results in decreased expression of ORM1 mRNA Progesterone affects the expression of ORM1 mRNA Progesterone results in increased expression of ORM1 mRNA
|
CTD |
PMID:8946472 PMID:16901474 PMID:17251523 PMID:17404688 PMID:19000923 |
|
NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:81,788,395...81,791,667
|
|
| G
|
Osbpl11
|
oxysterol binding protein-like 11
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of OSBPL11 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of OSBPL11 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr11:81,038,759...81,121,887
Ensembl chr11:81,038,985...81,101,299
|
|
| G
|
Osr1
|
odd-skipped related transcription factor 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of OSR1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:38,088,688...38,100,010
Ensembl chr 6:38,093,011...38,100,021
|
|
| G
|
Osr2
|
odd-skipped related transcription factor 2
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of OSR2 mRNA Progesterone inhibits the reaction [Estradiol results in increased expression of OSR2 mRNA]
|
CTD |
PMID:20864642 PMID:21795739 |
|
NCBI chr 7:68,372,500...68,380,195
Ensembl chr 7:68,373,049...68,380,805
|
|
| G
|
Otub1
|
OTU deubiquitinase, ubiquitin aldehyde binding 1
|
affects expression
|
ISO
|
Progesterone affects the expression of OTUB1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:213,816,400...213,824,679
Ensembl chr 1:213,816,400...213,824,679
|
|
| G
|
Otulinl
|
OTU deubiquitinase with linear linkage specificity like
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of OTULINL mRNA Progesterone results in increased expression of OTULINL mRNA
|
CTD |
PMID:18070364 PMID:20660070 PMID:21795739 |
|
NCBI chr 2:80,136,411...80,164,290
Ensembl chr 2:80,139,262...80,166,962
|
|
| G
|
Ovol1
|
ovo like transcriptional repressor 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of OVOL1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:212,284,601...212,296,106
Ensembl chr 1:212,284,605...212,296,106
|
|
| G
|
Oxt
|
oxytocin/neurophysin I prepropeptide
|
multiple interactions
|
EXP ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of OXT mRNA] [Estradiol co-treated with Progesterone] results in increased expression of OXT mRNA; ESR2 affects the reaction [[Estradiol co-treated with Progesterone] results in increased expression of OXT mRNA]
|
CTD |
PMID:12834440 PMID:17400809 |
|
NCBI chr 3:138,235,754...138,236,594
Ensembl chr 3:138,235,754...138,236,594
|
|
| G
|
Oxtr
|
oxytocin receptor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of OXTR mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 4:147,154,374...147,171,723
Ensembl chr 4:147,154,374...147,170,750
|
|
| G
|
P2rx3
|
purinergic receptor P2X 3
|
multiple interactions decreases activity
|
EXP
|
Mifepristone inhibits the reaction [Progesterone results in decreased activity of P2RX3 protein]
|
CTD |
PMID:21178388 |
|
NCBI chr 3:90,487,506...90,531,315
Ensembl chr 3:90,487,506...90,531,794
|
|
| G
|
P2ry14
|
purinergic receptor P2Y14
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of P2RY14 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of P2RY14 mRNA Progesterone results in increased expression of P2RY14 mRNA Progesterone inhibits the reaction [Estradiol results in increased expression of P2RY14 mRNA]
|
CTD |
PMID:17404688 PMID:18367319 PMID:20660070 PMID:20864642 |
|
NCBI chr 2:145,522,598...145,563,074
Ensembl chr 2:145,516,390...145,564,788
|
|
| G
|
P3h2
|
prolyl 3-hydroxylase 2
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of P3H2 mRNA [Estradiol co-treated with Progesterone] results in increased expression of P3H2 mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr11:88,139,086...88,280,221
Ensembl chr11:88,139,078...88,281,203
|
|
| G
|
P4ha2
|
prolyl 4-hydroxylase subunit alpha 2
|
affects expression
|
ISO
|
Progesterone affects the expression of P4HA2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:38,743,894...38,772,741
Ensembl chr10:38,743,894...38,772,993
|
|
| G
|
Padi2
|
peptidyl arginine deiminase 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PADI2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:158,492,087...158,534,662
Ensembl chr 5:158,492,066...158,534,662
|
|
| G
|
Paep
|
progestagen associated endometrial protein
|
multiple interactions increases abundance increases metabolic processing
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PAEP mRNA; [Estradiol co-treated with Progesterone] results in increased expression of PAEP mRNA PAEP protein modified form results in increased abundance of Progesterone; PAEP protein results in increased abundance of Progesterone PAEP protein modified form results in increased metabolism of Progesterone
|
CTD |
PMID:15852231 PMID:17649829 PMID:20660070 PMID:23029392 |
|
NCBI chr 3:28,929,252...28,932,592
|
|
| G
|
Pag1
|
phosphoprotein membrane anchor with glycosphingolipid microdomains 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PAG1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:93,842,747...93,984,314
Ensembl chr 2:93,964,594...93,977,227
|
|
| G
|
Pak1ip1
|
PAK1 interacting protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PAK1IP1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr17:23,947,978...23,959,055
Ensembl chr17:23,939,509...23,959,055
|
|
| G
|
Palmd
|
palmdelphin
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PALMD mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:207,574,413...207,626,239
Ensembl chr 2:207,574,249...207,626,239
|
|
| G
|
Pappa
|
pappalysin 1
|
multiple interactions decreases expression increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PAPPA mRNA; PAPPA protein affects the reaction [CGB3 protein results in increased abundance of Progesterone] Progesterone results in decreased expression of PAPPA mRNA Progesterone results in increased expression of PAPPA mRNA
|
CTD |
PMID:18497975 PMID:20130263 PMID:20660070 PMID:21273126 PMID:21795739 |
|
NCBI chr 5:83,513,358...83,751,364
Ensembl chr 5:83,513,358...83,751,361
|
|
| G
|
Papss2
|
3'-phosphoadenosine 5'-phosphosulfate synthase 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PAPSS2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:239,867,597...239,952,614
Ensembl chr 1:239,867,574...239,952,616
|
|
| G
|
Parm1
|
prostate androgen-regulated mucin-like protein 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of PARM1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr14:16,752,541...16,861,570
Ensembl chr14:16,752,541...16,881,138
|
|
| G
|
Patz1
|
POZ (BTB) and AT hook containing zinc finger 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PATZ1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr14:82,378,226...82,396,679
Ensembl chr14:82,377,697...82,396,686
|
|
| G
|
Pax5
|
paired box 5
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of PAX5 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 5:63,554,784...63,741,380
Ensembl chr 5:63,560,722...63,739,987
|
|
| G
|
Pbk
|
PDZ binding kinase
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of PBK mRNA Progesterone results in decreased expression of PBK mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr15:44,198,506...44,209,572
Ensembl chr15:44,198,544...44,209,570
|
|
| G
|
Pbx1
|
PBX homeobox 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PBX1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr13:82,811,664...83,121,447
Ensembl chr13:82,812,131...83,121,066
|
|
| G
|
Pcbp3
|
poly(rC) binding protein 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of PCBP3 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr20:11,635,579...11,877,721
Ensembl chr20:11,677,751...11,877,722
|
|
| G
|
Pcca
|
propionyl-CoA carboxylase subunit alpha
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of PCCA mRNA Progesterone results in increased expression of PCCA mRNA
|
CTD |
PMID:20726854 PMID:21540246 |
|
NCBI chr15:106,034,586...106,374,908
Ensembl chr15:106,034,610...106,374,908
|
|
| G
|
Pcdh18
|
protocadherin 18
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PCDH18 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:135,982,929...135,996,917
Ensembl chr 2:135,983,144...135,996,826
|
|
| G
|
Pcdh7
|
protocadherin 7
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PCDH7 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:56,684,817...57,114,976
Ensembl chr14:56,687,725...57,112,665
|
|
| G
|
Pcdh9
|
protocadherin 9
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PCDH9 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:75,748,472...76,646,644 NCBI chr15:76,078,024...76,127,778
Ensembl chr15:75,749,278...76,645,302
|
|
| G
|
Pcdhga1
|
protocadherin gamma subfamily A, 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PCDHGA1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr18:29,738,639...29,919,095
|
|
| G
|
Pcdhga11
|
protocadherin gamma subfamily A, 11
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PCDHGA11 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr18:29,834,606...29,919,095
|
|
| G
|
Pcdhga3
|
protocadherin gamma subfamily A, 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PCDHGA3 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr18:29,750,383...29,919,095
|
|
| G
|
Pcdhgc3
|
protocadherin gamma subfamily C, 3
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PCDHGC3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr18:29,884,245...29,919,095
|
|
| G
|
Pcgf2
|
polycomb group ring finger 2
|
affects expression
|
ISO
|
Progesterone affects the expression of PCGF2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:83,178,926...83,191,610
Ensembl chr10:83,179,916...83,183,999
|
|
| G
|
Pck1
|
phosphoenolpyruvate carboxykinase 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of PCK1 mRNA]; [Progesterone co-treated with Estradiol] inhibits the reaction [Phenobarbital results in decreased expression of PCK1 mRNA]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of PCK1 mRNA]; Progesterone inhibits the reaction [Phenobarbital results in decreased expression of PCK1 mRNA]; Progesterone promotes the reaction [Estradiol inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime inhibits the reaction [HNF4A protein binds to PCK1 promoter]]] 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [[Progesterone co-treated with Estradiol] results in increased expression of PCK1 mRNA]; [Progesterone co-treated with Estradiol] results in increased expression of PCK1 mRNA
|
CTD |
PMID:21768169 |
|
NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561
|
|
| G
|
Pck2
|
phosphoenolpyruvate carboxykinase 2 (mitochondrial)
|
increases expression
|
ISO
|
Progesterone results in increased expression of PCK2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr15:32,997,853...33,006,691
Ensembl chr15:32,997,834...33,016,864
|
|
| G
|
Pclaf
|
PCNA clamp associated factor
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of PCLAF mRNA Progesterone results in decreased expression of PCLAF mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr 8:75,311,028...75,328,108
Ensembl chr 8:75,315,707...75,328,106
|
|
| G
|
Pcna
|
proliferating cell nuclear antigen
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
Estradiol promotes the reaction [Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of PCNA protein]]; Lithium Chloride inhibits the reaction [Progesterone inhibits the reaction [Estradiol results in increased expression of PCNA protein]]; Progesterone inhibits the reaction [Estradiol results in increased expression of PCNA protein]; Progesterone inhibits the reaction [perfluorooctanoic acid results in decreased expression of PCNA protein]; Progesterone promotes the reaction [Estradiol inhibits the reaction [perfluorooctanoic acid results in decreased expression of PCNA protein]] Progesterone results in decreased expression of PCNA mRNA Progesterone results in increased expression of PCNA mRNA [Progesterone co-treated with Estrogens] results in increased expression of PCNA protein
|
CTD |
PMID:15845746 PMID:16966611 PMID:19847363 PMID:20726854 PMID:21258428 PMID:22414604 More...
|
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901
|
|
| G
|
Pcsk5
|
proprotein convertase subtilisin/kexin type 5
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PCSK5 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:224,263,823...224,694,350
Ensembl chr 1:224,264,678...224,694,347
|
|
| G
|
Pcsk6
|
proprotein convertase subtilisin/kexin type 6
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PCSK6 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of PCSK6 mRNA Progesterone results in increased expression of PCSK6 mRNA
|
CTD |
PMID:17404688 PMID:18070364 PMID:20660070 |
|
NCBI chr 1:128,839,742...129,038,087
Ensembl chr 1:128,839,232...129,052,128
|
|
| G
|
Pdap1
|
PDGFA associated protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of PDAP1 mRNA
|
CTD |
PMID:16888808 |
|
NCBI chr12:14,584,414...14,594,641
Ensembl chr12:14,584,398...14,594,641
|
|
| G
|
Pdcd4
|
programmed cell death 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of PDCD4 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 1:262,912,659...262,949,581
Ensembl chr 1:262,926,656...262,950,189
|
|
| G
|
Pdcl3
|
phosducin-like 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PDCL3 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 9:48,730,083...48,738,554
Ensembl chr 9:48,723,767...48,739,529
|
|
| G
|
Pde1c
|
phosphodiesterase 1C
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PDE1C mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 4:86,629,074...87,108,147
Ensembl chr 4:86,626,282...87,193,259
|
|
| G
|
Pde4b
|
phosphodiesterase 4B
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of PDE4B mRNA Progesterone results in increased expression of PDE4B mRNA
|
CTD |
PMID:18497975 PMID:21795739 |
|
NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:122,135,174...122,598,267
|
|
| G
|
Pde4dip
|
phosphodiesterase 4D interacting protein
|
increases expression
|
EXP
|
Progesterone results in increased expression of PDE4DIP mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:187,982,002...188,178,937
Ensembl chr 2:187,981,878...188,178,869
|
|
| G
|
Pde9a
|
phosphodiesterase 9A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PDE9A mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr20:9,471,136...9,564,286
Ensembl chr20:9,471,167...9,564,286
|
|
| G
|
Pdgfa
|
platelet derived growth factor subunit A
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PDGFA mRNA Progesterone results in increased expression of PDGFA mRNA
|
CTD |
PMID:16888808 PMID:17404688 |
|
NCBI chr12:20,759,366...20,780,337
Ensembl chr12:20,754,208...20,780,322
|
|
| G
|
Pdgfb
|
platelet derived growth factor subunit B
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PDGFB mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of PDGFB mRNA Progesterone results in decreased expression of PDGFB mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343
|
|
| G
|
Pdgfra
|
platelet derived growth factor receptor alpha
|
multiple interactions increases expression
|
ISO
|
[Progesterone results in increased secretion of [VEGFA protein binds to VEGFA protein]] which results in increased phosphorylation of PDGFRA protein; Progesterone promotes the reaction [Imatinib Mesylate results in decreased expression of PDGFRA protein modified form]; Progesterone promotes the reaction [Imatinib Mesylate results in decreased expression of PDGFRA protein] [Estradiol co-treated with Progesterone co-treated with Cuprizone] results in increased expression of PDGFRA mRNA Progesterone results in increased expression of PDGFRA mRNA
|
CTD |
PMID:16888808 PMID:17614352 PMID:19031445 PMID:22238285 |
|
NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,360,028...33,408,516
|
|
| G
|
Pdgfrb
|
platelet derived growth factor receptor beta
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of PDGFRB mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr18:56,770,348...56,809,228
Ensembl chr18:56,770,348...56,809,233
|
|
| G
|
Pdia3
|
protein disulfide isomerase family A, member 3
|
affects expression
|
ISO
|
Progesterone affects the expression of PDIA3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:128,841,781...128,865,733
Ensembl chr 3:128,841,917...128,867,327
|
|
| G
|
Pdia4
|
protein disulfide isomerase family A, member 4
|
affects expression
|
ISO
|
Progesterone affects the expression of PDIA4 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:78,134,144...78,153,191
Ensembl chr 4:78,134,144...78,153,191
|
|
| G
|
Pdia6
|
protein disulfide isomerase family A, member 6
|
affects expression
|
ISO
|
Progesterone affects the expression of PDIA6 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 6:45,791,704...45,808,947
Ensembl chr 6:45,791,678...45,810,091
|
|
| G
|
Pdk2
|
pyruvate dehydrogenase kinase 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of PDK2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:80,469,388...80,483,988
Ensembl chr10:80,469,389...80,484,355
|
|
| G
|
Pdlim1
|
PDZ and LIM domain 1
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of PDLIM1 mRNA Progesterone results in increased expression of PDLIM1 mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr 1:248,991,818...249,040,409
Ensembl chr 1:248,991,818...249,047,379
|
|
| G
|
Pdlim3
|
PDZ and LIM domain 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of PDLIM3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr16:53,085,020...53,116,495
Ensembl chr16:53,085,020...53,116,217
|
|
| G
|
Pdlim7
|
PDZ and LIM domain 7
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PDLIM7 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr17:9,129,603...9,144,956
Ensembl chr17:9,129,525...9,144,956
|
|
| G
|
Pdp1
|
pyruvate dehydrogenase phosphatase catalytic subunit 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PDP1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:30,245,699...30,252,494
Ensembl chr 5:30,242,704...30,253,960
|
|
| G
|
Pdpk1
|
3-phosphoinositide dependent protein kinase-1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PDPK1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:13,610,000...13,687,226
Ensembl chr10:13,610,063...13,679,181
|
|
| G
|
Pdpn
|
podoplanin
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PDPN mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:160,884,995...160,919,112
Ensembl chr 5:160,884,993...160,925,637
|
|
| G
|
Pds5a
|
PDS5 cohesin associated factor A
|
increases expression
|
ISO
|
Progesterone results in increased expression of PDS5A mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr14:42,905,734...43,004,740
Ensembl chr14:42,905,328...43,004,740
|
|
| G
|
Pdzd2
|
PDZ domain containing 2
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PDZD2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of PDZD2 mRNA Progesterone results in increased expression of PDZD2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 2:63,111,650...63,497,520
Ensembl chr 2:63,111,650...63,497,478
|
|
| G
|
Pecam1
|
platelet and endothelial cell adhesion molecule 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PECAM1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839
|
|
| G
|
Peg10
|
paternally expressed 10
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of PEG10 mRNA Progesterone results in increased expression of PEG10 mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr 4:33,809,026...33,822,224
Ensembl chr 4:33,817,190...33,819,166 Ensembl chr 4:33,817,190...33,819,166
|
|
| G
|
Pelo
|
pelota mRNA surveillance and ribosome rescue factor
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PELO mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:48,530,902...48,532,670
Ensembl chr 2:48,530,907...48,532,761
|
|
| G
|
Pemt
|
phosphatidylethanolamine N-methyltransferase
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PEMT mRNA Progesterone results in increased expression of PEMT mRNA
|
CTD |
PMID:20660070 PMID:20864642 |
|
NCBI chr10:45,275,434...45,349,651
Ensembl chr10:45,275,412...45,420,037
|
|
| G
|
Penk
|
proenkephalin
|
affects expression multiple interactions
|
ISO
|
Progesterone affects the expression of PENK mRNA [Estradiol co-treated with Progesterone] results in decreased expression of PENK mRNA
|
CTD |
PMID:17251523 PMID:19693291 |
|
NCBI chr 5:21,981,381...21,987,074
Ensembl chr 5:21,981,382...21,986,705
|
|
| G
|
Per1
|
period circadian regulator 1
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of PER1 mRNA; Progesterone results in increased expression of PER1 protein Mifepristone inhibits the reaction [Progesterone results in increased expression of PER1 mRNA]
|
CTD |
PMID:17761890 PMID:18037150 PMID:20096720 PMID:21795739 |
|
NCBI chr10:54,299,002...54,313,804
Ensembl chr10:54,302,641...54,314,211
|
|
| G
|
Per2
|
period circadian regulator 2
|
decreases expression increases expression multiple interactions
|
EXP ISO
|
Progesterone results in decreased expression of PER2 mRNA Progesterone results in increased expression of PER2 mRNA [Progesterone co-treated with Estradiol] results in increased expression of PER2 mRNA
|
CTD |
PMID:20096720 PMID:20726854 |
|
NCBI chr 9:99,454,828...99,497,069
Ensembl chr 9:99,454,830...99,496,993
|
|
| G
|
Per3
|
period circadian regulator 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PER3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 5:166,740,914...166,778,243
Ensembl chr 5:166,743,050...166,777,999
|
|
| G
|
Pfas
|
phosphoribosylformylglycinamidine synthase
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PFAS mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:54,189,157...54,210,685
Ensembl chr10:54,189,157...54,207,272
|
|
| G
|
Pfkm
|
phosphofructokinase, muscle
|
increases expression
|
EXP
|
Progesterone results in increased expression of PFKM mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 7:131,100,684...131,138,250
Ensembl chr 7:131,100,753...131,138,248
|
|
| G
|
Pfn2
|
profilin 2
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of PFN2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:144,217,100...144,222,936
Ensembl chr 2:144,205,636...144,222,936
|
|
| G
|
Pgap1
|
post-GPI attachment to proteins inositol deacylase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PGAP1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:63,470,023...63,538,772
Ensembl chr 9:63,470,024...63,538,772
|
|
| G
|
Pgbd5
|
piggyBac transposable element derived 5
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of PGBD5 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr19:69,234,171...69,299,315
Ensembl chr19:69,234,171...69,299,560
|
|
| G
|
Pglyrp1
|
peptidoglycan recognition protein 1
|
affects expression increases expression
|
ISO
|
Progesterone affects the expression of PGLYRP1 mRNA Progesterone results in increased expression of PGLYRP1 mRNA
|
CTD |
PMID:17251523 PMID:21549006 |
|
NCBI chr 1:87,659,863...87,665,048
Ensembl chr 1:87,651,271...87,665,048
|
|
| G
|
Pgm2l1
|
phosphoglucomutase 2-like 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PGM2L1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:163,983,917...164,033,027
Ensembl chr 1:163,983,917...164,033,027
|
|
| G
|
Pgm3
|
phosphoglucomutase 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of PGM3 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 8:96,398,331...96,416,045
Ensembl chr 8:96,398,269...96,416,021
|
|
| G
|
Pgr
|
progesterone receptor
|
multiple interactions affects expression increases expression affects binding decreases expression affects localization increases activity
|
ISO EXP
|
1-hydroxypyrene inhibits the reaction [Progesterone binds to PGR protein]; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene inhibits the reaction [Progesterone binds to PGR protein]; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene inhibits the reaction [Progesterone results in increased expression of PGR protein]; 4-hydroxy-2',3',4'-5'-tetrachlorobiphenyl inhibits the reaction [Progesterone binds to PGR protein]; 4-hydroxy-2',4',6'-trichlorobiphenyl inhibits the reaction [Progesterone binds to PGR protein]; 6-hydroxychrysene inhibits the reaction [Progesterone binds to PGR protein]; [8-Bromo Cyclic Adenosine Monophosphate co-treated with Progesterone co-treated with Estradiol] affects the expression of and affects the phosphorylation of PGR protein; [Progesterone affects the activity of PGR protein alternative form] which affects the expression of AREG mRNA; [Progesterone affects the activity of PGR protein alternative form] which affects the expression of IGFBP3 mRNA; [Progesterone affects the activity of PGR protein alternative form] which affects the expression of ITGB4 mRNA; [Progesterone affects the activity of PGR protein alternative form] which affects the expression of MT1L mRNA; [Progesterone co-treated with 1-hydroxypyrene] results in decreased expression of PGR mRNA; [Progesterone co-treated with 4-hydroxy-2',3',4'-5'-tetrachlorobiphenyl] results in decreased expression of PGR mRNA; [Progesterone co-treated with 4-hydroxy-2',4',6'-trichlorobiphenyl] results in decreased expression of PGR mRNA; [Progesterone co-treated with 6-hydroxychrysene] results in decreased expression of PGR mRNA; [Progesterone co-treated with Endosulfan] results in decreased expression of PGR mRNA; [Progesterone co-treated with Hexachlorocyclohexane] results in decreased expression of PGR mRNA; alachlor inhibits the reaction [Progesterone binds to PGR protein]; Aldicarb inhibits the reaction [Progesterone results in increased activity of PGR protein]; Aldrin inhibits the reaction [Progesterone binds to PGR protein]; Apigenin inhibits the reaction [Progesterone binds to PGR protein]; bendiocarb inhibits the reaction [Progesterone results in increased activity of PGR protein]; biochanin A inhibits the reaction [Progesterone binds to PGR protein]; bisphenol A inhibits the reaction [Progesterone binds to PGR protein]; bisphenol AF inhibits the reaction [Progesterone binds to PGR protein]; bisphenol B inhibits the reaction [Progesterone binds to PGR protein]; bisphenol Z inhibits the reaction [Progesterone binds to PGR protein]; Butylated Hydroxyanisole inhibits the reaction [Progesterone binds to PGR protein]; Carbaryl inhibits the reaction [Progesterone results in increased activity of PGR protein]; Chlordecone inhibits the reaction [Progesterone binds to PGR protein]; Chlorpyrifos inhibits the reaction [Progesterone binds to PGR protein]; Chlorpyrifos metabolite inhibits the reaction [Progesterone binds to PGR protein]; Coal Ash inhibits the reaction [Progesterone results in increased activity of PGR protein]; DDT inhibits the reaction [Progesterone binds to PGR protein]; DDT inhibits the reaction [Progesterone results in increased expression of PGR protein]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Progesterone binds to PGR protein]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [Progesterone results in increased expression of PGR protein]; Endosulfan inhibits the reaction [Progesterone binds to PGR protein]; Endosulfan inhibits the reaction [Progesterone results in increased expression of PGR protein]; Estradiol promotes the reaction [Progesterone binds to PGR protein]; fenvalerate inhibits the reaction [Progesterone results in increased expression of PGR protein]; Hexachlorocyclohexane inhibits the reaction [Progesterone binds to PGR protein]; Industrial Waste inhibits the reaction [Progesterone results in increased expression of PGR protein]; kaempferol inhibits the reaction [Progesterone binds to PGR protein]; Methomyl inhibits the reaction [Progesterone results in increased activity of PGR protein]; Methoxychlor inhibits the reaction [Progesterone binds to PGR protein]; Mifepristone inhibits the reaction [Progesterone results in increased expression of PGR protein]; Mifepristone promotes the reaction [Progesterone affects the expression of PGR mRNA]; Mitotane inhibits the reaction [Progesterone binds to PGR protein]; nonachlor inhibits the reaction [Progesterone binds to PGR protein]; nonylphenol inhibits the reaction [Progesterone binds to PGR protein]; nonylphenol inhibits the reaction [Progesterone results in increased expression of PGR protein]; O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate inhibits the reaction [Progesterone binds to PGR protein]; o,p'-DDT inhibits the reaction [Progesterone binds to PGR protein]; o,p'-DDT inhibits the reaction [Progesterone results in increased expression of PGR protein]; oxamyl inhibits the reaction [Progesterone results in increased activity of PGR protein]; Particulate Matter inhibits the reaction [Progesterone results in increased activity of PGR protein]; Permethrin inhibits the reaction [Progesterone results in increased expression of PGR protein]; Pesticides inhibits the reaction [Progesterone results in increased expression of PGR mRNA]; PGR protein affects the reaction [[Estradiol co-treated with Progesterone] results in increased expression of ITGA1]; PGR protein affects the reaction [Progesterone results in increased expression of TRIM22 mRNA]; phthalic acid analog inhibits the reaction [Progesterone binds to PGR protein]; Progesterone binds to and results in increased activity of PGR protein; Progesterone inhibits the reaction [Estradiol results in increased expression of PGR mRNA]; Progesterone promotes the reaction [PGR protein results in increased expression of CXCL14 mRNA]; Propoxur inhibits the reaction [Progesterone results in increased activity of PGR protein]; Resveratrol inhibits the reaction [PGR protein affects the reaction [[Estradiol co-treated with Progesterone] results in increased expression of ITGA1]]; Soil Pollutants inhibits the reaction [Progesterone results in increased expression of PGR mRNA]; Soot inhibits the reaction [Progesterone results in increased activity of PGR protein]; Toxaphene inhibits the reaction [Progesterone binds to PGR protein]; Vehicle Emissions inhibits the reaction [Progesterone results in increased activity of PGR protein]; vinclozolin inhibits the reaction [Progesterone binds to PGR protein]; vinclozolin inhibits the reaction [Progesterone results in increased expression of PGR protein]; zearalenol promotes the reaction [Progesterone binds to and results in increased activity of PGR protein]; Zearalenone inhibits the reaction [Progesterone binds to and results in increased activity of PGR protein]; ZNF366 protein inhibits the reaction [Progesterone results in increased activity of PGR protein] [Estradiol co-treated with Progesterone] results in increased expression of PGR mRNA; [Estrogens co-treated with Progesterone] results in increased phosphorylation of PGR protein; [Ethinyl Estradiol co-treated with Progesterone] results in increased expression of PGR protein; [Mifepristone binds to and results in decreased activity of PGR protein] which results in decreased susceptibility to Progesterone; [Progesterone co-treated with Estradiol] affects the expression of PGR mRNA; Atrazine inhibits the reaction [Progesterone binds to PGR protein]; Diethylstilbestrol inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of PGR protein]; Estradiol promotes the reaction [Progesterone binds to PGR protein]; Mifepristone inhibits the reaction [Progesterone results in increased expression of PGR mRNA]; o,p'-DDT promotes the reaction [Progesterone binds to PGR protein]; RNF4 protein promotes the reaction [Progesterone results in increased activity of PGR protein]; Simazine inhibits the reaction [Progesterone binds to PGR protein]; Ursodeoxycholic Acid inhibits the reaction [[Ethinyl Estradiol co-treated with Progesterone] results in increased expression of PGR protein] Progesterone binds to PGR protein; Progesterone binds to PGR protein alternative form Progesterone results in increased expression of PGR mRNA; Progesterone results in increased expression of PGR protein Progesterone results in decreased expression of PGR mRNA; Progesterone results in decreased expression of PGR protein Progesterone results in decreased expression of PGR mRNA; Progesterone results in decreased expression of PGR protein alternative form Progesterone affects the localization of PGR protein [Estradiol co-treated with Progesterone] affects the expression of PGR protein; [lipopolysaccharide, E coli O55-B5 co-treated with Progesterone] results in decreased expression of PGR protein alternative form; [Progesterone results in increased activity of PGR protein] which results in decreased expression of RBP4 mRNA; [Progesterone results in increased activity of PGR protein] which results in increased expression of ADH5 mRNA; [Progesterone results in increased activity of PGR protein] which results in increased expression of ALDH1A1 mRNA; [Progesterone results in increased activity of PGR protein] which results in increased expression of CITED2 mRNA; [Progesterone results in increased activity of PGR protein] which results in increased expression of CYP26A1 mRNA; [Progesterone results in increased activity of PGR protein] which results in increased expression of GATA2 mRNA; [Progesterone results in increased activity of PGR protein] which results in increased expression of KLK5 mRNA; [Progesterone results in increased activity of PGR protein] which results in increased expression of KLK6 mRNA; [Progesterone results in increased activity of PGR protein] which results in increased expression of RBP1 mRNA; bisphenol A inhibits the reaction [Progesterone results in increased expression of PGR mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of PGR mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of PGR protein]; octylphenol inhibits the reaction [Progesterone results in increased expression of PGR mRNA]; PGR gene mutant form inhibits the reaction [Progesterone results in increased expression of CCNG1 mRNA]; PGR protein affects the reaction [Progesterone results in decreased expression of BMP2 mRNA]; PGR protein affects the reaction [Progesterone results in decreased expression of BMP5 mRNA]; PGR protein affects the reaction [Progesterone results in decreased expression of WIF1 mRNA] Progesterone results in increased expression of PGR mRNA; Progesterone results in increased expression of PGR protein; Progesterone results in increased expression of PGR protein alternative form
|
CTD |
PMID:1544902 PMID:4375319 PMID:7414049 PMID:8812239 PMID:9126867 PMID:9144411 PMID:9710597 PMID:10888668 PMID:11507064 PMID:14579009 PMID:14728856 PMID:15189034 PMID:15661853 PMID:15806153 PMID:15845616 PMID:15866122 PMID:16198674 PMID:16284289 PMID:16326432 PMID:17251523 PMID:17556502 PMID:18060946 PMID:18262749 PMID:18653720 PMID:19903701 PMID:20008677 PMID:20726854 PMID:21258428 PMID:21795739 PMID:21803136 PMID:22238285 PMID:22414680 PMID:23183084 PMID:23275455 PMID:23409146 PMID:24777823 PMID:25210133 PMID:27264040 PMID:29248852 PMID:31195007 PMID:31566189 PMID:31889325 PMID:33728745 PMID:37009741 More...
|
|
NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271
|
|
| G
|
Pgrmc1
|
progesterone receptor membrane component 1
|
affects binding
|
EXP
|
Progesterone binds to PGRMC1 protein
|
CTD |
PMID:15934950 |
|
NCBI chr X:120,698,610...120,706,805
Ensembl chr X:120,698,610...120,706,805
|
|
| G
|
Phactr3
|
phosphatase and actin regulator 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PHACTR3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:185,582,134...185,801,404
Ensembl chr 3:185,582,796...185,801,822
|
|
| G
|
Phb1
|
prohibitin 1
|
multiple interactions
|
ISO
|
PHB1 protein inhibits the reaction [FSHB protein results in increased secretion of Progesterone]
|
CTD |
PMID:23254195 |
|
NCBI chr10:81,102,043...81,114,815
Ensembl chr10:81,102,028...81,116,233
|
|
| G
|
Phf7
|
PHD finger protein 7
|
affects expression
|
ISO
|
Progesterone affects the expression of PHF7 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr16:6,439,968...6,452,671
Ensembl chr16:6,439,970...6,452,671
|
|
| G
|
Phlda1
|
pleckstrin homology-like domain, family A, member 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of PHLDA1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of PHLDA1 mRNA [Estradiol co-treated with Progesterone] results in increased expression of PHLDA1 mRNA
|
CTD |
PMID:18556351 PMID:20660070 PMID:21795739 |
|
NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:48,853,260...48,857,542
|
|
| G
|
Phlda2
|
pleckstrin homology-like domain, family A, member 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of PHLDA2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:208,126,302...208,127,241
Ensembl chr 1:208,126,302...208,127,920
|
|
| G
|
Phox2a
|
paired-like homeobox 2a
|
increases expression
|
EXP
|
Progesterone results in increased expression of PHOX2A mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:165,590,757...165,595,122
Ensembl chr 1:165,590,757...165,595,122
|
|
| G
|
Phyh
|
phytanoyl-CoA 2-hydroxylase
|
increases expression
|
EXP
|
Progesterone results in increased expression of PHYH mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr17:78,238,747...78,255,645
Ensembl chr17:78,238,747...78,255,645
|
|
| G
|
Pi15
|
peptidase inhibitor 15
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PI15 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:6,178,427...6,206,548
Ensembl chr 5:6,174,963...6,247,841
|
|
| G
|
Pibf1
|
progesterone immunomodulatory binding factor 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of PIBF1 mRNA; Progesterone results in increased expression of PIBF1 protein
|
CTD |
PMID:17701593 |
|
NCBI chr15:82,258,243...82,427,546
Ensembl chr15:82,258,468...82,427,548
|
|
| G
|
Pid1
|
phosphotyrosine interaction domain containing 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PID1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of PID1 mRNA Progesterone results in increased expression of PID1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 9:92,732,471...92,951,168
Ensembl chr 9:92,734,214...92,750,070
|
|
| G
|
Piezo2
|
piezo-type mechanosensitive ion channel component 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PIEZO2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr18:58,738,734...59,115,252
Ensembl chr18:58,738,740...59,115,215
|
|
| G
|
Pik3r3
|
phosphoinositide-3-kinase regulatory subunit 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PIK3R3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 5:134,936,790...135,009,303
Ensembl chr 5:134,934,857...135,007,762
|
|
| G
|
Pim1
|
Pim-1 proto-oncogene, serine/threonine kinase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PIM1 mRNA; Mifepristone promotes the reaction [Progesterone affects the expression of PIM1 mRNA]
|
CTD |
PMID:20660070 PMID:22414680 |
|
NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764
|
|
| G
|
Pim3
|
Pim-3 proto-oncogene, serine/threonine kinase
|
increases expression
|
EXP
|
Progesterone results in increased expression of PIM3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 7:121,822,076...121,836,257
Ensembl chr 7:121,832,742...121,836,259
|
|
| G
|
Pip5k1b
|
phosphatidylinositol-4-phosphate 5-kinase type 1 beta
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PIP5K1B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:231,331,836...231,610,092
Ensembl chr 1:231,340,606...231,496,812
|
|
| G
|
Pitpnb
|
phosphatidylinositol transfer protein, beta
|
affects expression
|
ISO
|
Progesterone affects the expression of PITPNB mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr12:50,909,140...50,958,193
Ensembl chr12:50,909,143...50,958,140
|
|
| G
|
Pkd1
|
polycystin 1, transient receptor potential channel interacting
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PKD1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr10:14,077,733...14,125,682
Ensembl chr10:14,078,679...14,125,681
|
|
| G
|
Pkhd1l1
|
PKHD1 like 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PKHD1L1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:77,505,063...77,679,994
Ensembl chr 7:77,505,152...77,679,994
|
|
| G
|
Pkia
|
cAMP-dependent protein kinase inhibitor alpha
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PKIA mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 2:96,306,181...96,380,959
Ensembl chr 2:96,306,184...96,321,262
|
|
| G
|
Pkm
|
pyruvate kinase M1/2
|
affects expression
|
ISO
|
Progesterone affects the expression of PKM mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 8:68,949,731...68,975,394
Ensembl chr 8:68,948,815...68,975,396
|
|
| G
|
Pla2g10
|
phospholipase A2, group X
|
affects expression
|
ISO
|
Progesterone affects the expression of PLA2G10 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:2,104,927...2,117,998
Ensembl chr10:2,104,927...2,116,172
|
|
| G
|
Pla2g4a
|
phospholipase A2 group 4A
|
increases expression
|
ISO
|
Progesterone results in increased expression of PLA2G4A mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641
|
|
| G
|
Pla2g5
|
phospholipase A2, group V
|
increases expression decreases expression
|
EXP ISO
|
Progesterone results in increased expression of PLA2G5 mRNA Progesterone results in decreased expression of PLA2G5 mRNA
|
CTD |
PMID:20726854 PMID:22238285 |
|
NCBI chr 5:156,324,628...156,393,065
Ensembl chr 5:156,324,629...156,381,926
|
|
| G
|
Pla2g7
|
phospholipase A2 group VII
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PLA2G7 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 9:24,859,491...24,901,747
Ensembl chr 9:24,859,502...24,901,747
|
|
| G
|
Plaat3
|
phospholipase A and acyltransferase 3
|
increases expression
|
EXP
|
Progesterone results in increased expression of PLAAT3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:214,211,755...214,245,551
Ensembl chr 1:214,211,791...214,246,763
|
|
| G
|
Plac8
|
placenta associated 8
|
increases expression
|
ISO
|
Progesterone results in increased expression of PLAC8 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr14:9,356,950...9,378,586
Ensembl chr14:9,356,972...9,378,572
|
|
| G
|
Plat
|
plasminogen activator, tissue type
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of PLAT mRNA Progesterone results in decreased expression of PLAT mRNA
|
CTD |
PMID:21795739 PMID:22238285 |
|
NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696
|
|
| G
|
Plau
|
plasminogen activator, urokinase
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PLAU mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of PLAU mRNA Progesterone results in decreased expression of PLAU mRNA
|
CTD |
PMID:17404688 PMID:18070364 PMID:20660070 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030
|
|
| G
|
Plaur
|
plasminogen activator, urokinase receptor
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of PLAUR mRNA; Progesterone results in increased expression of PLAUR protein [Estradiol co-treated with Progesterone] results in decreased expression of PLAUR mRNA
|
CTD |
PMID:17170212 PMID:20660070 |
|
NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130
|
|
| G
|
Plcb1
|
phospholipase C beta 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PLCB1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:142,513,033...143,225,646
|
|
| G
|
Plcb4
|
phospholipase C, beta 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of PLCB4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:143,405,721...143,775,129
Ensembl chr 3:143,405,950...143,775,113
|
|
| G
|
Plce1
|
phospholipase C, epsilon 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PLCE1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:245,655,855...245,964,966
Ensembl chr 1:245,657,080...245,963,828
|
|
| G
|
Plch1
|
phospholipase C, eta 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PLCH1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:150,298,547...150,514,120
Ensembl chr 2:150,299,075...150,464,019
|
|
| G
|
Pld1
|
phospholipase D1
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PLD1 mRNA Progesterone results in decreased expression of PLD1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 2:112,777,820...112,975,857
Ensembl chr 2:112,777,951...112,976,245
|
|
| G
|
Plec
|
plectin
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PLEC mRNA
|
CTD |
PMID:18037150 PMID:18070364 |
|
NCBI chr 7:109,768,447...109,829,798
Ensembl chr 7:109,768,447...109,828,089
|
|
| G
|
Plek2
|
pleckstrin 2
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PLEK2 mRNA Progesterone results in decreased expression of PLEK2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 6:103,434,156...103,452,457
Ensembl chr 6:103,434,156...103,452,371
|
|
| G
|
Plekha7
|
pleckstrin homology domain containing A7
|
increases expression
|
ISO
|
Progesterone results in increased expression of PLEKHA7 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 1:179,798,856...179,982,155
Ensembl chr 1:179,799,040...179,982,281
|
|
| G
|
Plekho1
|
pleckstrin homology domain containing O1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PLEKHO1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:186,233,435...186,242,114
Ensembl chr 2:186,233,452...186,241,354
|
|
| G
|
Plk2
|
polo-like kinase 2
|
multiple interactions decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of PLK2 mRNA Progesterone results in decreased expression of PLK2 mRNA
|
CTD |
PMID:20660070 PMID:20726854 |
|
NCBI chr 2:43,702,536...43,708,305
Ensembl chr 2:43,701,865...43,708,296
|
|
| G
|
Plk4
|
polo-like kinase 4
|
affects expression
|
ISO
|
Progesterone affects the expression of PLK4 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:125,730,480...125,748,894
Ensembl chr 2:125,730,460...125,748,892
|
|
| G
|
Pllp
|
plasmolipin
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PLLP mRNA Progesterone results in increased expression of PLLP mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr19:10,321,080...10,341,869
Ensembl chr19:10,321,080...10,342,226
|
|
| G
|
Pln
|
phospholamban
|
increases expression multiple interactions
|
EXP
|
Progesterone results in increased expression of PLN mRNA Mifepristone inhibits the reaction [Progesterone inhibits the reaction [bisphenol A results in increased phosphorylation of PLN protein]]; Pertussis Toxin inhibits the reaction [Progesterone inhibits the reaction [bisphenol A results in increased phosphorylation of PLN protein]]; Progesterone inhibits the reaction [bisphenol A results in increased phosphorylation of PLN protein]; wortmannin inhibits the reaction [Progesterone inhibits the reaction [bisphenol A results in increased phosphorylation of PLN protein]]
|
CTD |
PMID:16376865 PMID:28324061 |
|
NCBI chr20:33,166,512...33,182,241
Ensembl chr20:33,172,494...33,182,241
|
|
| G
|
Plod2
|
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of PLOD2 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 8:101,964,318...102,047,022
Ensembl chr 8:101,964,318...102,047,022
|
|
| G
|
Plp1
|
proteolipid protein 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] inhibits the reaction [Cuprizone results in decreased expression of PLP1 mRNA]
|
CTD |
PMID:19031445 |
|
NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314
|
|
| G
|
Plpp3
|
phospholipid phosphatase 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of PLPP3 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:125,155,945...125,235,667
|
|
| G
|
Plscr4
|
phospholipid scramblase 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PLSCR4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:101,867,057...101,905,827
Ensembl chr 8:101,866,888...101,905,831
|
|
| G
|
Plxdc1
|
plexin domain containing 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PLXDC1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr10:83,418,837...83,478,451
Ensembl chr10:83,418,837...83,478,755
|
|
| G
|
Plxnc1
|
plexin C1
|
increases expression
|
ISO
|
Progesterone results in increased expression of PLXNC1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 7:31,276,978...31,430,823
Ensembl chr 7:31,276,978...31,431,092
|
|
| G
|
Pmaip1
|
phorbol-12-myristate-13-acetate-induced protein 1
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PMAIP1 mRNA Progesterone results in decreased expression of PMAIP1 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382
|
|
| G
|
Pmepa1
|
prostate transmembrane protein, androgen induced 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PMEPA1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:182,430,193...182,478,649
Ensembl chr 3:182,430,193...182,478,649
|
|
| G
|
Pmp22
|
peripheral myelin protein 22
|
multiple interactions increases expression
|
EXP
|
Progesterone inhibits the reaction [Streptozocin results in decreased expression of PMP22 mRNA] Progesterone results in increased expression of PMP22 mRNA
|
CTD |
PMID:16787508 PMID:17187935 |
|
NCBI chr10:48,294,932...48,324,941
Ensembl chr10:48,297,437...48,324,940
|
|
| G
|
Pnliprp1
|
pancreatic lipase-related protein 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PNLIPRP1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 1:267,854,027...267,869,654
Ensembl chr 1:267,854,027...267,869,654
|
|
| G
|
Pnma8a
|
PNMA family member 8A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PNMA8A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:86,763,475...86,771,117
Ensembl chr 1:86,756,168...86,815,182
|
|
| G
|
Pnoc
|
prepronociceptin
|
multiple interactions
|
EXP
|
nociceptin (1-13) amide inhibits the reaction [PNOC protein inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of LHB protein]]; PNOC protein inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of LHB protein]
|
CTD |
PMID:17640482 |
|
NCBI chr15:43,800,240...43,827,841
Ensembl chr15:43,800,246...43,827,470
|
|
| G
|
Pnrc2
|
proline-rich nuclear receptor coactivator 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PNRC2 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 5:153,387,522...153,390,506
Ensembl chr 5:153,378,863...153,390,748
|
|
| G
|
Podxl
|
podocalyxin-like
|
increases expression
|
EXP
|
Progesterone results in increased expression of PODXL mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:61,102,434...61,149,131
Ensembl chr 4:61,102,419...61,149,789
|
|
| G
|
Pof1b
|
POF1B, actin binding protein
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of POF1B mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr X:81,875,348...81,942,046
Ensembl chr X:81,875,348...81,941,906
|
|
| G
|
Pofut1
|
protein O-fucosyltransferase 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of POFUT1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:162,168,855...162,195,798
Ensembl chr 3:162,168,606...162,195,018
|
|
| G
|
Pold1
|
DNA polymerase delta 1, catalytic subunit
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of POLD1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:104,161,984...104,178,074
Ensembl chr 1:104,162,016...104,172,982
|
|
| G
|
Pole4
|
DNA polymerase epsilon 4, accessory subunit
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of POLE4 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 4:116,723,040...116,728,873
Ensembl chr 4:116,716,719...116,728,851
|
|
| G
|
Polr1b
|
RNA polymerase I subunit B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of POLR1B mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:136,787,130...136,811,608
Ensembl chr 3:136,787,107...136,811,607
|
|
| G
|
Polr2j
|
RNA polymerase II subunit J
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of POLR2J mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr12:26,179,649...26,185,201
Ensembl chr12:26,179,649...26,185,201
|
|
| G
|
Polr2m
|
RNA polymerase II subunit M
|
increases expression
|
EXP
|
Progesterone results in increased expression of POLR2M mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 8:81,012,770...81,020,201
Ensembl chr 8:81,012,771...81,020,302
|
|
| G
|
Polr3k
|
RNA polymerase III subunit K
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of POLR3K mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:189,360,349...189,364,546
Ensembl chr 3:189,360,171...189,366,697
|
|
| G
|
Pomc
|
proopiomelanocortin
|
multiple interactions increases abundance
|
ISO
|
[benzylphosphonic acid results in decreased activity of POMC protein] which results in decreased chemical synthesis of Progesterone; [oxophenylarsine results in decreased activity of POMC protein] which results in decreased chemical synthesis of Progesterone; HMOX1 protein inhibits the reaction [POMC protein results in increased abundance of Progesterone] Melatonin inhibits the reaction [POMC protein results in increased abundance of Progesterone]
|
CTD |
PMID:12530643 PMID:19489000 PMID:21332028 |
|
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173
|
|
| G
|
Porcn
|
porcupine O-acyltransferase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PORCN mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr X:16,957,811...16,970,440
Ensembl chr X:16,957,810...16,970,439
|
|
| G
|
Pou5f1
|
POU class 5 homeobox 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of POU5F1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598
|
|
| G
|
Pparg
|
peroxisome proliferator-activated receptor gamma
|
increases expression
|
EXP
|
Progesterone results in increased expression of PPARG mRNA
|
CTD |
PMID:16954335 |
|
NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104
|
|
| G
|
Ppargc1a
|
PPARG coactivator 1 alpha
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of PPARGC1A mRNA Progesterone results in increased expression of PPARGC1A mRNA
|
CTD |
PMID:17404688 PMID:23056435 |
|
NCBI chr14:63,073,505...63,729,215
Ensembl chr14:63,273,189...63,729,213
|
|
| G
|
Ppfibp1
|
PPFIA binding protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PPFIBP1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 4:181,538,249...181,682,079
Ensembl chr 4:181,539,450...181,682,076
|
|
| G
|
Ppfibp2
|
PPFIA binding protein 2
|
multiple interactions affects response to substance
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PPFIBP2 mRNA PPFIBP2 gene SNP affects the susceptibility to Progesterone
|
CTD |
PMID:17404688 PMID:25622337 |
|
NCBI chr 1:170,916,649...171,062,096
Ensembl chr 1:170,916,649...171,065,618
|
|
| G
|
Ppif
|
peptidylprolyl isomerase F
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of PPIF mRNA Progesterone results in increased expression of PPIF mRNA
|
CTD |
PMID:18037150 PMID:20726854 |
|
NCBI chr16:1,264,001...1,270,722
Ensembl chr16:1,263,541...1,316,954
|
|
| G
|
Ppl
|
periplakin
|
increases expression
|
ISO
|
Progesterone results in increased expression of PPL mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:10,957,388...11,003,035
Ensembl chr10:10,957,341...11,003,658
|
|
| G
|
Ppm1h
|
protein phosphatase, Mg2+/Mn2+ dependent, 1H
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PPM1H mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 7:60,224,087...60,484,947
Ensembl chr 7:60,223,745...60,488,140
|
|
| G
|
Ppp1r14a
|
protein phosphatase 1, regulatory (inhibitor) subunit 14A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PPP1R14A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:93,708,269...93,718,218
Ensembl chr 1:93,708,218...93,719,147
|
|
| G
|
Ppp1r14c
|
protein phosphatase 1, regulatory (inhibitor) subunit 14c
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PPP1R14C mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:42,177,977...42,358,654
Ensembl chr 1:42,179,523...42,376,419
|
|
| G
|
Ppp1r15a
|
protein phosphatase 1, regulatory subunit 15A
|
increases expression
|
ISO
|
Progesterone results in increased expression of PPP1R15A mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:105,136,525...105,139,774
|
|
| G
|
Ppp1r16b
|
protein phosphatase 1, regulatory subunit 16B
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PPP1R16B mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 3:167,743,518...167,839,511
Ensembl chr 3:167,743,952...167,839,242
|
|
| G
|
Ppp1r1a
|
protein phosphatase 1, regulatory (inhibitor) subunit 1A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PPP1R1A mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 7:136,533,031...136,540,687
Ensembl chr 7:136,523,604...136,540,683
|
|
| G
|
Ppp1r1b
|
protein phosphatase 1, regulatory (inhibitor) subunit 1B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PPP1R1B mRNA
|
CTD |
PMID:16966611 PMID:22238285 |
|
NCBI chr10:83,843,948...83,853,063
Ensembl chr10:83,844,036...83,853,063
|
|
| G
|
Ppp1r36
|
protein phosphatase 1, regulatory subunit 36
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PPP1R36 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:100,874,397...100,894,764
Ensembl chr 6:100,874,374...100,894,756
|
|
| G
|
Ppp2ca
|
protein phosphatase 2 catalytic subunit alpha
|
increases expression
|
EXP
|
Progesterone results in increased expression of PPP2CA mRNA
|
CTD |
PMID:16376865 |
|
NCBI chr10:36,856,534...36,878,789
|
|
| G
|
Ppp2r2b
|
protein phosphatase 2, regulatory subunit B, beta
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of PPP2R2B mRNA Progesterone results in decreased expression of PPP2R2B mRNA
|
CTD |
PMID:17251523 PMID:17556502 PMID:22238285 |
|
NCBI chr18:34,904,686...35,357,299
Ensembl chr18:34,904,686...35,356,977
|
|
| G
|
Ppp2r3c
|
protein phosphatase 2, regulatory subunit B'', gamma
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PPP2R3C mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:78,382,849...78,406,037
Ensembl chr 6:78,382,855...78,406,201
|
|
| G
|
Ppwd1
|
peptidylprolyl isomerase domain and WD repeat containing 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PPWD1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:37,069,744...37,094,252
Ensembl chr 2:37,071,083...37,094,242
|
|
| G
|
Prag1
|
PEAK1 related kinase activating pseudokinase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PRAG1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr16:62,791,249...62,844,532
Ensembl chr16:62,786,329...62,844,532
|
|
| G
|
Pramex1
|
PRAME like, X-linked 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PRAME mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr X:102,862,457...102,867,725
Ensembl chr X:102,861,881...102,870,708
|
|
| G
|
Prap1
|
proline-rich acidic protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PRAP1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:204,312,723...204,316,519
Ensembl chr 1:204,312,723...204,316,517
|
|
| G
|
Prc1
|
protein regulator of cytokinesis 1
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of PRC1 mRNA Progesterone results in decreased expression of PRC1 mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr 1:143,659,312...143,681,019
Ensembl chr 1:143,659,481...143,681,012
|
|
| G
|
Prdm12
|
PR/SET domain 12
|
increases expression
|
ISO
|
Progesterone results in increased expression of PRDM12 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 3:35,322,962...35,341,878
Ensembl chr 3:35,322,962...35,341,878
|
|
| G
|
Prkaa1
|
protein kinase AMP-activated catalytic subunit alpha 1
|
multiple interactions
|
EXP
|
[AICA ribonucleotide results in increased phosphorylation of PRKAA1 protein] which results in decreased secretion of Progesterone; PRKAA1 gene mutant form inhibits the reaction [Metformin results in decreased secretion of Progesterone]
|
CTD |
PMID:16020477 PMID:16760380 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:55,967,351...56,003,450
|
|
| G
|
Prkaa2
|
protein kinase AMP-activated catalytic subunit alpha 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of PRKAA2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:125,042,179...125,108,324
|
|
| G
|
Prkag2
|
protein kinase AMP-activated non-catalytic subunit gamma 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of PRKAG2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 4:10,744,695...10,985,939
Ensembl chr 4:10,744,588...10,985,939
|
|
| G
|
Prkar1b
|
protein kinase cAMP-dependent type I regulatory subunit beta
|
affects expression
|
ISO
|
Progesterone affects the expression of PRKAR1B mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr12:20,606,066...20,738,766
Ensembl chr12:20,618,757...20,738,766
|
|
| G
|
Prkca
|
protein kinase C, alpha
|
decreases phosphorylation multiple interactions
|
ISO
|
Progesterone results in decreased phosphorylation of PRKCA protein PRKCA protein promotes the reaction [[Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; Progesterone inhibits the reaction [C3 protein results in increased phosphorylation of PRKCA protein]
|
CTD |
PMID:18615583 PMID:21047949 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572
|
|
| G
|
Prkcd
|
protein kinase C, delta
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of PRKCD mRNA PRKCD protein promotes the reaction [[Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]
|
CTD |
PMID:17170212 PMID:21047949 |
|
NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839
|
|
| G
|
Prkce
|
protein kinase C, epsilon
|
decreases expression multiple interactions
|
EXP ISO
|
Progesterone results in decreased expression of PRKCE mRNA PRKCE protein promotes the reaction [[Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]
|
CTD |
PMID:17170212 PMID:21047949 |
|
NCBI chr 6:13,718,050...14,204,931
Ensembl chr 6:13,718,050...14,204,288
|
|
| G
|
Prkcq
|
protein kinase C, theta
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PRKCQ mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:72,156,215...72,288,508
Ensembl chr17:72,156,215...72,288,508
|
|
| G
|
Prkcz
|
protein kinase C, zeta
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [C3 protein results in increased phosphorylation of PRKCZ protein]
|
CTD |
PMID:18615583 |
|
NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:171,101,774...171,212,674
|
|
| G
|
Prkd1
|
protein kinase D1
|
multiple interactions
|
ISO
|
PRKD1 protein promotes the reaction [[Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]
|
CTD |
PMID:21047949 |
|
NCBI chr 6:73,460,640...73,774,433
Ensembl chr 6:73,460,640...73,836,509
|
|
| G
|
Prkx
|
protein kinase cAMP-dependent X-linked catalytic subunit
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of PRKX mRNA Progesterone results in increased expression of PRKX mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr X:45,701,747...45,745,210
Ensembl chr X:45,701,747...45,745,066
|
|
| G
|
Prl
|
prolactin
|
multiple interactions decreases abundance decreases expression increases secretion increases expression
|
ISO EXP
|
[Cyclic AMP co-treated with Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Estradiol co-treated with Progesterone] results in increased expression of PRL mRNA; [Estradiol co-treated with Progesterone] results in increased secretion of PRL protein; [Progesterone co-treated with Estradiol] results in increased expression of PRL mRNA; [Progesterone co-treated with Estrogens] results in increased secretion of PRL protein; Copper inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased secretion of PRL protein]; IL11 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]; IL11 protein promotes the reaction [INHBA protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]; INHBA protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]; INHBA protein promotes the reaction [IL11 protein promotes the reaction [[Estradiol co-treated with Progesterone] results in increased secretion of PRL protein]]; Lead inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased secretion of PRL protein]; PRL promoter mutant form affects the reaction [[Progesterone co-treated with Estradiol] results in increased expression of PRL mRNA]; Progesterone promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of PRL mRNA]; Progesterone promotes the reaction [Triclosan results in increased secretion of PRL protein] PRL protein results in decreased abundance of Progesterone [Dinoprost results in decreased abundance of Progesterone] which results in increased expression of PRL protein; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] affects the metabolism of 9,10-Dimethyl-1,2-benzanthracene; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1A1 protein]; [Estradiol co-treated with Progesterone co-treated with Hydrocortisone co-treated with PRL protein] inhibits the reaction [benz(a)anthracene results in increased expression of CYP1B1 protein]; MC2R protein promotes the reaction [PRL protein results in increased secretion of Progesterone]; PRL protein promotes the reaction [MC2R protein results in increased secretion of Progesterone]; Progesterone inhibits the reaction [Diethylstilbestrol results in increased expression of PRL protein]; Progesterone inhibits the reaction [Estradiol results in decreased expression of PRL mRNA]; Progesterone inhibits the reaction [PRL protein results in increased expression of CISH mRNA]; Progesterone inhibits the reaction [PRL protein results in increased expression of SOCS1 mRNA] Progesterone results in decreased expression of PRL mRNA Progesterone results in increased secretion of PRL protein Progesterone results in increased expression of PRL mRNA
|
CTD |
PMID:8674863 PMID:12650681 PMID:16403803 PMID:17187171 PMID:18325991 PMID:18609294 PMID:18815356 PMID:19082791 PMID:20074812 PMID:20864642 PMID:21540246 PMID:21654155 PMID:22064387 PMID:22785235 PMID:23275455 PMID:26604029 PMID:32004626 PMID:32446389 More...
|
|
NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217
|
|
| G
|
Prlr
|
prolactin receptor
|
decreases expression multiple interactions increases expression
|
EXP ISO
|
Progesterone results in decreased expression of PRLR mRNA [Progesterone co-treated with Estradiol] results in decreased expression of PRLR mRNA Progesterone results in increased expression of PRLR mRNA [Estradiol co-treated with Progesterone] results in decreased expression of PRLR mRNA
|
CTD |
PMID:16107292 PMID:20660070 PMID:20864642 PMID:33728745 |
|
NCBI chr 2:60,861,391...61,051,883
Ensembl chr 2:60,861,658...61,051,882
|
|
| G
|
Prmt7
|
protein arginine methyltransferase 7
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] affects the expression of PRMT7 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr19:51,020,596...51,071,401
Ensembl chr19:51,020,512...51,072,424
|
|
| G
|
Prnp
|
prion protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of PRNP mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:139,639,076...139,654,420
Ensembl chr 3:139,630,144...139,658,436
|
|
| G
|
Prodh1
|
proline dehydrogenase 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PRODH mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr11:96,414,275...96,431,604
Ensembl chr11:96,414,224...96,433,418
|
|
| G
|
Prok1
|
prokineticin 1
|
increases expression affects response to substance
|
ISO
|
Progesterone results in increased expression of PROK1 mRNA PROK1 protein affects the susceptibility to Progesterone
|
CTD |
PMID:21540246 PMID:21546446 |
|
NCBI chr 2:197,538,747...197,547,550
Ensembl chr 2:197,537,068...197,547,550
|
|
| G
|
Prom1
|
prominin 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PROM1 mRNA
|
CTD |
PMID:20864642 PMID:22238285 |
|
NCBI chr14:71,202,303...71,307,008
Ensembl chr14:71,202,336...71,307,002
|
|
| G
|
Prpf40a
|
pre-mRNA processing factor 40 homolog A
|
increases expression
|
ISO
|
Progesterone results in increased expression of PRPF40A mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:58,036,779...58,098,996
Ensembl chr 3:58,038,042...58,099,363
|
|
| G
|
Prpsap1
|
phosphoribosyl pyrophosphate synthetase-associated protein 1
|
multiple interactions increases expression
|
EXP
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of PRPSAP1 mRNA]
|
CTD |
PMID:10888668 |
|
NCBI chr10:102,199,949...102,221,642
Ensembl chr10:102,199,950...102,221,642
|
|
| G
|
Prr15
|
proline rich 15
|
increases expression
|
ISO
|
Progesterone results in increased expression of PRR15 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 4:84,762,357...84,765,403
Ensembl chr 4:84,761,523...84,768,442
|
|
| G
|
Prr15l
|
proline rich 15-like
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PRR15L mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:82,412,934...82,418,897
Ensembl chr10:82,402,733...82,419,558
|
|
| G
|
Prrc2a
|
proline-rich coiled-coil 2A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PRRC2A mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr20:3,660,981...3,686,715
Ensembl chr20:3,663,400...3,678,778
|
|
| G
|
Prrx1
|
paired related homeobox 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PRRX1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:78,136,783...78,205,379
Ensembl chr13:78,136,783...78,204,058
|
|
| G
|
Prss23
|
serine protease 23
|
decreases expression increases expression
|
ISO
|
Progesterone results in decreased expression of PRSS23 mRNA Progesterone results in increased expression of PRSS23 mRNA
|
CTD |
PMID:21273126 PMID:21795739 |
|
NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:152,813,670...152,947,871
|
|
| G
|
Prss29
|
serine protease 29
|
multiple interactions increases expression
|
ISO
|
Estrogens inhibits the reaction [Progesterone results in increased expression of PRSS29 protein] Progesterone results in increased expression of PRSS29 mRNA; Progesterone results in increased expression of PRSS29 protein
|
CTD |
PMID:15349836 |
|
NCBI chr10:14,841,808...14,845,531
Ensembl chr10:14,841,905...14,845,332
|
|
| G
|
Prune2
|
prune homolog 2 with BCH domain
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of PRUNE2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:223,779,617...224,130,058
Ensembl chr 1:223,969,102...224,051,592
|
|
| G
|
Psat1
|
phosphoserine aminotransferase 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of PSAT1 mRNA [Estradiol co-treated with Progesterone] results in increased expression of PSAT1 mRNA
|
CTD |
PMID:18037150 PMID:20660070 |
|
NCBI chr 1:222,623,553...222,646,187
Ensembl chr 1:222,623,556...222,655,693
|
|
| G
|
Psd3
|
pleckstrin and Sec7 domain containing 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PSD3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr16:26,238,595...26,802,535
Ensembl chr16:26,340,028...26,802,535
|
|
| G
|
Psen1
|
presenilin 1
|
multiple interactions decreases metabolic processing
|
ISO
|
Progesterone inhibits the reaction [PSEN1 gene mutant form results in decreased metabolism of Progesterone metabolite]
|
CTD |
PMID:17988898 |
|
NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189
|
|
| G
|
Psmc3ip
|
PSMC3 interacting protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PSMC3IP mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr10:86,524,546...86,527,764
Ensembl chr10:86,524,571...86,527,666
|
|
| G
|
Psmd12
|
proteasome 26S subunit, non-ATPase 12
|
affects expression
|
ISO
|
Progesterone affects the expression of PSMD12 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:92,937,957...92,956,601
Ensembl chr10:92,901,133...92,988,964
|
|
| G
|
Psmd5
|
proteasome 26S subunit, non-ATPase 5
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of PSMD5 mRNA Progesterone results in decreased expression of PSMD5 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 3:38,531,206...38,552,085
Ensembl chr 3:38,530,951...38,548,490
|
|
| G
|
Pspc1
|
paraspeckle component 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PSPC1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr15:34,941,445...35,027,460
Ensembl chr15:34,967,477...35,026,828
|
|
| G
|
Ptbp2
|
polypyrimidine tract binding protein 2
|
affects expression
|
ISO
|
Progesterone affects the expression of PTBP2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:210,497,610...210,558,497
Ensembl chr 2:210,497,706...210,558,291
|
|
| G
|
Ptch1
|
patched 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PTCH1 mRNA
|
CTD |
PMID:22958837 |
|
NCBI chr17:1,548,449...1,613,461
Ensembl chr17:1,548,449...1,613,461
|
|
| G
|
Ptchd4
|
patched domain containing 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PTCHD4 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 9:25,951,395...26,163,296
Ensembl chr 9:25,959,954...26,163,284
|
|
| G
|
Pten
|
phosphatase and tensin homolog
|
multiple interactions affects expression
|
EXP ISO
|
[Progesterone co-treated with Norepinephrine] results in increased expression of PTEN mRNA Progesterone affects the expression of PTEN mRNA
|
CTD |
PMID:16954335 PMID:17251523 |
|
NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330
|
|
| G
|
Ptgds
|
prostaglandin D2 synthase
|
increases expression decreases expression
|
EXP ISO
|
Progesterone results in increased expression of PTGDS mRNA Progesterone results in decreased expression of PTGDS mRNA
|
CTD |
PMID:20726854 PMID:22238285 |
|
NCBI chr 3:28,680,044...28,682,978
Ensembl chr 3:28,680,044...28,682,978
|
|
| G
|
Ptger1
|
prostaglandin E receptor 1
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of PTGER1 protein
|
CTD |
PMID:22257560 |
|
NCBI chr19:41,374,983...41,379,593
Ensembl chr19:41,374,471...41,378,284
|
|
| G
|
Ptger2
|
prostaglandin E receptor 2
|
increases expression decreases expression
|
ISO EXP
|
Progesterone results in increased expression of PTGER2 mRNA Progesterone results in increased expression of PTGER2 protein Progesterone results in decreased expression of PTGER2 protein
|
CTD |
PMID:19801535 PMID:21558462 PMID:21795739 |
|
NCBI chr15:20,694,765...20,708,475
Ensembl chr15:20,696,013...20,708,950
|
|
| G
|
Ptger3
|
prostaglandin E receptor 3
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of PTGER3 protein
|
CTD |
PMID:22257560 |
|
NCBI chr 2:249,264,985...249,409,966
Ensembl chr 2:249,264,985...249,409,846
|
|
| G
|
Ptger4
|
prostaglandin E receptor 4
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of PTGER4 protein
|
CTD |
PMID:19801535 |
|
NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:56,062,890...56,074,135
|
|
| G
|
Ptges
|
prostaglandin E synthase
|
increases expression
|
ISO
|
Progesterone results in increased expression of PTGES mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr 3:34,575,643...34,586,987
Ensembl chr 3:34,575,639...34,586,995
|
|
| G
|
Ptgfr
|
prostaglandin F receptor
|
increases expression
|
ISO
|
Progesterone results in increased expression of PTGFR mRNA
|
CTD |
PMID:21795739 PMID:22238285 |
|
NCBI chr 2:243,390,820...243,426,647
Ensembl chr 2:243,393,350...243,425,623
|
|
| G
|
Ptgfrn
|
prostaglandin F2 receptor inhibitor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PTGFRN mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:191,158,166...191,233,432
Ensembl chr 2:191,158,166...191,234,115
|
|
| G
|
Ptgr1
|
prostaglandin reductase 1
|
decreases activity multiple interactions increases expression
|
EXP ISO
|
Progesterone results in decreased activity of PTGR1 protein [Estradiol co-treated with Progesterone] results in decreased expression of PTGR1 mRNA Progesterone results in increased expression of PTGR1 mRNA
|
CTD |
PMID:11524419 PMID:20660070 PMID:20726854 |
|
NCBI chr 5:78,579,060...78,597,671
Ensembl chr 5:78,579,057...78,597,811
|
|
| G
|
Ptgr2
|
prostaglandin reductase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of PTGR2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:109,662,469...109,694,232
Ensembl chr 6:109,662,498...109,694,232
|
|
| G
|
Ptgs1
|
prostaglandin-endoperoxide synthase 1
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of PTGS1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of PTGS1 mRNA Progesterone results in increased expression of PTGS1 mRNA Progesterone results in decreased expression of PTGS1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20726854 PMID:21795739 PMID:22238285 |
|
NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990
|
|
| G
|
Ptgs2
|
prostaglandin-endoperoxide synthase 2
|
multiple interactions decreases expression affects expression increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of PTGS2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of PTGS2 mRNA Progesterone results in decreased expression of PTGS2 mRNA Progesterone affects the expression of PTGS2 Progesterone results in increased expression of PTGS2 mRNA [Estradiol co-treated with Progesterone co-treated with Corn Oil] results in increased expression of PTGS2 mRNA
|
CTD |
PMID:16399999 PMID:17404688 PMID:20660070 PMID:21770760 PMID:22130322 PMID:22238285 PMID:23407384 PMID:32186404 More...
|
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320
|
|
| G
|
Pth2r
|
parathyroid hormone 2 receptor
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of PTH2R mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 9:74,199,785...74,304,326
Ensembl chr 9:74,199,785...74,304,326
|
|
| G
|
Pthlh
|
parathyroid hormone-like hormone
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of PTHLH mRNA Progesterone results in increased expression of PTHLH mRNA Progesterone results in decreased expression of PTHLH mRNA
|
CTD |
PMID:17404688 PMID:18070364 PMID:20864642 PMID:21770760 |
|
NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:181,919,400...181,930,454
|
|
| G
|
Ptk2
|
protein tyrosine kinase 2
|
decreases expression increases expression multiple interactions
|
EXP
|
Progesterone results in decreased expression of PTK2 mRNA Progesterone results in increased expression of PTK2 protein Mifepristone inhibits the reaction [Progesterone results in increased expression of PTK2 protein]
|
CTD |
PMID:20726854 PMID:20959644 |
|
NCBI chr 7:107,015,730...107,220,865
Ensembl chr 7:107,015,733...107,172,091
|
|
| G
|
Ptn
|
pleiotrophin
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of PTN mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 4:66,260,764...66,342,614
Ensembl chr 4:66,260,764...66,342,482
|
|
| G
|
Ptprj
|
protein tyrosine phosphatase, receptor type, J
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of PTPRJ mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:96,861,785...97,017,702
Ensembl chr 3:96,861,785...97,017,656
|
|
| G
|
Ptprk
|
protein tyrosine phosphatase, receptor type, K
|
affects expression
|
ISO
|
Progesterone affects the expression of PTPRK mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:18,557,091...19,056,297
Ensembl chr 1:18,558,365...19,056,107
|
|
| G
|
Ptpro
|
protein tyrosine phosphatase, receptor type, O
|
increases expression
|
ISO
|
Progesterone results in increased expression of PTPRO mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:171,895,104...172,105,911
Ensembl chr 4:171,895,232...172,105,903
|
|
| G
|
Ptprr
|
protein tyrosine phosphatase, receptor type, R
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of PTPRR mRNA Progesterone results in increased expression of PTPRR mRNA
|
CTD |
PMID:17404688 PMID:20726854 PMID:21540246 |
|
NCBI chr 7:53,548,611...53,815,632
Ensembl chr 7:53,548,629...53,815,629
|
|
| G
|
Pttg1
|
PTTG1 regulator of sister chromatid separation, securin
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of PTTG1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309
|
|
| G
|
Ptx3
|
pentraxin 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of PTX3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:152,797,563...152,803,372
Ensembl chr 2:152,781,955...152,803,372
|
|
| G
|
Pwwp3b
|
PWWP domain containing 3B
|
increases expression
|
ISO
|
Progesterone results in increased expression of PWWP3B mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr X:107,593,062...107,627,215
Ensembl chr X:107,582,676...107,627,803
|
|
| G
|
Pygm
|
glycogen phosphorylase, muscle associated
|
increases expression
|
EXP
|
Progesterone results in increased expression of PYGM mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:213,119,805...213,134,622
Ensembl chr 1:213,119,791...213,134,612
|
|
| G
|
Qpct
|
glutaminyl-peptide cyclotransferase
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of QPCT mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 6:21,716,824...21,748,895
Ensembl chr 6:21,716,824...21,748,895
|
|
| G
|
Qsox1
|
quiescin sulfhydryl oxidase 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of QSOX1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr13:70,500,060...70,537,711
Ensembl chr13:70,500,060...70,537,733
|
|
| G
|
Rab15
|
RAB15, member RAS oncogene family
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of RAB15 mRNA Progesterone results in decreased expression of RAB15 mRNA
|
CTD |
PMID:17404688 PMID:21540246 |
|
NCBI chr 6:101,232,740...101,257,388
Ensembl chr 6:101,232,743...101,257,083
|
|
| G
|
Rab27b
|
RAB27B, member RAS oncogene family
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of RAB27B mRNA Progesterone results in decreased expression of RAB27B mRNA
|
CTD |
PMID:21795739 PMID:22238285 |
|
NCBI chr18:65,870,230...66,069,597
Ensembl chr18:65,876,342...66,067,700
|
|
| G
|
Rab31
|
RAB31, member RAS oncogene family
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RAB31 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:112,693,596...112,828,104
Ensembl chr 9:112,693,597...112,828,092
|
|
| G
|
Rab3b
|
RAB3B, member RAS oncogene family
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RAB3B mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 5:128,859,034...128,926,087
Ensembl chr 5:128,841,716...128,926,086
|
|
| G
|
Rab43
|
RAB43, member RAS oncogene family
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RAB43 mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 4:121,806,992...121,826,694
Ensembl chr 4:121,806,992...121,854,561
|
|
| G
|
Rac2
|
Rac family small GTPase 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RAC2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:111,981,825...112,009,201
Ensembl chr 7:111,996,742...112,009,267
|
|
| G
|
Racgap1
|
Rac GTPase-activating protein 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RACGAP1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 7:132,629,789...132,659,738
Ensembl chr 7:132,620,595...132,659,738
|
|
| G
|
Rad51
|
RAD51 recombinase
|
affects expression
|
ISO
|
Progesterone affects the expression of RAD51 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:126,554,210...126,578,888
Ensembl chr 3:126,554,190...126,579,469
|
|
| G
|
Rad51ap1
|
RAD51 associated protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of RAD51AP1 mRNA
|
CTD |
PMID:19000923 |
|
NCBI chr 4:161,445,610...161,458,661
Ensembl chr 4:161,445,512...161,458,680
|
|
| G
|
Raf1
|
Raf-1 proto-oncogene, serine/threonine kinase
|
decreases phosphorylation
|
ISO
|
Progesterone results in decreased phosphorylation of RAF1 protein
|
CTD |
PMID:17492661 |
|
NCBI chr 4:150,352,158...150,412,813
Ensembl chr 4:150,352,160...150,412,813
|
|
| G
|
Rai1
|
retinoic acid induced 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RAI1 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr10:45,412,748...45,507,747
Ensembl chr10:45,447,427...45,507,747
|
|
| G
|
Rai14
|
retinoic acid induced 14
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RAI14 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:61,273,439...61,411,141
Ensembl chr 2:61,273,439...61,409,791
|
|
| G
|
Ramp1
|
receptor activity modifying protein 1
|
affects expression increases expression
|
ISO EXP
|
Progesterone affects the expression of RAMP1 mRNA Progesterone results in increased expression of RAMP1 mRNA
|
CTD |
PMID:15469997 PMID:17251523 PMID:22238285 |
|
NCBI chr 9:99,213,031...99,263,696
|
|
| G
|
Ramp3
|
receptor activity modifying protein 3
|
affects expression
|
ISO
|
Progesterone affects the expression of RAMP3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr14:85,741,314...85,758,813
Ensembl chr14:85,755,211...85,758,818
|
|
| G
|
Ran
|
RAN, member RAS oncogene family
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RAN mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr12:33,311,155...33,314,339
Ensembl chr12:33,311,158...33,314,317
|
|
| G
|
Rap1b
|
RAP1B, member of RAS oncogene family
|
multiple interactions increases expression
|
EXP
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of RAP1B mRNA]
|
CTD |
PMID:10888668 |
|
NCBI chr 7:55,308,922...55,342,217
Ensembl chr 7:55,308,922...55,342,217
|
|
| G
|
Rarres1
|
retinoic acid receptor responder 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of RARRES1 mRNA Progesterone results in increased expression of RARRES1 mRNA
|
CTD |
PMID:17404688 PMID:21540246 |
|
NCBI chr 2:154,059,761...154,094,021
Ensembl chr 2:154,059,761...154,094,024
|
|
| G
|
Rarres2
|
retinoic acid receptor responder 2
|
decreases expression multiple interactions
|
ISO EXP
|
Progesterone results in decreased expression of RARRES2 mRNA RARRES2 protein inhibits the reaction [FSHB protein results in increased abundance of Progesterone]
|
CTD |
PMID:18037150 PMID:22948218 |
|
NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:78,853,453...78,856,457
|
|
| G
|
Rars2
|
arginyl-tRNA synthetase 2, mitochondrial
|
affects expression
|
ISO
|
Progesterone affects the expression of RARS2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:53,976,808...54,029,715
Ensembl chr 5:53,977,866...54,029,691
|
|
| G
|
Rasd1
|
ras related dexamethasone induced 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RASD1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:45,265,975...45,275,279
Ensembl chr10:45,265,979...45,267,710
|
|
| G
|
Rasgrp1
|
RAS guanyl releasing protein 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RASGRP1 mRNA; Mifepristone promotes the reaction [Progesterone affects the expression of RASGRP1 mRNA]
|
CTD |
PMID:20660070 PMID:22414680 |
|
NCBI chr 3:124,624,039...124,684,079
Ensembl chr 3:124,622,313...124,684,434
|
|
| G
|
Rasgrp2
|
RAS guanyl releasing protein 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of RASGRP2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 1:213,135,034...213,152,246
Ensembl chr 1:213,136,015...213,151,884
|
|
| G
|
Rasl11a
|
RAS-like family 11 member A
|
increases expression
|
ISO
|
Progesterone results in increased expression of RASL11A mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr12:13,372,023...13,374,784
Ensembl chr12:13,372,023...13,376,451
|
|
| G
|
Rasl12
|
RAS-like, family 12
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of RASL12 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 8:74,813,000...74,827,041
Ensembl chr 8:74,813,000...74,827,897
|
|
| G
|
Rassf4
|
Ras association domain family member 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RASSF4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:151,569,984...151,605,203
Ensembl chr 4:151,569,984...151,604,883
|
|
| G
|
Rassf5
|
Ras association domain family member 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of RASSF5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr13:45,189,768...45,255,277
Ensembl chr13:45,189,804...45,255,277
|
|
| G
|
Rassf9
|
Ras association domain family member 9
|
multiple interactions decreases expression
|
ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of RASSF9 mRNA] Progesterone results in decreased expression of RASSF9 mRNA
|
CTD |
PMID:21795739 PMID:22238285 |
|
NCBI chr 7:39,486,257...39,518,090
Ensembl chr 7:39,409,870...39,519,675
|
|
| G
|
Rb1
|
RB transcriptional corepressor 1
|
multiple interactions
|
ISO
|
Lithium Chloride inhibits the reaction [Progesterone inhibits the reaction [Estradiol results in increased phosphorylation of RB1 protein]]; Progesterone inhibits the reaction [Estradiol results in increased phosphorylation of RB1 protein]
|
CTD |
PMID:15845746 |
|
NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857
|
|
| G
|
Rb1cc1
|
RB1-inducible coiled-coil 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of RB1CC1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:17,948,522...18,012,434
Ensembl chr 5:17,948,522...18,012,434
|
|
| G
|
Rbbp6
|
RB binding protein 6, ubiquitin ligase
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of RBBP6 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:186,934,563...186,966,852
Ensembl chr 1:186,934,938...186,966,852
|
|
| G
|
Rbbp8
|
RB binding protein 8, endonuclease
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RBBP8 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr18:3,198,188...3,263,643
Ensembl chr18:3,197,310...3,263,985
|
|
| G
|
Rbm14
|
RNA binding motif protein 14
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of RBM14 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:211,476,298...211,535,077
Ensembl chr 1:211,523,972...211,535,065
|
|
| G
|
Rbms3
|
RNA binding motif, single stranded interacting protein 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RBMS3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:125,183,311...125,970,239
Ensembl chr 8:125,183,315...126,503,586
|
|
| G
|
Rbp1
|
retinol binding protein 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RBP1 mRNA; [Progesterone co-treated with Estrogens] results in increased expression of RBP1 mRNA; [Progesterone results in increased activity of PGR protein] which results in increased expression of RBP1 mRNA; IGF1 protein inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased expression of RBP1 mRNA] [Estradiol co-treated with Progesterone] results in decreased expression of RBP1 mRNA
|
CTD |
PMID:15845616 PMID:18556351 PMID:18562952 PMID:20660070 |
|
NCBI chr 8:107,904,589...107,926,109
Ensembl chr 8:107,887,417...107,983,847
|
|
| G
|
Rbp4
|
retinol binding protein 4
|
increases expression multiple interactions decreases expression
|
ISO
|
Progesterone results in increased expression of RBP4 mRNA [Progesterone co-treated with Estradiol] results in increased expression of RBP4 mRNA [Progesterone results in increased activity of PGR protein] which results in decreased expression of RBP4 mRNA; Mifepristone inhibits the reaction [Progesterone results in decreased expression of RBP4 mRNA]
|
CTD |
PMID:15845616 PMID:17404688 PMID:27264040 PMID:31566189 |
|
NCBI chr 1:245,306,349...245,313,551
Ensembl chr 1:245,306,349...245,313,898
|
|
| G
|
Rcan1
|
regulator of calcineurin 1
|
affects expression
|
ISO
|
Progesterone affects the expression of RCAN1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr11:45,108,123...45,188,065
Ensembl chr11:45,108,124...45,118,236
|
|
| G
|
Rcc1
|
regulator of chromosome condensation 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RCC1 mRNA
|
CTD |
PMID:17404688 PMID:18037150 |
|
NCBI chr 5:149,810,037...149,828,475
Ensembl chr 5:149,810,689...149,828,523
|
|
| G
|
Reck
|
reversion-inducing-cysteine-rich protein with kazal motifs
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RECK mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:62,898,717...62,965,274
Ensembl chr 5:62,898,668...62,965,270
|
|
| G
|
Reg3b
|
regenerating family member 3 beta
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of REG3B mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:112,419,776...112,423,014
Ensembl chr 4:112,419,776...112,423,014
|
|
| G
|
Rela
|
RELA proto-oncogene, NF-kB subunit
|
decreases expression multiple interactions increases expression decreases activity
|
ISO EXP
|
Progesterone results in decreased expression of RELA protein Progesterone promotes the reaction [Hydrogen Peroxide results in increased activity of RELA protein] Progesterone inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein] Progesterone results in increased expression of RELA mRNA Progesterone results in decreased activity of RELA protein RELA affects the reaction [[monobutyl phthalate co-treated with CGB3 protein] results in increased secretion of Progesterone]; RELA affects the reaction [[monobutyl phthalate co-treated with Colforsin] results in increased secretion of Progesterone]; VIM inhibits the reaction [RELA affects the reaction [[monobutyl phthalate co-treated with CGB3 protein] results in increased secretion of Progesterone]]
|
CTD |
PMID:15358673 PMID:16284289 PMID:17437195 PMID:21549006 PMID:22615136 PMID:26745512 More...
|
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817
|
|
| G
|
Retn
|
resistin
|
affects expression multiple interactions increases abundance
|
ISO EXP
|
Progesterone affects the expression of RETN mRNA RETN protein promotes the reaction [IGF1 protein results in increased abundance of Progesterone] RETN protein results in increased abundance of Progesterone
|
CTD |
PMID:17251523 PMID:21239528 |
|
NCBI chr12:6,508,653...6,511,115
Ensembl chr12:6,508,801...6,511,116
|
|
| G
|
Retreg1
|
reticulophagy regulator 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RETREG1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of RETREG1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 2:78,045,435...78,205,316
Ensembl chr 2:78,066,031...78,225,356
|
|
| G
|
Retsat
|
retinol saturase
|
increases expression
|
EXP
|
Progesterone results in increased expression of RETSAT mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:106,211,459...106,220,222
Ensembl chr 4:106,211,436...106,229,552
|
|
| G
|
Rev3l
|
REV3 like, DNA directed polymerase zeta catalytic subunit
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of REV3L mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr20:44,686,482...44,844,668
Ensembl chr20:44,686,940...44,844,668
|
|
| G
|
Rflnb
|
refilin B
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RFLNB mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:61,391,947...61,398,224
Ensembl chr10:61,390,659...61,398,224
|
|
| G
|
Rgcc
|
regulator of cell cycle
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of RGCC mRNA Progesterone results in increased expression of RGCC mRNA
|
CTD |
PMID:17404688 PMID:21795739 |
|
NCBI chr15:61,071,574...61,084,408
Ensembl chr15:61,071,574...61,084,408
|
|
| G
|
Rgs1
|
regulator of G-protein signaling 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of RGS1 mRNA
|
CTD |
PMID:21540246 PMID:22238285 |
|
NCBI chr13:58,568,844...58,573,187
Ensembl chr13:58,568,844...58,573,187
|
|
| G
|
Rgs2
|
regulator of G-protein signaling 2
|
multiple interactions increases expression affects expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RGS2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of RGS2 mRNA Progesterone results in increased expression of RGS2 mRNA Progesterone affects the expression of RGS2 mRNA
|
CTD |
PMID:17251523 PMID:17404688 PMID:18070364 PMID:20660070 PMID:22238285 |
|
NCBI chr13:58,350,063...58,352,666
Ensembl chr13:58,349,163...58,352,697
|
|
| G
|
Rgs3
|
regulator of G-protein signaling 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RGS3 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of RGS3 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 5:81,037,588...81,177,446
Ensembl chr 5:81,056,068...81,177,445
|
|
| G
|
Rgs4
|
regulator of G-protein signaling 4
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of RGS4 mRNA Progesterone results in decreased expression of RGS4 mRNA
|
CTD |
PMID:17404688 PMID:20864642 PMID:21795739 |
|
NCBI chr13:84,469,593...84,475,884
Ensembl chr13:84,469,593...84,475,884
|
|
| G
|
Rgs5
|
regulator of G-protein signaling 5
|
multiple interactions decreases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of RGS5 mRNA Progesterone results in decreased expression of RGS5 mRNA
|
CTD |
PMID:17404688 PMID:20726854 |
|
NCBI chr13:84,381,077...84,417,875
Ensembl chr13:84,380,910...84,421,352
|
|
| G
|
Rhoa
|
ras homolog family member A
|
increases expression
|
EXP
|
Progesterone results in increased expression of RHOA mRNA
|
CTD |
PMID:17170212 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302
|
|
| G
|
Rhou
|
ras homolog family member U
|
increases expression
|
ISO
|
Progesterone results in increased expression of RHOU mRNA
|
CTD |
PMID:18037150 PMID:20864642 |
|
NCBI chr19:68,538,960...68,548,733
Ensembl chr19:68,538,960...68,548,733
|
|
| G
|
Rhpn2
|
rhophilin, Rho GTPase binding protein 2
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of RHPN2 mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr 1:97,128,054...97,188,803
Ensembl chr 1:97,127,697...97,188,803
|
|
| G
|
Rictor
|
RPTOR independent companion of MTOR, complex 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RICTOR mRNA
|
CTD |
PMID:23541542 |
|
NCBI chr 2:57,539,279...57,631,291
Ensembl chr 2:57,539,311...57,631,288
|
|
| G
|
Rif1
|
replication timing regulatory factor 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of RIF1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 3:56,963,840...57,017,106
Ensembl chr 3:56,963,854...57,017,106
|
|
| G
|
Rilpl2
|
Rab interacting lysosomal protein-like 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RILPL2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr12:37,786,877...37,798,412
Ensembl chr12:37,786,825...37,798,412
|
|
| G
|
Rimbp2
|
RIMS binding protein 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of RIMBP2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr12:33,383,646...33,582,259
Ensembl chr12:33,384,007...33,593,999
|
|
| G
|
Rit2
|
Ras-like without CAAX 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of RIT2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr18:22,839,914...23,196,137
Ensembl chr18:22,839,915...23,269,823
|
|
| G
|
Rnase4
|
ribonuclease A family member 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of RNASE4 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr15:26,786,287...26,803,634
Ensembl chr15:26,786,079...26,803,639
|
|
| G
|
Rnaset2
|
ribonuclease T2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RNASET2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 1:55,133,532...55,150,701
Ensembl chr 1:55,117,492...55,150,701
|
|
| G
|
Rnd3
|
Rho family GTPase 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of RND3 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 3:55,981,142...55,998,494
Ensembl chr 3:55,980,355...55,998,536
|
|
| G
|
Rnf125
|
ring finger protein 125
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RNF125 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr18:12,528,995...12,550,646
Ensembl chr18:12,528,838...12,554,430
|
|
| G
|
Rnf135
|
ring finger protein 135
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of RNF135 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr10:65,668,441...65,687,671
|
|
| G
|
Rnf139
|
ring finger protein 139
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RNF139 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 7:92,329,201...92,340,386
Ensembl chr 7:92,329,157...92,341,721
|
|
| G
|
Rnf144b
|
ring finger protein 144B
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RNF144B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:17,637,564...17,786,685
Ensembl chr17:17,639,079...17,769,037
|
|
| G
|
Rnf150
|
ring finger protein 150
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RNF150 mRNA Progesterone results in increased expression of RNF150 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr19:41,912,276...42,133,217
Ensembl chr19:41,912,276...42,133,217
|
|
| G
|
Rnf4
|
ring finger protein 4
|
multiple interactions
|
EXP
|
RNF4 protein promotes the reaction [Progesterone results in increased activity of PGR protein]
|
CTD |
PMID:9710597 |
|
NCBI chr14:80,625,864...80,647,138
Ensembl chr14:80,625,866...80,647,148
|
|
| G
|
Rnf43
|
ring finger protein 43
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RNF43 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:72,958,744...73,034,540
Ensembl chr10:72,961,641...73,034,551
|
|
| G
|
Rnf5
|
ring finger protein 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of RNF5 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr20:4,150,032...4,152,593
Ensembl chr20:4,150,138...4,152,591
|
|
| G
|
Robo1
|
roundabout guidance receptor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ROBO1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:24,067,869...25,108,694
Ensembl chr11:24,067,878...25,108,694
|
|
| G
|
Rogdi
|
rogdi atypical leucine zipper
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ROGDI mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr10:11,074,288...11,078,907
Ensembl chr10:11,074,262...11,078,906
|
|
| G
|
Rorb
|
RAR-related orphan receptor B
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of RORB mRNA [Estradiol co-treated with Progesterone] results in increased expression of RORB mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20864642 |
|
NCBI chr 1:225,790,216...225,970,973
Ensembl chr 1:225,790,216...225,970,973
|
|
| G
|
Rpa2
|
replication protein A2
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of RPA2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 5:150,260,668...150,271,329
Ensembl chr 5:150,260,723...150,271,546
|
|
| G
|
Rpl22l1
|
ribosomal protein L22 like 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of RPL22L1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 2:113,683,196...113,685,132
Ensembl chr 2:113,683,196...113,685,132
|
|
| G
|
Rpl27a
|
ribosomal protein L27A
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of RPL27A mRNA Progesterone results in decreased expression of RPL27A mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:172,971,957...172,977,591
|
|
| G
|
Rpl29
|
ribosomal protein L29
|
affects expression
|
ISO
|
Progesterone affects the expression of RPL29 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 8:115,056,443...115,949,677
Ensembl chr 8:115,947,394...115,950,565
|
|
| G
|
Rpl6
|
ribosomal protein L6
|
increases expression
|
ISO
|
Progesterone results in increased expression of RPL6 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr12:41,008,142...41,012,756
Ensembl chr12:41,008,142...41,025,733
|
|
| G
|
Rprm
|
reprimo, TP53 dependent G2 arrest mediator homolog
|
increases expression
|
ISO
|
Progesterone results in increased expression of RPRM mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:58,948,618...58,950,035
Ensembl chr 3:58,799,866...58,950,542
|
|
| G
|
Rps20
|
ribosomal protein S20
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of RPS20 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of RPS20 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 5:21,616,687...21,618,068
Ensembl chr 3:42,839,965...43,095,621 Ensembl chr 9:42,839,965...43,095,621 Ensembl chr 5:42,839,965...43,095,621
|
|
| G
|
Rps6ka3
|
ribosomal protein S6 kinase A3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RPS6KA3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr X:39,325,926...39,432,017
Ensembl chr X:39,325,926...39,433,678
|
|
| G
|
Rps6ka5
|
ribosomal protein S6 kinase A5
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of RPS6KA5 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 6:125,558,434...125,736,576
Ensembl chr 6:125,558,434...125,735,856
|
|
| G
|
Rps6kb1
|
ribosomal protein S6 kinase B1
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased phosphorylation of RPS6KB1 protein
|
CTD |
PMID:22465879 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238
|
|
| G
|
Rptor
|
regulatory associated protein of MTOR, complex 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RPTOR mRNA
|
CTD |
PMID:23541542 |
|
NCBI chr10:105,376,943...105,675,416
Ensembl chr10:105,376,943...105,675,413
|
|
| G
|
Rrm1
|
ribonucleotide reductase catalytic subunit M1
|
affects expression
|
ISO
|
Progesterone affects the expression of RRM1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:166,235,904...166,260,206
Ensembl chr 1:166,235,900...166,260,944
|
|
| G
|
Rrm2
|
ribonucleotide reductase regulatory subunit M2
|
decreases expression increases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of RRM2 mRNA Progesterone results in increased expression of RRM2 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of RRM2 mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]; 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]; 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one inhibits the reaction [Progesterone results in increased expression of RRM2 protein]; 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one promotes the reaction [7-hydroxystaurosporine inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]]; 7-hydroxystaurosporine inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]; 7-hydroxystaurosporine inhibits the reaction [Progesterone results in increased expression of RRM2 protein]; 7-hydroxystaurosporine promotes the reaction [Mifepristone inhibits the reaction [Progesterone results in increased expression of RRM2 protein]]; [5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one results in decreased activity of MYC protein] inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]; Cycloheximide inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]; Estrogens inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of RRM2 protein]; MYC protein promotes the reaction [Progesterone results in increased expression of RRM2 mRNA] Progesterone results in increased expression of RRM2 mRNA; Progesterone results in increased expression of RRM2 protein
|
CTD |
PMID:17404688 PMID:18070364 PMID:21795739 PMID:22403396 |
|
NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370
|
|
| G
|
Rrp9
|
ribosomal RNA processing 9, U3 small nucleolar RNA binding protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RRP9 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 8:115,995,119...116,004,832
Ensembl chr 8:115,996,169...116,004,824
|
|
| G
|
Rrs1
|
ribosome biogenesis regulator 1 homolog
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RRS1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:14,516,303...14,517,936
Ensembl chr 5:14,515,254...14,517,943
|
|
| G
|
Rspo3
|
R-spondin 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of RSPO3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:30,112,529...30,197,267
Ensembl chr 1:30,112,114...30,197,938
|
|
| G
|
RT1-A2
|
RT1 class Ia, locus A2
|
multiple interactions increases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of HLA-E mRNA]
|
CTD |
PMID:22490650 |
|
NCBI chr20:4,872,720...4,876,425
|
|
| G
|
RT1-CE5
|
RT1 class I, locus CE5
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of HLA-F mRNA Mifepristone inhibits the reaction [Progesterone results in increased expression of HLA-F mRNA]
|
CTD |
PMID:22490650 |
|
NCBI chr20:3,407,880...3,484,130
|
|
| G
|
RT1-Da
|
RT1 class II, locus Da
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of HLA-DRA mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr20:4,515,393...4,520,387
Ensembl chr20:4,513,908...4,520,383
|
|
| G
|
RT1-Db1
|
RT1 class II, locus Db1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of HLA-DRB1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr20:4,550,594...4,560,182
Ensembl chr20:4,550,596...4,560,165
|
|
| G
|
RT1-M3-1
|
RT1 class Ib, locus M3, gene 1
|
multiple interactions increases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of HLA-G mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of HLA-G protein] Progesterone results in increased expression of HLA-G mRNA; Progesterone results in increased expression of HLA-G protein
|
CTD |
PMID:16210391 PMID:19527229 PMID:22490650 |
|
NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366
|
|
| G
|
Rtn1
|
reticulon 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of RTN1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:96,499,137...96,719,340
Ensembl chr 6:96,499,134...96,719,340
|
|
| G
|
Rtn3
|
reticulon 3
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of RTN3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:214,041,838...214,098,644
Ensembl chr 1:214,041,838...214,109,638
|
|
| G
|
Rundc3b
|
RUN domain containing 3B
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RUNDC3B mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:26,417,501...26,554,404
Ensembl chr 4:26,417,437...26,554,403
|
|
| G
|
Runx2
|
RUNX family transcription factor 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RUNX2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027
|
|
| G
|
Ruvbl1
|
RuvB-like AAA ATPase 1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of RUVBL1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:122,489,754...122,524,666
Ensembl chr 4:122,489,680...122,524,665
|
|
| G
|
Rxfp1
|
relaxin family peptide receptor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of RXFP1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:167,070,414...167,191,616
Ensembl chr 2:167,070,417...167,191,556
|
|
| G
|
Rxra
|
retinoid X receptor alpha
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of RXRA mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417
|
|
| G
|
Rxylt1
|
ribitol xylosyltransferase 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of RXYLT1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 7:59,656,274...59,668,140
Ensembl chr 7:59,656,276...59,668,050
|
|
| G
|
Ryr2
|
ryanodine receptor 2
|
increases expression multiple interactions decreases expression
|
EXP ISO
|
Progesterone results in increased expression of RYR2 mRNA Mifepristone inhibits the reaction [Progesterone results in decreased expression of RYR2 mRNA]
|
CTD |
PMID:20726854 PMID:27264040 PMID:31566189 |
|
NCBI chr17:63,081,527...63,667,141
Ensembl chr17:63,081,527...63,666,705
|
|
| G
|
Ryr3
|
ryanodine receptor 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of RYR3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:119,886,129...120,433,465
Ensembl chr 3:119,885,878...120,433,677
|
|
| G
|
S100a10
|
S100 calcium binding protein A10
|
increases expression
|
ISO
|
Progesterone results in increased expression of S100A10 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103
|
|
| G
|
S100a14
|
S100 calcium binding protein A14
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of S100A14 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:178,305,976...178,308,004
Ensembl chr 2:178,306,025...178,307,999
|
|
| G
|
S100a2
|
S100 calcium binding protein A2
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of S100A2 mRNA [Estradiol co-treated with Progesterone] results in increased expression of S100A2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of S100A2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 2:178,374,659...178,375,903
|
|
| G
|
S100a8
|
S100 calcium binding protein A8
|
affects expression
|
ISO
|
Progesterone affects the expression of S100A8 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:178,464,702...178,465,221
|
|
| G
|
S100a9
|
S100 calcium binding protein A9
|
affects expression
|
ISO
|
Progesterone affects the expression of S100A9 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:178,487,941...178,490,870
|
|
| G
|
S100g
|
S100 calcium binding protein G
|
multiple interactions affects expression increases expression decreases expression
|
ISO
|
fulvestrant inhibits the reaction [Progesterone results in increased expression of S100G mRNA]; Mifepristone inhibits the reaction [Progesterone results in decreased expression of S100G mRNA]; NCOA2 protein affects the reaction [Progesterone results in decreased expression of S100G mRNA]; S100G protein inhibits the reaction [Progesterone results in increased expression of BAX protein]; S100G protein inhibits the reaction [Progesterone results in increased expression of CASP3 protein] Progesterone affects the expression of S100G mRNA
|
CTD |
PMID:15509668 PMID:17556502 PMID:21882229 PMID:22238285 PMID:27264040 |
|
NCBI chr X:35,337,636...35,340,205
Ensembl chr X:35,337,675...35,340,205
|
|
| G
|
Samd11
|
sterile alpha motif domain containing 11
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SAMD11 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 5:172,113,900...172,142,026
Ensembl chr 5:172,113,654...172,131,927
|
|
| G
|
Samd12
|
sterile alpha motif domain containing 12
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SAMD12 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 7:86,658,709...86,953,879
Ensembl chr 7:86,658,072...87,207,686
|
|
| G
|
Samd9
|
sterile alpha motif domain containing 9
|
increases expression
|
ISO
|
Progesterone results in increased expression of SAMD9 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 4:32,119,318...32,139,008
Ensembl chr 4:32,117,137...32,171,759
|
|
| G
|
Sardh
|
sarcosine dehydrogenase
|
increases expression
|
EXP
|
Progesterone results in increased expression of SARDH mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 3:30,908,621...30,973,409
Ensembl chr 3:30,908,621...30,972,137
|
|
| G
|
Sars1
|
seryl-tRNA synthetase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SARS1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:198,753,673...198,769,411
Ensembl chr 2:198,753,675...198,769,365
|
|
| G
|
Sash1
|
SAM and SH3 domain containing 1
|
multiple interactions affects expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SASH1 mRNA Progesterone affects the expression of SASH1 mRNA
|
CTD |
PMID:17251523 PMID:17404688 |
|
NCBI chr 1:4,940,207...5,238,777
Ensembl chr 1:4,940,207...5,238,530
|
|
| G
|
Sbk1
|
SH3 domain binding kinase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SBK1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:190,237,677...190,282,494
Ensembl chr 1:190,273,642...190,282,473
|
|
| G
|
Sc5d
|
sterol-C5-desaturase
|
increases expression
|
ISO
|
Progesterone results in increased expression of SC5D mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 8:51,526,669...51,538,277
Ensembl chr 8:51,529,346...51,538,277
|
|
| G
|
Scarb1
|
scavenger receptor class B, member 1
|
increases expression multiple interactions increases abundance
|
ISO
|
Progesterone results in increased expression of SCARB1 mRNA [Chloroquine co-treated with Lovastatin] inhibits the reaction [SCARB1 protein results in increased abundance of Progesterone]
|
CTD |
PMID:19000923 PMID:20404351 |
|
NCBI chr12:36,957,302...37,023,982
Ensembl chr12:36,957,496...37,023,980
|
|
| G
|
Scd
|
stearoyl-CoA desaturase
|
affects expression increases expression multiple interactions
|
ISO
|
Progesterone affects the expression of SCD1 mRNA Progesterone results in increased expression of SCD mRNA [Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SCD1 mRNA]; [Progesterone co-treated with Estradiol] inhibits the reaction [Phenobarbital results in decreased expression of SCD1 mRNA]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SCD1 mRNA]; Progesterone inhibits the reaction [Phenobarbital results in decreased expression of SCD1 mRNA] 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [[Progesterone co-treated with Estradiol] results in increased expression of SCD1 mRNA]; [Progesterone co-treated with Estradiol] results in increased expression of SCD1 mRNA
|
CTD |
PMID:17251523 PMID:18070364 PMID:21768169 |
|
NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785
|
|
| G
|
Scg2
|
secretogranin II
|
increases expression
|
EXP
|
Progesterone results in increased expression of SCG2 mRNA
|
CTD |
PMID:16376865 |
|
NCBI chr 9:88,251,531...88,257,208
Ensembl chr 9:88,251,354...88,269,598
|
|
| G
|
Scgb1d2
|
secretoglobin, family 1D, member 2
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SCGB1D2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of SCGB1D2 mRNA Progesterone results in increased expression of SCGB1D2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 1:215,653,464...215,658,101
Ensembl chr 1:215,653,464...215,656,710
|
|
| G
|
Scgb2a1
|
secretoglobin, family 2A, member 1
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of SCGB2A1 mRNA [Progesterone co-treated with Estradiol] results in increased expression of SCGB2A1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:215,922,751...215,926,114
Ensembl chr 1:215,794,572...215,797,345 Ensembl chr 1:215,794,572...215,797,345
|
|
| G
|
Scin
|
scinderin
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SCIN mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:62,836,641...62,915,287
Ensembl chr 6:62,836,641...62,915,287
|
|
| G
|
Scn1b
|
sodium voltage-gated channel beta subunit 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of SCN1B mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:95,481,298...95,491,211
Ensembl chr 1:95,481,298...95,491,197
|
|
| G
|
Scnn1a
|
sodium channel epithelial 1 subunit alpha
|
affects expression multiple interactions decreases expression
|
ISO EXP
|
Progesterone affects the expression of SCNN1A mRNA Progesterone affects the activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]; Progesterone results in decreased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] Progesterone affects the expression of SCNN1A mRNA; Progesterone affects the expression of SCNN1A protein Progesterone results in decreased expression of SCNN1A mRNA
|
CTD |
PMID:16172119 PMID:16555725 PMID:17939260 PMID:21540246 |
|
NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405
|
|
| G
|
Scnn1b
|
sodium channel epithelial 1 subunit beta
|
multiple interactions affects expression
|
EXP
|
Progesterone affects the activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]; Progesterone results in decreased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] Progesterone affects the expression of SCNN1B mRNA; Progesterone affects the expression of SCNN1B protein
|
CTD |
PMID:16172119 PMID:17939260 |
|
NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:185,854,733...185,916,049
|
|
| G
|
Scnn1g
|
sodium channel epithelial 1 subunit gamma
|
multiple interactions affects expression
|
EXP
|
Progesterone affects the activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein]; Progesterone results in decreased activity of [SCNN1A protein binds to SCNN1B protein binds to SCNN1G protein] Progesterone affects the expression of SCNN1G mRNA; Progesterone affects the expression of SCNN1G protein
|
CTD |
PMID:16172119 PMID:17939260 |
|
NCBI chr 1:185,736,225...185,770,099
Ensembl chr 1:185,736,191...185,770,097
|
|
| G
|
Sct
|
secretin
|
affects expression
|
ISO
|
Progesterone affects the expression of SCT mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:205,812,435...205,813,246
Ensembl chr 1:205,812,435...205,813,246
|
|
| G
|
Scx
|
scleraxis bHLH transcription factor
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of SCX mRNA Progesterone results in decreased expression of SCX mRNA
|
CTD |
PMID:17251523 PMID:22238285 |
|
NCBI chr 7:110,056,897...110,059,283
Ensembl chr 7:110,054,601...110,061,438
|
|
| G
|
Sdc1
|
syndecan 1
|
decreases expression
|
ISO EXP
|
Progesterone results in decreased expression of SDC1 mRNA
|
CTD |
PMID:18037150 PMID:20726854 PMID:21795739 |
|
NCBI chr 6:37,282,041...37,304,503
Ensembl chr 6:37,297,010...37,304,500
|
|
| G
|
Sdc2
|
syndecan 2
|
affects expression decreases expression
|
ISO EXP
|
Progesterone affects the expression of SDC2 mRNA Progesterone results in decreased expression of SDC2 mRNA
|
CTD |
PMID:17251523 PMID:20726854 |
|
NCBI chr 7:66,012,405...66,125,101
Ensembl chr 7:66,108,853...66,126,294
|
|
| G
|
Sdc4
|
syndecan 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SDC4 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:173,574,239...173,593,670
|
|
| G
|
Sdf2l1
|
stromal cell-derived factor 2-like 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SDF2L1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr11:97,376,878...97,379,120
Ensembl chr11:97,376,878...97,379,120
|
|
| G
|
Sec14l1
|
SEC14-like lipid binding 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SEC14L1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of SEC14L1 mRNA Progesterone results in increased expression of SEC14L1 mRNA
|
CTD |
PMID:17404688 PMID:18037150 PMID:18070364 PMID:20660070 |
|
NCBI chr10:102,818,693...102,865,841
Ensembl chr10:102,818,693...102,865,839
|
|
| G
|
Sec14l2
|
SEC14-like lipid binding 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of SEC14L2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr14:83,197,384...83,222,059
Ensembl chr14:83,197,387...83,217,317
|
|
| G
|
Sec62
|
SEC62 homolog, preprotein translocation factor
|
affects expression
|
ISO
|
Progesterone affects the expression of SEC62 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 2:114,499,317...114,526,705
Ensembl chr 2:114,499,317...114,530,321
|
|
| G
|
Sectm1b
|
secreted and transmembrane 1B
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of SECTM1 mRNA [Progesterone co-treated with Estradiol] results in increased expression of SECTM1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:106,822,397...106,832,105
Ensembl chr10:106,822,397...106,832,104
|
|
| G
|
Seh1l
|
SEH1-like nucleoporin
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SEH1L mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr18:63,612,228...63,639,852
Ensembl chr18:63,616,768...63,639,840
|
|
| G
|
Sel1l3
|
SEL1L family member 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SEL1L3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr14:61,988,350...62,095,542
Ensembl chr14:61,988,346...62,095,542
|
|
| G
|
Sele
|
selectin E
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of SELE mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr13:78,935,997...78,945,905
Ensembl chr13:78,936,036...78,945,903
|
|
| G
|
Selenbp1
|
selenium binding protein 1
|
affects expression increases expression
|
ISO EXP
|
Progesterone affects the expression of SELENBP1 mRNA Progesterone results in increased expression of SELENBP2 mRNA
|
CTD |
PMID:17251523 PMID:20726854 |
|
NCBI chr 2:185,183,022...185,193,612
Ensembl chr 2:185,183,004...185,194,295
|
|
| G
|
Selenop
|
selenoprotein P
|
increases expression
|
EXP
|
Progesterone results in increased expression of SELENOP mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:54,225,736...54,236,022
Ensembl chr 2:54,225,152...54,236,019
|
|
| G
|
Selp
|
selectin P
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of SELP mRNA
|
CTD |
PMID:22903158 |
|
NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987
|
|
| G
|
Sema3b
|
semaphorin 3B
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SEMA3B mRNA; Mifepristone inhibits the reaction [Progesterone results in increased expression of SEMA3B protein]; telmisartan inhibits the reaction [Progesterone results in increased expression of SEMA3B protein]
|
CTD |
PMID:20660070 PMID:21933904 |
|
NCBI chr 8:117,150,307...117,161,570
Ensembl chr 8:117,150,589...117,157,658
|
|
| G
|
Sema3c
|
semaphorin 3C
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SEMA3C mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:18,538,452...18,702,453
Ensembl chr 4:18,538,454...18,701,740
|
|
| G
|
Sema3f
|
semaphorin 3F
|
multiple interactions increases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of SEMA3F protein]; telmisartan inhibits the reaction [Progesterone results in increased expression of SEMA3F protein]
|
CTD |
PMID:21933904 |
|
NCBI chr 8:117,236,269...117,265,206
Ensembl chr 8:117,236,269...117,265,206
|
|
| G
|
Sema4b
|
semaphorin 4B
|
affects expression
|
ISO
|
Progesterone affects the expression of SEMA4B mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:143,545,727...143,587,037
Ensembl chr 1:143,537,690...143,587,037
|
|
| G
|
Sema4d
|
semaphorin 4D
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SEMA4D mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:13,582,085...13,688,889
Ensembl chr17:13,582,098...13,688,891
|
|
| G
|
Senp18
|
Sumo1/sentrin/SMT3 specific peptidase 18
|
increases expression
|
EXP
|
Progesterone results in increased expression of SENP18 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 4:162,752,390...162,753,817
Ensembl chr 4:162,750,058...162,754,014
|
|
| G
|
Serpina3n
|
serpin family A member 3N
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of SERPINA3N mRNA [Progesterone co-treated with Estradiol] results in increased expression of SERPINA3 mRNA
|
CTD |
PMID:17404688 PMID:20726854 |
|
NCBI chr 6:129,088,392...129,095,950
Ensembl chr 6:129,088,398...129,097,415
|
|
| G
|
Serpina6
|
serpin family A member 6
|
increases transport
|
ISO
|
SERPINA6 protein results in increased transport of Progesterone
|
CTD |
PMID:22932886 |
|
NCBI chr 6:128,544,828...128,555,064
Ensembl chr 6:128,544,831...128,555,139
|
|
| G
|
Serpinb1a
|
serpin family B member 1A
|
increases expression
|
ISO
|
Progesterone results in increased expression of SERPINB1A mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:31,799,446...31,807,853
Ensembl chr17:31,799,415...31,808,166
|
|
| G
|
Serpinb2
|
serpin family B member 2
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SERPINB2 mRNA Progesterone results in decreased expression of SERPINB2 mRNA
|
CTD |
PMID:17404688 PMID:20864642 PMID:21795739 |
|
NCBI chr13:24,051,933...24,065,032
Ensembl chr13:24,056,021...24,065,031
|
|
| G
|
Serpinb5
|
serpin family B member 5
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SERPINB5 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr13:23,500,203...23,520,401
Ensembl chr13:23,500,198...23,520,400
|
|
| G
|
Serpinb9
|
serpin family B member 9
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SERPINB9 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974
|
|
| G
|
Serpine1
|
serpin family E member 1
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of SERPINE1 mRNA Progesterone results in increased expression of SERPINE1 mRNA Progesterone inhibits the reaction [Fructose results in increased expression of SERPINE1 mRNA]; Progesterone inhibits the reaction [Fructose results in increased expression of SERPINE1 protein]
|
CTD |
PMID:17404688 PMID:20864642 PMID:21795739 PMID:23016136 |
|
NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357
|
|
| G
|
Serpine2
|
serpin family E member 2
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of SERPINE2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:88,573,149...88,637,202
|
|
| G
|
Serpinf1
|
serpin family F member 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SERPINF1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr10:60,748,504...60,760,898
Ensembl chr10:60,748,506...60,760,898
|
|
| G
|
Serping1
|
serpin family G member 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SERPING1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:90,249,423...90,258,717
|
|
| G
|
Sertad4
|
SERTA domain containing 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SERTAD4 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:106,889,019...106,899,777
Ensembl chr13:106,889,019...106,900,309
|
|
| G
|
Sesn2
|
sestrin 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of SESN2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255
|
|
| G
|
Sesn3
|
sestrin 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SESN3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:19,415,307...19,470,943
Ensembl chr 8:19,415,347...19,466,904
|
|
| G
|
Sestd1
|
SEC14 and spectrin domain containing 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SESTD1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 3:82,530,796...82,627,960
Ensembl chr 3:82,537,092...82,588,078
|
|
| G
|
Set
|
Set nuclear proto-oncogene
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SET mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 3:33,732,319...33,743,433
|
|
| G
|
Sf3a1
|
splicing factor 3A subunit 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SF3A1 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr14:83,254,971...83,275,720
Ensembl chr14:83,254,971...83,275,720
|
|
| G
|
Sfn
|
stratifin
|
decreases expression increases phosphorylation multiple interactions
|
ISO EXP
|
Progesterone results in decreased expression of SFN mRNA Progesterone results in increased phosphorylation of SFN protein [Estradiol co-treated with Progesterone] results in increased expression of SFN mRNA
|
CTD |
PMID:16966611 PMID:17303654 PMID:18556351 |
|
NCBI chr 5:151,110,582...151,111,854
Ensembl chr 5:151,110,530...151,111,995
|
|
| G
|
Sfpq
|
splicing factor proline and glutamine rich
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of SFPQ mRNA Progesterone results in increased expression of SFPQ mRNA
|
CTD |
PMID:18037150 PMID:18497975 PMID:20726854 |
|
NCBI chr 5:144,621,678...144,637,930
Ensembl chr 5:144,622,476...144,637,926
|
|
| G
|
Sfrp4
|
secreted frizzled-related protein 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of SFRP4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr17:49,974,532...50,026,448
Ensembl chr17:50,015,812...50,026,395
|
|
| G
|
Sfta2
|
surfactant associated 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SFTA2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr20:3,098,313...3,099,038
Ensembl chr20:3,098,313...3,099,038
|
|
| G
|
Sftpb
|
surfactant protein B
|
increases expression
|
ISO
|
Progesterone results in increased expression of SFTPB mRNA
|
CTD |
PMID:21398497 |
|
NCBI chr 4:105,917,495...105,926,631
Ensembl chr 4:105,917,578...105,927,646
|
|
| G
|
Sftpd
|
surfactant protein D
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SFTPD mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr16:17,080,575...17,093,047
Ensembl chr16:17,080,567...17,094,036
|
|
| G
|
Sfxn3
|
sideroflexin 3
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of SFXN3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:253,856,935...253,866,219
Ensembl chr 1:253,856,882...253,887,542
|
|
| G
|
Sgcd
|
sarcoglycan, delta
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SGCD mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:31,847,713...32,829,554
Ensembl chr10:31,781,748...32,419,064
|
|
| G
|
Sgip1
|
SH3GL interacting endocytic adaptor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SGIP1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:122,755,216...122,963,677
Ensembl chr 5:122,765,890...122,963,659
|
|
| G
|
Sgk1
|
serum/glucocorticoid regulated kinase 1
|
increases expression multiple interactions
|
ISO EXP
|
Progesterone results in increased expression of SGK1 mRNA ESR1 protein affects the reaction [Progesterone results in increased expression of SGK1 mRNA]; Fulvestrant inhibits the reaction [Progesterone results in increased expression of SGK1 mRNA]
|
CTD |
PMID:18070364 PMID:20726854 PMID:33405908 |
|
NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231
|
|
| G
|
Sgk3
|
serum/glucocorticoid regulated kinase family, member 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of SGK3 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 5:14,128,628...14,255,099
Ensembl chr 5:14,126,257...14,198,331
|
|
| G
|
Sgo2
|
shugoshin 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SGO2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 9:67,032,083...67,067,439
Ensembl chr 9:67,042,833...67,068,152
|
|
| G
|
Sh2d1b
|
SH2 domain containing 1B
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SH2D1B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr13:85,018,078...85,056,263
Ensembl chr13:85,019,508...85,052,125
|
|
| G
|
Sh3bp4
|
SH3-domain binding protein 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SH3BP4 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 9:97,107,877...97,186,878
Ensembl chr 9:97,107,877...97,186,878
|
|
| G
|
Sh3kbp1
|
SH3 domain-containing kinase-binding protein 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of SH3KBP1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr X:38,686,530...39,031,658
Ensembl chr X:38,686,530...39,031,393
|
|
| G
|
Sh3rf2
|
SH3 domain containing ring finger 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SH3RF2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr18:34,296,753...34,397,880
Ensembl chr18:34,296,733...34,397,876
|
|
| G
|
Shbg
|
sex hormone binding globulin
|
affects binding
|
ISO
|
Progesterone binds to SHBG protein
|
CTD |
PMID:25349334 |
|
NCBI chr10:54,831,716...54,849,162
Ensembl chr10:54,831,718...54,838,760
|
|
| G
|
Shc1
|
SHC adaptor protein 1
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of SHC1 mRNA; [Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of SHC1 protein
|
CTD |
PMID:22465879 |
|
NCBI chr 2:177,135,649...177,147,257
Ensembl chr 2:177,135,659...177,147,914
|
|
| G
|
Shc4
|
SHC adaptor protein 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SHC4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:133,334,026...133,428,404
Ensembl chr 3:133,334,034...133,427,826
|
|
| G
|
Shcbp1
|
SHC binding and spindle associated 1
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of SHCBP1 mRNA Progesterone results in decreased expression of SHCBP1 mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr16:91,373,843...91,405,409
Ensembl chr16:91,373,871...91,405,409
|
|
| G
|
Shh
|
sonic hedgehog signaling molecule
|
multiple interactions decreases expression
|
ISO
|
4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of SHH mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of SHH mRNA; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of SHH mRNA]; U 0126 promotes the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of SHH mRNA] Progesterone results in decreased expression of SHH mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:7,687,872...7,697,025
Ensembl chr 4:7,687,846...7,697,901
|
|
| G
|
Shisa2
|
shisa family member 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SHISA2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr15:37,982,913...37,987,211
Ensembl chr15:37,982,169...37,988,535
|
|
| G
|
Shmt1
|
serine hydroxymethyltransferase 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SHMT1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:45,968,959...45,990,341
Ensembl chr10:45,960,434...45,997,326
|
|
| G
|
Siglec15
|
sialic acid binding Ig-like lectin 15
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SIGLEC15 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of SIGLEC15 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr18:73,781,536...73,797,014
Ensembl chr18:73,781,536...73,797,014
|
|
| G
|
Sim1
|
SIM bHLH transcription factor 1
|
affects expression
|
ISO
|
Progesterone affects the expression of SIM1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr20:55,409,814...55,489,450
Ensembl chr20:55,410,577...55,489,449
|
|
| G
|
Sipa1l1
|
signal-induced proliferation-associated 1 like 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SIPA1L1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:107,570,569...107,849,613
Ensembl chr 6:107,737,392...107,848,160
|
|
| G
|
Sipa1l2
|
signal-induced proliferation-associated 1 like 2
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of SIPA1L2 mRNA]
|
CTD |
PMID:21795739 |
|
NCBI chr19:70,287,134...70,437,810
Ensembl chr19:70,287,147...70,437,773
|
|
| G
|
Sirpa
|
signal-regulatory protein alpha
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SIRPA mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:137,272,932...137,311,279
Ensembl chr 3:137,273,042...137,311,279
|
|
| G
|
Skp2
|
S-phase kinase associated protein 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SKP2 protein
|
CTD |
PMID:23029392 |
|
NCBI chr 2:59,888,406...59,916,471
Ensembl chr 2:59,888,413...59,916,438
|
|
| G
|
Slain1
|
SLAIN motif family, member 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLAIN1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr15:86,897,476...86,957,113
Ensembl chr15:86,897,476...86,957,113
|
|
| G
|
Slc13a5
|
solute carrier family 13 member 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC13A5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:57,364,806...57,389,500
Ensembl chr10:57,364,806...57,389,516
|
|
| G
|
Slc14a1
|
solute carrier family 14 member 1 (Kidd blood group)
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SLC14A1 mRNA Progesterone results in decreased expression of SLC14A1 mRNA
|
CTD |
PMID:17404688 PMID:21795739 PMID:22238285 |
|
NCBI chr18:73,840,568...73,883,925
Ensembl chr18:73,840,569...73,870,489
|
|
| G
|
Slc15a1
|
solute carrier family 15 member 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SLC15A1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:104,944,461...104,991,316
Ensembl chr15:104,944,463...104,989,369
|
|
| G
|
Slc15a2
|
solute carrier family 15 member 2
|
multiple interactions increases expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SLC15A2 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of SLC15A2 mRNA Progesterone results in increased expression of SLC15A2 mRNA Progesterone results in decreased expression of SLC15A2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21540246 |
|
NCBI chr11:77,519,565...77,548,609
Ensembl chr11:77,519,529...77,548,606
|
|
| G
|
Slc16a1
|
solute carrier family 16 member 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of SLC16A1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:194,812,502...194,832,977
|
|
| G
|
Slc16a6
|
solute carrier family 16, member 6
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SLC16A6 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of SLC16A6 mRNA Progesterone results in decreased expression of SLC16A6 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20864642 PMID:22238285 |
|
NCBI chr10:94,923,888...94,946,990
Ensembl chr10:94,923,888...94,947,965
|
|
| G
|
Slc16a7
|
solute carrier family 16 member 7
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC16A7 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 7:62,929,067...63,096,995
Ensembl chr 7:62,936,567...63,040,386
|
|
| G
|
Slc19a2
|
solute carrier family 19 member 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC19A2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr13:79,135,118...79,149,316
Ensembl chr13:79,135,059...79,149,315
|
|
| G
|
Slc1a1
|
solute carrier family 1 member 1
|
multiple interactions increases expression increases activity
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of SLC1A1 mRNA Progesterone results in increased expression of SLC1A1 mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Progesterone results in increased activity of SLC1A1 protein]; calphostin C inhibits the reaction [Progesterone results in increased activity of SLC1A1 protein]; chelerythrine inhibits the reaction [Progesterone results in increased activity of SLC1A1 protein]; Staurosporine inhibits the reaction [Progesterone results in increased activity of SLC1A1 protein]; wortmannin inhibits the reaction [Progesterone results in increased activity of SLC1A1 protein]
|
CTD |
PMID:20660070 PMID:21540246 PMID:23602688 |
|
NCBI chr 1:235,963,455...236,043,572
Ensembl chr 1:235,963,437...236,045,469
|
|
| G
|
Slc1a3
|
solute carrier family 1 member 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SLC1A3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:59,482,707...59,557,808
Ensembl chr 2:59,482,709...59,557,808
|
|
| G
|
Slc1a4
|
solute carrier family 1 member 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC1A4 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr14:98,718,646...98,761,672
Ensembl chr14:98,730,450...98,761,790
|
|
| G
|
Slc20a1
|
solute carrier family 20 member 1
|
affects expression
|
ISO
|
Progesterone affects the expression of SLC20A1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:136,880,360...136,894,255
Ensembl chr 3:136,880,290...136,894,249
|
|
| G
|
Slc22a1
|
solute carrier family 22 member 1
|
multiple interactions decreases activity
|
ISO EXP
|
Progesterone inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Progesterone results in decreased activity of SLC22A1 protein Progesterone inhibits the reaction [SLC22A1 protein results in increased uptake of Tetraethylammonium]
|
CTD |
PMID:9830022 PMID:12110607 |
|
NCBI chr 1:50,624,339...50,651,437
Ensembl chr 1:50,624,377...50,651,436
|
|
| G
|
Slc22a19
|
solute carrier family 22, member 19
|
increases expression
|
EXP
|
Progesterone results in increased expression of SLC22A24 mRNA; Progesterone results in increased expression of SLC22A24 protein
|
CTD |
PMID:20865662 |
|
NCBI chr 1:214,339,594...214,394,681
Ensembl chr 1:214,339,599...214,394,681
|
|
| G
|
Slc22a2
|
solute carrier family 22 member 2
|
multiple interactions
|
EXP
|
Progesterone inhibits the reaction [SLC22A2 protein results in increased uptake of Tetraethylammonium]
|
CTD |
PMID:9830022 |
|
NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019
|
|
| G
|
Slc22a25
|
solute carrier family 22, member 25
|
decreases activity affects localization
|
ISO
|
Progesterone results in decreased activity of SLC22A9 protein Progesterone affects the localization of SLC22A9 protein
|
CTD |
PMID:17341544 |
|
NCBI chr 1:214,767,837...214,956,535
Ensembl chr 1:214,767,837...214,862,340
|
|
| G
|
Slc22a3
|
solute carrier family 22 member 3
|
decreases activity multiple interactions
|
ISO EXP
|
Progesterone results in decreased activity of SLC22A3 protein Progesterone inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Progesterone inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]
|
CTD |
PMID:9830022 PMID:12110607 |
|
NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:50,783,218...50,872,353
|
|
| G
|
Slc22a5
|
solute carrier family 22 member 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC22A5 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077
|
|
| G
|
Slc23a1
|
solute carrier family 23 member 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC23A1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr18:27,490,549...27,504,563
Ensembl chr18:27,490,374...27,504,702
|
|
| G
|
Slc23a2
|
solute carrier family 23 member 2
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [SLC23A2 protein results in increased uptake of Ascorbic Acid]
|
CTD |
PMID:17092984 |
|
NCBI chr 3:139,755,583...139,913,304
Ensembl chr 3:139,755,584...139,847,343
|
|
| G
|
Slc24a3
|
solute carrier family 24 member 3
|
multiple interactions decreases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of SLC24A3 mRNA Progesterone results in decreased expression of SLC24A3 mRNA Progesterone inhibits the reaction [Estradiol results in increased expression of SLC24A3 mRNA]
|
CTD |
PMID:19464262 PMID:21104767 |
|
NCBI chr 3:153,005,418...153,504,497
Ensembl chr 3:153,004,987...153,504,497
|
|
| G
|
Slc25a10
|
solute carrier family 25 member 10
|
affects expression
|
ISO
|
Progesterone affects the expression of SLC25A10 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:106,264,396...106,271,895
Ensembl chr10:106,264,344...106,273,498
|
|
| G
|
Slc25a13
|
solute carrier family 25 member 13
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC25A13 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:35,145,721...35,328,403
Ensembl chr 4:35,145,721...35,328,360
|
|
| G
|
Slc25a16
|
solute carrier family 25 member 16
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC25A16 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr20:25,659,847...25,717,080
Ensembl chr20:25,660,339...25,689,285 Ensembl chr20:25,660,339...25,689,285
|
|
| G
|
Slc25a25
|
solute carrier family 25 member 25
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of SLC25A25 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 3:36,106,448...36,139,812
Ensembl chr 3:36,106,449...36,140,011
|
|
| G
|
Slc25a29
|
solute carrier family 25 member 29
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC25A29 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 6:133,506,403...133,517,322
Ensembl chr 6:133,506,331...133,517,827
|
|
| G
|
Slc25a4
|
solute carrier family 25 member 4
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of SLC25A4 mRNA Progesterone results in increased expression of SLC25A4 mRNA
|
CTD |
PMID:19693291 PMID:20726854 |
|
NCBI chr16:52,805,521...52,809,316
Ensembl chr16:52,805,523...52,811,700
|
|
| G
|
Slc26a1
|
solute carrier family 26 member 1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of SLC26A1 protein
|
CTD |
PMID:19002488 |
|
NCBI chr14:1,180,465...1,190,257
Ensembl chr14:1,184,649...1,190,255
|
|
| G
|
Slc26a2
|
solute carrier family 26 member 2
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of SLC26A2 mRNA Progesterone results in increased expression of SLC26A2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr18:56,918,662...56,937,032
Ensembl chr18:56,923,337...56,937,012
|
|
| G
|
Slc26a4
|
solute carrier family 26 member 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC26A4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:53,835,102...53,873,968
Ensembl chr 6:53,835,110...53,873,216
|
|
| G
|
Slc26a7
|
solute carrier family 26 member 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC26A7 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:32,681,653...32,819,110
Ensembl chr 5:32,684,288...32,818,905
|
|
| G
|
Slc27a2
|
solute carrier family 27 member 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SLC27A2 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581
|
|
| G
|
Slc2a1
|
solute carrier family 2 member 1
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Bucladesine] results in increased expression of SLC2A1 protein; [Progesterone co-treated with Estradiol] results in decreased expression of SLC2A1 protein Progesterone results in increased expression of SLC2A1 protein Progesterone promotes the reaction [Oxygen deficiency results in increased expression of SLC2A1 mRNA] Progesterone results in increased expression of SLC2A1 mRNA [Progesterone results in increased expression of SLC2A1 protein] which results in increased uptake of Glucose; Estradiol inhibits the reaction [Progesterone results in increased expression of and results in increased localization of SLC2A1 protein]; Estradiol inhibits the reaction [Progesterone results in increased expression of SLC2A1 protein]; Mifepristone inhibits the reaction [Progesterone results in increased expression of SLC2A1 protein]; Progesterone results in increased expression of and results in increased localization of SLC2A1 protein
|
CTD |
PMID:15350188 PMID:18948400 PMID:20726854 PMID:23307114 |
|
NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742
|
|
| G
|
Slc2a3
|
solute carrier family 2 member 3
|
affects expression multiple interactions increases expression
|
ISO EXP
|
Progesterone affects the expression of SLC2A3 mRNA Progesterone promotes the reaction [Oxygen deficiency results in increased expression of SLC2A3 mRNA] Progesterone results in increased expression of SLC2A3 mRNA
|
CTD |
PMID:17251523 PMID:22238285 PMID:23307114 |
|
NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186
|
|
| G
|
Slc2a4
|
solute carrier family 2 member 4
|
increases expression
|
EXP
|
Progesterone results in increased expression of SLC2A4 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270
|
|
| G
|
Slc30a2
|
solute carrier family 30 member 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SLC30A2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:151,843,451...151,855,674
Ensembl chr 5:151,843,389...151,855,670
|
|
| G
|
Slc35g1
|
solute carrier family 35, member G1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC35G1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:245,576,011...245,584,533
Ensembl chr 1:245,575,996...245,584,529
|
|
| G
|
Slc37a2
|
solute carrier family 37 member 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC37A2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 8:45,134,596...45,160,551
Ensembl chr 8:45,134,596...45,277,989
|
|
| G
|
Slc37a4
|
solute carrier family 37 member 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SLC37A4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:53,619,952...53,626,110
Ensembl chr 8:53,620,141...53,626,110
|
|
| G
|
Slc38a1
|
solute carrier family 38, member 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of SLC38A1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 7:129,612,414...129,681,727
Ensembl chr 7:129,617,387...129,681,778
|
|
| G
|
Slc38a2
|
solute carrier family 38, member 2
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of SLC38A2 mRNA [Estradiol co-treated with Progesterone] results in increased expression of SLC38A2 mRNA
|
CTD |
PMID:18037150 PMID:18556351 |
|
NCBI chr 7:129,730,450...129,742,619
Ensembl chr 7:129,730,450...129,742,619
|
|
| G
|
Slc38a4
|
solute carrier family 38, member 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC38A4 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 7:130,022,039...130,082,169
Ensembl chr 7:130,023,980...130,082,097
|
|
| G
|
Slc39a14
|
solute carrier family 39 member 14
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SLC39A14 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:51,786,517...51,833,260
Ensembl chr15:51,786,623...51,833,229
|
|
| G
|
Slc39a4
|
solute carrier family 39 member 4
|
affects expression
|
ISO
|
Progesterone affects the expression of SLC39A4 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:110,214,017...110,218,202
Ensembl chr 7:110,214,017...110,218,202
|
|
| G
|
Slc39a8
|
solute carrier family 39 member 8
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SLC39A8 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:226,929,644...226,992,667
|
|
| G
|
Slc3a1
|
solute carrier family 3 member 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SLC3A1 mRNA Progesterone results in increased expression of SLC3A1 mRNA
|
CTD |
PMID:18692832 PMID:20660070 |
|
NCBI chr 6:15,361,037...15,396,695
Ensembl chr 6:15,361,046...15,394,775
|
|
| G
|
Slc40a1
|
solute carrier family 40 member 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SLC40A1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:55,525,532...55,543,460
|
|
| G
|
Slc41a2
|
solute carrier family 41 member 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC41A2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 7:22,271,298...22,378,764
Ensembl chr 7:22,271,313...22,378,764
|
|
| G
|
Slc44a2
|
solute carrier family 44 member 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SLC44A2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:28,147,023...28,181,496
Ensembl chr 8:28,147,030...28,181,495
|
|
| G
|
Slc44a3
|
solute carrier family 44, member 3
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of SLC44A3 mRNA NCOA2 protein affects the reaction [Progesterone results in decreased expression of SLC44A3 mRNA] [Estradiol co-treated with Progesterone] results in increased expression of SLC44A3 mRNA
|
CTD |
PMID:17556502 PMID:20660070 |
|
NCBI chr 2:212,234,425...212,312,886
Ensembl chr 2:212,236,853...212,312,982
|
|
| G
|
Slc46a3
|
solute carrier family 46, member 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC46A3 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr12:12,176,776...12,193,256
Ensembl chr12:12,176,807...12,193,255
|
|
| G
|
Slc47a1
|
solute carrier family 47 member 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SLC47A1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of SLC47A1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr10:46,533,580...46,590,128
Ensembl chr10:46,533,583...46,587,096
|
|
| G
|
Slc4a11
|
solute carrier family 4 member 11
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC4A11 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:138,353,305...138,365,983
Ensembl chr 3:138,353,305...138,365,754
|
|
| G
|
Slc4a7
|
solute carrier family 4 member 7
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SLC4A7 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr15:13,015,854...13,095,485
Ensembl chr15:13,015,854...13,095,292
|
|
| G
|
Slc5a11
|
solute carrier family 5 member 11
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC5A11 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:187,166,609...187,226,291
Ensembl chr 1:187,166,811...187,282,848
|
|
| G
|
Slc5a2
|
solute carrier family 5 member 2
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of SLC5A2 protein
|
CTD |
PMID:22262063 |
|
NCBI chr 1:192,277,621...192,283,742
Ensembl chr 1:192,277,621...192,283,742
|
|
| G
|
Slc5a3
|
solute carrier family 5 member 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC5A3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr11:44,799,787...44,802,233
Ensembl chr11:44,790,297...44,818,157
|
|
| G
|
Slc5a7
|
solute carrier family 5 member 7
|
increases expression
|
EXP
|
Progesterone results in increased expression of SLC5A7 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 9:7,922,693...7,953,509
Ensembl chr 9:7,922,697...7,953,509
|
|
| G
|
Slc5a8
|
solute carrier family 5 member 8
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC5A8 protein
|
CTD |
PMID:21360409 |
|
NCBI chr 7:25,160,280...25,201,185
Ensembl chr 7:25,159,897...25,204,419
|
|
| G
|
Slc5a9
|
solute carrier family 5 member 9
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SLC5A9 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:131,937,368...131,966,405
Ensembl chr 5:131,938,216...131,961,922
|
|
| G
|
Slc6a11
|
solute carrier family 6 member 11
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SLC6A11 mRNA Progesterone results in decreased expression of SLC6A11 mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr 4:148,853,557...148,968,895
Ensembl chr 4:148,853,554...148,969,019
|
|
| G
|
Slc7a11
|
solute carrier family 7 member 11
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLC7A11 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695
|
|
| G
|
Slc7a2
|
solute carrier family 7 member 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of SLC7A2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr16:58,115,991...58,174,256
Ensembl chr16:58,120,968...58,174,256
|
|
| G
|
Slc7a3
|
solute carrier family 7 member 3
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of SLC7A3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr X:70,250,089...70,256,610
Ensembl chr X:70,250,099...70,256,059
|
|
| G
|
Slc7a4
|
solute carrier family 7, member 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC7A4 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr11:96,939,456...96,943,127
Ensembl chr11:96,939,444...96,943,802
|
|
| G
|
Slc7a5
|
solute carrier family 7 member 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLC7A5 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412
|
|
| G
|
Slc7a8
|
solute carrier family 7 member 8
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of SLC7A8 mRNA Progesterone results in increased expression of SLC7A8 mRNA
|
CTD |
PMID:17404688 PMID:20864642 PMID:21795739 |
|
NCBI chr15:32,153,016...32,212,715
Ensembl chr15:32,153,018...32,212,715
|
|
| G
|
Slc8a1
|
solute carrier family 8 member A1
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [Estradiol results in increased expression of SLC8A1 mRNA]
|
CTD |
PMID:21795739 |
|
NCBI chr 6:18,975,498...19,299,704
Ensembl chr 6:18,946,798...19,287,964
|
|
| G
|
Slc9a1
|
solute carrier family 9 member A1
|
increases expression
|
EXP
|
Progesterone results in increased expression of SLC9A1 mRNA; Progesterone results in increased expression of SLC9A1 protein
|
CTD |
PMID:23509787 |
|
NCBI chr 5:150,859,412...150,913,525
Ensembl chr 5:150,860,228...150,913,517
|
|
| G
|
Slc9a2
|
solute carrier family 9 member A2
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of SLC9A2 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 9:50,427,612...50,510,043
Ensembl chr 9:50,426,798...50,510,040
|
|
| G
|
Slco2a1
|
solute carrier organic anion transporter family, member 2a1
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SLCO2A1 mRNA; Mifepristone promotes the reaction [Progesterone affects the expression of SLCO2A1 mRNA] Progesterone results in decreased expression of SLCO2A1 mRNA
|
CTD |
PMID:20660070 PMID:22238285 PMID:22414680 |
|
NCBI chr 8:112,467,739...112,551,923
Ensembl chr 8:112,467,160...112,551,921
|
|
| G
|
Slco3a1
|
solute carrier organic anion transporter family, member 3a1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SLCO3A1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:137,516,037...137,797,836
Ensembl chr 1:137,505,158...137,797,836
|
|
| G
|
Slco5a1
|
solute carrier organic anion transporter family, member 5A1
|
multiple interactions increases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in increased expression of SLCO5A1 mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr 5:11,012,001...11,141,180
Ensembl chr 5:11,012,075...11,141,177
|
|
| G
|
Slit1
|
slit guidance ligand 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SLIT1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:250,358,917...250,507,476
Ensembl chr 1:250,358,919...250,507,476
|
|
| G
|
Slit3
|
slit guidance ligand 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of SLIT3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:20,075,929...20,660,704
Ensembl chr10:20,076,021...20,660,704
|
|
| G
|
Slitrk4
|
SLIT and NTRK-like family, member 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SLITRK4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr X:147,728,163...147,755,086
Ensembl chr X:147,727,983...147,755,557
|
|
| G
|
Slpi
|
secretory leukocyte peptidase inhibitor
|
affects expression
|
ISO
|
Progesterone affects the expression of SLPI mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:173,501,573...173,503,822
Ensembl chr 3:173,501,573...173,503,822
|
|
| G
|
Smad2
|
SMAD family member 2
|
affects expression multiple interactions
|
ISO
|
Progesterone affects the expression of SMAD2 mRNA [4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] promotes the reaction [FSHB protein results in increased chemical synthesis of Progesterone]
|
CTD |
PMID:17251523 PMID:21520325 |
|
NCBI chr18:72,124,792...72,193,345
Ensembl chr18:72,124,863...72,187,388
|
|
| G
|
Smad3
|
SMAD family member 3
|
multiple interactions decreases expression
|
ISO
|
[4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased activity of [SMAD2 protein co-treated with SMAD3 protein]] promotes the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride results in decreased activity of SMAD3 protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [Estradiol co-treated with Progesterone] results in decreased expression of SMAD3 mRNA Progesterone results in decreased expression of SMAD3 mRNA
|
CTD |
PMID:20660070 PMID:20864642 PMID:21520325 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:73,024,760...73,132,324
|
|
| G
|
Smad4
|
SMAD family member 4
|
affects expression
|
ISO
|
Progesterone affects the expression of SMAD4 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr18:69,518,988...69,549,684
Ensembl chr18:69,518,988...69,549,684
|
|
| G
|
Smad6
|
SMAD family member 6
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SMAD6 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 8:73,345,457...73,414,985
Ensembl chr 8:73,345,460...73,414,149
|
|
| G
|
Smad7
|
SMAD family member 7
|
increases expression
|
EXP
|
Progesterone results in increased expression of SMAD7 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr18:71,263,508...71,291,849
Ensembl chr18:71,263,508...71,291,849
|
|
| G
|
Smad9
|
SMAD family member 9
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SMAD9 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 2:141,106,668...141,156,477
Ensembl chr 2:141,106,668...141,156,477
|
|
| G
|
Smc2
|
structural maintenance of chromosomes 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of SMC2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 5:71,592,428...71,648,636
Ensembl chr 5:71,602,308...71,648,632
|
|
| G
|
Smc4
|
structural maintenance of chromosomes 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SMC4 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:155,550,262...155,578,695
Ensembl chr 2:155,550,262...155,581,937
|
|
| G
|
Smim3
|
small integral membrane protein 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of SMIM3 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr18:56,200,458...56,252,778
Ensembl chr18:56,200,459...56,227,379
|
|
| G
|
Smoc1
|
SPARC related modular calcium binding 1
|
affects expression
|
ISO
|
Progesterone affects the expression of SMOC1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 6:106,432,592...106,593,956
Ensembl chr 6:106,432,603...106,593,956
|
|
| G
|
Smoc2
|
SPARC related modular calcium binding 2
|
multiple interactions affects expression increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SMOC2 mRNA Progesterone affects the expression of SMOC2 mRNA Progesterone results in increased expression of SMOC2 mRNA
|
CTD |
PMID:17251523 PMID:20660070 PMID:22238285 |
|
NCBI chr 1:63,935,627...64,064,952
Ensembl chr 1:63,935,647...64,064,955
|
|
| G
|
Smpdl3a
|
sphingomyelin phosphodiesterase, acid-like 3A
|
increases expression
|
ISO
|
Progesterone results in increased expression of SMPDL3A mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr20:37,679,004...37,701,979
Ensembl chr20:37,678,964...37,704,260
|
|
| G
|
Smtn
|
smoothelin
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of SMTN mRNA Progesterone results in decreased expression of SMTN mRNA
|
CTD |
PMID:17251523 PMID:21795739 |
|
NCBI chr14:82,622,223...82,644,525
Ensembl chr14:82,621,375...82,644,514
|
|
| G
|
Smyd3
|
SET and MYND domain containing 3
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SMYD3 mRNA Progesterone results in increased expression of SMYD3 mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr13:93,241,274...93,798,221
Ensembl chr13:93,241,279...93,798,237
|
|
| G
|
Snap23
|
synaptosome associated protein 23
|
affects expression
|
ISO
|
Progesterone affects the expression of SNAP23 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 3:127,966,184...127,999,929
Ensembl chr 3:127,967,886...127,998,067
|
|
| G
|
Sncaip
|
synuclein, alpha interacting protein
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SNCAIP mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr18:48,402,164...48,542,246
Ensembl chr18:48,404,531...48,574,002
|
|
| G
|
Snrk
|
SNF related kinase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SNRK mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 8:130,657,204...130,711,461
Ensembl chr 8:130,657,266...130,711,457
|
|
| G
|
Snrpd3
|
small nuclear ribonucleoprotein D3 polypeptide
|
affects expression
|
ISO
|
Progesterone affects the expression of SNRPD3 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr20:13,129,555...13,145,100
Ensembl chr20:13,109,294...13,145,763
|
|
| G
|
Sntg2
|
syntrophin, gamma 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of SNTG2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:52,529,481...52,730,972
Ensembl chr 6:52,529,481...52,730,972
|
|
| G
|
Snx10
|
sorting nexin 10
|
increases expression
|
ISO
|
Progesterone results in increased expression of SNX10 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 4:81,943,262...82,007,667
Ensembl chr 4:81,943,287...82,007,651
|
|
| G
|
Socs1
|
suppressor of cytokine signaling 1
|
multiple interactions decreases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of SOCS1 mRNA; [Progesterone co-treated with TGFB1 protein] results in decreased expression of SOCS1 mRNA Progesterone results in decreased expression of SOCS1 mRNA Progesterone promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of SOCS1 mRNA]; Progesterone promotes the reaction [Poly I-C results in increased expression of SOCS1 mRNA] Progesterone inhibits the reaction [Estrogens results in increased expression of SOCS1 mRNA]; Progesterone inhibits the reaction [PRL protein results in increased expression of SOCS1 mRNA]
|
CTD |
PMID:17404688 PMID:18325991 PMID:21768398 PMID:22546503 |
|
NCBI chr10:5,389,574...5,391,265
Ensembl chr10:5,389,334...5,391,847
|
|
| G
|
Socs2
|
suppressor of cytokine signaling 2
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of SOCS2 mRNA [Estradiol co-treated with Progesterone] results in increased expression of SOCS2 mRNA; [Progesterone co-treated with TGFB1 protein] results in decreased expression of SOCS2 mRNA
|
CTD |
PMID:20660070 PMID:21768398 |
|
NCBI chr 7:31,890,564...31,932,092
Ensembl chr 7:31,874,463...31,930,423
|
|
| G
|
Socs3
|
suppressor of cytokine signaling 3
|
affects expression multiple interactions increases expression
|
ISO EXP
|
Progesterone affects the expression of SOCS3 mRNA [Progesterone co-treated with TGFB1 protein] results in increased expression of SOCS3 mRNA Progesterone results in increased expression of SOCS3 mRNA Progesterone inhibits the reaction [Estrogens results in increased expression of SOCS3 mRNA]
|
CTD |
PMID:17251523 PMID:18325991 PMID:21768398 |
|
NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825
|
|
| G
|
Sod1
|
superoxide dismutase 1
|
multiple interactions increases activity increases abundance
|
EXP ISO
|
[Progesterone co-treated with Estradiol] results in increased activity of SOD1 protein Progesterone results in increased activity of SOD1 protein SOD1 protein results in increased abundance of Progesterone
|
CTD |
PMID:15820610 PMID:21900685 |
|
NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399
|
|
| G
|
Sod2
|
superoxide dismutase 2
|
multiple interactions decreases expression decreases activity
|
ISO EXP
|
Estradiol inhibits the reaction [Progesterone results in decreased expression of SOD2 mRNA] Mifepristone inhibits the reaction [Progesterone results in decreased expression of SOD2 mRNA]; Progesterone inhibits the reaction [Estradiol results in increased expression of SOD2 mRNA] Progesterone results in decreased activity of SOD2 protein [Estradiol co-treated with Progesterone] results in decreased expression of SOD2 mRNA
|
CTD |
PMID:16195479 PMID:20660070 |
|
NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168
|
|
| G
|
Sod3
|
superoxide dismutase 3
|
decreases expression multiple interactions decreases activity
|
ISO EXP
|
Progesterone results in decreased expression of SOD3 mRNA Estradiol inhibits the reaction [Progesterone results in decreased expression of SOD3 mRNA] Mifepristone inhibits the reaction [Progesterone results in decreased expression of SOD3 mRNA]; Progesterone inhibits the reaction [Estradiol results in increased expression of SOD3 mRNA] Progesterone results in decreased activity of SOD3 protein
|
CTD |
PMID:16195479 |
|
NCBI chr14:62,822,865...62,828,602
Ensembl chr14:62,811,177...62,829,125
|
|
| G
|
Sorbs1
|
sorbin and SH3 domain containing 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SORBS1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 1:249,057,324...249,279,703
Ensembl chr 1:249,057,324...249,279,608
|
|
| G
|
Sorbs2
|
sorbin and SH3 domain containing 2
|
increases expression multiple interactions decreases expression
|
ISO
|
Progesterone results in increased expression of SORBS2 mRNA [Progesterone co-treated with Estradiol] results in increased expression of SORBS2 mRNA Progesterone results in decreased expression of SORBS2 mRNA
|
CTD |
PMID:17404688 PMID:21540246 |
|
NCBI chr16:53,167,795...53,481,300
Ensembl chr16:53,167,827...53,358,986
|
|
| G
|
Sord
|
sorbitol dehydrogenase
|
increases expression
|
EXP
|
Progesterone results in increased expression of SORD mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 3:129,638,282...129,669,727
Ensembl chr 3:129,638,302...129,686,100
|
|
| G
|
Sort1
|
sortilin 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SORT1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 2:198,609,466...198,690,481
Ensembl chr 2:198,612,148...198,690,481
|
|
| G
|
Sos1
|
SOS Ras/Rac guanine nucleotide exchange factor 1
|
multiple interactions
|
EXP
|
[Estradiol co-treated with Progesterone co-treated with Methylnitrosourea] results in increased expression of SOS1 mRNA
|
CTD |
PMID:22465879 |
|
NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:20,286,117...20,363,350
|
|
| G
|
Sox10
|
SRY-box transcription factor 10
|
increases expression
|
EXP
|
Progesterone results in increased expression of SOX10 mRNA; Progesterone results in increased expression of SOX10 protein
|
CTD |
PMID:17478888 |
|
NCBI chr 7:112,605,721...112,615,097
Ensembl chr 7:112,605,721...112,615,990
|
|
| G
|
Sox11
|
SRY-box transcription factor 11
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SOX11 mRNA Progesterone results in decreased expression of SOX11 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 6:49,736,773...49,738,794
Ensembl chr 6:49,736,304...49,738,691
|
|
| G
|
Sox4
|
SRY-box transcription factor 4
|
multiple interactions affects expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SOX4 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of SOX4 mRNA Progesterone affects the expression of SOX4 mRNA Progesterone results in decreased expression of SOX4 mRNA
|
CTD |
PMID:17251523 PMID:17404688 PMID:20660070 PMID:21795739 |
|
NCBI chr17:35,876,298...35,881,004
Ensembl chr17:35,875,756...35,884,024
|
|
| G
|
Sox7
|
SRY-box transcription factor 7
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of SOX7 mRNA] [Estradiol co-treated with Progesterone] results in increased expression of SOX7 mRNA
|
CTD |
PMID:17556502 PMID:20660070 |
|
NCBI chr15:42,356,405...42,363,166
Ensembl chr15:42,356,289...42,363,164
|
|
| G
|
Sox9
|
SRY-box transcription factor 9
|
multiple interactions decreases expression increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SOX9 mRNA Progesterone results in decreased expression of SOX9 mRNA Progesterone results in increased expression of SOX9 mRNA
|
CTD |
PMID:17404688 PMID:21795739 PMID:22238285 |
|
NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250
|
|
| G
|
Sp5
|
Sp5 transcription factor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SP5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:75,682,677...75,685,479
Ensembl chr 3:75,682,677...75,685,479
|
|
| G
|
Spag5
|
sperm associated antigen 5
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of SPAG5 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr10:63,693,300...63,714,813
Ensembl chr10:63,696,466...63,714,811
|
|
| G
|
Sparc
|
secreted protein acidic and cysteine rich
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SPARC mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr10:40,017,065...40,038,816
Ensembl chr10:40,017,075...40,039,268
|
|
| G
|
Sparcl1
|
SPARC like 1
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SPARCL1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of SPARCL1 mRNA Progesterone results in increased expression of SPARCL1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20864642 |
|
NCBI chr14:5,937,484...5,968,532
Ensembl chr14:5,914,535...5,969,120
|
|
| G
|
Spata6
|
spermatogenesis associated 6
|
affects expression
|
ISO
|
Progesterone affects the expression of SPATA6 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:131,821,585...131,905,011
Ensembl chr 5:131,821,585...131,905,014
|
|
| G
|
Spats2l
|
spermatogenesis associated, serine-rich 2-like
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SPATS2L mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 9:66,814,217...66,988,084
Ensembl chr 9:66,814,228...66,988,578
|
|
| G
|
Spc25
|
SPC25 component of NDC80 kinetochore complex
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of SPC25 mRNA Progesterone results in decreased expression of SPC25 mRNA
|
CTD |
PMID:21540246 PMID:22238285 |
|
NCBI chr 3:74,337,872...74,396,825
Ensembl chr 3:74,383,548...74,396,718
|
|
| G
|
Speg
|
striated muscle enriched protein kinase
|
increases expression
|
EXP
|
Progesterone results in increased expression of SPEG mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 9:84,314,387...84,371,816
Ensembl chr 9:84,314,387...84,371,813
|
|
| G
|
Sphk1
|
sphingosine kinase 1
|
multiple interactions increases expression
|
EXP
|
Mifepristone inhibits the reaction [Progesterone results in increased expression of SPHK1 mRNA]; onapristone inhibits the reaction [Progesterone results in increased expression of SPHK1 mRNA]
|
CTD |
PMID:17164439 |
|
NCBI chr10:102,257,413...102,263,086
Ensembl chr10:102,258,975...102,263,082
|
|
| G
|
Spink1
|
serine peptidase inhibitor, Kazal type 1
|
multiple interactions affects expression
|
ISO
|
[Progesterone co-treated with bazedoxifene] results in increased expression of SPINK1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of SPINK1 mRNA; [Progesterone co-treated with Lasofoxifene] results in increased expression of SPINK1 mRNA; [Progesterone co-treated with Raloxifene Hydrochloride] results in increased expression of SPINK1 mRNA Progesterone affects the expression of SPINK1 mRNA
|
CTD |
PMID:17251523 PMID:18367319 |
|
NCBI chr18:36,121,626...36,133,596
Ensembl chr18:36,076,399...36,133,545
|
|
| G
|
Spink13
|
serine peptidase inhibitor Kazal type 13
|
increases expression
|
ISO
|
Progesterone results in increased expression of SPINK13 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr18:58,335,146...58,476,569
Ensembl chr18:58,335,146...58,476,569
|
|
| G
|
Spink5
|
serine peptidase inhibitor, Kazal type 5
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SPINK5 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr18:36,515,347...36,584,038
Ensembl chr18:36,515,347...36,583,799
|
|
| G
|
Spink8
|
serine peptidase inhibitor, Kazal type 8
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SPINK8 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 8:118,686,362...118,707,449
Ensembl chr 8:118,686,366...118,707,544
|
|
| G
|
Spn
|
sialophorin
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SPN mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr 1:191,177,449...191,190,115
Ensembl chr 1:191,178,096...191,187,852
|
|
| G
|
Spon1
|
spondin 1
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SPON1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:177,363,526...177,662,689
Ensembl chr 1:177,363,197...177,662,676
|
|
| G
|
Spon2
|
spondin 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SPON2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr14:81,713,070...81,742,510
Ensembl chr14:81,731,188...81,742,609
|
|
| G
|
Spp1
|
secreted phosphoprotein 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SPP1 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of SPP1 mRNA
|
CTD |
PMID:20226447 PMID:20660070 |
|
NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820
|
|
| G
|
Sprr1a
|
small proline-rich protein 1A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SPRR1A mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:180,750,709...180,752,625
Ensembl chr 2:180,750,709...180,752,991
|
|
| G
|
Sprr2a
|
small proline rich protein 2A
|
affects expression multiple interactions
|
ISO
|
Progesterone affects the expression of SPRR2A mRNA Progesterone inhibits the reaction [bisphenol A results in increased expression of SPRR2A mRNA]; Progesterone inhibits the reaction [Estradiol results in increased expression of SPRR2A mRNA]
|
CTD |
PMID:17251523 PMID:20438831 |
|
NCBI chr 2:180,511,568...180,511,840
|
|
| G
|
Sprr2b
|
small proline rich protein 2B
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of SPRR2B mRNA Progesterone inhibits the reaction [bisphenol A results in increased expression of SPRR2B mRNA]; Progesterone inhibits the reaction [Estradiol results in increased expression of SPRR2B mRNA]
|
CTD |
PMID:17404688 PMID:20438831 |
|
NCBI chr 2:180,548,428...180,548,700
|
|
| G
|
Sprr2f
|
small proline rich protein 2F
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of SPRR2F mRNA Progesterone results in decreased expression of SPRR2F mRNA
|
CTD |
PMID:17251523 PMID:22238285 |
|
NCBI chr 2:180,685,587...180,685,817
Ensembl chr 2:180,685,587...180,685,817
|
|
| G
|
Spry1
|
sprouty RTK signaling antagonist 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SPRY1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 2:122,484,995...122,490,008
Ensembl chr 2:122,484,355...122,492,956
|
|
| G
|
Spry4
|
sprouty RTK signaling antagonist 4
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of SPRY4 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of SPRY4 mRNA
|
CTD |
PMID:18037150 PMID:20660070 |
|
NCBI chr18:30,687,633...30,702,546
Ensembl chr18:30,687,039...30,704,173
|
|
| G
|
Spsb1
|
splA/ryanodine receptor domain and SOCS box containing 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SPSB1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 5:165,641,255...165,701,482
Ensembl chr 5:165,642,851...165,654,225
|
|
| G
|
Sptbn1
|
spectrin, beta, non-erythrocytic 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SPTBN1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:108,042,629...108,217,884
Ensembl chr14:108,042,629...108,217,836
|
|
| G
|
Sptssa
|
serine palmitoyltransferase, small subunit A
|
increases expression
|
ISO
|
Progesterone results in increased expression of SPTSSA mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 6:77,879,931...77,891,344
Ensembl chr 6:77,879,941...77,891,403
|
|
| G
|
Sqle
|
squalene epoxidase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SQLE mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 7:92,758,175...92,773,049
Ensembl chr 7:92,757,409...92,773,050
|
|
| G
|
Sqor
|
sulfide quinone oxidoreductase
|
increases expression
|
ISO
|
Progesterone results in increased expression of SQOR mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:130,294,783...130,341,655
Ensembl chr 3:130,292,814...130,340,799
|
|
| G
|
Sqstm1
|
sequestosome 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SQSTM1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750
|
|
| G
|
Srd5a1
|
steroid 5 alpha-reductase 1
|
affects metabolic processing decreases activity decreases expression increases metabolic processing multiple interactions increases reduction
|
ISO EXP
|
SRD5A1 protein affects the metabolism of Progesterone Progesterone analog results in decreased activity of SRD5A1 protein Progesterone results in decreased expression of SRD5A1 protein SRD5A1 protein results in increased metabolism of Progesterone [SRD5A1 protein results in increased metabolism of Progesterone] which results in increased chemical synthesis of 5-alpha-Dihydroprogesterone SRD5A1 protein results in increased reduction of Progesterone
|
CTD |
PMID:15261307 PMID:15555913 PMID:20359488 PMID:23183084 PMID:25463305 |
|
NCBI chr 1:35,514,914...35,548,898
Ensembl chr 1:35,514,846...35,548,903
|
|
| G
|
Srd5a2
|
steroid 5 alpha-reductase 2
|
decreases activity
|
ISO
|
Progesterone analog results in decreased activity of SRD5A2 protein
|
CTD |
PMID:20359488 |
|
NCBI chr 6:27,178,089...27,217,588
Ensembl chr 6:27,178,079...27,217,588
|
|
| G
|
Srebf1
|
sterol regulatory element binding transcription factor 1
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]; [Progesterone co-treated with Estradiol] inhibits the reaction [Phenobarbital results in decreased expression of SREBF1 mRNA]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]]; NR1I3 mutant form inhibits the reaction [Progesterone inhibits the reaction [Phenobarbital results in decreased expression of SREBF1 mRNA]]; Progesterone inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in decreased expression of SREBF1 mRNA]; Progesterone inhibits the reaction [Phenobarbital results in decreased expression of SREBF1 mRNA] 1,4-bis(2-(3,5-dichloropyridyloxy))benzene inhibits the reaction [[Progesterone co-treated with Estradiol] results in increased expression of SREBF1 mRNA]; [Progesterone co-treated with Estradiol] results in increased expression of SREBF1 mRNA Progesterone results in increased expression of SREBF1 mRNA
|
CTD |
PMID:20726854 PMID:21768169 |
|
NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164
|
|
| G
|
Srgn
|
serglycin
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SRGN mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr20:30,985,508...31,022,296
Ensembl chr20:30,985,508...31,000,327
|
|
| G
|
Srpx
|
sushi-repeat-containing protein, X-linked
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of SRPX mRNA; [Progesterone co-treated with Estradiol] results in increased expression of SRPX mRNA Progesterone results in increased expression of SRPX mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20726854 PMID:21795739 |
|
NCBI chr X:15,349,498...15,420,389
Ensembl chr X:15,349,440...15,420,392
|
|
| G
|
Srsf10
|
serine and arginine rich splicing factor 10
|
affects expression decreases expression
|
ISO EXP
|
Progesterone affects the expression of SRSF10 mRNA Progesterone results in decreased expression of SRSF10 mRNA
|
CTD |
PMID:17251523 PMID:20726854 |
|
NCBI chr 5:153,372,307...153,386,520
Ensembl chr 5:153,372,316...153,386,513
|
|
| G
|
Srsf6
|
serine and arginine rich splicing factor 6
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SRSF6 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 3:172,009,072...172,014,395
Ensembl chr 3:172,009,061...172,014,392
|
|
| G
|
Sry
|
sex determining region Y
|
increases expression
|
ISO
|
Progesterone results in increased expression of SRY mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr Y:465,260...465,772
Ensembl chr Y:465,260...465,772
|
|
| G
|
Sspn
|
sarcospan
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SSPN mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:180,620,762...180,666,893
Ensembl chr 4:180,627,848...180,662,284
|
|
| G
|
Sst
|
somatostatin
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of SST mRNA Progesterone results in increased expression of SST mRNA
|
CTD |
PMID:16376865 PMID:17404688 |
|
NCBI chr11:90,461,546...90,462,823
Ensembl chr11:90,461,546...90,462,823
|
|
| G
|
Sstr1
|
somatostatin receptor 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SSTR1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 6:81,567,237...81,571,759
Ensembl chr 6:81,566,850...81,571,992
|
|
| G
|
St14
|
ST14 transmembrane serine protease matriptase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ST14 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:37,798,994...37,839,881
Ensembl chr 8:37,798,995...37,855,652
|
|
| G
|
St3gal1
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ST3GAL1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 7:100,734,300...100,802,443
Ensembl chr 7:100,734,300...100,745,242
|
|
| G
|
St3gal5
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 5
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ST3GAL5 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:105,692,840...105,750,774
Ensembl chr 4:105,692,840...105,750,775
|
|
| G
|
St3gal6
|
ST3 beta-galactoside alpha-2,3-sialyltransferase 6
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ST3GAL6 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr11:55,530,120...55,590,950
Ensembl chr11:55,530,248...55,598,720
|
|
| G
|
St6gal2
|
ST6 beta-galactoside alpha-2,6-sialyltransferase 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ST6GAL2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 9:9,508,928...9,606,900
Ensembl chr 9:9,509,548...9,594,007
|
|
| G
|
St6galnac1
|
ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of ST6GALNAC1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr10:102,471,481...102,481,876
Ensembl chr10:102,471,493...102,481,876
|
|
| G
|
St7
|
suppression of tumorigenicity 7
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ST7 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 4:47,007,568...47,255,639
Ensembl chr 4:47,008,095...47,255,637
|
|
| G
|
St8sia1
|
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ST8SIA1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 4:177,513,966...177,651,553
Ensembl chr 4:177,520,926...177,651,553
|
|
| G
|
Stambpl1
|
STAM binding protein-like 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of STAMBPL1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:241,095,695...241,158,225
Ensembl chr 1:241,113,239...241,158,225
|
|
| G
|
Stap1
|
signal transducing adaptor family member 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of STAP1 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr14:22,301,278...22,336,218
Ensembl chr14:22,236,616...22,342,652
|
|
| G
|
Star
|
steroidogenic acute regulatory protein
|
decreases expression multiple interactions
|
ISO EXP
|
Progesterone results in decreased expression of STAR mRNA [[NR0B1 protein binds to STAR promoter] which results in decreased expression of STAR mRNA] which results in decreased abundance of Progesterone; [[T0901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone; [LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone; [LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone; [T0901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone; [T0901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone; [Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Tetradecanoylphorbol Acetate results in increased expression of STAR protein] which results in increased abundance of Progesterone; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; LG 100268 promotes the reaction [[T0901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of STAR protein] which results in increased abundance of Progesterone]; PRKCA protein promotes the reaction [[Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; PRKCD protein promotes the reaction [[Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; PRKCE protein promotes the reaction [[Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; PRKD1 protein promotes the reaction [[Tetradecanoylphorbol Acetate results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; T0901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]; Tetradecanoylphorbol Acetate promotes the reaction [[Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone] [BMP15 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [BMP2 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [BMP4 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [BMP6 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [BMP7 protein results in decreased expression of STAR mRNA] inhibits the reaction [FSHB protein results in increased abundance of Progesterone]; [FSHB protein results in increased expression of STAR mRNA] which results in increased abundance of Progesterone; GH1 protein promotes the reaction [[FSHB protein results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]; IGF1 protein promotes the reaction [[FSHB protein results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]
|
CTD |
PMID:14630719 PMID:18070364 PMID:18787026 PMID:19282384 PMID:21047949 PMID:22067323 PMID:23362264 More...
|
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447
|
|
| G
|
Stat3
|
signal transducer and activator of transcription 3
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]
|
CTD |
PMID:21768398 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359
|
|
| G
|
Stat5a
|
signal transducer and activator of transcription 5A
|
affects localization increases expression multiple interactions affects abundance
|
ISO
|
Progesterone affects the localization of STAT5A protein Progesterone results in increased expression of STAT5A protein [Estradiol co-treated with Progesterone] results in increased expression of STAT5A protein STAT5A protein affects the abundance of Progesterone Progesterone promotes the reaction [IL2 protein results in increased phosphorylation of STAT5A protein]
|
CTD |
PMID:15471942 PMID:16175315 PMID:17884938 PMID:21768398 |
|
NCBI chr10:86,285,859...86,310,187
Ensembl chr10:86,285,547...86,310,184
|
|
| G
|
Stat5b
|
signal transducer and activator of transcription 5B
|
affects localization increases expression affects abundance multiple interactions
|
ISO
|
Progesterone affects the localization of STAT5B protein Progesterone results in increased expression of STAT5B protein STAT5B protein affects the abundance of Progesterone Progesterone promotes the reaction [IL2 protein results in increased phosphorylation of STAT5B protein]
|
CTD |
PMID:15471942 PMID:16175315 PMID:21768398 |
|
NCBI chr10:86,205,148...86,276,178
Ensembl chr10:86,207,293...86,275,990
|
|
| G
|
Stc1
|
stanniocalcin 1
|
multiple interactions decreases expression increases expression
|
ISO EXP
|
4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of STC1 mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of STC1 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of STC1 mRNA; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of STC1 mRNA]; pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of STC1 mRNA]; U 0126 promotes the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of STC1 mRNA] Progesterone results in decreased expression of STC1 mRNA Progesterone results in increased expression of STC1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20864642 PMID:21770760 PMID:21795739 |
|
NCBI chr15:50,709,439...50,720,093
Ensembl chr15:50,709,415...50,720,082
|
|
| G
|
Stc2
|
stanniocalcin 2
|
increases expression multiple interactions decreases expression
|
ISO
|
Progesterone results in increased expression of STC2 mRNA 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of STC2 mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of STC2 mRNA; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of STC2 mRNA]; U 0126 inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of STC2 mRNA] Progesterone results in decreased expression of STC2 mRNA
|
CTD |
PMID:18037150 PMID:20660070 |
|
NCBI chr10:16,755,508...16,765,275
Ensembl chr10:16,755,267...16,767,447
|
|
| G
|
Steap4
|
STEAP4 metalloreductase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of STEAP4 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of STEAP4 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 4:27,032,096...27,054,769
Ensembl chr 4:27,009,584...27,067,105
|
|
| G
|
Stip1
|
stress-induced phosphoprotein 1
|
affects expression
|
ISO
|
Progesterone affects the expression of STIP1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:213,638,641...213,657,654
Ensembl chr 1:213,638,641...213,657,654
|
|
| G
|
Stmn1
|
stathmin 1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of STMN1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 5:151,964,308...151,970,843
Ensembl chr 5:151,964,351...151,970,842
|
|
| G
|
Stmn2
|
stathmin 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of STMN2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 2:95,112,017...95,159,642
Ensembl chr 2:95,112,019...95,159,335
|
|
| G
|
Stmn4
|
stathmin 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of STMN4 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr15:44,716,825...44,734,776
Ensembl chr15:44,716,880...44,742,086
|
|
| G
|
Strbp
|
spermatid perinuclear RNA binding protein
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of STRBP mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:41,738,096...41,879,054
Ensembl chr 3:41,712,311...41,824,707
|
|
| G
|
Stx3
|
syntaxin 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of STX3 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:217,940,697...218,114,865
Ensembl chr 1:217,909,169...218,110,466
|
|
| G
|
Stxbp6
|
syntaxin binding protein 6
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of STXBP6 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:67,647,721...67,884,369
Ensembl chr 6:67,650,556...67,884,725
|
|
| G
|
Sulf2
|
sulfatase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of SULF2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 3:175,241,322...175,323,808
Ensembl chr 3:175,241,322...175,323,651
|
|
| G
|
Sult1a1
|
sulfotransferase family 1A member 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of SULT1A1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131
|
|
| G
|
Sult1e1
|
sulfotransferase family 1E member 1
|
multiple interactions increases expression affects expression
|
ISO
|
13beta-methyl 19-nor-steroid inhibits the reaction [Progesterone results in increased expression of SULT1E1 mRNA]; 4-nonylphenol inhibits the reaction [Progesterone results in increased expression of SULT1E1 mRNA]; Apigenin inhibits the reaction [Progesterone results in increased expression of SULT1E1 mRNA]; bisphenol A inhibits the reaction [Progesterone results in increased expression of SULT1E1 mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of SULT1E1 mRNA]; Mifepristone inhibits the reaction [Progesterone results in increased expression of SULT1E1 protein]; perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of SULT1E1 mRNA]; Progesterone inhibits the reaction [perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of SULT1E1 mRNA]] Progesterone results in increased expression of SULT1E1 mRNA; Progesterone results in increased expression of SULT1E1 protein
|
CTD |
PMID:22414680 PMID:31896193 |
|
NCBI chr14:20,700,444...20,718,719
Ensembl chr14:20,700,292...20,718,716
|
|
| G
|
Sumo1
|
small ubiquitin-like modifier 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SUMO1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 9:68,572,901...68,602,803
Ensembl chr 9:68,572,911...68,602,890
|
|
| G
|
Sv2b
|
synaptic vesicle glycoprotein 2b
|
increases expression
|
EXP
|
Progesterone results in increased expression of SV2B mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 1:138,388,268...138,562,635
Ensembl chr 1:138,388,266...138,562,258
|
|
| G
|
Svep1
|
sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SVEP1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:77,606,523...77,783,292
Ensembl chr 5:77,606,523...77,783,711
|
|
| G
|
Svil
|
supervillin
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SVIL mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:57,343,910...57,539,508
Ensembl chr17:57,343,910...57,462,660
|
|
| G
|
Sybu
|
syntabulin
|
multiple interactions increases expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SYBU mRNA; [Progesterone co-treated with Estradiol] results in increased expression of SYBU mRNA Progesterone results in increased expression of SYBU mRNA Progesterone results in decreased expression of SYBU mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21540246 |
|
NCBI chr 7:77,731,662...77,833,413
Ensembl chr 7:77,731,605...77,833,686
|
|
| G
|
Syne1
|
spectrin repeat containing nuclear envelope protein 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SYNE1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:43,917,640...44,388,802
Ensembl chr 1:43,895,994...44,388,721
|
|
| G
|
Synj2
|
synaptojanin 2
|
multiple interactions decreases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of SYNJ2 mRNA Progesterone results in decreased expression of SYNJ2 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:48,923,742...49,027,153
Ensembl chr 1:48,923,737...49,038,650
|
|
| G
|
Synm
|
synemin
|
increases expression
|
ISO
|
Progesterone results in increased expression of SYNM mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:130,743,891...130,774,254
Ensembl chr 1:130,743,897...130,773,824
|
|
| G
|
Synpo2
|
synaptopodin 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of SYNPO2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:213,901,685...214,055,844
Ensembl chr 2:213,900,868...214,055,844
|
|
| G
|
Synpo2l
|
synaptopodin 2-like
|
increases expression
|
ISO
|
Progesterone results in increased expression of SYNPO2L mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr15:3,681,224...3,690,673
Ensembl chr15:3,681,104...3,690,673
|
|
| G
|
Syt16
|
synaptotagmin 16
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of SYT16 mRNA
|
CTD |
PMID:20864642 PMID:21795739 |
|
NCBI chr 6:98,456,582...98,735,306
Ensembl chr 6:98,457,274...98,707,936
|
|
| G
|
Sytl4
|
synaptotagmin-like 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of SYTL4 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr X:101,428,785...101,479,207
Ensembl chr X:101,428,785...101,479,151
|
|
| G
|
Sytl5
|
synaptotagmin-like 5
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of SYTL5 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr X:15,461,215...15,702,660
Ensembl chr X:15,460,472...15,550,471
|
|
| G
|
Syvn1
|
synoviolin 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of SYVN1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:212,766,736...212,775,426
Ensembl chr 1:212,768,907...212,776,457
|
|
| G
|
Tac1
|
tachykinin, precursor 1
|
multiple interactions decreases metabolic processing
|
EXP
|
SR 140333 inhibits the reaction [TAC1 protein results in decreased metabolism of Progesterone]
|
CTD |
PMID:15951421 |
|
NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546
|
|
| G
|
Tac3
|
tachykinin precursor 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of TAC2 mRNA
|
CTD |
PMID:19627578 PMID:22238285 |
|
NCBI chr 7:65,447,817...65,454,427
Ensembl chr 7:65,447,817...65,454,427
|
|
| G
|
Tacc2
|
transforming, acidic coiled-coil containing protein 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of TACC2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 1:194,546,428...194,758,152
Ensembl chr 1:194,569,650...194,758,152
|
|
| G
|
Tacstd2
|
tumor-associated calcium signal transducer 2
|
affects expression multiple interactions
|
ISO
|
Progesterone affects the expression of TACSTD2 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of TACSTD2 mRNA
|
CTD |
PMID:17251523 PMID:20660070 |
|
NCBI chr 4:98,037,620...98,039,320
Ensembl chr 4:98,033,251...98,039,323
|
|
| G
|
Taf9
|
TATA-box binding protein associated factor 9
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TAF9 mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 2:33,528,388...33,532,395
Ensembl chr 2:33,531,368...33,536,078
|
|
| G
|
Tafa2
|
TAFA chemokine like family member 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of TAFA2 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 7:60,827,985...61,303,873
Ensembl chr 7:60,891,958...61,303,869
|
|
| G
|
Tagln
|
transgelin
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TAGLN mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 8:55,121,647...55,127,121
Ensembl chr 8:55,121,301...55,127,563
|
|
| G
|
Tap2
|
transporter 2, ATP binding cassette subfamily B member
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TAP2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr20:4,638,257...4,652,296
Ensembl chr20:4,638,257...4,651,537
|
|
| G
|
Tardbp
|
TAR DNA binding protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TARDBP mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:164,330,452...164,348,435
Ensembl chr 5:164,334,924...164,345,204
|
|
| G
|
Tax1bp3
|
Tax1 binding protein 3
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of TAX1BP3 mRNA Progesterone results in decreased expression of TAX1BP3 mRNA
|
CTD |
PMID:17251523 PMID:18037150 |
|
NCBI chr10:58,294,357...58,298,875
Ensembl chr10:58,294,073...58,298,875
|
|
| G
|
Tbc1d1
|
TBC1 domain family member 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of TBC1D1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr14:44,289,241...44,489,246
Ensembl chr14:44,289,241...44,488,167
|
|
| G
|
Tbc1d19
|
TBC1 domain family, member 19
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of TBC1D19 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr14:61,297,193...61,413,106
Ensembl chr14:61,296,800...61,413,028
|
|
| G
|
Tbc1d2
|
TBC1 domain family, member 2
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TBC1D2 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 5:65,679,670...65,727,978
Ensembl chr 5:65,679,680...65,726,996
|
|
| G
|
Tbc1d25
|
TBC1 domain family, member 25
|
increases expression
|
ISO
|
Progesterone results in increased expression of TBC1D25 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr X:16,986,629...17,010,228
Ensembl chr X:16,986,269...17,010,230
|
|
| G
|
Tbccd1
|
TBCC domain containing 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of TBCCD1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr11:91,672,948...91,710,120
Ensembl chr11:91,672,964...91,709,883
|
|
| G
|
Tbl1x
|
transducin (beta)-like 1 X-linked
|
affects expression
|
ISO
|
Progesterone affects the expression of TBL1X mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr X:45,452,983...45,609,532
Ensembl chr X:45,454,482...45,609,525
|
|
| G
|
Tbx20
|
T-box transcription factor 20
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of TBX20 mRNA Mifepristone inhibits the reaction [Progesterone results in decreased expression of TBX20 mRNA]
|
CTD |
PMID:31566189 |
|
NCBI chr 8:31,475,963...31,534,051
Ensembl chr 8:31,475,963...31,534,009
|
|
| G
|
Tc2n
|
tandem C2 domains, nuclear
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TC2N mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:126,526,006...126,622,163
Ensembl chr 6:126,526,009...126,614,215
|
|
| G
|
Tcea3
|
transcription elongation factor A3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TCEA3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:153,760,401...153,792,934
Ensembl chr 5:153,760,407...153,792,930
|
|
| G
|
Tcf25
|
TCF25 ribosome quality control complex subunit
|
affects expression
|
ISO
|
Progesterone affects the expression of TCF25 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr19:68,323,789...68,358,226
Ensembl chr19:68,323,867...68,358,240
|
|
| G
|
Tcf4
|
transcription factor 4
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of TCF4 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr18:65,216,840...65,563,186
Ensembl chr18:65,216,849...65,558,401
|
|
| G
|
Tdo2
|
tryptophan 2,3-dioxygenase
|
increases expression
|
ISO
|
Progesterone results in increased expression of TDO2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:169,567,654...169,585,586
|
|
| G
|
Tdrd5
|
tudor domain containing 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of TDRD5 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr13:70,944,441...70,992,345
Ensembl chr13:70,943,690...70,991,580
|
|
| G
|
Tek
|
TEK receptor tyrosine kinase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TEK mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:114,722,815...114,849,535
Ensembl chr 5:114,723,006...114,849,991
|
|
| G
|
Tenm4
|
teneurin transmembrane protein 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TENM4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:157,699,611...160,674,549
Ensembl chr 1:159,974,017...160,674,549
|
|
| G
|
Tent5a
|
terminal nucleotidyltransferase 5A
|
increases expression
|
ISO
|
Progesterone results in increased expression of TENT5A mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 8:95,102,349...95,109,100
Ensembl chr 8:95,105,412...95,109,100
|
|
| G
|
Tex12
|
testis expressed 12
|
affects response to substance
|
ISO
|
TEX12 gene SNP affects the susceptibility to Progesterone
|
CTD |
PMID:25622337 |
|
NCBI chr 8:59,804,662...59,809,595
Ensembl chr 8:59,804,662...59,813,423
|
|
| G
|
Tfam
|
transcription factor A, mitochondrial
|
multiple interactions increases expression
|
EXP
|
[Progesterone co-treated with Norepinephrine] results in increased expression of TFAM mRNA Progesterone results in increased expression of TFAM mRNA
|
CTD |
PMID:16954335 |
|
NCBI chr20:17,355,373...17,367,422
Ensembl chr20:17,355,363...17,369,877
|
|
| G
|
Tfap2c
|
transcription factor AP-2 gamma
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TFAP2C mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:181,733,524...181,742,412
Ensembl chr 3:181,733,419...181,741,404
|
|
| G
|
Tfcp2l1
|
transcription factor CP2-like 1
|
affects expression decreases expression
|
ISO
|
Progesterone affects the expression of TFCP2L1 mRNA Progesterone results in decreased expression of TFCP2L1 mRNA
|
CTD |
PMID:17251523 PMID:21540246 |
|
NCBI chr13:32,286,643...32,346,671
Ensembl chr13:32,286,643...32,346,671
|
|
| G
|
Tfeb
|
transcription factor EB
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TFEB mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:20,696,440...20,752,265
Ensembl chr 9:20,696,441...20,727,863
|
|
| G
|
Tff1
|
trefoil factor 1
|
multiple interactions decreases expression increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TFF1 mRNA; [Progesterone co-treated with Estradiol] affects the expression of TFF1 mRNA; Fulvestrant inhibits the reaction [Progesterone results in increased expression of TFF1 mRNA] Progesterone results in decreased expression of TFF1 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:22562034 |
|
NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,237,095...9,240,956
|
|
| G
|
Tff3
|
trefoil factor 3
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of TFF3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr20:9,194,623...9,199,333
Ensembl chr20:9,194,626...9,199,333
|
|
| G
|
Tfpi
|
tissue factor pathway inhibitor
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TFPI mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 3:89,939,862...89,989,253
Ensembl chr 3:89,939,868...89,980,742
|
|
| G
|
Tfpi2
|
tissue factor pathway inhibitor 2
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TFPI2 mRNA Progesterone results in increased expression of TFPI2 mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr 4:32,936,462...32,941,385
Ensembl chr 4:32,936,854...32,941,426
|
|
| G
|
Tfrc
|
transferrin receptor
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of TFRC mRNA [Estradiol co-treated with Progesterone] results in increased expression of TFRC mRNA
|
CTD |
PMID:18556351 PMID:20726854 |
|
NCBI chr11:81,668,478...81,690,318
Ensembl chr11:81,668,478...81,690,318
|
|
| G
|
Tgds
|
TDP-glucose 4,6-dehydratase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TGDS mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr15:101,581,765...101,602,779
Ensembl chr15:101,582,227...101,602,718
|
|
| G
|
Tgfa
|
transforming growth factor alpha
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of TGFA mRNA Progesterone results in increased expression of TGFA mRNA
|
CTD |
PMID:18591650 PMID:20660070 |
|
NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339
|
|
| G
|
Tgfb1
|
transforming growth factor, beta 1
|
increases secretion increases expression multiple interactions decreases secretion decreases expression
|
ISO EXP
|
Progesterone results in increased secretion of TGFB1 protein Progesterone results in increased expression of TGFB1 protein 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide inhibits the reaction [[FSHB protein co-treated with TGFB1 protein] results in increased abundance of Progesterone]; [FSHB protein co-treated with TGFB1 protein] results in increased abundance of Progesterone; Progesterone promotes the reaction [Hydrogen Peroxide results in increased expression of TGFB1 mRNA]; Progesterone promotes the reaction [Hydrogen Peroxide results in increased expression of TGFB1 protein] Progesterone results in increased expression of TGFB1 mRNA 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [TGFB1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]]; [Progesterone co-treated with TGFB1 protein] results in decreased expression of SOCS1 mRNA; [Progesterone co-treated with TGFB1 protein] results in decreased expression of SOCS2 mRNA; [Progesterone co-treated with TGFB1 protein] results in increased expression of ASB2 mRNA; [Progesterone co-treated with TGFB1 protein] results in increased expression of CD38 mRNA; [Progesterone co-treated with TGFB1 protein] results in increased expression of HIC1 mRNA; [Progesterone co-treated with TGFB1 protein] results in increased expression of IFIT3 mRNA; [Progesterone co-treated with TGFB1 protein] results in increased expression of LZTFL1 mRNA; [Progesterone co-treated with TGFB1 protein] results in increased expression of SOCS3 mRNA; [Progesterone co-treated with TGFB1 protein] results in increased expression of TMT1A mRNA; Fulvestrant inhibits the reaction [TGFB1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]]; Progesterone inhibits the reaction [Vaccines, Virus-Like Particle results in decreased expression of TGFB1 protein]; TGFB1 protein promotes the reaction [FSHB protein results in increased abundance of Progesterone]; TGFB1 protein promotes the reaction [Progesterone results in increased expression of CCL5 mRNA]; TGFB1 protein promotes the reaction [Progesterone results in increased expression of EBI3 mRNA]; TGFB1 protein promotes the reaction [Progesterone results in increased expression of GFI1 mRNA]; TGFB1 protein promotes the reaction [Progesterone results in increased expression of OAS1 mRNA]; TGFB1 protein promotes the reaction [Progesterone results in increased expression of TNFSF13B mRNA] TGFB1 protein results in decreased secretion of Progesterone [Progesterone co-treated with Estrogens] results in increased expression of TGFB1 mRNA; IGF1 protein inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased expression of TGFB1 mRNA]; Progesterone inhibits the reaction [Ozone results in increased expression of TGFB1 protein] Progesterone results in decreased expression of TGFB1 protein
|
CTD |
PMID:15618244 PMID:16284289 PMID:16403803 PMID:18511507 PMID:18562952 PMID:18635743 PMID:20130130 PMID:21768398 PMID:21826657 PMID:28279894 More...
|
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899
|
|
| G
|
Tgfb2
|
transforming growth factor, beta 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TGFB2 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of TGFB2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856
|
|
| G
|
Tgfb3
|
transforming growth factor, beta 3
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of TGFB3 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:111,435,170...111,456,946
|
|
| G
|
Tgfbr2
|
transforming growth factor, beta receptor 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of TGFBR2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469
|
|
| G
|
Tgfbr3
|
transforming growth factor beta receptor 3
|
increases expression
|
EXP
|
Progesterone results in increased expression of TGFBR3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr14:2,634,294...2,810,269
Ensembl chr14:2,634,188...2,810,271
|
|
| G
|
Tgif1
|
TGFB-induced factor homeobox 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of TGIF1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 9:118,194,735...118,204,354
Ensembl chr 9:118,194,444...118,204,442
|
|
| G
|
Tgm2
|
transglutaminase 2
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in decreased expression of TGM2 mRNA Progesterone results in increased expression of TGM2 mRNA
|
CTD |
PMID:17404688 PMID:20726854 PMID:21540246 |
|
NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:167,192,612...167,304,240
|
|
| G
|
Th
|
tyrosine hydroxylase
|
decreases phosphorylation decreases activity
|
EXP
|
Progesterone results in decreased phosphorylation of TH protein Progesterone results in decreased activity of TH protein
|
CTD |
PMID:18096660 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:207,500,962...207,557,227
|
|
| G
|
Thbd
|
thrombomodulin
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of THBD mRNA; [Progesterone co-treated with Estradiol] results in increased expression of THBD mRNA Progesterone results in increased expression of THBD mRNA Progesterone results in decreased expression of THBD mRNA
|
CTD |
PMID:17404688 PMID:18070364 PMID:20660070 PMID:20726854 PMID:20864642 |
|
NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:156,306,632...156,320,582
|
|
| G
|
Thbs1
|
thrombospondin 1
|
decreases expression multiple interactions increases expression
|
ISO
|
Progesterone results in decreased expression of THBS1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of THBS1 mRNA Progesterone results in increased expression of THBS1 mRNA
|
CTD |
PMID:18037150 PMID:18070364 PMID:20660070 PMID:21795739 |
|
NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402
|
|
| G
|
Thbs2
|
thrombospondin 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of THBS2 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr 1:64,343,523...64,372,918
Ensembl chr 1:64,343,523...64,372,918
|
|
| G
|
Thbs3
|
thrombospondin 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of THBS3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 2:176,919,549...176,931,357
Ensembl chr 2:176,919,230...176,931,357
|
|
| G
|
Them4
|
thioesterase superfamily member 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of THEM4 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:184,642,603...184,663,752
Ensembl chr 2:184,642,595...184,665,344
|
|
| G
|
Thrsp
|
thyroid hormone responsive
|
affects expression
|
ISO
|
Progesterone affects the expression of THRSP mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 1:161,134,640...161,138,964
Ensembl chr 1:161,133,453...161,139,827
|
|
| G
|
Thsd4
|
thrombospondin type 1 domain containing 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of THSD4 mRNA
|
CTD |
PMID:21273126 |
|
NCBI chr 8:69,280,397...69,880,144
Ensembl chr 8:69,284,646...69,917,342
|
|
| G
|
Thsd7a
|
thrombospondin type 1 domain containing 7A
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of THSD7A mRNA Progesterone results in increased expression of THSD7A mRNA
|
CTD |
PMID:17404688 PMID:20864642 |
|
NCBI chr 4:41,427,276...41,865,524
Ensembl chr 4:41,426,275...41,865,723
|
|
| G
|
Thumpd1
|
THUMP domain containing 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of THUMPD1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:183,510,242...183,516,282
Ensembl chr 1:183,431,657...183,516,282
|
|
| G
|
Thy1
|
Thy-1 cell surface antigen
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of THY1 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:53,286,148...53,291,540
|
|
| G
|
Ticam1
|
TIR domain containing adaptor molecule 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of TICAM1 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr 9:1,189,717...1,197,730
Ensembl chr 9:1,172,963...1,196,892
|
|
| G
|
Ticam2
|
TIR domain containing adaptor molecule 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of TICAM2 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr18:41,481,057...41,498,065
Ensembl chr18:41,478,539...41,512,243
|
|
| G
|
Tigar
|
TP53 induced glycolysis regulatory phosphatase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TIGAR mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 4:161,613,306...161,632,248
Ensembl chr 4:161,613,306...161,632,229
|
|
| G
|
Tigd2
|
tigger transposable element derived 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TIGD2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:89,744,516...89,747,608
Ensembl chr 4:89,744,510...89,747,940
|
|
| G
|
Timeless
|
timeless circadian regulator
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of TIMELESS mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 7:1,239,388...1,263,344
Ensembl chr 7:1,239,450...1,263,337
|
|
| G
|
Timm10
|
translocase of inner mitochondrial membrane 10
|
increases expression
|
EXP
|
Progesterone results in increased expression of TIMM10 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 3:90,315,048...90,318,613
Ensembl chr 3:90,315,092...90,318,614
|
|
| G
|
Timp1
|
TIMP metallopeptidase inhibitor 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of TIMP1 mRNA Progesterone results in increased expression of TIMP1 mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135
|
|
| G
|
Timp2
|
TIMP metallopeptidase inhibitor 2
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Triclosan] results in decreased expression of TIMP2 mRNA
|
CTD |
PMID:26604029 |
|
NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214
|
|
| G
|
Timp3
|
TIMP metallopeptidase inhibitor 3
|
multiple interactions increases expression decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of TIMP3 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of TIMP3 mRNA Progesterone results in increased expression of TIMP3 mRNA Progesterone results in decreased expression of TIMP3 mRNA
|
CTD |
PMID:20226447 PMID:20660070 PMID:20726854 PMID:20864642 PMID:26604029 |
|
NCBI chr 7:19,408,539...19,459,558
Ensembl chr 7:19,409,631...19,459,547
|
|
| G
|
Tiparp
|
TCDD-inducible poly(ADP-ribose) polymerase
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TIPARP mRNA Progesterone results in increased expression of TIPARP mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr 2:152,063,769...152,090,414
Ensembl chr 2:152,063,751...152,090,406
|
|
| G
|
Tjp2
|
tight junction protein 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TJP2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:231,136,218...231,264,750
Ensembl chr 1:231,136,243...231,264,750
|
|
| G
|
Tjp3
|
tight junction protein 3
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of TJP3 mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr 7:9,078,757...9,097,003
Ensembl chr 7:9,084,315...9,096,984
|
|
| G
|
Tk1
|
thymidine kinase 1
|
increases expression decreases expression
|
ISO EXP
|
Progesterone results in increased expression of TK1 mRNA Progesterone results in decreased expression of TK1 mRNA
|
CTD |
PMID:16966611 PMID:18070364 PMID:20726854 PMID:21795739 |
|
NCBI chr10:103,533,449...103,544,818
Ensembl chr10:103,533,449...103,556,228
|
|
| G
|
Tle2
|
TLE family member 2, transcriptional corepressor
|
increases expression
|
ISO
|
Progesterone results in increased expression of TLE2 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 7:8,769,815...8,789,493
Ensembl chr 7:8,769,816...8,785,256
|
|
| G
|
Tll2
|
tolloid-like 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of TLL2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 1:249,862,050...249,977,566
Ensembl chr 1:249,862,050...249,977,566
|
|
| G
|
Tlr2
|
toll-like receptor 2
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of TLR2 mRNA Progesterone results in increased expression of TLR2 mRNA Progesterone results in increased expression of TLR2 mRNA; Progesterone results in increased expression of TLR2 protein
|
CTD |
PMID:17404688 PMID:21549006 |
|
NCBI chr 2:171,499,189...171,504,831
Ensembl chr 2:171,497,060...171,520,194
|
|
| G
|
Tlr4
|
toll-like receptor 4
|
multiple interactions increases expression
|
ISO
|
[Proteoglycans co-treated with Progesterone] inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein]; Progesterone inhibits the reaction [[Lipopolysaccharides co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA] Progesterone results in increased expression of TLR4 mRNA; Progesterone results in increased expression of TLR4 protein
|
CTD |
PMID:17701593 PMID:20864642 PMID:22014880 PMID:22314502 |
|
NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007
|
|
| G
|
Tlr5
|
toll-like receptor 5
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of TLR5 mRNA Progesterone results in decreased expression of TLR5 mRNA
|
CTD |
PMID:17701593 PMID:21540246 |
|
NCBI chr13:97,166,430...97,190,642
Ensembl chr13:97,166,405...97,192,525
|
|
| G
|
Tlr7
|
toll-like receptor 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of TLR7 mRNA
|
CTD |
PMID:17701593 |
|
NCBI chr X:30,644,324...30,670,796
Ensembl chr X:30,644,355...30,672,151
|
|
| G
|
Tlr9
|
toll-like receptor 9
|
increases expression
|
ISO
|
Progesterone results in increased expression of TLR9 mRNA; Progesterone results in increased expression of TLR9 protein
|
CTD |
PMID:21549006 |
|
NCBI chr 8:115,743,407...115,747,523
Ensembl chr 8:115,742,889...115,750,148
|
|
| G
|
Tlx1
|
T-cell leukemia, homeobox 1
|
multiple interactions
|
EXP
|
bisphenol A inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of TLX1 mRNA]
|
CTD |
PMID:18653720 |
|
NCBI chr 1:253,954,197...253,960,458
Ensembl chr 1:253,954,197...253,960,458
|
|
| G
|
Tm6sf1
|
transmembrane 6 superfamily member 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of TM6SF1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 1:145,209,052...145,237,725
Ensembl chr 1:145,209,585...145,237,715
|
|
| G
|
Tmc4
|
transmembrane channel-like 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of TMC4 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 1:74,455,135...74,467,043
Ensembl chr 1:74,454,909...74,467,043
|
|
| G
|
Tmed8
|
transmembrane p24 trafficking protein family member 8
|
increases expression
|
ISO
|
Progesterone results in increased expression of TMED8 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 6:112,537,921...112,572,199
Ensembl chr 6:112,542,932...112,572,383
|
|
| G
|
Tmem120b
|
transmembrane protein 120B
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TMEM120B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr12:39,108,280...39,148,090
Ensembl chr12:39,108,280...39,148,090
|
|
| G
|
Tmem132a
|
transmembrane protein 132A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TMEM132A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:216,931,962...216,943,644
Ensembl chr 1:216,931,962...216,943,644
|
|
| G
|
Tmem132c
|
transmembrane protein 132C
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TMEM132C mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr12:34,752,362...35,073,821
Ensembl chr12:34,751,807...35,073,903
|
|
| G
|
Tmem139
|
transmembrane protein 139
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TMEM139 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 4:72,113,437...72,115,786
Ensembl chr 4:72,113,526...72,115,778
|
|
| G
|
Tmem140
|
transmembrane protein 140
|
increases expression
|
ISO
|
Progesterone results in increased expression of TMEM140 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 4:64,503,621...64,514,620
Ensembl chr 4:64,500,439...64,521,990
|
|
| G
|
Tmem158
|
transmembrane protein 158
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TMEM158 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of TMEM158 mRNA Progesterone results in decreased expression of TMEM158 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 8:131,791,137...131,792,135
Ensembl chr 8:131,787,277...131,796,882
|
|
| G
|
Tmem163
|
transmembrane protein 163
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TMEM163 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr13:41,520,595...41,693,938
Ensembl chr13:41,520,359...41,693,938
|
|
| G
|
Tmem164
|
transmembrane protein 164
|
increases expression
|
ISO
|
Progesterone results in increased expression of TMEM164 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr X:111,084,830...111,245,419
Ensembl chr X:111,085,712...111,245,417
|
|
| G
|
Tmem200a
|
transmembrane protein 200A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TMEM200A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:21,142,500...21,242,022
Ensembl chr 1:21,141,432...21,426,175
|
|
| G
|
Tmem204
|
transmembrane protein 204
|
increases expression
|
ISO
|
Progesterone results in increased expression of TMEM204 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr10:14,581,025...14,608,878
Ensembl chr10:14,581,026...14,606,427
|
|
| G
|
Tmem221
|
transmembrane protein 221
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TMEM221 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr16:18,296,036...18,305,077
Ensembl chr16:18,295,931...18,305,246
|
|
| G
|
Tmem238
|
transmembrane protein 238
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TMEM238 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:78,085,880...78,091,272
Ensembl chr 1:78,085,670...78,093,983
|
|
| G
|
Tmem37
|
transmembrane protein 37
|
increases expression
|
ISO
|
Progesterone results in increased expression of TMEM37 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr13:33,737,096...33,743,602
Ensembl chr13:33,736,308...33,743,747
|
|
| G
|
Tmem45a
|
transmembrane protein 45A
|
increases expression
|
ISO
|
Progesterone results in increased expression of TMEM45A mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr11:57,181,686...57,268,630
Ensembl chr11:57,182,785...57,282,722
|
|
| G
|
Tmem45b
|
transmembrane protein 45b
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TMEM45B mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 8:38,123,423...38,168,599
Ensembl chr 8:38,123,423...38,168,599
|
|
| G
|
Tmem47
|
transmembrane protein 47
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of TMEM47 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of TMEM47 mRNA
|
CTD |
PMID:18037150 PMID:20660070 |
|
NCBI chr X:49,338,532...49,365,026
Ensembl chr X:49,338,326...49,521,541
|
|
| G
|
Tmem54
|
transmembrane protein 54
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TMEM54 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 5:146,733,557...146,740,048
Ensembl chr 5:146,733,511...146,740,047
|
|
| G
|
Tmem61
|
transmembrane protein 61
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TMEM61 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:126,495,615...126,505,242
Ensembl chr 5:126,495,615...126,505,242
|
|
| G
|
Tmem64
|
transmembrane protein 64
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TMEM64 mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr 5:33,495,992...33,542,390
Ensembl chr 5:33,496,032...33,542,389
|
|
| G
|
Tmem97
|
transmembrane protein 97
|
increases expression
|
ISO
|
Progesterone results in increased expression of TMEM97 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:63,936,276...63,945,359
Ensembl chr10:63,936,271...63,945,818
|
|
| G
|
Tmod1
|
tropomodulin 1
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of TMOD1 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of TMOD1 mRNA
|
CTD |
PMID:20660070 PMID:20726854 |
|
NCBI chr 5:65,112,062...65,189,563
Ensembl chr 5:65,134,132...65,189,561
|
|
| G
|
Tmpo
|
thymopoietin
|
affects expression decreases expression
|
ISO EXP
|
Progesterone affects the expression of TMPO mRNA Progesterone results in decreased expression of TMPO mRNA
|
CTD |
PMID:17251523 PMID:20726854 |
|
NCBI chr 7:27,529,977...27,554,980
Ensembl chr 7:27,529,978...27,554,937
|
|
| G
|
Tmprss2
|
transmembrane serine protease 2
|
affects expression
|
ISO
|
Progesterone affects the expression of TMPRSS2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr11:50,403,707...50,443,224
Ensembl chr11:50,398,349...50,443,114
|
|
| G
|
Tmprss3
|
transmembrane serine protease 3
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of TMPRSS3 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of TMPRSS3 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr20:9,253,497...9,275,167
Ensembl chr20:9,255,467...9,275,720
|
|
| G
|
Tmsb15b2
|
thymosin beta 15B2
|
decreases expression multiple interactions
|
EXP ISO
|
Progesterone results in decreased expression of TMSB15B2 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of TMSB15A mRNA Progesterone results in decreased expression of TMSB15A mRNA
|
CTD |
PMID:17404688 PMID:20726854 PMID:21795739 |
|
NCBI chr X:105,090,980...105,093,094
Ensembl chr X:105,090,980...105,093,094
|
|
| G
|
Tmt1a
|
thiol methyltransferase 1A
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with TGFB1 protein] results in increased expression of TMT1A mRNA Progesterone results in increased expression of TMT1A mRNA
|
CTD |
PMID:18070364 PMID:20864642 PMID:21768398 PMID:21795739 |
|
NCBI chr 7:133,330,141...133,377,172
Ensembl chr 7:133,330,447...133,338,959
|
|
| G
|
Tmtc1
|
transmembrane O-mannosyltransferase targeting cadherins 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TMTC1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:182,874,350...183,089,408
Ensembl chr 4:182,878,802...183,102,532
|
|
| G
|
Tnc
|
tenascin C
|
multiple interactions increases expression decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TNC mRNA; [Progesterone co-treated with Estradiol] results in increased expression of TNC mRNA Progesterone results in increased expression of TNC mRNA Progesterone results in decreased expression of TNC mRNA
|
CTD |
PMID:18692832 PMID:20226447 PMID:20660070 PMID:20864642 PMID:21795739 |
|
NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131
|
|
| G
|
Tnf
|
tumor necrosis factor
|
multiple interactions increases expression decreases abundance decreases expression
|
ISO EXP
|
[[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the abundance of Lipids; [[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the abundance of Reactive Oxygen Species; [[IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]] which affects the expression of ALB protein; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the abundance of Lipids; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the abundance of Reactive Oxygen Species; [[Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]] which affects the expression of ALB protein; [IL6 protein co-treated with IL1B protein co-treated with TNF protein] affects the susceptibility to [Testosterone co-treated with Estradiol co-treated with Progesterone]; [Progesterone co-treated with Estradiol] inhibits the reaction [Vaccines, Virus-Like Particle results in increased expression of TNF protein]; [Progesterone co-treated with Lipopolysaccharides] results in increased expression of TNF protein; [Testosterone co-treated with Estradiol co-treated with Progesterone] affects the susceptibility to [IL6 protein co-treated with IL1B protein co-treated with TNF protein]; Mifepristone inhibits the reaction [Progesterone inhibits the reaction [[Estradiol co-treated with TNF protein] results in increased activity of NFKB1 protein]]; Mifepristone inhibits the reaction [Progesterone inhibits the reaction [[Estradiol co-treated with TNF protein] results in increased expression of CXCL8 mRNA]]; Progesterone inhibits the reaction [[Estradiol co-treated with TNF protein] results in increased activity of NFKB1 protein]; Progesterone inhibits the reaction [[Estradiol co-treated with TNF protein] results in increased expression of CXCL8 mRNA]; Progesterone inhibits the reaction [[Estradiol co-treated with TNF protein] results in increased expression of CXCL8 protein]; Progesterone inhibits the reaction [Vaccines, Virus-Like Particle results in increased expression of TNF protein] Progesterone results in increased expression of TNF protein TNF protein results in decreased abundance of Progesterone Progesterone results in decreased expression of TNF protein Mifepristone inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of TNF mRNA]]; Progesterone inhibits the reaction [[IFNG protein co-treated with TNF protein] results in increased abundance of Nitric Oxide]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Progesterone promotes the reaction [Halothane results in increased expression of TNF mRNA] Progesterone results in decreased expression of TNF mRNA
|
CTD |
PMID:11063824 PMID:15804489 PMID:15866594 PMID:16318612 PMID:16891052 PMID:17868700 PMID:20130130 PMID:20621171 PMID:21501669 PMID:22615136 More...
|
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303
|
|
| G
|
Tnfaip2
|
TNF alpha induced protein 2
|
affects expression
|
ISO
|
Progesterone affects the expression of TNFAIP2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 6:136,297,388...136,311,106
Ensembl chr 6:136,298,082...136,311,106
|
|
| G
|
Tnfaip3
|
TNF alpha induced protein 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of TNFAIP3 mRNA
|
CTD |
PMID:21549006 |
|
NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979
|
|
| G
|
Tnfaip6
|
TNF alpha induced protein 6
|
multiple interactions decreases expression increases expression
|
ISO
|
4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFAIP6 mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of TNFAIP6 mRNA; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFAIP6 mRNA]; pepstatin inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFAIP6 mRNA] Progesterone results in decreased expression of TNFAIP6 mRNA Progesterone results in increased expression of TNFAIP6 mRNA
|
CTD |
PMID:18070364 PMID:20660070 |
|
NCBI chr 3:56,911,398...56,930,797
Ensembl chr 3:56,911,252...56,930,796
|
|
| G
|
Tnfaip8
|
TNF alpha induced protein 8
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TNFAIP8 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr18:45,370,334...45,486,036
Ensembl chr18:45,370,406...45,486,036
|
|
| G
|
Tnfrsf11a
|
TNF receptor superfamily member 11A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF11A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr13:22,442,930...22,501,257
Ensembl chr13:22,442,665...22,501,257
|
|
| G
|
Tnfrsf11b
|
TNF receptor superfamily member 11B
|
multiple interactions decreases expression
|
ISO
|
4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF11B mRNA]; [Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF11B mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of TNFRSF11B mRNA; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF11B mRNA]; SB 203580 promotes the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF11B mRNA] Progesterone results in decreased expression of TNFRSF11B mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075
|
|
| G
|
Tnfrsf12a
|
TNF receptor superfamily member 12A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TNFRSF12A mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr10:13,211,670...13,213,666
Ensembl chr10:13,211,673...13,213,704
|
|
| G
|
Tnfrsf19
|
TNF receptor superfamily member 19
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF19 mRNA Progesterone results in decreased expression of TNFRSF19 mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr15:39,268,305...39,334,566
Ensembl chr15:39,268,305...39,356,438
|
|
| G
|
Tnfrsf1a
|
TNF receptor superfamily member 1A
|
increases expression
|
ISO EXP
|
Progesterone results in increased expression of TNFRSF1A mRNA
|
CTD |
PMID:21549006 PMID:21770760 |
|
NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816
|
|
| G
|
Tnfrsf1b
|
TNF receptor superfamily member 1B
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF1B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:162,353,848...162,387,411
|
|
| G
|
Tnfrsf21
|
TNF receptor superfamily member 21
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF21 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of TNFRSF21 mRNA Progesterone results in increased expression of TNFRSF21 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:21795739 |
|
NCBI chr 9:25,376,400...25,451,323
Ensembl chr 9:25,376,400...25,451,323
|
|
| G
|
Tnfrsf4
|
TNF receptor superfamily member 4
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of TNFRSF4 mRNA
|
CTD |
PMID:17404688 PMID:18692832 |
|
NCBI chr 5:171,889,134...171,891,824
Ensembl chr 5:171,889,117...171,892,616
|
|
| G
|
Tnfsf10
|
TNF superfamily member 10
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of TNFSF10 mRNA [Estradiol co-treated with Progesterone] results in decreased expression of TNFSF10 mRNA
|
CTD |
PMID:18070364 PMID:20660070 |
|
NCBI chr 2:112,136,550...112,155,903
|
|
| G
|
Tnfsf11
|
TNF superfamily member 11
|
multiple interactions increases expression
|
ISO EXP
|
bisphenol A promotes the reaction [Progesterone results in increased expression of TNFSF11 mRNA] [Progesterone co-treated with Estrogens] results in increased expression of TNFSF11 mRNA
|
CTD |
PMID:21258428 PMID:21903720 |
|
NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479
|
|
| G
|
Tnfsf13b
|
TNF superfamily member 13b
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of TNFSF13B mRNA TGFB1 protein promotes the reaction [Progesterone results in increased expression of TNFSF13B mRNA]
|
CTD |
PMID:21768398 |
|
NCBI chr16:86,164,377...86,195,072
Ensembl chr16:86,164,377...86,194,499
|
|
| G
|
Tnnc1
|
troponin C1, slow skeletal and cardiac type
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TNNC1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr16:6,408,607...6,412,070
Ensembl chr16:6,408,607...6,412,070
|
|
| G
|
Tnnc2
|
troponin C2, fast skeletal type
|
increases expression
|
ISO
|
Progesterone results in increased expression of TNNC2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 3:173,932,611...173,935,339
Ensembl chr 3:173,932,611...173,935,339
|
|
| G
|
Tnni2
|
troponin I2, fast skeletal type
|
increases expression
|
ISO
|
Progesterone results in increased expression of TNNI2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:206,882,358...207,027,034
Ensembl chr 1:207,024,416...207,027,038
|
|
| G
|
Tnni3
|
troponin I3, cardiac type
|
increases expression multiple interactions decreases expression
|
EXP ISO
|
Progesterone results in increased expression of TNNI3 mRNA Mifepristone inhibits the reaction [Progesterone results in decreased expression of TNNI3 mRNA]
|
CTD |
PMID:20726854 PMID:31566189 |
|
NCBI chr 1:78,342,571...78,346,255
Ensembl chr 1:78,342,592...78,346,253
|
|
| G
|
Tns1
|
tensin 1
|
increases expression
|
EXP
|
Progesterone results in increased expression of TNS1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 9:82,941,068...83,152,007
Ensembl chr 9:82,941,068...83,152,007
|
|
| G
|
Tob2
|
transducer of ERBB2, 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TOB2 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr 7:115,242,843...115,251,563
Ensembl chr 7:115,239,895...115,258,155
|
|
| G
|
Top2a
|
DNA topoisomerase II alpha
|
decreases expression increases expression
|
ISO EXP
|
Progesterone results in decreased expression of TOP2A mRNA Progesterone results in increased expression of TOP2A mRNA
|
CTD |
PMID:18070364 PMID:20726854 PMID:21540246 PMID:21795739 |
|
NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366
|
|
| G
|
Tox3
|
TOX high mobility group box family member 3
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TOX3 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr19:32,820,957...32,929,776
Ensembl chr19:32,820,977...32,929,776
|
|
| G
|
Tp53
|
tumor protein p53
|
decreases expression increases response to substance increases expression multiple interactions
|
ISO EXP
|
Progesterone results in decreased expression of TP53 protein TP53 protein results in increased susceptibility to Progesterone TRP53 protein results in increased susceptibility to Progesterone Progesterone results in increased expression of TP53 mRNA; Progesterone results in increased expression of TP53 protein bisphenol A inhibits the reaction [Progesterone results in increased expression of TP53 mRNA]; TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1A mRNA]; TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1A protein]; TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1B mRNA]; TP53 mutant form inhibits the reaction [Progesterone results in increased expression of CDKN1B protein]; TP53 protein affects the reaction [Progesterone results in increased expression of TRIM22 mRNA] [Estradiol co-treated with Methylnitrosourea co-treated with Progesterone] results in decreased expression of TP53 mRNA; [Methylnitrosourea co-treated with Progesterone] results in decreased expression of TP53 mRNA [Progesterone co-treated with Estrogens] results in increased expression of TRP53 mRNA; IGF1 protein inhibits the reaction [[Progesterone co-treated with Estrogens] results in increased expression of TRP53 mRNA]
|
CTD |
PMID:11053243 PMID:14529565 PMID:18562952 PMID:18850315 PMID:20732338 PMID:37009741 More...
|
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299
|
|
| G
|
Tp53i3
|
tumor protein p53 inducible protein 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of TP53I3 mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 6:33,537,779...33,545,204
|
|
| G
|
Tp63
|
tumor protein p63
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TP63 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177
|
|
| G
|
Tpbg
|
trophoblast glycoprotein
|
increases expression decreases expression
|
ISO EXP
|
Progesterone results in increased expression of TPBG mRNA Progesterone results in decreased expression of TPBG mRNA
|
CTD |
PMID:18037150 PMID:20726854 |
|
NCBI chr 8:95,673,993...95,677,364
Ensembl chr 8:95,629,267...95,678,394
|
|
| G
|
Tpd52l1
|
TPD52 like 1
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TPD52L1 mRNA Progesterone results in decreased expression of TPD52L1 mRNA
|
CTD |
PMID:20660070 PMID:21540246 PMID:22238285 |
|
NCBI chr 1:27,991,114...28,109,767
Ensembl chr 1:27,991,131...28,110,158
|
|
| G
|
Tpm1
|
tropomyosin 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TPM1 mRNA
|
CTD |
PMID:18037150 PMID:21795739 |
|
NCBI chr 8:76,516,654...76,543,661
Ensembl chr 8:76,511,871...76,543,468
|
|
| G
|
Tppp
|
tubulin polymerization promoting protein
|
increases expression
|
ISO
|
Progesterone results in increased expression of TPPP mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:31,085,680...31,109,703
Ensembl chr 1:31,089,824...31,109,654
|
|
| G
|
Tppp3
|
tubulin polymerization-promoting protein family member 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of TPPP3 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr19:50,255,809...50,259,655
Ensembl chr19:50,255,810...50,259,489
|
|
| G
|
Tpsb2
|
tryptase beta 2
|
affects expression
|
ISO
|
Progesterone affects the expression of TPSB2 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:14,886,310...14,888,102
Ensembl chr10:14,886,360...14,888,100
|
|
| G
|
Tpte2
|
transmembrane phosphoinositide 3-phosphatase and tensin homolog 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of TPTE2 mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr16:76,361,330...76,455,664
Ensembl chr16:76,361,333...76,455,646
|
|
| G
|
Tpx2
|
TPX2, microtubule nucleation factor
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TPX2 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 3:161,778,709...161,820,941
Ensembl chr 3:161,778,742...161,820,724
|
|
| G
|
Tra2a
|
transformer 2 alpha
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TRA2A mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 4:79,551,699...79,570,621
Ensembl chr 4:79,551,542...79,570,619
|
|
| G
|
Tradd
|
TNFRSF1A-associated via death domain
|
affects expression
|
ISO
|
Progesterone affects the expression of TRADD mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr19:50,046,057...50,048,158
Ensembl chr19:50,046,061...50,052,550
|
|
| G
|
Traf6
|
TNF receptor associated factor 6
|
increases expression
|
ISO EXP
|
Progesterone results in increased expression of TRAF6 mRNA
|
CTD |
PMID:21549006 PMID:21770760 |
|
NCBI chr 3:108,418,537...108,443,330
Ensembl chr 3:108,418,513...108,443,328
|
|
| G
|
Trerf1
|
transcriptional regulating factor 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TRERF1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 9:21,131,772...21,355,830
Ensembl chr 9:21,131,777...21,176,016
|
|
| G
|
Trh
|
thyrotropin releasing hormone
|
increases expression
|
EXP
|
Progesterone results in increased expression of TRH mRNA
|
CTD |
PMID:21770760 |
|
NCBI chr 4:126,299,236...126,301,762
Ensembl chr 4:126,299,236...126,301,762
|
|
| G
|
Trib2
|
tribbles pseudokinase 2
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TRIB2 mRNA; [Progesterone co-treated with Estradiol] results in decreased expression of TRIB2 mRNA Progesterone results in decreased expression of TRIB2 mRNA
|
CTD |
PMID:17404688 PMID:20660070 |
|
NCBI chr 6:44,274,762...44,299,139
Ensembl chr 6:44,274,762...44,299,094
|
|
| G
|
Trib3
|
tribbles pseudokinase 3
|
increases expression
|
ISO
|
Progesterone results in increased expression of TRIB3 mRNA
|
CTD |
PMID:18037150 PMID:21795739 |
|
NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802
|
|
| G
|
Trim16
|
tripartite motif-containing 16
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TRIM16 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr10:47,985,235...48,008,242
Ensembl chr10:47,958,677...48,051,136
|
|
| G
|
Trim63
|
tripartite motif containing 63
|
increases expression
|
EXP
|
Progesterone results in increased expression of TRIM63 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 5:151,817,209...151,831,026
Ensembl chr 5:151,817,225...151,831,058
|
|
| G
|
Trnp1
|
TMF1-regulated nuclear protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of TRNP1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 5:150,990,312...150,997,148
Ensembl chr 5:150,989,973...150,997,277
|
|
| G
|
Trnt1
|
tRNA nucleotidyl transferase 1
|
affects expression
|
ISO
|
Progesterone affects the expression of TRNT1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:141,236,937...141,259,700
Ensembl chr 4:141,236,979...141,259,698
|
|
| G
|
Trpc4
|
transient receptor potential cation channel, subfamily C, member 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of TRPC4 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 2:140,457,841...140,629,556
Ensembl chr 2:140,458,296...140,626,969
|
|
| G
|
Trpc6
|
transient receptor potential cation channel, subfamily C, member 6
|
multiple interactions decreases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in decreased expression of TRPC6 mRNA Progesterone results in decreased expression of TRPC6 mRNA
|
CTD |
PMID:20660070 PMID:20726854 |
|
NCBI chr 8:14,044,216...14,148,808
Ensembl chr 8:14,043,877...14,149,304
|
|
| G
|
Trpm4
|
transient receptor potential cation channel, subfamily M, member 4
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TRPM4 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 1:104,918,462...104,949,453
Ensembl chr 1:104,918,462...104,948,653
|
|
| G
|
Trpv2
|
transient receptor potential cation channel, subfamily V, member 2
|
multiple interactions decreases expression
|
ISO
|
Mifepristone inhibits the reaction [Progesterone results in decreased expression of TRPV2 mRNA]; Mifepristone inhibits the reaction [Progesterone results in decreased expression of TRPV2 protein] Progesterone results in decreased expression of TRPV2 mRNA; Progesterone results in decreased expression of TRPV2 protein
|
CTD |
PMID:27264040 PMID:31566189 |
|
NCBI chr10:47,772,223...47,797,956
Ensembl chr10:47,764,839...47,793,533
|
|
| G
|
Trpv6
|
transient receptor potential cation channel, subfamily V, member 6
|
multiple interactions
|
EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of TRPV6 mRNA
|
CTD |
PMID:21228508 |
|
NCBI chr 4:71,474,006...71,489,667
Ensembl chr 4:71,474,007...71,489,671
|
|
| G
|
Tsc22d3
|
TSC22 domain family, member 3
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of TSC22D3 mRNA; [Progesterone co-treated with Estradiol] results in increased expression of TSC22D3 mRNA Progesterone results in increased expression of TSC22D3 mRNA
|
CTD |
PMID:17404688 PMID:20660070 PMID:20726854 PMID:20864642 PMID:21795739 |
|
NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519
|
|
| G
|
Tslp
|
thymic stromal lymphopoietin
|
increases expression
|
ISO
|
Progesterone results in increased expression of TSLP mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr18:24,723,990...24,728,419
Ensembl chr18:24,720,257...24,728,420
|
|
| G
|
Tspan11
|
tetraspanin 11
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TSPAN11 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:162,424,327...162,491,653
Ensembl chr 4:162,424,549...162,492,932
|
|
| G
|
Tspan12
|
tetraspanin 12
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TSPAN12 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 4:51,279,562...51,355,030
Ensembl chr 4:51,279,563...51,355,030
|
|
| G
|
Tspan13
|
tetraspanin 13
|
affects expression
|
ISO
|
Progesterone affects the expression of TSPAN13 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 6:58,466,051...58,492,804
Ensembl chr 6:58,465,684...58,492,819
|
|
| G
|
Tspan8
|
tetraspanin 8
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of TSPAN8 mRNA]
|
CTD |
PMID:17556502 PMID:22238285 |
|
NCBI chr 7:53,331,019...53,365,402
Ensembl chr 7:53,330,963...53,365,401
|
|
| G
|
Ttc29
|
tetratricopeptide repeat domain 29
|
increases expression
|
ISO
|
Progesterone results in increased expression of TTC29 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr19:46,436,526...46,654,891
Ensembl chr19:46,424,935...46,654,870
|
|
| G
|
Ttc39b
|
tetratricopeptide repeat domain 39B
|
affects expression
|
ISO
|
Progesterone affects the expression of TTC39B mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 5:102,649,259...102,754,092
Ensembl chr 5:102,655,322...102,782,162
|
|
| G
|
Ttf2
|
transcription termination factor 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of TTF2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 2:191,054,942...191,086,331
Ensembl chr 2:191,054,966...191,086,386
|
|
| G
|
Ttll12
|
tubulin tyrosine ligase like 12
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TTLL12 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 7:116,612,609...116,631,244
Ensembl chr 7:116,612,609...116,631,577
|
|
| G
|
Ttpa
|
alpha tocopherol transfer protein
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of TTPA mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr 5:38,294,415...38,315,471
Ensembl chr 5:38,292,665...38,315,804
|
|
| G
|
Ttr
|
transthyretin
|
multiple interactions increases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in increased expression of TTR mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr18:12,216,684...12,225,972
Ensembl chr18:12,216,732...12,225,969
|
|
| G
|
Tubb2a
|
tubulin, beta 2A class IIa
|
multiple interactions increases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in increased expression of TUBB2A mRNA] [Estradiol co-treated with Progesterone] results in increased expression of TUBB2A mRNA
|
CTD |
PMID:17556502 PMID:20660070 |
|
NCBI chr17:31,002,186...31,006,057
Ensembl chr17:30,983,387...31,006,838
|
|
| G
|
Tubb2b
|
tubulin, beta 2B class IIb
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of TUBB2B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr17:30,953,086...30,956,133
Ensembl chr17:30,952,923...30,955,990
|
|
| G
|
Tubb3
|
tubulin, beta 3 class III
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of TUBB3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr19:68,365,687...68,374,741
Ensembl chr19:68,365,587...68,374,740
|
|
| G
|
Tubb5
|
tubulin, beta 5 class I
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of TUBB mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr20:2,917,577...2,921,726
Ensembl chr20:2,917,539...2,921,726
|
|
| G
|
Tulp2
|
TUB like protein 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of TULP2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:105,098,884...105,136,243
Ensembl chr 1:105,127,650...105,137,277
|
|
| G
|
Tut7
|
terminal uridylyl transferase 7
|
increases expression
|
ISO
|
Progesterone results in increased expression of TUT7 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr17:4,854,553...4,908,758
Ensembl chr17:4,855,936...4,909,070
|
|
| G
|
Twist1
|
twist family bHLH transcription factor 1
|
decreases expression multiple interactions
|
ISO
|
Progesterone results in decreased expression of TWIST1 mRNA [Progesterone co-treated with Estradiol] results in decreased expression of TWIST1 mRNA
|
CTD |
PMID:17404688 PMID:18692832 |
|
NCBI chr 6:56,402,309...56,404,303
Ensembl chr 6:56,398,061...56,404,965
|
|
| G
|
Txnip
|
thioredoxin interacting protein
|
decreases expression
|
ISO EXP
|
Progesterone results in decreased expression of TXNIP mRNA
|
CTD |
PMID:18037150 PMID:20726854 |
|
NCBI chr 2:186,781,933...186,785,736
Ensembl chr 2:186,781,163...186,785,731
|
|
| G
|
Tyms
|
thymidylate synthetase
|
increases expression decreases expression
|
ISO
|
Progesterone results in increased expression of TYMS mRNA Progesterone results in decreased expression of TYMS mRNA
|
CTD |
PMID:18070364 PMID:21795739 |
|
NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097
|
|
| G
|
Tyro3
|
TYRO3 protein tyrosine kinase
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of TYRO3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 3:127,231,468...127,254,806
Ensembl chr 3:127,231,903...127,250,943
|
|
| G
|
Ubald2
|
UBA-like domain containing 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of UBALD2 mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr10:102,161,370...102,165,952
Ensembl chr10:102,160,866...102,168,041
|
|
| G
|
Ubash3b
|
ubiquitin associated and SH3 domain containing, B
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of UBASH3B mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:50,282,510...50,430,034
Ensembl chr 8:50,285,431...50,326,351
|
|
| G
|
Ubd
|
ubiquitin D
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of UBD mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr20:1,390,734...1,392,685
Ensembl chr20:1,390,600...1,413,965
|
|
| G
|
Ube2h
|
ubiquitin-conjugating enzyme E2H
|
increases expression
|
ISO
|
Progesterone results in increased expression of UBE2H mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 4:59,802,102...59,897,583
Ensembl chr 4:59,802,102...59,897,583
|
|
| G
|
Ubl4a
|
ubiquitin-like 4A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of UBL4A mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr X:157,302,528...157,305,380
Ensembl chr X:157,304,254...157,305,380
|
|
| G
|
Ubtf
|
upstream binding transcription factor
|
affects expression
|
ISO
|
Progesterone affects the expression of UBTF mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr10:87,758,346...87,775,377
Ensembl chr10:87,758,346...87,773,088
|
|
| G
|
Uchl1
|
ubiquitin C-terminal hydrolase L1
|
decreases expression
|
EXP
|
Progesterone results in decreased expression of UCHL1 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr14:41,838,859...41,849,743
Ensembl chr14:41,838,861...41,849,417
|
|
| G
|
Ugcg
|
UDP-glucose ceramide glucosyltransferase
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of UGCG mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 5:78,828,006...78,860,725
Ensembl chr 5:78,828,006...78,860,417
|
|
| G
|
Ugt1a1
|
UDP glucuronosyltransferase family 1 member A1
|
multiple interactions
|
ISO EXP
|
[Progesterone co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA [Progesterone co-treated with Estradiol] affects the expression of UGT1A1 mRNA
|
CTD |
PMID:18098064 PMID:24777823 |
|
NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264
|
|
| G
|
Uhrf1
|
ubiquitin-like with PHD and ring finger domains 1
|
affects expression
|
ISO
|
Progesterone affects the expression of UHRF1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 9:1,220,162...1,241,792
Ensembl chr 9:1,222,063...1,241,792
|
|
| G
|
Ulk4
|
unc-51 like kinase 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of ULK4 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 8:129,548,431...129,843,555
Ensembl chr 8:129,548,431...129,843,501
|
|
| G
|
Umps
|
uridine monophosphate synthetase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of UMPS mRNA
|
CTD |
PMID:18037150 PMID:19693291 |
|
NCBI chr11:80,311,269...80,321,678
Ensembl chr11:80,311,214...80,327,828
|
|
| G
|
Ung
|
uracil-DNA glycosylase
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of UNG mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr12:48,145,838...48,154,789
Ensembl chr12:48,145,838...48,155,257
|
|
| G
|
Upb1
|
beta-ureidopropionase 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of UPB1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr20:13,216,693...13,243,016
Ensembl chr20:13,216,691...13,277,562
|
|
| G
|
Upk1a
|
uroplakin 1A
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of UPK1A mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 1:94,987,110...94,998,083
Ensembl chr 1:94,987,108...94,997,787
|
|
| G
|
Upp1
|
uridine phosphorylase 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of UPP1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:88,023,155...88,043,036
Ensembl chr14:88,023,351...88,043,034
|
|
| G
|
Uso1
|
USO1 vesicle transport factor
|
increases expression
|
ISO
|
Progesterone results in increased expression of USO1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr14:16,150,921...16,216,389
Ensembl chr14:16,150,923...16,216,389
|
|
| G
|
Usp53
|
ubiquitin specific peptidase 53
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of USP53 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 2:213,744,106...213,805,619
Ensembl chr 2:213,744,106...213,790,544
|
|
| G
|
Ust
|
uronyl-2-sulfotransferase
|
increases expression
|
ISO
|
Progesterone results in increased expression of UST mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr 1:4,487,316...4,782,579
Ensembl chr 1:4,489,925...4,782,356
|
|
| G
|
Vash1
|
vasohibin 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of VASH1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 6:112,060,086...112,076,689
Ensembl chr 6:112,060,086...112,076,689
|
|
| G
|
Vasp
|
vasodilator-stimulated phosphoprotein
|
increases expression
|
ISO
|
Progesterone results in increased expression of VASP mRNA
|
CTD |
PMID:18497975 |
|
NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650
|
|
| G
|
Vax2
|
ventral anterior homeobox 2
|
increases expression
|
EXP
|
Progesterone results in increased expression of VAX2 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 4:117,753,180...117,777,242
Ensembl chr 4:117,753,180...117,777,242
|
|
| G
|
Vcam1
|
vascular cell adhesion molecule 1
|
multiple interactions increases expression
|
ISO EXP
|
[Progesterone co-treated with Estradiol] results in increased expression of VCAM1 mRNA; Mifepristone inhibits the reaction [Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]; Org 31710 inhibits the reaction [Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]]; Progesterone inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein] Progesterone results in increased expression of VCAM1 mRNA
|
CTD |
PMID:15358673 PMID:18692832 PMID:21770760 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801
|
|
| G
|
Vcan
|
versican
|
increases expression multiple interactions
|
EXP ISO
|
Progesterone results in increased expression of VCAN mRNA [Estradiol co-treated with Progesterone] results in decreased expression of VCAN mRNA
|
CTD |
PMID:18692832 PMID:20660070 PMID:20726854 |
|
NCBI chr 2:22,497,035...22,595,955
Ensembl chr 2:22,497,035...22,595,955
|
|
| G
|
Vegfa
|
vascular endothelial growth factor A
|
increases expression multiple interactions decreases expression
|
ISO EXP
|
Progesterone results in increased expression of VEGFA mRNA; Progesterone results in increased expression of VEGFA mRNA alternative form; Progesterone results in increased expression of VEGFA protein [Progesterone results in increased secretion of [VEGFA protein binds to VEGFA protein]] which results in increased phosphorylation of PDGFRA protein; Progesterone promotes the reaction [CGB3 protein results in increased expression of VEGFA mRNA]; Progesterone results in increased secretion of [VEGFA protein binds to VEGFA protein] [Estradiol co-treated with Progesterone] results in decreased expression of VEGFA mRNA; [Estradiol co-treated with Progesterone] results in increased expression of VEGFA mRNA [Estradiol co-treated with Progesterone] results in increased expression of VEGFA mRNA; [Estradiol co-treated with Progesterone] results in increased expression of VEGFA protein; [Methylnitrosourea co-treated with Progesterone co-treated with Estradiol] results in increased expression of VEGFA mRNA; [Methylnitrosourea co-treated with Progesterone] results in increased expression of VEGFA mRNA Progesterone results in decreased expression of VEGFA mRNA
|
CTD |
PMID:8344219 PMID:16888808 PMID:17010073 PMID:18591213 PMID:19693291 PMID:20732338 PMID:21277368 PMID:33728745 More...
|
|
NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194
|
|
| G
|
Vegfd
|
vascular endothelial growth factor D
|
affects expression increases expression
|
ISO EXP
|
Progesterone affects the expression of VEGFD mRNA Progesterone results in increased expression of VEGFD mRNA
|
CTD |
PMID:17251523 PMID:20726854 |
|
NCBI chr X:33,704,582...33,740,305
Ensembl chr X:33,706,055...33,740,167
|
|
| G
|
Vim
|
vimentin
|
multiple interactions increases secretion
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of VIM mRNA VIM affects the reaction [[monobutyl phthalate co-treated with CGB3 protein] results in increased secretion of Progesterone]; VIM affects the reaction [[monobutyl phthalate co-treated with Colforsin] results in increased secretion of Progesterone]; VIM inhibits the reaction [RELA affects the reaction [[monobutyl phthalate co-treated with CGB3 protein] results in increased secretion of Progesterone]] VIM protein results in increased secretion of Progesterone
|
CTD |
PMID:20660070 PMID:26745512 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746
|
|
| G
|
Vip
|
vasoactive intestinal peptide
|
increases abundance multiple interactions increases secretion
|
ISO EXP
|
VIP protein results in increased abundance of Progesterone [VIP protein results in increased secretion of Progesterone] which results in decreased expression of NGF mRNA; [VIP protein results in increased secretion of Progesterone] which results in decreased expression of NOS2 protein; [VIP protein results in increased secretion of Progesterone] which results in decreased expression of NTRK1 mRNA
|
CTD |
PMID:19926922 PMID:20150881 |
|
NCBI chr 1:44,470,232...44,478,561
Ensembl chr 1:44,470,462...44,478,558
|
|
| G
|
Vipr2
|
vasoactive intestinal peptide receptor 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of VIPR2 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:143,139,672...143,213,609
Ensembl chr 6:143,144,523...143,213,609
|
|
| G
|
Vit
|
vitrin
|
increases expression
|
ISO
|
Progesterone results in increased expression of VIT mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr 6:22,198,095...22,317,758
Ensembl chr 6:22,198,006...22,317,733
|
|
| G
|
Vnn1
|
vanin 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of VNN1 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 1:23,356,324...23,366,629
Ensembl chr 1:23,356,330...23,366,629
|
|
| G
|
Vps54
|
VPS54 subunit of GARP complex
|
multiple interactions
|
ISO
|
Progesterone inhibits the reaction [VPS54 gene mutant form results in decreased activity of CHAT protein]; Progesterone inhibits the reaction [VPS54 gene mutant form results in decreased expression of BDNF mRNA]; Progesterone inhibits the reaction [VPS54 gene mutant form results in decreased expression of CHAT protein]; Progesterone inhibits the reaction [VPS54 mutant form results in decreased expression of CHAT protein]; Progesterone inhibits the reaction [VPS54 mutant form results in increased expression of GAP43 mRNA]
|
CTD |
PMID:17052708 PMID:19693665 |
|
NCBI chr14:99,580,120...99,657,178
Ensembl chr14:99,580,148...99,657,164
|
|
| G
|
Vstm4
|
V-set and transmembrane domain containing 4
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of VSTM4 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr16:8,126,630...8,206,556
Ensembl chr16:8,122,355...8,206,549
|
|
| G
|
Vsx2
|
visual system homeobox 2
|
multiple interactions
|
EXP
|
bisphenol A inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of VSX2 mRNA]; Diethylstilbestrol inhibits the reaction [[Estradiol co-treated with Progesterone] results in increased expression of VSX2 mRNA]
|
CTD |
PMID:18653720 |
|
NCBI chr 6:109,932,943...109,972,005
Ensembl chr 6:109,948,313...109,971,100
|
|
| G
|
Vtcn1
|
V-set domain containing T cell activation inhibitor 1
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of VTCN1 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 2:190,942,224...191,010,280
Ensembl chr 2:190,942,224...191,010,280
|
|
| G
|
Vtn
|
vitronectin
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of VTN mRNA
|
CTD |
PMID:20226447 |
|
NCBI chr10:63,892,782...63,895,862
Ensembl chr10:63,892,766...63,895,860
|
|
| G
|
Vwf
|
von Willebrand factor
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of VWF mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr 4:160,042,900...160,177,757
Ensembl chr 4:160,047,982...160,177,757
|
|
| G
|
Was
|
WASP actin nucleation promoting factor
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of WAS mRNA [Progesterone co-treated with Estradiol] results in increased expression of WAS mRNA
|
CTD |
PMID:18692832 |
|
NCBI chr X:17,077,057...17,085,802
Ensembl chr X:17,073,314...17,085,802
|
|
| G
|
Wbp1
|
WW domain binding protein 1
|
affects expression
|
ISO
|
Progesterone affects the expression of WBP1 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:117,182,880...117,185,279
Ensembl chr 4:117,182,880...117,185,326
|
|
| G
|
Wbp11
|
WW domain binding protein 11
|
affects expression
|
ISO
|
Progesterone affects the expression of WBP11 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 4:171,412,187...171,425,634
Ensembl chr 4:171,412,189...171,425,634
|
|
| G
|
Wdhd1
|
WD repeat and HMG-box DNA binding protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of WDHD1 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr15:22,957,492...23,002,820
Ensembl chr15:22,958,069...23,002,820
|
|
| G
|
Wdr3
|
WD repeat domain 3
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of WDR3 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:190,194,474...190,217,087
Ensembl chr 2:190,194,474...190,217,087
|
|
| G
|
Wdr4
|
WD repeat domain 4
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of WDR4 mRNA
|
CTD |
PMID:21453500 |
|
NCBI chr20:9,588,532...9,604,718
Ensembl chr20:9,588,532...9,605,007
|
|
| G
|
Wdr72
|
WD repeat domain 72
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of WDR72 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 8:83,718,897...83,902,128
Ensembl chr 8:83,718,914...83,900,286
|
|
| G
|
Wdr77
|
WD repeat domain 77
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of WDR77 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:196,123,882...196,133,853
Ensembl chr 2:196,123,848...196,134,567
|
|
| G
|
Wdr91
|
WD repeat domain 91
|
affects response to substance
|
ISO
|
WDR91 gene SNP affects the susceptibility to Progesterone
|
CTD |
PMID:25622337 |
|
NCBI chr 4:64,521,504...64,558,873
Ensembl chr 4:64,521,504...64,558,873
|
|
| G
|
Wfdc1
|
WAP four-disulfide core domain 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of WFDC1 mRNA
|
CTD |
PMID:22238285 |
|
NCBI chr19:64,628,689...64,647,739
Ensembl chr19:64,607,794...64,648,028
|
|
| G
|
Wfdc17
|
WAP four-disulfide core domain 17
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ANOS1 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr10:69,059,451...69,060,298
|
|
| G
|
Wfdc2
|
WAP four-disulfide core domain 2
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of WFDC2 mRNA Progesterone results in decreased expression of WFDC2 mRNA
|
CTD |
PMID:20660070 PMID:21540246 |
|
NCBI chr 3:173,706,091...173,735,055
Ensembl chr 3:173,706,460...173,712,161
|
|
| G
|
Wif1
|
Wnt inhibitory factor 1
|
multiple interactions decreases expression
|
ISO
|
PGR protein affects the reaction [Progesterone results in decreased expression of WIF1 mRNA]
|
CTD |
PMID:17556502 |
|
NCBI chr 7:58,433,326...58,503,853
Ensembl chr 7:58,384,643...58,503,852
|
|
| G
|
Wls
|
Wnt ligand secretion mediator
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of WLS mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr 2:251,590,653...251,705,991
Ensembl chr 2:251,590,614...251,706,380
|
|
| G
|
Wnt11
|
Wnt family member 11
|
increases expression affects expression multiple interactions
|
ISO
|
Progesterone results in increased expression of WNT11 mRNA Progesterone affects the expression of WNT11 mRNA perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of WNT11 mRNA]; Progesterone inhibits the reaction [perfluorooctanoic acid inhibits the reaction [Progesterone affects the expression of WNT11 mRNA]]
|
CTD |
PMID:19164167 PMID:22238285 PMID:31896193 |
|
NCBI chr 1:162,545,660...162,565,456
Ensembl chr 1:162,545,680...162,564,660
|
|
| G
|
Wnt16
|
Wnt family member 16
|
multiple interactions decreases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of WNT16 mRNA Progesterone results in decreased expression of WNT16 mRNA
|
CTD |
PMID:20660070 PMID:22238285 |
|
NCBI chr 4:51,786,728...51,797,137
Ensembl chr 4:51,786,660...51,816,568
|
|
| G
|
Wnt4
|
Wnt family member 4
|
affects expression multiple interactions increases expression affects abundance decreases expression
|
ISO EXP
|
Progesterone affects the expression of WNT4 mRNA bisphenol A promotes the reaction [Progesterone results in increased expression of WNT4 mRNA] [Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA; NR3C1 protein promotes the reaction [[Progesterone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with Estradiol] results in increased expression of WNT4 mRNA] WNT4 protein affects the abundance of Progesterone Progesterone results in decreased expression of WNT4 mRNA [Progesterone co-treated with Estrogens] results in increased expression of WNT4 mRNA
|
CTD |
PMID:17251523 PMID:20371632 PMID:21258428 PMID:21903720 PMID:22238285 PMID:23275455 More...
|
|
NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:154,797,311...154,817,128
|
|
| G
|
Wnt5a
|
Wnt family member 5A
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of WNT5A mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr16:3,702,300...3,724,860
Ensembl chr16:3,703,665...3,724,860
|
|
| G
|
Wnt5b
|
Wnt family member 5B
|
multiple interactions increases expression
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of WNT5B mRNA Progesterone results in increased expression of WNT5B mRNA
|
CTD |
PMID:20660070 PMID:21795739 |
|
NCBI chr 4:154,281,852...154,406,081
Ensembl chr 4:154,281,852...154,405,681
|
|
| G
|
Wnt7a
|
Wnt family member 7A
|
multiple interactions decreases expression
|
ISO
|
NCOA2 protein affects the reaction [Progesterone results in decreased expression of WNT7A mRNA]
|
CTD |
PMID:17556502 PMID:22238285 |
|
NCBI chr 4:125,420,276...125,466,149
Ensembl chr 4:125,420,276...125,466,149
|
|
| G
|
Wt1
|
WT1 transcription factor
|
increases expression
|
ISO
|
Progesterone results in increased expression of WT1 mRNA; Progesterone results in increased expression of WT1 mRNA alternative form; Progesterone results in increased expression of WT1 protein
|
CTD |
PMID:14662165 |
|
NCBI chr 3:112,019,721...112,068,454
Ensembl chr 3:112,021,641...112,068,444
|
|
| G
|
Wwc1
|
WW and C2 domain containing 1
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in increased expression of WWC1 mRNA
|
CTD |
PMID:18556351 |
|
NCBI chr10:20,804,173...20,958,437
Ensembl chr10:20,799,237...20,958,437
|
|
| G
|
Xbp1
|
X-box binding protein 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of XBP1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr14:84,604,623...84,609,707
Ensembl chr14:84,604,107...84,609,706
|
|
| G
|
Xcl1
|
X-C motif chemokine ligand 1
|
multiple interactions increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of XCL1 mRNA Progesterone results in increased expression of XCL1 mRNA
|
CTD |
PMID:17404688 PMID:21540246 |
|
NCBI chr13:79,781,784...79,785,440
Ensembl chr13:79,781,784...79,785,440
|
|
| G
|
Xdh
|
xanthine dehydrogenase
|
multiple interactions increases expression
|
ISO EXP
|
[Estradiol co-treated with Progesterone] results in increased expression of XDH mRNA Progesterone results in increased expression of XDH mRNA
|
CTD |
PMID:20660070 PMID:20726854 |
|
NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350
|
|
| G
|
Xpnpep2
|
X-prolyl aminopeptidase 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of XPNPEP2 mRNA; Progesterone results in increased expression of XPNPEP2 protein
|
CTD |
PMID:19126663 |
|
NCBI chr X:132,165,696...132,194,937
Ensembl chr X:132,165,701...132,195,126
|
|
| G
|
Xpo5
|
exportin 5
|
increases expression
|
ISO
|
Progesterone results in increased expression of XPO5 mRNA
|
CTD |
PMID:20852728 |
|
NCBI chr 9:22,237,760...22,275,745
Ensembl chr 9:22,237,760...22,275,745
|
|
| G
|
Xpot
|
exportin for tRNA
|
affects expression
|
ISO
|
Progesterone affects the expression of XPOT mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr 7:58,997,025...59,037,506
Ensembl chr 7:58,997,025...59,037,502
|
|
| G
|
Xrcc4
|
X-ray repair cross complementing 4
|
increases expression
|
ISO
|
Progesterone results in increased expression of XRCC4 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr 2:22,686,506...22,932,929
Ensembl chr 2:22,686,508...22,933,160
|
|
| G
|
Ythdc2
|
YTH N6-methyladenosine RNA binding protein C2
|
increases expression
|
ISO
|
Progesterone results in increased expression of YTHDC2 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr18:37,517,286...37,582,551
Ensembl chr18:37,517,248...37,582,550
|
|
| G
|
Zbtb16
|
zinc finger and BTB domain containing 16
|
multiple interactions affects expression increases expression
|
ISO
|
[Progesterone co-treated with Estradiol] results in increased expression of ZBTB16 mRNA Progesterone affects the expression of ZBTB16 mRNA Progesterone results in increased expression of ZBTB16 mRNA
|
CTD |
PMID:17251523 PMID:17404688 PMID:20864642 PMID:22238285 |
|
NCBI chr 8:57,885,886...58,073,507
Ensembl chr 8:57,891,081...58,073,507
|
|
| G
|
Zcchc10
|
zinc finger CCHC-type containing 10
|
increases expression
|
ISO
|
Progesterone results in increased expression of ZCCHC10 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr10:37,971,459...37,981,860
Ensembl chr10:37,969,340...37,981,992
|
|
| G
|
Zcchc14
|
zinc finger CCHC-type containing 14
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ZCCHC14 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr19:66,582,800...66,627,136
Ensembl chr19:66,582,800...66,627,136
|
|
| G
|
Zdhhc11
|
zinc finger, DHHC-type containing 11
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ZDHHC11 mRNA
|
CTD |
PMID:21540246 |
|
NCBI chr 1:31,124,900...31,156,075
Ensembl chr 1:31,124,900...31,155,498
|
|
| G
|
Zeb1
|
zinc finger E-box binding homeobox 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of ZEB1 mRNA
|
CTD |
PMID:20864642 |
|
NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745
|
|
| G
|
Zeb2
|
zinc finger E-box binding homeobox 2
|
increases expression
|
ISO
|
Progesterone results in increased expression of ZEB2 mRNA
|
CTD |
PMID:19000923 |
|
NCBI chr 3:49,624,028...49,754,323
Ensembl chr 3:49,624,028...49,754,323
|
|
| G
|
Zfp275
|
zinc finger protein 275
|
affects expression
|
ISO
|
Progesterone affects the expression of ZFP275 mRNA
|
CTD |
PMID:17251523 |
|
NCBI chr X:156,208,873...156,225,732
Ensembl chr X:156,208,914...156,225,617
|
|
| G
|
Zfp36
|
zinc finger protein 36
|
increases expression
|
ISO
|
Progesterone results in increased expression of ZFP36 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr 1:92,796,628...92,799,108
Ensembl chr 1:92,796,628...92,799,108
|
|
| G
|
Zfp366
|
zinc finger protein 366
|
multiple interactions
|
ISO
|
ZNF366 protein inhibits the reaction [Progesterone results in increased activity of PGR protein]
|
CTD |
PMID:20008677 |
|
NCBI chr 2:32,312,712...32,376,996
Ensembl chr 2:32,312,907...32,374,315
|
|
| G
|
Zfp367
|
zinc finger protein 367
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ZNF367 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr17:970,896...990,025
Ensembl chr17:970,741...990,029
|
|
| G
|
Zfp36l1
|
zinc finger protein 36, C3H type-like 1
|
increases expression
|
ISO
|
Progesterone results in increased expression of ZFP36L1 mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 6:104,663,396...104,669,815
Ensembl chr 6:104,663,399...104,687,979
|
|
| G
|
Zfp426
|
zinc finger protein 426
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ZNF426 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 8:27,272,830...27,305,116
Ensembl chr 8:27,272,831...27,305,259
|
|
| G
|
Zfp428
|
zinc finger protein 428
|
multiple interactions
|
ISO
|
[Progesterone co-treated with Estradiol] results in decreased expression of ZNF428 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr 1:89,227,442...89,236,797
Ensembl chr 1:89,227,376...89,236,796
|
|
| G
|
Zfp521
|
zinc finger protein 521
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ZNF521 mRNA
|
CTD |
PMID:21795739 |
|
NCBI chr18:5,050,297...5,343,188
Ensembl chr18:5,056,236...5,343,054
|
|
| G
|
Zfp532
|
zinc finger protein 532
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ZNF532 mRNA
|
CTD |
PMID:18070364 |
|
NCBI chr18:61,350,084...61,473,653
Ensembl chr18:61,364,378...61,473,649
|
|
| G
|
Zfp600
|
zinc finger protein 600
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ZNF300 mRNA
|
CTD |
PMID:20660070 |
|
|
|
| G
|
Zfp652
|
zinc finger protein 652
|
increases expression multiple interactions
|
ISO
|
Progesterone results in increased expression of ZNF652 mRNA [Progesterone co-treated with Estradiol] affects the expression of ZNF652 mRNA
|
CTD |
PMID:17404688 |
|
NCBI chr10:81,123,326...81,203,153
Ensembl chr10:81,146,507...81,198,827
|
|
| G
|
Zfp711
|
zinc finger protein 711
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ZNF711 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr X:81,838,483...81,871,767
Ensembl chr X:81,838,620...81,871,784
|
|
| G
|
Zfr
|
zinc finger RNA binding protein
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ZFR mRNA
|
CTD |
PMID:18037150 |
|
NCBI chr 2:62,864,333...62,927,377
Ensembl chr 2:62,864,338...62,929,133
|
|
| G
|
Zhx3
|
zinc fingers and homeoboxes 3
|
increases expression
|
EXP
|
Progesterone results in increased expression of ZHX3 mRNA
|
CTD |
PMID:20726854 |
|
NCBI chr 3:169,837,497...169,968,371
Ensembl chr 3:169,837,516...169,935,530
|
|
| G
|
Zkscan5
|
zinc finger with KRAB and SCAN domains 5
|
decreases expression
|
ISO
|
Progesterone results in decreased expression of ZKSCAN5 mRNA
|
CTD |
PMID:19693291 |
|
NCBI chr12:14,498,342...14,519,537
Ensembl chr12:14,498,342...14,519,537
|
|
| G
|
Zmiz2
|
zinc finger, MIZ-type containing 2
|
multiple interactions
|
ISO
|
[Estradiol co-treated with Progesterone] results in decreased expression of ZMIZ2 mRNA
|
CTD |
PMID:20660070 |
|
NCBI chr14:85,465,323...85,481,860
Ensembl chr14:85,465,373...85,481,860
|
|